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ABSTRACT 
 
Red cell allo and autoantibodies have the potential to cause haemolytic 
transfusion reactions and can also create challenges with subsequent 
compatibility testing, sourcing compatible blood, delays in the provision of 
blood and cost implications. This is particularly relevant in patients who 
are dependent on chronic transfusion support; such as those with sickle 
cell disease, thalassaemia, haematological malignancies and renal 
disease.  A retrospective review of chronically transfused patients with 
haematological malignancies and renal disease, treated at the Royal 
Devon and Exeter NHS Foundation Trust (RD&E), revealed considerably 
higher costs associated with provision of blood for patients with red cell 
allo/autoantibodies than for non-immunised patients, providing new 
evidence to support the cost effectiveness of extended antigen matching 
for these groups of patients.  
 
The risk of development of red cell allo/autoantibodies could be reduced 
by a type and match strategy for, at least, Rh (CcEe) and K antigens as 
well as the standard ABO and RhD match. To support this strategy a 
novel technique was validated for high throughput extended automated 
red cell antigen serological phenotyping suitable for use in the hospital 
transfusion setting.  
 
Red cell genotyping assays can also support a type and match strategy; 
however, these assays have not been evaluated for use in the hospital 
transfusion service setting in the United Kingdom (UK). A platform for this 
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technique was evaluated; the results compared well to the serological 
assay, and the assay showed some potential for routine use.  
 
A large scale randomised controlled trial to investigate the benefit and 
cost effectiveness of a type and match strategy has not been attempted 
in the UK, therefore a pilot study was performed in which patients were 
randomly assigned to a standard care or intervention (type and match) 
group. The pilot study demonstrated the feasibility of a larger scale trial 
and provided new evidence supporting the potential to implement a type 
and match strategy within the hospital transfusion service, using routine 
blood stocks. 
 
Implementation of an extended type and match strategy, utilising the new 
assay for extended serological phenotyping and the lessons learned from 
the pilot study, has been implemented for patients with haematological 
malignancies and renal disease at the RD&E. Patients identified as 
potential recipients of chronic transfusion support are serologically 
phenotyped for Rh (CcEe) and K antigens prior to transfusion. Changes 
have been made to the red cell stock storage area and the laboratory 
information management system to support provision of matched blood 
for transfusion.  The program is being monitored for its effectiveness in 
reducing both allo/autoimmunisation rate and the cost of provision of 
blood.    
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1 INTRODUCTION 
 
1.1 Blood and blood components for transfusion 
 
The collection and storage of blood for transfusion was introduced during 
the First World War (WW1) in 1917 (Robertson, 1918; Makins, 1922). 
Blood was collected from “lightly wounded” soldiers and mixed with a 
preservative/anticoagulant solution of sodium citrate with glucose, 
allowing storage for up to 14 days. This process became known as blood 
banking and it gave the army the ability to transfuse close to the front line 
with lifesaving effects (Makins, 1922). The birth of the modern blood 
bank, with blood collected from volunteer donors from the general 
population is attributed to Percy Lane Oliver, who, in 1921, received a 
request for an emergency donor and within five years had recruited 400 
volunteers to a donor panel (Starr, 1999). 
 
In the interval between the First and Second World Wars, methods for the 
separation of whole blood into its component parts (red cells and 
plasma), led to the clinical use of plasma for treating severe infections by 
Strumia and his group in 1927 (Strumia and McGraw, 1941). The 
introduction of plastic bags for the storage of blood in 1950 (Walter and 
Murphy, 1952), rather than the glass bottles as originally used, facilitated 
further separation of the donated blood. This enabled the separation of 
whole blood into the blood components (including fresh frozen plasma, 
platelet concentrates, and cryoprecipitate) available today. The 
availability of these blood components enables targeted therapy for 
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specific deficiencies of blood constituents in patients, caused by inherited 
or acquired conditions. 
 
Blood and blood components are used in a wide variety of medical and 
surgical conditions and their life saving qualities are without question. In 
the United Kingdom (UK) more than 50% of the red cell components 
collected, processed and distributed by the National Health Service Blood 
and Transplant (NHSBT) are transfused for non-surgical conditions 
(JPAC, 2014). A national audit of blood use in medical patients conducted 
in 2011 in the UK (NCABT, 2011) revealed that the majority of red cells 
were transfused to patients with haematological diagnoses (28%), despite 
the audit restricting the number of patients with those conditions that were 
included within the review. Other recipients of red cells were patients with 
acute or chronic gastrointestinal haemorrhage (17%), non-haematological 
cancer (15%), patients in intensive care units (7%) and patients with renal 
failure (4%). A later audit in 2014 (NCABT, 2014) revealed that medical 
usage accounted for 67.4% of all red cell units used in the UK, with 
haematological and non-haematological (including renal failure) anaemia 
being the largest user (54.5%) Other blood usage was seen in 
gastrointestinal bleeding (12%), obstetrics and gynaecology (6%), 
cardiothoracic surgery (6%), gastrointestinal surgery (4%), trauma (4%) 
and orthopaedics (4%).  Thus, a large proportion of the approximately two 
million red cell components collected annually in the UK are given to 
patients requiring chronic transfusion support, namely those with 
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haematological malignancies, non-haematological cancers and renal 
failure. 
 
At the Royal Devon and Exeter NHS Foundation Trust (RD&E) the red 
cell usage is broken down as follows; medical conditions (78%), surgery 
(21%) and obstetrics/gynaecology (1%). The majority of red cell usage is 
for patients with haematological (41%) and non-haematological anaemia 
(27%), followed by gastrointestinal bleed (8%) and trauma (8%). The 
RD&E clinical haematology department has an inpatient and outpatient 
service providing care for patients with haematological conditions, and 
also performs autologous peripheral blood stem cell transplants for 
patients with conditions such as myeloma and lymphoma. A 
comprehensive day case, inpatient and outpatient renal service is 
provided at the main hospital site and in five satellite hospital units. The 
service provides treatment for patients with acute (usually reversible) and 
chronic (usually irreversible) kidney failure, and those with kidney 
transplant. The fact that the majority of red cells are transfused to patients 
with haematological or renal anaemia provided the rationale for the focus 
on these cohorts within the research work. The non-emergency nature of 
blood transfusion in chronic anaemia, compared to that in gastrointestinal 
haemorrhage and trauma, would, in theory, allow for antigen typing and 
extended matching of blood for these patients.   
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1.2 Blood component support in chronic transfusion 
 
Cancer is the one of the most common causes of mortality in the 
developed world (Cartwright et al., 1999; Ferlay et al., 2007; Office for 
National Statistics, 2012). In 2012 lymphoid cancer, a haematological 
malignancy, accounted for 2.6% of the death rate in males (Office for 
National Statistics, 2012). In addition to the substantial mortality rate for 
this type of cancer, and other haematological malignancies, treatment 
costs can also be high, including prolonged hospitalisation, 
chemotherapy, drugs and other specialised support such as blood 
component therapy (Yu et al., 2007). 
 
The haematological malignancies are a diverse group which  were 
originally divided into the leukaemias/myelodysplasias, coded by the 
French-American-British (FAB) classification (Bennet et al., 1976) and the 
Morphology Immunology Cytogenetic classification (Van den Berghe, 
1988), and the lymphomas, which historically were subjected to a 
multitude of classifications (Gerrard-Marchant et al., 1974; Lukes and 
Butler, 1986; Harris et al., 1994; Chan et al., 1994; Chan et al., 1995).  
They were classified according to lineage by the World Health 
Organization Clinical Advisory Committee (Swerdlow et al., 2008) in an 
attempt to present a classification system that is recognised worldwide. 
The classifications have been more recently revised in 2016 for lymphoid 
neoplasms (Swerdlow et al., 2016) and myeloid neoplasms and acute 
leukaemia (Arber et al., 2016). A simplified version of the World Health 
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Organisation (WHO) classification of lymphoid neoplasms, myeloid 
neoplasms and acute leukaemias is shown in table 1.1. 
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Table 1.1: World Health Organisation (WHO) classification of lymphoid neoplasms, myeloid neoplasms and acute 
leukaemia 
The table shows a simplified version of the WHO classification of lymphoid neoplasms (Swerdlow et al., 2016) myeloid neoplasms and 
acute leukaemia (Arber et al., 2016). For the purposes of this study the table only includes the major subtypes (in bold type) and 
categories seen in the patients included within the retrospective review (chapter 3) and the pilot study (chapter 6). The full 
classifications can be found using the hyperlinks for lymphoid neoplasms and myeloid neoplasms and acute leukaemia. 
Lymphoid neoplasms Myeloid neoplasms Acute leukaemia 
Chronic lymphocytic leukaemia (CLL) Myelodysplastic/myeloproliferative 
neoplasms (MDS/MPS) 
Acute myeloid leukaemia (AML) 
Hairy cell leukaemia (HCL) Chronic myelomonocytic leukaemia 
(CMML) 
Acute lymphoblastic leukaemia (ALL) (B-
cell or T-cell) 
Waldenström macroglobulinemia Chronic myeloid leukaemia (CML)  
Mantle cell lymphoma (MCL)   
Diffuse large B-cell lymphoma (DLBCL)   
Hodgkin lymphoma   
Plasma cell myeloma   
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Morbidity and mortality rates have historically been high in patients with 
haematological malignancies, with mortality rates reaching 75.6% in 
certain countries (Grais, 1962). In England and Wales during the years 
1945 to 1957, mortality rates were found to range between 19.8% for 
chronic myeloid leukaemia to 59% for acute leukaemia (Court-Brown and 
Doll, 1959). Recent advances in the treatment of patients with 
haematological malignancies, using chemotherapy or high dose 
chemotherapy combined with bone marrow or stem cell transplantation, 
have increased the survival rate in this group of patients (Champlin and 
Gale, 1987), with complete remission rates of more than 80% seen in 
young adult patients with acute lymphocytic leukaemia (Dombret and 
Gardin, 2016). However, the intense treatment regimens directed at the 
progenitor cells within the bone marrow result in anaemia and 
thrombocytopenia, which, if untreated, are also life threatening conditions, 
consequently the patient’s survival becomes dependent on blood 
component support (NICE 2003).  
  
Patients with acute or chronic kidney disease may also suffer from 
anaemia caused by the disease (Brugnara and Eckardt, 2011) and be 
dependent on blood transfusion for periods of time. Anaemia is common 
in patients with kidney disease, which is caused by decreased synthesis 
of erythropoietin, a hormone produced by the kidneys that stimulates the 
bone marrow to make red blood cells (Erslev, 1953; Jacobson et al., 
1957). The identification and treatment of anaemia in this group of 
patients is important because anaemia has the potential to cause adverse 
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effects including reduced oxygen utilisation, increased cardiac output and 
left ventricular hypertrophy, increase in the progression of the disease 
and reduction in immune responsiveness (NICE 2011). A study in 
diabetic nephropathy, the leading cause of end stage renal disease 
(ESRD), found that even mild anaemia increased the risk of progression 
to ESRD and that anaemia was an independent risk factor for disease 
progression (Mohanram et al., 2004). For patients with ESRD a common 
treatment option is haemodialysis, however, this process can cause blood 
loss during the processing stage within the haemodialysis machine, 
exacerbating the extent of anaemia (NIH, 2016).  The prevalence of 
anaemia in chronic kidney disease in the UK is approximately 12% (NICE 
2011). A review in the United States estimated that anaemia in patients 
with kidney disease ranged from 2% in the early stages to over 70% in 
ESRD (Astor et al., 2002).  
 
The Canadian Hemodialysis Morbidity Study found that for patients with 
ESRD on haemodialysis the probability of surviving 12 months without 
receiving a blood transfusion was 47.2% for males and 27.5% for females 
(Churchill et al., 1992). Although blood transfusion therapy in patients 
with renal disease has dramatically reduced over the last 20 years since 
the introduction of human recombinant erythropoietin (hrEPO) therapy, 
blood transfusion is still a treatment option if clinically indicated (NICE 
2011; Mikhail et al., 2010) especially during haemodialysis. In addition 
approximately 10% of patients become resistant to the effects of hrEPO 
(Van der Putten et al., 2008) for various reasons including iron deficiency, 
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infection/inflammation, severe hyperparathyroidism and inadequate 
dialysis (Drüeke, 2001; Priyadarshi and Shapiro, 2006; Ribeiro et al., 
2013). 
 
 
1.3 Blood group systems and red cell antigens 
 
1.3.1 Blood group systems 
 
The term blood group refers to variations and polymorphisms in the 
blood, related to red cell surface antigens (Daniels, 2013). The most well-
known system is the ABO system and the most well-known antigen is the 
RhD, due to their use in the blood donor setting. Variations in the 
antigens on the red cell surface can only be called a blood group if they 
are defined by an antibody.  
 
The ABO blood group system and corresponding antibodies were first 
discovered by Landsteiner in 1900 using direct agglutination techniques 
(Landsteiner, 1900 cited in Daniels 2013). However, not all blood group 
antibodies are able to directly agglutinate red cells, and it was not until 
the development of the indirect antiglobulin test (IAT) in 1945 (Coombs et 
al., 1945a; Coombs et al., 1945b) that other, so-called “incomplete” red 
cell antibodies could be identified, and their corresponding blood group 
systems and antigens named. New DNA based technologies have 
facilitated the identification of new blood group systems and allowed 
mapping of the genes controlling the expression of the antigens within the 
system to the chromosomal location. As such, the number of recognised 
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blood group systems is ever increasing. A standard nomenclature for 
these blood groups and their antigens was first developed by the 
International Society of Blood Transfusion (ISBT) Working Party on Red 
Cell Immunogenetics and Blood Group Terminology in 1980. Each blood 
group system is assigned a number, the system name which, for the well-
known systems may be the historically assigned name, the system 
symbol and the symbol for each gene within the system (table 1-2). To 
facilitate international standardisation of gene symbols, each gene 
symbol for the blood group families are recognised and approved by the 
Human Genome Organisation (HUGO). Application of this nomenclature 
on an international scale ensures that publications including information 
on blood group systems have standardised terminology, facilitating 
literature searches for researchers.   In order for a red cell antigen to be 
named as a blood group system it is required to fulfil the criteria set out 
by the ISBT; it must be defined by a corresponding human alloantibody, it 
must be an inherited character, the gene encoding the antigen must have 
been identified and sequenced and its chromosomal location must be 
known (Daniels et al., 2004). 
 
An explanation of the structure, molecular basis and function of blood 
group systems relevant to this study are given in section 1.3.2. This 
includes blood group antigens detected using the serological phenotyping 
assay (chapter 4) and/or the genotyping assay (chapter 5) described in 
this study. As such, the section will focus on the following blood group 
systems; ABO, Rh, Kell, Kidd, Duffy, MNS, Diego, Dombrock, Colton, Yt 
and Lutheran.  
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Table 1.2: The blood group systems with the gene symbols as recognised by the HUGO (Human Genome 
Organisation) Gene Nomenclature Committee and the ISBT (International Society of Blood Transfusion) 
Table of the blood group systems with the gene symbols as recognised by the HUGO Gene Nomenclature Committee (www.genenames.org 
updated October 2012) and the ISBT. Approval by the HUGO Gene Nomenclature Committee ensures that each gene symbol is unique thus 
facilitating electronic data retrieval from publications and databases. The nature of the encoded protein is included; if unknown this is denoted in the 
table. Key:N/A = not applicable 
 
No. System name System 
symbol 
No. of 
antigens 
Gene symbol(s) Chromosomal 
location 
CD number Nature of the encoded protein 
001 ABO ABO 4 ABO 9q34.2 N/A Galactosyltransferase and N-
acetylgalactoseaminyltransferase 
002 MNS MNS 48 GYPA, GYPB, 
GYPE 
4q31.21 CD235 Unknown 
003 P1PK P1PK 3 A4GALT 22q13.2 N/A Galactosyltransferase 
004 Rh  RH 55 RHD, RHCE 1p36.11 CD240 Unknown 
005 Lutheran LU 22 LU 19q13.32 CD239 Adhesion molecule 
006 Kell KEL 36 KEL 7q34 CD238 Metalloendopeptidase? 
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No. 
(continued) 
System name 
(continued) 
System 
symbol 
(continued) 
No. of 
antigens 
(continued) 
Gene symbol(s) 
(continued) 
Chromosomal 
location (continued) 
CD number 
(continued) 
Nature of the encoded protein 
(continued) 
007 Lewis LE 6 GUT3 19q13.3 N/A Fucosyltransferase 
008 Duffy FY 5 DARC 1q23.2 CD234 Chemokine receptor 
009 Kidd JK 3 SLC14A1 18q12.3 N/A Urea transporter 
010 Diego DI 22 SLC4A1 17q21.31 CD233 Anion exchanger 
011 Yt YT 3 ACHE 7q22.1 N/A Acetylcholinesterase 
012 Xg XG 2 XG, MIC2 Xp22.33 CD99 (MIC2 
product) 
Adhesion molecule 
013 Scianna SC 7 ERMAP 1p34.2 N/A Adhesion molecule? 
014 Dombrock DO 7 ART4 12p12.3 CD297 ADP ribosyltransferase 
015 Colton CO 4 AQP1 
 
7p14.3 N/A Water channel 
016 Landsteiner-
Wiener 
LW 3 ICAM4 19p13.2 CD242 Adhesion molecule 
017 Chido/Rodgers CH/RG 9 C4A, C4B 6p21.3 N/A Complement factor 
018 H H 1 FUT1 19q13.33 CD173 Fucosyltransferase 
019 Kx XK 1 XK Xp21.1 N/A Membrane transport protein? 
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No. 
(continued) 
System name 
(continued) 
System 
symbol 
(continued) 
No. of 
antigens 
(continued) 
Gene symbol(s) 
(continued) 
Chromosomal 
location (continued) 
CD number 
(continued) 
Nature of the encoded protein 
(continued) 
020 Gerbich GE 11 GYPC 2q14.3 CD236 Cytoskeletal element 
021 Cromer CROM 19 CD55 1q32.2 CD55 Complement cascade regulator 
022 Knops KN 9 CR1 1q32.2 CD35 Cell surface receptor 
023 Indian IN 5 CD44 
 
11p13 CD44 Adhesion molecule 
024 Ok OK 3 BSG 
 
19p13.3 CD147 Plasma membrane protein 
025 Raph RAPH 1 CD151 11p15.5 CD151 Adhesion molecule 
026 John Milton 
Hagen 
JMH 6 SEMA7A 15q24.1 CD108 Adhesion and signalling molecule? 
027 I I 1 GCNT2 6p24.2 N/A N-acetylglucosaminyltransferase 
028 Globoside GLOB 1 B3GALT3 3q26.1 N/A N-acetyl galactosaminyltransferase 
029 Gill GIL 1 AQP3 9p13.3 N/A Water channel 
030 Rh-associated 
glycoprotein 
RHAG 4 RHAG 6p21-qter CD241 Ammonium and carbon dioxide 
transporter 
031 FORS FORS 1 GBGT1 9q34.13 N/A Unknown 
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No. 
(continued) 
System name 
(continued) 
System 
symbol 
(continued) 
No. of 
antigens 
(continued) 
Gene symbol(s) 
(continued) 
Chromosomal 
location (continued) 
CD number 
(continued) 
Nature of the encoded protein 
(continued) 
032 JR JR 1 ABCG2 4q22 N/A Unknown 
033 LAN LAN 1 ABCB6 2q36 N/A Unknown 
034 Vel VEL 1 SMIM1 1p36.32 N/A Unknown 
035 CD59 CD59 2 CD59 11p14-p13 CD59 Unknown 
036 Augustine AUG 2 SCL29A1 6p21.1 N/A Unknown 
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1.3.2 Biochemistry, genetic basis and function of blood groups 
systems 
 
Blood group antigens are either protein determinants, which represent the 
primary products of blood group system genes, or carbohydrate 
determinants on glycoproteins or glycolipids, in which the products of the 
genes controlling antigen expression are glycosyltransferase enzymes 
(Daniels, 2013). The following subsections explain the biochemistry, 
molecular basis and function of the blood group systems and antigens 
important to this study. Unless otherwise referenced, the information in 
sections 1.3.2.1 to 1.3.2.11 is taken from the Human Blood Groups 
reference book by Daniels (2013).  
 
1.3.2.1 ABO system 
 
The ABO blood group system comprises of four antigens, the H antigen 
encoded by the FUT1 locus on chromosome 19 and the ABO antigens 
encoded by the ABO gene on chromosome 9. The H allele produces 
α1,2-L fucosyltransferase at the FUT1 locus, this enzyme catalyses the 
transfer of L-fucose to its acceptor substrate, D-Galactose, resulting in 
the H determinant. The ABO blood group type is determined by alleles at 
the ABO locus. The product of the A allele is α1,3-N-acetyl-D-
galactosaminyltransferase, which attaches N-acetylgalactosamine to the 
H determinant and the B allele produces α1,5-D-galactosyltransferase, 
which attaches D-Galactose to the H determinant. The third allele at the 
locus, O, does not produce an active enzyme and so the H determinant 
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remains unchanged. ABO antigens are expressed on carbohydrate 
chains on glycoproteins, mainly the poly-N-acetyllactosaminyl N-glycans 
of the band 3 or band 4.5 proteins. Expression of the antigens is 
dependent on the presence of specific monosaccharides attached to a 
precursor disaccharide at the non-reducing end of a carbohydrate chain, 
shown in simple diagrammatic form in figure 1.1. The carbohydrate 
chains are built up by the sequential addition of monosaccharides 
catalysed by a specific glycoslytransferase. It is these 
glycoslytransferases that represent the primary products of the ABO 
genes.  
 
The function of the ABO antigens is unknown; however, the carbohydrate 
structures which carry the ABO red cell antigens form part of the 
glycocalyx, an extra-cellular matrix acting to protect the cell from damage 
or invasion by pathogenic micro-organisms (Viitala and Järnefelt, 1985; 
Kościelak, 2012). The ABH determinants on the red cells are carried, 
mainly, on the anion exchange protein, band 3, and band 4.5 which is a 
glucose transporter. 
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Figure 1.1 Structure of the ABO antigens 
 
The diagram shows the immunodominant sugars in the ABO blood group 
system. The L-Fucose sugar denoting the blood group O is, more 
correctly, known as the H determinant, if this sugar is not present then A 
or B antigens cannot be expressed, even if the genes are present. This 
results in the rare H-deficient (Bombay) phenotype. Expression of A and 
B antigens is determined by enzymes produced by alleles at the ABO 
locus which catalyse the attachment of the relevant sugar determinants to 
the H structure. (Adapted from Diamed, cited in Immunobase 1, 
http://www.bio-rad.com/en-uk/product/immunobase?ID=LO52IK5Y7). 
  
Red cell membrane 
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1.3.2.2 Rh system 
 
The Rh blood group system is a highly complex system, with 55 antigens 
encoded by two homologous, closely linked genes on chromosome 1 
(ISBT 004 RHCE alleles v4.0_20180208). The RHD gene produces the 
RhD antigen, and the RHCE gene produces the Cc and Ee antigens.  C 
and c, E and e represent two pairs of antithetical antigens, with 
polymorphisms controlled by RHCE. The C/c and E/e phenotypes arise 
as a result of a single amino acid substitution; serine to proline at position 
103 for C/c and proline to alanine at position 226 for E/e. 
 
Each antigen has been allocated a number, for example, RH1 (D), RH2 
(C), RH3 (E), RH4 (c), RH5 (e) and RH8 (Cw). The alleles are inherited as 
haplotypes, often referred to using the Fisher-Race or Wiener 
terminology. The Fisher-Race terminology was based on the premise that 
the Rh phenotype was controlled by three closely linked loci on each 
chromosome of a homologous pair, each of which has its own set of 
alleles; Dd, Cc and Ee (the d antigen does not exist but is used in this 
terminology to denote the absence of the D antigen). They postulated that 
the loci were so closely linked that the three genes on chromosome were 
always inherited together (Fisher, cited in Race, 1944). Wiener, 
conversely, theorised that there was only one gene complex with eight 
alleles, Ro, R1, R2, Rz, r, r', r", ry, controlling the Rh phenotype (Wiener, 
1943). Both theories are too simplistic to explain the Rh system antigens 
and resultant phenotypes but they are commonly used for the 
interpretation of serological reactions within hospital transfusion services.  
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The Rh system antigens (RhD, C, c, E and e) are carried on hydrophobic, 
non-glycosylated proteins which cross the red cell membrane 12 times 
(Daniels, 2013)(figure 1.2). An associated protein, the RhAG glycoprotein 
forms complexes with the Rh protein within the cell membrane. The exact 
functions of the Rh and RhAG proteins are not yet known, but there is 
some evidence to suggest that the RhAG is involved in the transport of 
ammonium ions and carbon dioxide (Marini et al., 1997; Endeward et al., 
2008). The RhD negative phenotype is a result of the total absence of the 
RhD polypeptide from the red cell membrane, in Caucasian populations 
this is usually as a result of homozygosity of a deletion of RHD. In black 
Africans, however, the D negative phenotype is often caused by the 
presence of an inactive RHD called the RHD pseudogene, or a hybrid 
gene RHD-CE-Ds. The hybrid genes do not produce a D antigen, but 
probably produce an abnormal C antigen, and are associated with the 
VS+V- phenotype (Daniels, 2013). There are many variant antigens 
within the Rh system, as described by Daniels (2013), which create 
challenges for serological phenotyping and genotyping assays. The most 
common variants in the UK involve the D antigen, recommended practice 
in hospital laboratories is to test the patient cells against an IgM 
monoclonal anti-D reagent that does not detect the DVI variant (BCSH 
2012).  This practice is recommended as individuals with the DVI 
phenotype are likely to produce anti-D if transfused with D positive red 
cells, whereas other D variants are at less risk of developing anti-D. 
Variants to other Rh antigens are rare, particularly in Caucasian 
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populations, and so testing is not included in serological phenotyping 
assays. However, assays for some of these variants are included in 
genotyping assays (see chapter 5). The Rhnull phenotype, in which neither 
RhD nor CcEe antigens are expressed on the red cell surface, is 
extremely rare. There are two types of Rhnull; the amorph type, which is a 
result of inactivating mutations in the RHCE and deletion of the RHD, or 
the regulator type, in which the Rh genes are normal but there are 
inactivating mutations in the RHAG gene. 
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Figure 1.2 Diagrammatic representations of the RhD and RhCE 
antigen structures 
 
 
 
 
The RhD and RhCE proteins span the red cell membrane and are similar, 
differing by only 32 to 35 amino acids, the sections of the protein above 
and below the cell membrane are denoted by dotted lines on the diagram. 
RhD is composed of many different epitopes (highlighted in the oval 
above the cell membrane). The RhD variant phenotype occurs when one 
or more of these epitopes are missing. The RhCE protein carries the Cc 
and Ee antigens, two pairs of antithetical antigens that differ by a single 
amino acid change. At position 103 C antigen expression is result of 
serine and c antigen expression by proline, and at position 226 E results 
from proline and e from alanine. (Diagram adapted from Westhoff, 2007)   
  
        C/c        
Ser103Pro 
      E/e 
Pro226Ala 
Red cell membrane 
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1.3.2.3 Kell system 
 
The Kell system comprises of 36 antigens encoded by a single gene 
(KEL) on chromosome 7 ((ISBT 006) blood group alleles v4.0 160701). 
The system includes seven sets of antigens with allelic relationships: K 
and k; Kpa, Kpb and Kpc; Jsa and Jsb; K11 and K17; KEL14 and KEL24; 
KEL25 and KEL28; KEL31 and KEL38. The antithetical antigens arise as 
a result of single amino acid changes at different positions on the Kell 
glycoprotein. The Kell antigens are located on CD238, a red cell 
transmembrane glycoprotein, which is closely associated with another 
protein, Xk (see figure 1.3). The Kell-Xk heterodimer is part of the red cell 
membrane complex that contains band 3, the Rh complex and 
glycophorin C. 
 
The prevalence of the commonly encountered Kell antigens differs by 
ethnic group: for example, K positive is more common in Caucasian 
samples and less often seen in African-Americans; Kp(a+) phenotype is 
almost always found in whites; and Js(a+) is almost exclusively found in 
individuals of African ethnicity (Westhoff and Shaz, 2013). Similar to the 
RhD antigen, the K antigen is strongly immunogenic and the antibody is 
clinically significant, hence it is recommended in the UK to select K 
negative red cells for transfusion in females of child bearing potential 
(BCSH 2012).  The Kell-null phenotype (K0), in which none of the Kell 
antigens are expressed on the red cell, is a result of homozygosity for 
KEL inactivating mutations. In the Kmod phenotype, which also results 
from KEL mutations, the antigens are present but expressed weakly.  
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The function of the Kell glycoprotein is unclear, although suggestions 
have been made regarding possible physiological functions in heart, red 
cell ion transport, neovascularisation in tumours and motor function (Zhu 
et al., 2009) and a role in erythropoiesis (Belhacene et al., 1998). 
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Figure 1.3 The Kell and Xk heterodimer 
 
 
The Xk protein and the Kell glycoprotein are linked by a disulphide bond. 
The diagram shows the approximate locations of the antithetical antigens, 
K/k, Jsa/Jsb and Kpa/Kpb on the Kell glycoprotein. The antithetical 
antigens arise as a result of single amino acid changes in the 
glycoprotein; K/k change at position 578 (threonine to methionine), 
Jsa/Jsb at position 597 (leucine to proline) and Kpb/Kpa at position 281 
(arginine to tryptophan). The Kx system consists of one antigen which is 
encoded by the X-linked gene, XK, and located on the Xk protein. The 
glycoprotein structure also carries a pentameric zinc-binding motif, 
HELLH. Picture adapted from Slideshare 
(https://image.slidesharecdn.com/kellbloodgroupsystem-150908110628-
lva1-app6892/95/kell-blood-group-system-10-638.jpg?cb=1441710657).  
  
Xk 
K/k 
Js
a
/Js
b
 
Cell membrane 
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1.3.2.4 MNS system 
 
 
The MNS system is another highly complex blood group system, with 48 
antigens included in the system, encoded by three genes (GYPA, GYPB 
and GYPE) located on chromosome 4 (MNS (ISBT 002) blood group 
alleles v4.1 170119). M and N determinants are carried on glycophorin A 
(GPA), the major red cell sialic acid-rich glycoprotein. The M and N 
antigen status of red cells is defined by an amino acid sequence 
polymorphism at positions 1 and 5 on Glycophorin A. The M antigen has 
serine at position 1 and glycine at position 5, whereas, the N antigen has 
leucine at position 1 and glycine at position 5. In addition, the first 26 
amino acids of the Glycophorin B protein on the red cell surface are 
identical to those of the N antigen on Glycophorin A (Daniels, 2013). This 
gives rise to an antigen denoted “N” to distinguish it from the N antigen on 
Glycophorin A, this antigen is present on almost all human red cells, 
irrespective of their MN status.. Rarely, individuals may lack the GPA, 
and cannot express M and N antigens, this is known as the En(a-) 
phenotype.  
 
The S and s antigens are located on Glycophorin B (GPB); the S antigen 
has methionine at position 29, whereas the s antigen has threonine.  
Individuals deficient in GPB do not express the S, s or the high frequency 
U antigens. The S-s- phenotype is very rare in Europeans but is noted 
with a higher frequency in African populations. 
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Mur is a low incidence antigen, part of the, now obsolete, Miltenberger 
series, which arises as a result of a replacement of a small section of 
GYPB with a 55 base pair section of GYPB. This gives rise to a hybrid 
glycophorin GP (B-A-B) expressing the Mur antigen. Although the Mur 
phenotype is rare in white populations, it is relatively common in Asia and 
is important in terms of clinical significance (see section 1.4.1), hence 
testing for the antigen is a useful addition to genotyping assays. 
 
GPA and GPB cross the cell membrane once, and probably exist in their 
monomeric and dimeric forms. GPA is closely associated with band 3 and 
is part of the band 3/Rh macrocomplex. Glycophorins have a long, 
glycosylated extracellular domain, which carries a negative charge. It is 
thought that the function of the glycophorins may involve prevention of 
aggregation of red cells, protection against mechanical damage and 
microbial attack. It is known that individuals with the En(a-) phenotype 
and those with S-s- have red cells that are less susceptible to malarial 
invasion.  
 
1.3.2.5 Duffy system 
 
The Duffy blood group system consists of five antigens encoded by a 
single gene (DARC) located on chromosome 1 ((ISBT 008) blood group 
alleles v4.1 160816). The system includes the antithetical antigens Fya 
and Fyb, which are polymorphic in both black and white populations, and 
the high frequency antigens Fy3, Fy5 and Fy6. The Fy(a-b-) phenotype is 
common in the African population as it confers resistance to the malarial 
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parasite, Plasmodium vivax. This phenotype is caused by homozygosity 
for a mutation within an erythroid-specific, GATA-1 transcription-factor 
binding site upstream of the coding region of the Duffy gene. The Duffy 
antigens are located on a glycoprotein which acts as a chemokine 
receptor (Pruenster and Rot, 2006) (see figure 1.4), hence it is often 
referred to as the Duffy antigen receptor for chemokines (DARC). DARC 
is N-glycoslyated and appears to be a member of the band 3, Rh, Kell/Xk 
macrocomplex. The GATA mutation prevents the expression of the Duffy 
glycoprotein on the red cells. The Fya/Fyb polymorphism is a result of an 
amino acid change from glycine to aspartic acid at position 42. Fy3 and 
Fy6 are high frequency antigens expressed on red cells of all Duffy 
phenotypes and Fy5 is similar to Fy3, with the exception that it is not 
expressed on Fy(a-b-) and Rhnull cells. The Fy
x phenotype, which is 
encoded by the FY*X allele results in an amino acid substitution in the 
intracellular domain of the glycoprotein. This phenotype, which is 
relatively common in white populations, behaves as a weak expression of 
the Fyb antigen. It is also associated with reduced expression of Fy3, Fy5 
and Fy6, suggesting that it is a product of reduced levels of DARC in the 
membrane. 
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Figure 1.4 The Duffy glycoprotein 
              
          
 
A diagrammatic illustration of the Duffy glycoprotein showing how the 
structure spans the red cell membrane seven times, the cylindrical 
shapes represent the area of the glycoprotein that passes through the cell 
membrane.  The Fya/Fyb polymorphism is located at position 42 near the 
N terminal. Fyx is expressed in the intracellular component at position 89 
and is thought to be associated with reduced levels of DARC. The 
approximate positions of the Fy3 and Fy6 antigens are shown on the 
diagram. 
Adapted from Genome Research 
(http://genome.cshlp.org/content/17/5/577/F3.expansion). 
C-terminal domain 
N-terminal domain 
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1.3.2.6 Kidd system 
 
 
The Kidd blood group system comprises of three antigens encoded by 
the SLC14A1 gene on chromosome 18 ((ISBT 009) blood group alleles 
v4.0 160705). The antigens include the antithetical pair, Jka and Jkb and 
the high incidence antigen Jk3. The Kidd antigens are carried on a 
glycoprotein that spans the red cell membrane 10 times (figure 1.5). The 
antithetical antigens, Jka and Jkb, are differentiated by a single amino acid 
change on the fourth extracellular loop of the glycoprotein (aspartic acid 
to asparagine at position 280). 
 
The null phenotype, Jk(a-b-), is rare in most populations, with the 
exception of the Polynesians. It is caused by homozygosity, or compound 
heterozygosity for a variety of inactivating mutations in the SLC14A1 
gene. Another rare cause of the Jk null phenotype, seen in a Japanese 
family was considered to be the result of a dominant inhibitor gene that is 
not inherited at the JK locus. 
 
The Kidd glycoprotein is known to be a urea transporter (Sidoux-Walter et 
al., 1999). It is very similar to another urea transporter, UT-A (Olives et 
al., 1996), and it is thought that compensating activity by this urea 
transporter is one of the reasons why the Kidd null phenotype is not 
associated with any clinical problems. 
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Figure 1.5 The Kidd glycoprotein 
 
Diagrammatic representation of the Kidd glycoprotein which spans the 
red cell membrane 10 times. The Jka and Jkb antigen site is located at 
position 280 (demonstrated by the filled circle on the diagram); the 
difference between the two antigens is the result of a single amino acid 
change (aspartic acid and asparagine). The Jk3 phenotype is expressed 
when either Jka and/or Jkb are present. 
(Adapted from: https://ars.els-cdn.com/content/image/1-s2.0-
S0065242316300518-f06-04-9780128046869.jpg) 
 
1.3.2.7 Diego system 
 
The Diego system comprises of 22 antigens encoded by a single gene 
(SLC4A1) located on chromosome 17 ((ISBT 010) blood group alleles 
v3.0 160630). The system includes three pairs of antithetical antigens 
(Dia and Dib, Wra and Wrb, Wu and DISK) and 16 low frequency antigens. 
Jk
a
/Jk
b
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The Diego antigens are expressed on the red cell membrane glycoprotein 
band 3, Dia and Dib, and Wra and Wrb are the result of single amino acid 
substitutions, leucine/proline and glutamic acid/lysine, at their respective 
positions 854 and 658. The Wu/DISK polymorphism is a result of a single 
amino acid substitution, alanine/glycine, at position 565 (see figure 1.6). 
The remaining low frequency antigens in the Diego system are also the 
result of a single amino acid substitutions. 
 
Band 3 is an intrinsic membrane glycoprotein acting as a structural 
protein and also an anion exchanger (Tanner, 1993). Band 3 plays a vital 
role in the red cell membrane which is why the Diego null phenotype 
(band 3 deficiency) has not been reported. 
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Figure 1.6 Diego antigens located on band 3 glycoprotein 
 
 
 
 
 
Diagrammatic representation of the band 3 glycoprotein with associated 
Diego antigens, including the antithetical antigens Wra/Wrb, Dia/Dib and 
Wu/DISK antigens at positions 658, 854 and 565 respectively, expressed 
as a result of single amino acid substitutions. The approximate positions 
of some of the other low frequency antigens in the system are also shown 
on the diagram. 
(Adapted from: 
http://www.bloodjournal.org/content/bloodjournal/92/12/4836/F2.large.
jpg?sso-checked=true ) 
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1.3.2.8 Dombrock system 
 
The Dombrock system includes 7 antigens ((ISBT 014) blood group 
alleles v4.0 160623) encoded by a single gene (ART4) located on 
chromosome 12. The system includes the antithetical antigens Doa and 
Dob, and the high frequency antigens Gya, Hy, Joa, DOYA, DOMR and 
DOLG. Doa and Dob are expressed as a result of a single amino acid 
substitution (asparagine to aspartic acid) at position 265. Expression of 
the remaining high frequency antigens are also the result of single amino 
acid substitutions, with the exception of Gya. The Gya negative phenotype 
can result from a variety of different mutations in the gene, and includes 
the Donull phenotype in which the red cell lacks all of the Dombrock 
antigens.  
 
The Dombrock antigens are located on the ART4 glycoprotein, which is 
attached to the red cell membrane through glycosylphosphatidylinositol 
(see figure 1.7). The exact function of the ART4 glycoprotein is not 
known, although it does belong to a family of adenosine diphosphate 
(ADP)-ribosyltransferases responsible for catalysing the transfer of ADP-
ribose from nicotinamide adenine to a protein substrate. 
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Figure 1.7 Dombrock antigens on the ART4 glycoprotein 
 
 
Diagrammatic representation of the structure (shown here as a line) that 
expresses the antigens of the Dombrock system. The Doa/Dob 
polymorphism arises as a result of a single amino acid substitution at 
position 265 (asparagine to aspartic acid). The ART4 glycoprotein is 
attached to the red cell membrane via the GPI anchor which is inserted 
into the red cell membrane.  
(Adapted from: https://clinicalgate.com/human-blood-group-antigens-and-
antibodies/) 
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1.3.2.9 Colton system 
 
The Colton blood group system includes four antigens encoded by the 
AQP1 gene located on chromosome 7 ((ISBT 015) blood group alleles 
v3.0 160623). The system includes the antithetical antigens Coa and Cob, 
and two high frequency antigens Co3 and Co4. The Colton polymorphism 
is represented by a single amino acid change at position 45; alanine 
gives rise to Coa and valine to Cob. The Co3 antigen is present on all cells 
with the exception of the Conull phenotype Co(a-b-). The Co4 antigen is 
represented by glutamine at position 47. 
 
The glycoprotein structure that carries the Colton antigens acts as a 
water channel (King et al., 2004 (a)). The structure spans the red cell 
membrane six times (see figure 1.8), and includes three extracellular 
loops and two cytoplasmic loops. One extracellular loop and one 
cytoplasmic loop pass into the membrane to create the channel which 
allows water molecules to pass. 
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Figure 1.8 The Colton glycoprotein structure 
 
                                                       
Model of the glycoprotein structure that carries with Colton antigens, 
which spans the red cell membrane six times, as represented by the 
cylindrical structures in the diagram. The extracellular and cytoplasmic 
loops that create the water channel are represented by B and E. The two 
antithetical antigens Coa and Cob, which result from a single amino acid 
change, are expressed at position 45, the approximate position of the 
antigens on the glycoprotein are demonstrated in the diagram. 
(Adapted from: 
https://www.sciencedirect.com/science/article/pii/S1246782001001422) 
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1.3.2.10 Yt system 
 
The Yt system consists of two antigens, Yta and Ytb, encoded by the 
ACHE gene located on chromosome 7 ((ISBT 011) blood group alleles 
v5.0 180207). The antigens Yta and Ytb are antithetical, and are 
represented by a single amino acid change at position 353 (histidine to 
asparagine). A third antigen, YTEG, a high frequency antigen, was 
reported in 2017 (Laundy et al., 2017). An inherited Ytnull phenotype, Yt(a-
b-) has not been reported. 
 
The Yt antigens are located on acetylcholinesterase (AChE), a GPI linked 
glycoprotein, similar to the Dombrock antigens (see figure 1.7). The exact 
nature of the red cell AChE is not known, but AChE is known to play an 
essential role in neurotransmission. This essential role may explain why 
the null phenotype is not seen. 
 
1.3.2.11 Lutheran system 
 
The Lutheran system has 22 antigens ((ISBT 005) blood group alleles 
v4.1 170106) and is encoded by the LU gene on chromosome 19. The 
system includes four pairs of antithetical antigens: Lua and Lub, Lu6 and 
Lu9, Lu8 and Lu14 and Aua and Aub. These antithetical antigens are all 
the products of single amino acid changes; Lua/Lub (histidine to arginine 
at position 77), Lu6/Lu9 (phenylalanine to serine at position 275), 
Lu8/Lu14 (lysine to methionine at position 204) and Aua/Aub (alanine to 
threonine at position 539). The null phenotype, Lu(a-b-) exists as a result 
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of homozygosity for an inactivated Lutheran gene. Red cells of individuals 
with the null phenotype lack all Lutheran antigens. 
 
 
Lutheran antigens are located on glycoprotein structures which are 
members of the immunoglobulin superfamily, a large family of receptors 
and adhesion molecules (Isacke and Horton, 2000). The Lutheran 
antigens are associated with two glycoproteins, which act as ligands for 
laminin, an extracellular matrix glycoprotein (see figure 1.9).  
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Figure 1.9 Structure of the Lutheran glycoprotein 
 
         
 
Diagrammatic representation of the Lutheran glycoproteins, which consist 
of five extracellular domains, with a flexible linker and laminin binding site 
between domains 2 and 3. Each domain is composed of two β-sheets 
stabilised by a disulphide bond and consists of approximately 100 amino 
acids. The position of the laminin binding site and the approximate 
locations of the four antithetical pairs of antigens (which result from single 
amino acid substitutions) on the immunoglobulin superfamily domains are 
shown on the diagram.  
(Adapted from: http://www.bloodjournal.org/content/89/11/4219) 
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1.4 Antibodies to red cell antigens and their clinical relevance 
 
1.4.1 Clinical relevance of red cell antibodies 
 
One of the effects of the transfusion of allogeneic blood in any group of 
patients and in particular with chronic blood transfusion, is the 
development of red cell alloantibodies, produced in response to antigenic 
differences between the recipient and the donor red cells. As the blood 
group antigens are extremely polymorphic it is almost inevitable that there 
will be antigenic differences between the donor (transfused) red cells and 
the recipient red cells. This can lead to the recognition of these foreign 
antigens by the recipient immune system and the production of 
alloantibodies. 
 
Alloimmunisation has the potential to cause transfusion reactions in 
individuals if they are subsequently transfused with allogeneic red cells 
bearing the corresponding antigen. Immune mediated transfusion 
reactions can be acute or delayed. Acute reactions are defined by the 
Serious Hazards of Transfusion (SHOT) group as fever and other 
symptoms/signs of haemolysis within 24 hours of transfusion, whereas 
delayed reactions may be seen more than 24 hours after transfusion 
(SHOT 2016). Transfusion reactions can result in deleterious health 
effects including haemolysis, jaundice, fever, renal failure and shock, and 
may be fatal in some cases (Beauregard and Blajchman, 1994; SHOT 
2016). Red cell antibodies most commonly implicated in transfusion 
reactions include; Anti-D, -C, -c, -E, -e, (Rh system) -K, -k, (Kell system) -
Jka, -Jkb, (Kidd system) -M, -S, -s, -U, (MNS system) -Fya, -Fyb (Duffy 
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system) and Wra (Diego system) (BCSH 2013).   Antibodies to antigens 
within the Dombrock, Colton, and Yt systems have been implicated in 
haemolytic transfusion reactions, and antibodies to Lutheran antigens 
may cause mild or delayed transfusion reaction (Daniels, 2013). 
 
Alloimmunisation also has the potential to cause haemolytic disease of 
the fetus and newborn (HDFN), if there is an antigenic difference between 
the maternal red cells and the fetal red cells. Maternal red cell antibodies, 
which may have developed as a result of transfusion or via transfer of 
fetal cells to the maternal circulation, may cross the placenta and cause 
destruction of the fetal red cells. Certain antibodies, notably anti-D, anti-c 
and anti-K can cause severe fetal symptoms, including anaemia, 
jaundice, hydrops and stillbirth (RCOG, 2014).  
 
Red cell alloantibodies are typically IgM or IgG in nature and are usually 
produced in response to a foreign red cell antigen stimulus. Others, such 
as the IgM antibodies directed against the well-known A and B antigens, 
are believed to be naturally occurring as there is no requirement for red 
cell antigen exposure. Instead they are probably made in response to 
bacterial antigens that are similar in structure to red cell antigens 
(Springer et al., 1959a; Springer et al., 1959b; Springer and Horton, 
1969).  Some red cell antibodies, such as the IgM type anti-A and anti-B, 
are capable of causing intravascular lysis of the red cell by their ability to 
activate the complement cascade through the formation of the membrane 
attack complex, and the subsequent release of anaphylatoxins leading to 
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acute systemic effects (Murphy et al., 2013). Other red cell alloantibodies, 
normally IgG type, can cause extravascular destruction of foreign red 
cells, in the spleen, by interacting with the Fcγ receptors on the cells of 
the mononuclear phagocytic system (Murphy et al., 2013). 
 
Red cell alloantibodies may be transient in nature, this is particularly well 
known for alloantibodies such as anti-Jka and anti-Jkb. Non-persistent 
antibody detection has been reported in several studies (Ramsey and 
Larson, 1988; Rosse et al., 1990; Reverberi, 2008). A similar 
phenomenon has also been reported for autoantibodies (Young et al., 
2004). The reasons given for this phenomenon may include; lack of 
antigenic stimulus resulting in decrease of antibody production over time, 
low levels of antibody production that are at the limit of the antibody 
detection assays and may only be detectable on some occasions, 
improvements in the sensitivity of antibody detection assays over time 
and inter-batch variation within the same assay technique.    
1.4.2 Laboratory relevance of red cell antibodies 
 
In addition to having the potential to cause haemolytic transfusion 
reactions, the presence of red cell alloantibodies in patient blood samples 
also brings laboratory related issues. They increase the workload and 
cost pressures on the hospital transfusion laboratory services by 
introducing requirements for specialised testing techniques and sourcing 
antigen matched blood for transfusion, which may cause delays in blood 
provision. Standard laboratory testing, within the hospital transfusion 
service, prior to the transfusion of red cells, includes ABO and RhD typing 
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of the patient red cells and a screening technique for the detection of any 
atypical red cell antibodies in the patient’s plasma, commonly referred to 
as a group and antibody screen. Additional testing, if atypical red cells 
antibodies are detected, includes identification of the antibody specificity, 
serological red cell phenotyping, direct agglutination test (DAT) and 
serological crossmatch of donor red cells to determine compatibility. At 
the RD&E all of these assays are performed in the hospital transfusion 
laboratory. If antibody specificity or compatibility cannot be determined 
using the techniques available in the hospital transfusion laboratory, 
referral to a reference laboratory at the NHSBT may be required. A 
simplified flow chart for pre-transfusion testing in the hospital transfusion 
laboratory is shown below: 
 
 
 
 
 
 
 
 
 
 
 
 
 
Group and 
antibody 
screen 
No atypical 
antibodies 
detected 
Atypical antibodies 
detected 
Red cells issued 
with no further 
testing 
Antibody 
identification 
DAT 
Serological 
phenotype 
Red cells issued following 
compatibility testing by 
serological crossmatch 
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1.4.2.1 Group and antibody screen 
 
Prior to any blood transfusion episode, a blood sample must be taken 
from the patient for blood grouping (ABO and RhD) and antibody 
screening. Blood grouping and antibody screening may be performed 
using manual or automated techniques. ABO and RhD typing utilises 
direct agglutination techniques with patient red cells using commercial 
anti-sera. Antibody screening is performed using indirect antiglobulin 
techniques using patient plasma against commercial antibody screening 
cells with a known antigen profile. For the purposes of detection of 
clinically significant red cell antibodies (that are known to be capable of 
causing haemolysis of transfused red cells) in patient samples presented 
for testing within the hospital transfusion setting the BCSH (2013) 
recommend that the screening cell set employed contains the following 
common antigens: 
C, c, Cw, D, E, e, K, k, Fya, Fyb, Jka, Jkb, S, s, M, N, P1, Lea and Leb. 
 
If no red cell alloantibodies are detected in the patient’s plasma there is 
no requirement for further laboratory testing. Blood for transfusion is 
selected that is ABO and RhD compatible for the patient and may be 
issued electronically, with no serological compatibility testing between the 
donor cells and recipient plasma, in accordance with BCSH guidelines 
(BCSH 2013).  
 
At the RD&E red cells are selected for transfusion dependent patients 
(excluding SCD) in accordance with the BCSH (2013) recommendations; 
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ABO/D matched. The BCSH guidance states that additional typing and 
matching for Rh and K should be a local decision. At the RD&E it has 
been recommended that red cells for these patients should be K 
negative, but this was not policy and there were no processes in place to 
ensure that this occured.  
 
To reduce the risk of the development of red cell antibodies known to 
cause Haemolytic Disease of the Fetus and Newborn, in some countries, 
including France, red cell transfusions for females with child-bearing 
potential may be matched for Rh (CcEe) and K antigens (French 
Transfusion guidelines cited in Moncharmont et al., 2015). In the UK it is 
recommended that K negative red cell units are selected for this group of 
patients, but without the requirement for K typing the patient (BCSH 
2013). At the RD&E it is recommended that red cell units are selected 
that are also negative for Rh c and E antigens wherever possible. 
However, phenotyping has not been advocated in our institution as 
transfusion is uncommon in this group of patients and suitable red cells 
can easily be sourced from routine stocks.  
 
1.4.2.2 Antibody Identification 
 
If red cell alloantibodies are detected in the antibody screening technique 
further laboratory assays are required in order to ascertain the specificity 
of the alloantibody. Antibody identification techniques employ the same 
principles as the antibody screening techniques but using commercial 
cells with an extended range of known antigen profiles. Whereas a 
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screening cell set is commonly composed of two or three red cell 
reagents, an antibody identification set may contain more than 10, the 
extended range enabling determination of the antibody specificity, rather 
than just the presence of a red cell alloantibody. As with antibody 
screening methodology, antibody identification may be performed 
manually or on an automated system, column agglutination and solid 
phase technology being commonly employed. 
 
To avoid potential haemolytic transfusion reactions the BCSH (2013) 
recommend that, for patients whose plasma has been shown to contain 
clinically significant antibodies as identified in antibody screening and 
identification techniques, either antigen negative blood, or unselected but 
crossmatch compatible (by IAT) blood should be selected for transfusion. 
As a general rule if the patient has an antibody that has been reported to 
cause haemolytic transfusion reactions then antigen negative blood must 
be selected, whereas the presence of an antibody with no reported cases 
of transfusion reactions needs only to be crossmatch compatible (table 1-
3) (BCSH, 2013). 
 
1.4.2.3 Serological red cell phenotyping 
 
Serological phenotyping is the identification of red cell antigens present 
on the patient red cells, other than ABO/D, using commercially available 
antisera. Currently available methods for serological phenotyping include 
direct and indirect agglutination either by tube techniques (see section 
1.6.1), or column agglutination techniques based on the principles of 
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Lapierre (1990) (section 1.6.2). Additionally, solid phase tests, based on 
the principles of Plapp (1984) and Juji (1972) (section 1.6.3), in which red 
blood cells are bound to a solid support such as a microtitre plate well, 
can be used for the identification of red cell antigens.   Serological red cell 
phenotyping is explained in more detail in section 1.5. 
 
1.4.2.4 Direct Antiglobulin Test 
 
Direct Antiglobulin Testing (DAT) may also be required; this test detects 
the presence of antibodies or complement fractions on the surface of the 
patient’s red cells. Methodology commonly employed in hospital 
transfusion laboratories includes column agglutination tests or solid 
phase technology, which may be performed manually or on automated 
systems.  
 
1.4.2.5 Serological crossmatch 
 
If atypical red cell antibodies are present, compatibility testing, known as 
crossmatching, of each unit of blood must be performed. Testing must be 
performed by IAT, either column agglutination or solid phase may be 
used to ensure compatibility of the selected red cell units for transfusion 
(BCSH, 2013). The technique may be performed manually or by 
automated technology. 
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Table 1.3: Likely clinical significance of red cell alloantibodies  
Likely clinical significance of red cell antibodies reported in this study and 
recommendations for the selection of blood for patients with their 
presence. Taken from the BCSH guidelines for pre-transfusion 
compatibility procedures in blood transfusion laboratories (BCSH 2013) 
and Daniels (2013).  
System Antibody Likely clinical 
significance in 
transfusion 
Recommendation 
ABO Anti-A1 No IAT crossmatch 
compatible 
H Anti-H (in A1 and A1B 
patients) 
No IAT crossmatch 
compatible 
Rh 
 
Anti-D,-C,-c,-E,-e,-f Yes Antigen negative 
Rh Cw No IAT crossmatch 
compatible  
Kell 
 
Anti-K,-k, Yes Antigen negative 
Kell Anti-Kpa No IAT crossmatch 
compatible  
Kidd 
 
Anti-Jka,-Jkb Yes Antigen negative 
MNS 
 
Anti-M (active at 37oC) Yes Antigen negative 
MNS Anti-M (not active at 
37oC) 
No IAT crossmatch 
compatible 
MNS Anti-N, -Mur, -Hut No IAT crossmatch 
compatible 
MNS Anti-S,-s,-U 
 
Yes Antigen negative 
Duffy Anti-Fya,-Fyb 
 
Yes Antigen negative 
P Anti-P1 No IAT crossmatch 
compatible 
Lewis Anti-Lea,-Leb,-Le-a+b No IAT crossmatch 
compatible 
Lutheran Anti-Lua No IAT crossmatch 
compatible 
Diego Anti-Wra Yes IAT Crossmatch 
compatible 
Yt Anti- Yta, -Ytb Possible IAT crossmatch, least 
incompatible for anti-
Yta 
Chido/Rodge
rs 
Anti-Chido-Rodgers No IAT Crossmatch 
compatible 
Knops Anti-Knops McCoy No IAT Crossmatch 
compatible 
Others Autoantibodies No ABO/D Rh (CcEe) 
and K matched 
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1.5 Serological red cell phenotyping 
 
Positive identification of a red cell alloantibody in a patient’s plasma also 
includes testing the patient’s red cell antigen type. This is performed by 
serological phenotyping using a combination of monoclonal and 
polyclonal reagent antisera, utilising direct or indirect agglutination 
techniques. Identification of alloantibody specificity can be supported if 
the patient’s red cells are negative for the corresponding antigen (BCSH, 
2013). Methods for serological phenotyping within the hospital transfusion 
setting include direct agglutination in tube technology, column 
agglutination and microtitre plates and indirect agglutination using column 
agglutination and solid phase methods. However, unlike blood grouping, 
antibody screening and antibody identification, serological phenotyping 
methods are currently, generally performed manually, and may employ a 
combination of the available techniques. Automation of these techniques 
has been limited by the availability of appropriate reagents and testing 
profiles that could be used on the high throughput blood grouping 
analysers commonly used by hospital transfusion services in the UK. 
However, manual techniques are labour intensive and are prone to errors 
during sample preparation, testing, result interpretation and result 
reporting stages.  It is for this reason that extended phenotyping, typing 
for the presence of more than the antigen implicated by the antibody 
identification, has not been common practice, even though the 
information gained from the extended phenotype could be used to select 
blood that might protect the patient from further alloimmunisation. In 
addition, extended serological phenotyping could be used for prophylactic 
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antigen matching of blood to prevent alloimmunisation for patients with 
conditions that might require chronic transfusion in the future.  
 
1.5.1 Principles of direct agglutination in tube technology 
 
Direct agglutination is a well-recognised technique (as described by Issitt 
and Anstee, 1998) for detecting the presence of antibodies or antigens 
and is used across many applications in clinical medicine. Some 
commercially available monoclonal antisera are capable of agglutinating 
red cells in test tubes to determine the presence of specific blood group 
antigens on red cells. In these techniques, an aliquot of a suspension of 
patient red cells, with unknown antigen status, is placed in a test tube 
along with the antisera. A short incubation period allows the antisera to 
combine with the red cell antigens, if present, on the patient red cells. 
Centrifugation of the test tube then forces the red cells together, allowing 
the antisera to crosslink between red cells, causing agglutinates to form. 
In the absence of the corresponding antigens on the patient red cells, 
there will be no antigen-antibody reaction and no agglutinates will form 
following centrifugation. The presence of agglutinates is determined 
macroscopically by gently shaking the test tube after the centrifugation 
stage, and the agglutination strength may be graded as shown in figure 
1.10. This technique is performed manually and the macroscopic reading 
of the results is subjective and dependent on the experience of the 
operator. As a result of these factors the technique is labour intensive and 
prone to the known errors of manual testing (Stainsby et al., 2006) in both 
preparation and the result determination. 
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Figure 1.10: Principles and reactions of the direct agglutination 
assay tube technique for the determination of red cell antigen status 
 
 
 
In direct agglutination assays patient red cell suspension is mixed with the 
relevant anti-serum and incubated within the test tube. Centrifugation forces 
the red cells together allowing antigen-antibody complexes to form if antigen 
is present on the patient red cells; reaction patterns are graded from strongly 
positive (4+) to weakly positive (+/)-, as indicated in the figure. A negative 
reaction is seen if the patient red cells do not carry the antigen and therefore 
do not form complexes.  
(Picture courtesy of Bio-Rad, cited in Immunobase 1 – Diamed, 
http://www.bio-rad.com/en-uk/product/immunobase?ID=LO52IK5Y7).  
 
 
Reactions are 
graded from 
strongly positive 
(4+) through to 
negative (0) 
    4+           3+          2+           1+         +/-          0 
52 
 
1.5.2 Principles of the Column Agglutination Test (CAT) 
 
The column agglutination test is performed in specially designed cards 
which employ the use of either antisera within the column designed to 
capture red cells with the corresponding antigen (direct agglutination), or 
via agglutination of red cells through indirect agglutination techniques. 
The techniques may be performed manually or using automated 
methods. At the RD&E lack of automation for these tests means that they 
must be performed and read manually, thus introducing the risk of error. 
Phenotyping using monoclonal antisera, for Rh (CcEe) and K antigens 
using the Diamed technique (Bio-Rad Laboratories Inc.), is performed on 
a single card containing six separate reaction columns. Each column 
contains a specific antiserum (anti-C, anti-c, anti-E, anti-e or anti-K) within 
a gel matrix and a negative control well is included to confirm that any 
positive reactions are due to the presence of the corresponding red cell 
antigen on the patient’s cells and not false positive reactions due to auto-
agglutination.  A red cell suspension containing patient cells of unknown 
antigen status is added to the top of the column, the card is then 
centrifuged which forces the patient red cells through the gel matrix 
containing the specific antisera. If the patient red cells carry the 
corresponding antigen, antigen-antibody complexes form, trapping the 
cells in the column and demonstrating a positive result. Conversely, cells 
lacking the corresponding antigen will not form antigen-antibody 
complexes and will be forced to the bottom of the column denoting a 
negative reaction (see figure 1.11). Results can be read macroscopically 
if performed manually or this can be performed via an automated system. 
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Figure 1.11: Principles of the column agglutination assay  
                                  
 
 
 
A diagrammatic representation of the principle of the column agglutination 
technique for the determination of red cell antigen status. The patient cell 
suspension is added to the column and centrifugation forces the red cells 
through the gel matrix containing the anti-serum. Red cells positive for the 
antigen form antigen-antibody complexes and are trapped in the gel matrix. 
Cells that do not express the antigen travel to the bottom of the column during 
centrifugation. See section 1.5.4 for information on grading of results. 
 (Picture courtesy of Bio-Rad, cited in Immunobase 1 – Diamed, 
http://www.bio-rad.com/en-uk/product/immunobase?ID=LO52IK5Y7).  
  
Patient cell suspension 
is added to the column 
Anti-serum is contained in 
the gel matrix 
Red cells carrying the 
antigen are trapped in the 
gel matrix  
Red cells lacking the 
antigen travel to the 
bottom of the column 
Reaction strengths are graded 
from negative (-) to strongly 
positive (++++) 
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Phenotyping techniques using column agglutination may also be 
performed via indirect agglutination. Generally this is required when using 
polyclonal antisera, which are incapable of forming antigen-antibody 
complexes that can bridge between red cells forming agglutinates 
directly. In these techniques, the use of antihuman globulin (antibodies to 
human antibodies, usually of goat or murine extraction) is employed to 
link red cells coated with the specific antiserum. An aliquot of a 
suspension of patient red cells of unknown antigen status is incubated 
with the specific antiserum in an incubation chamber at the top of the 
column. An incubation period performed at 37oC, simulating an in vivo 
situation, allows antigen-antibody complexes to form if the corresponding 
antigen is present on the patient red cells. A centrifugation stage then 
forces the red cells through the gel matrix containing antihuman globulin 
(AHG), if antigen-antibody complexes are present on the patient red cells 
they are trapped by the AHG within the column. In the absence of 
antigen-antibody complexes the red cells will travel to the bottom of the 
column, denoting a negative result (see figure 1.12). The results can be 
read macroscopically or via automated technology.  
 
 
 
 
 
  
55 
 
Figure 1.12: Reaction patterns of the column agglutination assay  
 
A diagrammatic representation of the results seen with IAT column 
agglutination technique for the determination of red cell antigen status 
Patient red cells are incubated with the commercial anti-sera to allow 
antigen-antibody complexes to form in the incubation well. Centrifugation 
then forces the red cell/antiserum mix through the gel matrix containing 
Anti-Human Globulin (AHG). If the patient red cells do not carry the 
antigen being tested then the unsensitised red cells will fall to bottom of 
the column. Positive reactions are denoted by patient red cells trapped in 
the gel. Positive reactions are graded from strongly positive (4+) through 
to weakly positive (+/-).  
(Picture courtesy of Bio-Rad, cited in Immunobase 1 – Diamed, 
http://www.bio-rad.com/en-uk/product/immunobase?ID=LO52IK5Y7).  
Patient plasma is incubated 
with the reagent red cells to 
allow antigen-antibody 
complexes to form 
Anti-Human Globulin is 
contained in the gel matrix 
Positive reactions are seen if the 
patient’s plasma contains red cell 
antibodies 
Reactions are given a numerical 
grading to denote the variations in 
strength of positive reactions 
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1.5.3 Principles of automated phenotyping methodology on the 
Immucor NEO® analyser 
 
Development of high throughput automated methods for extended red 
cell phenotyping would not only introduce a technique for reducing 
manual testing (with its inherent risks) for patients who had developed a 
red cell alloantibody, but also facilitate extended phenotyping for patients 
prior to transfusion. This has the potential to allow for more specific 
matching of red cell antigens on the donor blood for patients likely to 
require chronic transfusion support, thus potentially reducing the risk of 
alloimmunisation. Column agglutination technology may be automated, 
currently available platforms that could support this type of automated 
phenotyping include; the Bio-Rad IH500 and IH1000 (Bio-Rad 
Laboratories Ltd., Watford, UK), the Grifols Erytra and Erytra Eflexis 
(Grifols UK Ltd., Cambridge, UK) and the Ortho AutoVue® Innova System 
(Ortho Clinical Diagnostics, Buckinghamshire, UK).  
        
The Immucor NEO Iris and ECHO Lumena automated analysers (IBG 
Immucor Ltd., West Midlands, UK) offer serological phenotyping using 
direct agglutination techniques in microtitre plates and solid phase 
methodology. The Immucor NEO analyser is currently utilised in the 
RD&E transfusion laboratory for routine ABO/D typing, antibody 
screening and antibody identification, but has not been developed for 
automated serological phenotyping. This study details the development 
and validation of a novel, high throughput method for extended 
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serological red cell phenotyping using the Immucor NEO® analyser 
system.  
 
The automated technique using the Immucor NEO® analysers employs 
two distinct methods for the determination of the presence of red cell 
antigens; direct agglutination and solid phase technology. In the direct 
agglutination test the patient red cells are mixed with the specific 
antiserum in a well of the microtitre plate, an incubation phase allows the 
red cells to settle together permitting cross-linking of the IgM molecules in 
the antiserum with the corresponding antigen on the red cells. This effect 
is increased during a centrifugation phase enabling a quicker reaction to 
occur.  Direct agglutination of red cells with a particular reagent indicates 
the presence of the corresponding antigen. The microtitre plate is then 
gently shaken by the analyser, during this process red cells that have not 
been agglutinated by the antiserum will break apart and form a loose 
layer of cells in suspension, and cells that have agglutinated may stay 
together forming a clump, reactions similar to those seen in direct 
agglutination in tubes. The analyser captures images of these reactions 
and the differing patterns are then converted into reactions grades (which 
vary from negative (no agglutinates), through to strongly positive 
(indicated by a tight button of cells at the bottom of the well) using in-built 
computerised algorithms. 
 
Solid phase (Capture-R) assays are based on the procedure of Plapp 
(Plapp et al., 1984) and Juji (Juji et al., 1972) and are used in conjunction 
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with polyclonal antisera that are not capable of direct agglutination. The 
individual wells of the microwell strips are coated with an affinity isolated 
goat anti-murine antibody and a murine anti-RBC antibody; these are 
used to support the formation of a red cell monolayer, created from the 
patient sample by the automated analyser, to the microwell surface. 
Reagent antiserum is then dispensed into the well, followed by low ionic 
strength saline (LISS) and an incubation phase. Lowering the ionic 
strength acts to increase the rate of formation of antigen-antibody 
complexes, and can reduce the incubation time needed for the 
complexes to form (cited in Rolih et al., 1985). During the incubation 
period the antigens carried on the immobilised patient red cells are bound 
to the specific IgG antibodies in the antiserum. Following incubation, 
residual unbound immunoglobulins are removed from the wells by an 
automated washing step and anti-human IgG coated Capture-R Ready 
indicator red cells are added. A centrifugation step allows the indicator 
red cells to come into contact with any antibodies bound onto the surface 
of the patient’s immobilised red cells. If the patient’s cells are positive for 
the antigen being identified then IgG-anti-IgG complexes will form 
between the indicator cells and the sensitised patient red cells. The 
indicator cells will then adhere to the surface of the immobilised patient 
red cells forming a second layer of cells. If the patient cells are negative 
for the antigen being determined then the indicator cells will not bind to 
the immobilised cells and, during the centrifugation phase, will form a 
pellet at the bottom of the well (see figure 1.13). The analyser image 
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capture system converts the reactions seen in the wells into reaction 
grades denoting the presence or absence of the specific red cell antigen. 
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Figure 1.13: Principles of the solid phase phenotyping assay  
 
 
 
 
 
 
 
 
 
Diagrammatic view of the solid phase technology utilised by the IBG NEO® 
analyser system Red cells are bound to the microwell surface by the analyser, a 
potentiator LISS (low ionic strength saline) is added which increases the rate of 
formation of antigen-antibody complexes. Antibodies to red cell antigens are 
“captured” on the microwell during incubation, unbound immunoglobulins are 
then rinsed from the wells in a wash phase. Capture R anti-IgG Indicator red 
cells are added, which “sandwich” the “captured” antibodies, making them 
visible. A centrifugation phase then brings the indicator red cells in contact with 
antibodies bound to the reagent red cell membranes. (Diagram courtesy of 
Caryn Conway, Immucor, personal communication).  
  
Specific red cell antigen antisera is 
added to the red cell monolayer 
LISS acts as a potentiator  
Indicator cells coated with anti-IgG will 
bind to any anti-sera captured on the 
red cell monolayer 
Unbound Indicator cells will be 
forced into a button by the 
centrifugation stage, interpreted as 
a negative reaction by the analyser 
software 
Bound indicator cells remain on 
the red cell monolayer and are 
interpreted as a positive reaction 
Test red cells are fixed to the 
microtitre well 
The reagent antiserum binds to the 
antigens on the test cells if the 
antigen is present (denoted by a ^) 
Indicator red cells 
WASH 
CENTRIFUGE 
SIDE VIEW 
TOP VIEW 
STRONG POSITIVE WEAK POSITIVE NEGATIVE 
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1.5.4 Grading reactions in phenotyping techniques 
 
The reaction strengths in the different methods for serological red cell 
antigen phenotyping can be graded from negative (-) through to strongly 
positive (4+); a comparison of the grading reactions seen in Capture-R 
Select, tube agglutination and gel column agglutination techniques is 
shown in figure 1.14. The grading of the reaction strength is important as 
weak, or mixed field, reactions may be indicative of the presence of 
transfused red cells, or, in the case of polyclonal antisera, the presence of 
a positive DAT (BCSH, 2013). In either case the true phenotype of the 
patient cannot be determined until the cause of the weak or mixed field 
reaction has been investigated. Grading of reaction strengths for tests 
performed manually is subjective and dependent on the experience of the 
individual performing the test, thus some operators may misclassify a 
weak, false positive, reaction as a positive reaction and report an 
incorrect result without further investigation (SHOT, 2014). Automation of 
phenotyping methods, as for the column agglutination and solid phase 
assays, removes this subjectivity and allows a more standardised 
approach to grading, thus reducing the risk of misreading a false positive 
result due to the presence of transfused cells or a positive DAT (Stainsby 
et al., 2006). 
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Figure 1.14: Comparison of reaction patterns in phenotyping assays  
 
 
A comparison of grading reaction between Capture R Select (IBG NEO 
analyser), haemagglutination performed in a tube (direct agglutination) 
and column agglutination (Gel/CAT). Grading ranges from 0 (negative), 
no reactions between the red cells and the plasma, through 1+ (weakly 
positive reactions) to 4+ (strongly positive reaction) Note: weak (+/-) 
reactions shown in previous figures are not demonstrated.  
(Picture courtesy of Caryn Conway, Immucor – personal 
correspondence). 
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1.6 Red cell antigen genotyping 
 
Serological red cell phenotyping in patients with a recent history of blood 
transfusion is complicated by the presence of donor red cells within the 
circulation. In these situations it is not possible to determine whether 
positive reactions seen in serological phenotyping tests are due to the 
presence of red cell antigens on the patient (recipient) cells, or on those 
of the transfused donor cells. In these circumstances the red cell 
phenotype may be predicted by genotyping the patient’s DNA. Genetic 
testing of patient DNA to determine the red cell antigen genotype, and 
thus predict the phenotype, is possible post transfusion, because DNA is 
extracted from the patient’s white blood cells, which are uncontaminated 
by transfused blood containing only red cells. However, this is an 
expensive, labour intensive, specialised test that, currently, does not lend 
itself to the hospital setting; the DNA based approaches that are available 
include the BLOODChip (Progenika Biopharma SA) (Avent et al., 2007), 
sequence-specific primer-polymerase chain reaction (SSP-PCR) (Renoud 
et al., 2006), BeadChip (Hashmi et al., 2005; Hashmi et al., 2007), PCR-
restriction fragment length polymorphism GenomeLab SNPstream 
(Denomme and Van Oene, 2005; Montpetit et al., 2006) and the matrix-
assisted laser desorption/ionisation time-of-flight mass spectrometry 
(MALDI-TOF MS) (Gassner et al., 2013).  The availability of some of 
these techniques on high throughput platforms, such as the BLOODChip 
(using the Luminex xMAP analyser) and the MALDI-TOF MS, are making 
these options more attractive to the hospital transfusion service.  
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As discussed in section 1.3, the molecular basis of most blood group 
antigens is now known. The majority of blood group polymorphisms are 
caused by single nucleotide polymorphisms (SNPs) in the genes that 
dictate the blood group antigen; this may be the protein itself where the 
gene codes for the blood protein antigen, or where gene codes for a 
glycosyltransferase which then catalyses the addition of 
monosaccharide(s) to the blood group oligosaccharide (Avent, 2009). 
Commercial blood group genotyping techniques use polymerase chain 
reaction (PCR) to amplify DNA obtained from a whole blood sample, 
using target specific primers. The amplified products can then be 
identified using probes corresponding to allelic pairs of blood group 
SNPs. Scanning systems are employed to detect the allele specific 
probes and specially designed software systems can interpret these 
results into genotypes and predicted phenotypes.  
 
High throughput, automated genotyping techniques have been available 
now for more than a decade but have yet to be adopted into routine use 
in the UK, either in the NHSBT for donor typing, or in the hospital 
transfusion service for patient typing. One of the reasons for this slow 
uptake is the cost of genotyping; new equipment would be required as the 
assays could not be added to the current equipment performing 
serological testing. In addition, manual steps in the PCR processing 
phase remain a limiting factor in the implementation of the technique into 
a busy hospital transfusion laboratory setting. A common criticism of 
genotyping is that the genotype does not always reflect the phenotype 
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(Avent, 2009). This may be due to the null phenotypes seen in some 
blood group systems, such as, Rh, ABO, Jk and Fy, or due to a new, 
previously unknown allele. The length of time for genotype testing is also 
considered restrictive, particularly within the hospital transfusion service 
where provision of matched blood may be required urgently. The 
BLOODChip IDCOREXT assay has been demonstrated to have a 
processing time of less than 4 hours, which is shorter than that for other 
systems including PCR-SSP and BeadChip (Finning et al., 2016). 
Wagner and co-workers (Wagner et al.; 2017) have attempted to address 
this by devising a novel method using PCR amplification without the need 
for DNA extraction. This group have reported that, using the new method 
results can be available within 40 minutes of receipt of the blood sample, 
which may make the technique applicable to the hospital transfusion 
setting. 
 
This study aimed to compare the results from blood group genotyping 
using one of the currently commercially available genotyping assays, 
BLOODChip, with those found by traditional serological methods for a 
variety of blood group antigens. Additionally, the study aimed to assess 
the feasibility of implementing such a DNA based approach in the routine 
hospital laboratory, including a cost comparison of the two different 
approaches to red cell antigen typing and their advantages and 
disadvantages. 
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1.6.1 Principles of the BLOODChip blood group genotyping assay 
 
The BLOODChip IDCOREXT (Progenika Biopharma, Derio, Spain) uses 
a microarray system for the determination of polymorphisms within the 
Rh, Kell, Kidd, Duffy, MNS, Diego, Dombrock, Colton, Yt (previously 
Cartwright) and Lutheran blood group systems (see section 5.1). 
Extracted DNA is amplified using a PCR mix containing HotStarTaq 
polymerase, primers, biotinylated nucleotides and a buffer solution. The 
amplification products are then hybridised to allele specific 
oligonucleotide probes attached to microspheres, and then labelled with 
fluorescence-conjugated streptavidin-phycoerythrin (SAPE) (figure 1.15).  
The microspheres contain two distinct dyes, red and infrared, which emit 
light in different regions of the spectrum. The combination of dyes in 
different concentrations results in 100 unique fluorescent colour tones, 
each correlating to a different spectral address defining a bead class 
(Goldman et al., 2015). Quantification of the amounts of labelled PCR 
products hybridised to the beads is then performed using the Luminex 
xMAP analyser system (Luminex Corporation, Austin, Texas, USA).  
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Figure 1.15: The principles of the IDCOREXT Assay 
Diagrammatic representation of the amplification, hybridisation and labelling phases in the IDCOREXT assay, 
Step 1:  The amplification phase separates the DNA strands allowing the target specific primers to bind to the DNA. The addition of the HotStarTaq 
polymerase allows new DNA strands to be produced. The cycle is repeated 40 times to produce sufficient DNA for analysis (picture courtesy of Dr Ruth 
Morse, University of the West of England, personal communication).  
 
A: Double stranded DNA extracted from patient sample 
 
B: The DNA strands are denatured at 96
o
C to create single 
stranded DNA 
 
 
C: The primers contained in the IDCOREXT assay kit then 
bind to the DNA strand when the temperature is lowered to 
50
o
C 
D: The HotStarTaq polymerase is then added 
 
68 
 
 
  
 
 
E: The HotStarTaq polymerase then synthesises 
nucleotides from the end of the primer to create a new 
stand of DNA 
 
 
F: The temperature is then raised again to denature the 
DNA.  
The entire process (A-F) is repeated 40 times to amplify the 
the target DNA 
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Step 2: The amplified DNA is then hybridised with allele specific probes attached to beads in suspension (picture courtesy of Louise Redfern, Grifols, 
personal communication).  
 
 
 
 
 
 
Step 3: A fluorescent marker (SAPE) is then added to the bead suspension. This marker will then attach to the DNA if present on the allele specific probe 
forming a dye-DNA conjugate. Excitation of the dye-DNA conjugate by the Luminex analyser then allows the bead specific emission to be quantified by the 
Luminex xMAP analyser. (Picture courtesy of Louise Redfern, Grifols, personal communication). 
 
 
  
 
 
Bead with allele specific probe attached 
Probe specific for blood group gene of interest 
 
 
 
Streptavidin R-Phycoerythrin Conjugate (SAPE) 
attached 
Biotinylated PCR product 
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Step 4: The sample is analysed on the Luminex xMAP analyser system. The allele specific probes are attached to beads of different combinations of red and 
infrared dyes which allow the Luminex xMAP analyser to distinguish one bead set from another and hence identify the presence of specific alleles (picture 
courtesy of Luminex (figure courtesy of Lawrence Rentoul, Merck Millipore, personal communication)). 
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1.6.2 Principles of the Luminex xMAP analyser 
 
 
The Luminex xMAP analyser system uses a multiplexing system to detect 
multiple nucleic acid sequences in a single reaction. In a process similar 
to that of a flow cytometer, the analyser directs the beads into a cuvette 
and past red and green lasers. The beads are sorted into their different 
classes, in accordance with the dye concentration, by the red laser, 
allowing the analyser to distinguish one bead class from another. The 
green laser excites the SAPE allowing the analyser to identify the 
presence of a specific allele hybridised to an allele specific probe. 
Fluorescence and side scatter are measured and the information is 
reported as median fluorescent intensity (MFI) (see figure 1.16). The 
BLOODChip analysis software extracts this information from the analyser 
and converts this into a report containing the genotypes and predicted 
phenotypes. The system can test up to 48 samples in a single batch. The 
manufacturer recommends that a negative and positive control is 
included with each batch. 
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Figure 1.16 Principles of the Luminex xMAP analyser 
The Luminex xMAP® technology uses fluidics, optics, and digital signal 
processing combined with the BLOODChip IDCOREXT proprietary 
microsphere technology to deliver multiplexed assay capabilities. The 
sample is moved through the instrument and reaches the cuvette. As the 
beads enter the cuvette, the sheath fluid moves at 90ul/sec and forms a 
core around the beads which move at 1ul/sec.  This is known as 
hydrodynamic focusing. The red laser excites the red and infrared dyes of 
each of the beads, the analyser collects this information to determine 
where the bead falls on the bead map, and side scatter is also measured 
to determine if the bead is 5.6μm. A Double Discriminator is gated to rid 
the data of any outliers such as small particulates and doublet beads. The 
green laser excites the reporter dye, SAPE, and the information is 
interpreted to determine the analyte being tested.  (Picture reproduced 
courtesy of Louise Redfern, Grifols, personal communication).  
 
 
  
Beads with attached allele 
specific probes are 
directed through the 
cuvette 
The red laser excites the 
dye within the bead and 
the green laser excites the 
SAPE 
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1.7 Risk of alloimmunisation in chronic transfusion 
 
The risk of alloimmunisation is dependent on the immunogenicity of the 
red cell antigen, hence it has long been advocated that all blood 
transfusions should be matched for the highly immunogenic RhD antigen 
(Woodrow and Donohoe, 1968) as well as the standard ABO antigens 
discovered by Landsteiner (1900 cited in Daniels 2013). Other red cell 
antigens which may evoke an immune response, and cause a transfusion 
reaction, in antigen negative transfusion recipients include those of the 
Rh (CcEe), K, Fy, Jk, MN and Ss blood group systems. However, these 
are only weakly immunogenic, immunising only 2-6% of transfusion 
recipients (Seyfried and Walewska, 1990; Heddle et al., 1995; Hoeltge et 
al., 1995) compared to the RhD antigen which has an alloimmunisation 
rate of 30-90% (Freda et al., 1967; Gunson et al., 1970; Cook, 1971; 
Frohn et al., 2003). The RhD antigen is particularly immunogenic as RhD 
negative individuals lack the entire RhD protein from the red cell 
membrane (Daniels, 2013).  
 
Studies have suggested that alloimmunisation may also be influenced by 
other factors such as; underlying disease, gender, age, inflammatory 
status and the frequency and number of transfusions (Coles et al., 1981; 
Blumberg et al., 1983; Blumberg et al., 1984; Fluit et al., 1990; 
Hendrickson et al., 2006). Alloimmunisation rates in patients with 
haematological malignancies vary. A retrospective study undertaken in 
the Netherlands (Schonewille et al., 1999) found an overall 
alloimmunisation rate of 9% in patients with malignant myeloproliferative 
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and lymphoproliferative diseases whereas another study by Blumberg 
and co-workers (1983) showed rates of 16% in patients with 
myelogenous leukaemias and 11% in aplastic anaemia but no 
alloimmunisation in patients with lymphocytic leukaemias. Another study 
demonstrated a relatively high alloimmunisation rate amongst patients 
with myelodysplastic syndrome MDS; 36% of patients given more than 30 
units of blood, and 64% given in excess of 100 units were found to have 
developed alloantibodies (Milic et al., 2011).  
 
More recent studies have been published regarding the alloimmunisation 
rates of patients with non-haematological malignancies or renal 
insufficiency. Alloimmunisation rates of 13.8% have been reported for 
patients with SCD (Master et al., 2016) and 7.98% for those with 
thalassamia (Abdelrazik et al., 2016). An interesting study by Türkmen 
and co-workers (2016) reported an alloimmunisation rate of 0.12% in a 
cohort of neonates and children up to the age of 3 years. In contrast, their 
control group, comprising of adult patients aged 45 years and older, had 
an immunisation rate of 3.55% after a median of 5 red cell transfusions, 
rising to 10.24% after 40 red cell units.  A review of the published 
literature regarding alloimmunisation rates in SCD by Zheng and Maitta 
(2016) revealed that the United States had a higher immunisation rate 
(22.3%) compared to other regions (16.5%) including South America, the 
Caribbean, Middle East, Africa and Europe. They concluded that this was 
probably a result of the limited ethnicity of the donor pool, where Black 
donors represent a minority. In populations where donors and recipients 
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are ethnically similar, such as Uganda and Jamaica, the alloimmunisation 
rate is much lower (Olujohungbe et al., 2001). Differential expression of 
red cell antigens are noted between Caucasian and Black populations for 
many of the blood group systems, most notably for Rh (Daniels, 2013).  
 
There is a paucity of recent publications on the alloimmunisation rates in 
the UK for chronically transfused patients with haematological 
malignancies or renal insufficiency, providing a rationale for this research.  
 
 
1.8 Red cell autoantibodies 
 
Patients with haematological malignancies may also make antibodies to 
red cell antigens on their own cells (Timura et al., 2000; Solal-Celigny et 
al., 1984) and this can also create challenges with the provision of blood 
by the hospital transfusion services. The production of red blood cell 
autoantibodies has been shown to be associated with blood transfusion 
and the subsequent production of alloantibodies by the recipient (Young 
et al., 2004). This can sometimes cause haemolytic episodes (Young et 
al., 2004) but probably occurs more commonly with no ill effects in the 
patient (Garratty, 2004).  It has been suggested that the production of 
autoantibodies in a transfused patient may be due to the presence of 
donor lymphocytes in the transfused blood that produce an alloantibody 
to the recipient red cells, thus mimicking an autoantibody (Ishikura et al., 
1993). In the United Kingdom (UK) there is currently no reported data on 
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the occurrence of red cell autoantibodies associated with 
alloimmunisation following blood transfusion in patients with renal disease 
or haematological malignancies and whether the presence of these 
antibodies has an effect on the transfusion requirements of the patients 
remains unknown.   
 
1.9  Extended red cell antigen matching of blood in chronic 
transfusion 
 
There is no current evidence on the rates of alloimmunisation and 
autoimmunisation in patients with chronic transfusion requirements as a 
result of haematological malignancies or renal failure in the UK and 
whether there are risk factors within this heterogeneous group of patients 
that could be used to predict those at greatest risk of producing allo 
and/or autoantibodies during the course of their treatment.  
 
It has been advocated by some workers (Michail-Merianou et al., 1987; 
Rosse et al., 1990) that certain groups of chronically transfused patients, 
for example those with sickle cell disease (SCD) and thalassaemia, 
should receive blood that is matched for more than the standard ABO and 
RhD antigens. In the UK the British Committee for Standards in 
Haematology (BCSH) also endorse this practice for patients with SCD 
and thalassaemia (BCSH, 2013) but it is not standard practice for other 
groups of chronically transfused patients, such as those with 
haematological malignancies. This has mainly been due to the cost 
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implications of performing the tests, the perceived difficulties in providing 
matched blood for large numbers of patients and the lack of evidence of 
the benefits of such an approach. 
 
Blood transfusions in patients with renal disease and haematological 
malignancies account for a substantial proportion of the total red cells 
transfused within the hospital setting. At the RD&E this usage is 
approximately 30% of the total red cells transfused. There are some 
historical studies (Fluit et al., 1990; Shirey et al., 2002; Schonewille et al., 
2009; Kadar, 2010; Schonewille et al., 1999; Domen and Ramirez, 1988; 
Blumberg et al., 1984) that have investigated the occurrence of red cell 
antibodies in these groups of patients and the potential benefits and cost 
effectiveness of strategies to reduce immunisation. However, the advent 
of improvements in high throughput automated analysers in the hospital 
transfusion service, allowing rapid automated red cell phenotyping, along 
with novel genotyping platforms and increased red cell antigen typing of 
donor red cells has now made this topic relevant to review.  
 
This research aimed to review the current extent of allo and/or 
autoimmunisation in chronically transfused patients attending the RD&E, 
and review the effect that extending matching of blood for transfusion 
from ABO/D to additional antigens might have on the immunisation rate. It 
aimed to validate a new technique for extended serological phenotyping 
using the IBG NEO analyser and investigate the feasibility of introducing 
a genotyping assay into a hospital transfusion laboratory. It aimed to 
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review the cost effectiveness of implementing serological phenotyping or 
genotyping assays to support a type and match program. In addition, 
ethical approval was obtained from the National Research Ethics Service 
(NRES) Committee South West - Cornwall & Plymouth (MREC 
No.12/SW/0251 R&D Study No. 13017733), to recruit patients attending 
the haematology clinic at the RD&E to a pilot study, a small randomised 
controlled trial. Patients recruited to the study were randomly assigned to 
one of two groups; patients assigned to group 1 received standard care 
with regard to blood transfusions (ABO and RhD compatible blood) and 
group 2 patients were to be assigned blood that was matched for Rh (C, 
e, E and e) and K in addition to the standard ABO and RhD.  The pilot 
study was designed to investigate the feasibility of the provision of blood 
matched for Rh (CcEe) and K antigens within this cohort of patients as 
well as reviewing recruitment and drop-out rates. A more extensive 
randomised controlled trial has been performed by Sanquin in the 
Netherlands (Schonewille et al, 2016); this multicentre study aimed to 
review the incidence of alloimmunisation in a general transfusion 
population using a multi-centre, parallel group randomised trial. 
Randomisation of study participants into one of two study arms; ABO-D 
matched only, or extended match (including c, C, K, Fya, Jka and S 
antigens) demonstrated a 64% reduction in alloimmunisation risk in 
surgical patients. The pilot study undertaken in our institution was 
designed to investigate the feasibility of performing a larger multicentre 
study in the UK. The results of the pilot study could then be used to 
design a larger randomised control trial with the aim of investigating the 
79 
 
benefits and cost effectiveness of a strategy for preventive extended 
antigen matching for patients with haematological malignancies. Neither a 
pilot study, nor a randomised control trial such as this, has yet been 
attempted in the UK. 
 
A type and match program for chronically transfused patients has the 
potential to reduce the risk of alloimmunisation, with the subsequent 
patient safety benefits of reduction of risk of transfusion reaction or HDFN 
(see section 1.4). It is this hypothesis that underpins this research project.   
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1.10  Aims and Hypothesis 
 
 The hypothesis underpinning this research is that allo and 
autoimmunisation in chronically transfused patients can be 
reduced by the provision of blood subjected to extended red cell 
phenotyping and/or genotyping. 
 The research aims to test the hypothesis are: 
o To evaluate the frequency of allo- and autoantibodies in two 
cohorts of patients with chronic transfusion requirements 
using retrospective patient data from patient cohorts 
transfused at the RD&E (Haematology and Renal patients) 
o To identify any risk factors for the development of allo- and 
autoantibodies in these two cohorts of patients with chronic 
transfusion requirements using the retrospective patient 
data 
o To evaluate the use of novel fully automated, high 
throughput, red cell serological phenotyping profiles on the 
NEO® analyser (IBG Immucor) automated analyser 
o To evaluate and compare the cost effectiveness of a 
strategy of red cell phenotyping and matching blood for 
transfusion in patients treated for haematological 
malignancies and those treated for renal insufficiency using 
information obtained from the retrospective patient data. 
o To evaluate the use of the BLOODChip IDCOREXT blood 
group genotyping kit and compare the predicted phenotypes 
obtained from genotypes with those obtained by the 
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automated serological phenotyping profiles on the NEO® 
analyser. 
o To evaluate the results of a pilot study recruiting patients 
with haematological malignancies investigating the effects 
of prospectively typing and matching red cell antigens for 
this cohort of patients. This pilot study is designed to assist 
with the protocol for a larger randomised controlled trial. 
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2  MATERIALS AND METHODS 
 
2.1 Overview of the project 
 
An overview of the work undertaken for this research is show in the form 
of a flow chart:   
 
 
 
 
 
 
 
 
 
  
Retrospective review of chronically transfused patients treated at the RD&E to establish: 
 Rate of allo/autoimmunisation 
 Risk factors for allo/autoimmunisation 
 Costs associated with allo/autoimmunisation 
 Potential benefit of a type and match strategy 
 
Validation of a fully automated high throughput serological phenotyping assay to support a type and 
match strategy: 
 Comparison of phenotype results with current manual methods 
 Cost analysis 
 Suitability for routine use to support type and match strategy 
Validation of the BLOODChip IDCOREXT blood group genotyping assay:  
 Comparison of IDCOREXT predicted phenotype with the serological phenotype 
 Feasibility of technique for use in hospital transfusion service 
 Cost analysis 
 Suitability for routine use to support type and match strategy 
Pilot study – randomised controlled trial: 
 Feasibility of introducing a type and match stategy in a hospital transfusion service 
 Identification of changes required in service provision to support the strategy  
Cost analysis: 
 Analysis of the costs associated with allo/autoimmunisation in chronically transfused patients 
and methods for high throughput phenotyping/genotyping 
 Review of cost effectiveness of a type and match strategy 
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2.2 Retrospective review of chronically transfused patients 
 
2.2.1 Sample size for retrospective review 
 
Two cohorts of transfusion dependent patients were selected for inclusion 
in the retrospective review; patients with haematological malignancies 
and patients with renal insufficiency. Sample size for the retrospective 
review was calculated with the aim of achieving a 95% confidence level 
with the minimum margin of error (<5%), whilst taking into account the 
amount of historic information available in the computer records and the 
timeframe of the study. The decision was taken to include a minimum of 
800 patients in each study cohort, giving a margin of error of 3.4%.  
 
2.2.2 Patients with haematological malignancies 
 
Data were collected for 1107 randomly selected patients admitted for red 
cell transfusions within the haematology ward and haematology day case 
unit at the RD&E between 1995 and 2012. Patients were identified using 
an in-house enquiry package designed to extract the hospital number and 
name of patients who had crossmatch tests recorded in the pathology 
computer system (Integrated Pathology System (IPS)) and had the 
location codes of YAR (haematology in-patient ward) or YARD 
(haematology day case). Patients who had received at least one unit of 
blood on one occasion were included in the database. Ethical approval 
was not considered appropriate for this retrospective audit as agreed at 
the Cornwall and Plymouth Research Ethics Committee on the 5th 
September 2012 (MREC No.12/SW/0251 R&D Study No. 13017733).  
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Blood samples from patients attending the haematology ward and day 
case unit at the RD&E during this time period were routinely screened for 
atypical red cell antibodies, using a selected set of reagent red cells for 
antibody detection, as part of the pre-compatibility testing. From 1995 to 
2000 antibody detection was undertaken manually using the low ionic 
strength solution (LISS) gel cards (column agglutination technology; 
Diamed UK). From the years 2000 to 2008 automated antibody screening 
was performed by the IBG Multisampler (IBG Immucor) robotic system 
using low ionic strength solution gel test cards (Diamed UK). From 2008 
to the present day, antibody screening has been undertaken using 
capture technology (solid phase technology) on the IBG Galileo/NEO and 
Echo fully automated analysers (IBG Immucor). Over the study period, 
antibody identification was performed using a variety of techniques 
including column agglutination (Diamed UK) and automated Capture 
Ready ID (IBG Immucor). Laboratory processes for antibody identification 
also included the DAT by column agglutination (Diamed UK) and, if 
appropriate, the use of column agglutination with monospecific anti-
human globulin (AHG) reagents to identify the type of antibody and/or 
complement fraction coating the red cells.  
 
Test costs were calculated using an in-house spreadsheet calculator 
(Microsoft Excel) taking into account reagent costs, equipment 
maintenance, consumables, quality control and staff time incurred during 
the financial year 2011-2012. Total test costs for the additional testing 
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performed on patient samples during the retrospective review period were 
calculated using current tests costs, although it is accepted that this is an 
approximation of the actual costs of the tests performed and is subject to 
error due to variations such as different testing techniques and inflation. 
 
Data were collected on the gender, age at first transfusion, red cell 
transfusion history, platelet transfusion history, requirement for irradiated 
blood components, allo/autoantibody status and additional testing 
requirements for 1107 patients admitted for red cell transfusions within 
the haematology ward and day case unit at the RD&E between 1995 and 
2012.  
 
 
2.2.3 Patients with renal insufficiency 
 
Data were collected for 877 randomly selected patients admitted for red 
cell transfusions within the renal ward and haemodialysis unit at the 
RD&E between 1995 and 2013. Patient data were collected as described 
for haematology patients in section 2.2.2, with the exception that the 
location codes of SID (renal in-patient ward) or CRE (haemodialysis unit) 
were used in the computer enquiry. Patients who had received at least 
one unit of blood on one occasion were included.  Ethical approval was 
not considered appropriate for this retrospective audit as agreed at the 
Cornwall and Plymouth Research Ethics Committee on the 5th 
September 2012 (MREC No.12/SW/0251 R&D Study No. 13017733). 
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Screening of patients’ samples for atypical red cell antibodies during this 
time period was as for patients admitted to the haematology wards. Data 
were collected on the gender, age at first transfusion, red cell transfusion 
history, renal transplant history, allo/autoantibody status and additional 
testing requirements for 877 patients admitted for red cell transfusions 
within the renal ward and haemodialysis unit at the RD&E between 1995 
and 2013. 
 
2.3 Comparison of manual and automated red cell 
phenotyping 
 
One hundred patient samples, to be discarded, were selected for 
comparative extended serological red cell antigen phenotyping in the 
current manual systems and novel automated method. The BCSH 
guidelines for validation and qualification of new techniques in the 
laboratory setting (BCSH, 2012) recommend that a predetermined 
number of samples are tested in duplicate with the current system, 
quoting “2 weeks or 250 samples whichever occurs first” as a target 
value. At the time of the validation approximately 140 samples per year 
were phenotyped for Rh (CcEe) and K antigens, and less typed for Jk, 
Fy, Ss and MN antigens. It was, therefore, considered that 100 samples 
would be an acceptable size for comparison testing, which would test all 
the reagents and provide the sensitivity required to give confidence in the 
performance of the technique. All samples were collected into EDTA 
anticoagulant and stored at 2-8oC until tested. Patients who had records 
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on the hospital computer system, of blood transfusion in the three months 
prior to the collection of the sample were excluded from analysis due to 
the interference caused by circulating transfused red cells in these 
serological techniques. Ethical approval for this stage of the project was 
not required as it was considered to be service development. Samples 
had been taken for routine blood group and antibody screening and no 
additional samples were required. 
 
2.3.1 Manual red cell phenotyping 
 
Manual red cell phenotyping for Rh (CcEe) and K antigens was 
performed by column agglutination using DiaClon Rh-Subgroups and K 
(Catalogue number: 50110, Bio-Rad, Watford, UK) microgel card for 100 
patient samples. The microgel card contains monoclonal antibodies (anti-
C (cell line MS-24), anti-c (cell line MS-33), anti-E (cell line MS-260), anti-
e (cell lines MS-16, MS-21 and MS-63) and anti-K (cell line MS-56)) 
within each gel matrix and also includes a negative control well.  
 
Method: 
A 5% suspension of patient red cells was prepared by mixing 0.5mL of 
ID-Diluent 2, a modified, low ionic strength solution (catalogue number 
05761, Bio-Rad) with 25 µL of packed cells, in accordance with 
manufacturer’s instructions.  
Patient red cell suspension (10 µL) was then added to each well of the 
microgel and the card was then centrifuged in an ID-Centrifuge 12 S II 
(Bio-Rad) at 85xg for 10 minutes.  
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The results were read macroscopically, with positive reactions denoted by 
red cell agglutinates visible in the gel matrix and negative reactions by a 
button of red cells at the bottom of the column (see figure 2.1).  
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Figure 2.1: Rh and K antigen phenotyping by column agglutination  
 
     
 
 
Example of a patient red cell phenotype performed using column agglutination 
methodology (Bio-Rad). Each column within the card contains a specific antiserum, a 
suspension of the patient red cells is added to each column, and centrifugation then 
forces the patient red cells through the gel matrix containing the antiserum. If the patient 
red cells have the corresponding antigen then the cells are trapped in the gel matrix, if 
the red cell antigen is absent then the patient cells will travel to the bottom of the 
column. The patient phenotype in the example shown here is C+, c+, E-, e+, K-; the 
negative reaction in the control column validates the results and confirms the absence of 
any false positive reactions caused by auto-agglutination.  
  
Specific antiserum is 
contained within the gel 
matrix 
Positive reactions are 
seen if the antigen is 
present on the patient 
red cells  
 
Negative reactions are 
seen if the antigen is not 
present on the patient 
red cells 
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Manual red cell phenotyping for the Fy (a and b), Jk (a and b), s and k 
antigens was performed using polyclonal reagents supplied by Lorne 
(Lorne Laboratories Limited, Early, UK) in an IAT. The following reagents 
were used: monoclonal anti-Fya (cell line DG-FYA-02 code 774002) anti-s 
(cell line P3YAN3 code 771002) and anti-Fyb (code 317002), anti-Jka 
(code 323002), anti-Jkb (code 324002), anti-k (code 320002) prepared 
from pooled human sera.  
 
Method: 
A 0.9% suspension of patient red cells was prepared by mixing 10 µL of 
packed red cells with 1mL of ID-Diluent 2 (Bio-Rad).  
Patient red cell suspension (50 µL) was then added to each well of a 
LISS Coombs Anti-IgG microgel card (Catalogue number: 50540, anti-
IgG, rabbit, Bio-Rad) followed by 25 µL of the appropriate anti-sera.  
A control well was included on the microgel card by the addition of 50 µL 
of patient red cell suspension to one of the wells within the Coombs Anti-
IgG microgel card.   
The microgel was incubated for 15 minutes in a DiaMed-ID Incubator 
37oC (Bio-Rad) and then centrifuged in an ID-Centrifuge 12 S II (Bio-Rad) 
at 85 x g for 10 minutes.  
The results were then read macroscopically, a positive reaction in the 
control well invalidated the results (see figure 2.2).  
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Figure 2.2: Manual Serological phenotyping for Fy (a and b), Jk (a 
and b) and s antigens by column agglutination 
                    
           
 
 
In the manual column agglutination Indirect Antiglobulin Test (Bio-Rad) 
patient red cells in suspension are incubated with specific antisera at 
37oC to allow antigen-antibody complexes to form. Centrifugation then 
forces the red cells through a gel containing anti-human globulin. Red 
cells with antibodies attached are then caught by the anti-human globulin 
within the gel. Negative reactions are denoted by a button of patient red 
cells at the bottom of the column and positive reactions by red cell 
agglutinates trapped within the gel matrix. The patient shown in this figure 
has the phenotype Fy (a-b+), Jk (a+b-) and s+, the negative reaction in 
the control well indicates that the reactions with the antisera are valid and 
not due to the presence of a positive Direct Antiglobulin Test. 
 
  
Incubation well 
Positive reactions are seen if the 
antigen is present on the patient red 
cells  
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Manual red cell phenotyping for the M, N, S and Cw antigens was 
performed using monoclonal reagents manufactured by Millipore 
(Millipore UK Ltd, Watford, UK). The following antisera were utilised; Anti-
M (cell line LM110/140), anti-N (cell line BO3), anti-S (cell line MS-94) 
and anti-Cw (cell line MS-110). A 3-5% red cell suspension was prepared 
by mixing 0.5mL of Phosphate Buffered Saline (PBS 0.9% pH7.0, IBG 
Immucor) with 75 µL of the patient packed cells. The same cell 
suspension was used for all the tube techniques described below. 
 
Method: 
N antigen status was determined by adding 75 µL of cell suspension and 
75 µL of anti-N to an appropriately labelled test tube.  
The mixture was agitated gently and then centrifuged in an Immufuge II 
(Baxter Healthcare Ltd, Newbury, UK) for 1 minute at approximately 200-
300 x g.  
The results were then read by gently agitating the tube to dislodge the red 
cells and examining macroscopically for agglutination.  
 
M antigen status was determined by adding 75 µL of red cell suspension 
and 75 µL of anti-M to an appropriately labelled test tube.  
This was mixed well and incubated at room temperature for 5 minutes. 
The tube was then centrifuged at approximately 1000 x g for 20 seconds. 
The results were then read by gently agitating the tube to dislodge the red 
cells and examining macroscopically for agglutination.  
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S antigen status was determined by adding 75 µL of patient red cell 
suspension and 75 µL of anti-S to an appropriately labelled test tube.  
This was mixed and then centrifuged at approximately 1000 x g for 20 
seconds.  
The results were then read by gently agitating the tube to dislodge the red 
cells and examining macroscopically for agglutination. Cw antigen status 
was determined by the same methodology as the S antigen status. 
 
All negative and weakly positive reactions for M, N, S and Cw antigens 
were then incubated at room temperature for a further five minutes before 
being centrifuged (Immufuge II; Baxter Healthcare Ltd) for 1 minute at 
approximately 200-300 x g) again for repeat macroscopic reading.  
                                              
 
2.3.2 Automated red cell phenotyping using the NEO analyser 
 
Automated red cell phenotyping was performed using the fully automated 
Galileo-NEO® analyser (IBG Immucor). This analyser is used within the 
transfusion laboratory at the RD&E for routine ABO/D typing, antibody 
screening and antibody identification techniques. It also has the capacity 
for automated DAT testing and crossmatching, although these tests have 
yet to be validated on the analyser at the RD&E. Reagents for red cell 
antigen typing are also supplied by IBG Immucor, which are CE marked 
for tube, slide and automated techniques, however, these are not used 
for automated testing within the UK (personal communication from 
Berndine Kokkelink, IBG Immucor). Provision of extended, automated 
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serological phenotyping profiles was considered to be a novel way of 
introducing high throughput phenotyping technology within the hospital 
transfusion service, which could then be adopted by other centres using 
the same platforms. The assay would enable identification of a range of 
red cell antigens in a single, automated test profile, which is not yet 
available in the UK.  
 
A profile to determine the Rh (CcEeCw), K, M and N antigen status was 
set up on the NEO® analyser. Immuclone® IgM (IBG Immucor) 
monoclonal reagents suitable for use on the IBG NEO® analyser system 
in 96 well U-bottom microplates were utilised for this profile. The 
monoclonal reagents used were; anti-C (derived from cell line MS-24), 
anti-c (derived from cell line MS-33), anti-E (derived from cell lines MS-80 
and MS-258), anti-e (derived from cell lines MS-16, MS-21 and MS-63), 
anti-K (derived from cell line MS-56), anti-M (clone M-11H2), anti-N 
(clone 1422-C7) and anti-Cw (derived from human cell line MS-110). The 
reagents were loaded into a single reagent rack, enabling a simple and 
fast method for reagent presentation to the analyser. The patient primary 
blood sample was centrifuged in a Labofuge400 centrifuge for 11 minutes 
at 2,250 x g prior to placing on the NEO® analyser.   
 
Method: 
The automated process enables the analyser to produce a red cell 
suspension from the patient primary sample tube; 10μL of red cells taken 
95 
 
from the primary sample are mixed with 314μL of Diluent (IBG Immucor 
kit, ref: 0066058).  
Aliquots (40μL) of this cell suspension are then added to the first eight 
wells of the 96 well U-bottom microplate in a vertical pattern.  
An aliquot (10μL of anti-Cw, -C, -c, -E, -e, -K or 20μL of anti-M, -N) of the 
monoclonal reagent is then added to the appropriate well of the microtitre 
plate in the order shown in figure 2.3.  
 
An incubation phase performed at 20oC for 10 minutes allows the 
antigen-antibody complexes to form, if the antigens are present. 
Centrifugation of the plate (30 seconds at 80 x g followed by 30 seconds 
at 170 x g) enhances the antigen-antibody reaction by forcing the red 
cells closer together allowing the antisera to bind red cells together as 
agglutinates.  
 
Automated shaking of the plate for 60 seconds then disperses red cells 
that have not been agglutinated, leaving a loose layer of red cells within 
the microwell. Cells that had been agglutinated by the formation of 
antigen-antibody complexes remained as a tight button of cells at the 
bottom of the microwell.   
 
The automated reader within the analyser is then able to interpret the 
reaction patterns of the red cells, recognising a positive reaction (tight 
button of cells at the bottom of the microwell) from a negative reaction 
(loose layer of cells around the microwell).  The pattern of cells detected 
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by the automated reader is then converted into a numerical reaction 
strength (between 0 and 99) and a corresponding reaction grade 
(between 0 and 4; figure 2.3). The user is able to view both reaction 
strengths and grades; the availability of the reaction grade allows some 
comparability with manual techniques that may also be employed in the 
laboratory.  
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Figure 2.3: Reaction patterns generated by automated red cell 
antigen phenotyping for Rh(CCwcEe), K, M and N antigens 
 
Format of the results and reaction patterns generated by the automated 
monoclonal profile on the NEO®. The left hand side of the screen shows 
the laboratory number associated with the patient sample being tested 
and the antigen status of the patient red cells. The right hand side of the 
screen shows the image of the reaction in the well captured by the 
analyser camera, the reaction strength generated by the analyser and the 
grade of reaction. A negative reaction is equivalent to reaction strength of 
23 or below, equivocal and positive reactions are variable and dependent 
on the antisera used. The “well image” column shows a photographic 
image of the agglutination of the cells (positive reaction) or the loose layer 
of non-agglutinated cells denoting a negative reaction.  (Picture courtesy 
of Caryn Conway, IBG Immucor, personal communication).        
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Automated red cell phenotyping for Fy(a and b), Jk(a and b), S, s and k 
antigens was performed using commercial polyclonal antisera prepared 
from pools of human sera (IBG Immucor) in Capture-R Select microwell 
strips (IBG Immucor ref: 006446). The reagents are loaded in a single 
reagent rack, as for the monoclonal reagents. The patient primary blood 
sample was centrifuged in a Labofuge400 centrifuge for 11 minutes at 
2,250 x g prior to placing on the NEO® analyser.  
 
Method: 
 The automated process enables the analyser to produce a red cell 
suspension from the patient primary sample tube; 4μL of red cells from 
the sample tube are mixed with 270μL of Diluent (IBG Immucor kit). 
Aliquots (40μL) of this cell suspension are then added to the first eight 
wells of the 96 well of the Capture-R Select microwell strips in a vertical 
pattern. The Capture-R Select microwell is supplied as a ready to use kit 
and is pre-coated with an affinity isolated goat anti-murine and an anti-
RBC antibody to immobilise red blood cells to the microwell surface.  
The analyser performs a shake phase for 15 seconds to enable the 
patient red cells to bind to the Capture-R Select coated microwell.  
A double centrifugation stage (60 seconds at 150 x g followed by 60 
seconds at 500 x g) then enables the formation of the red cell monolayer. 
An aliquot (25μL) of the polyclonal reagent was then added to the 
appropriate well of the microtitre plate along with 35μL of negative control 
reagent (IBG Immucor) in the order shown in figure 2.4.  
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An incubation phase performed at 39oC (enabling a 37oC temperature 
within the reaction well) for 20 minutes allows the antigen-antibody 
complexes to form, if the antigens are present on the patient’s red cells. 
The analyser then completes a wash cycle to remove any unbound 
antibodies. Immucor Capture-R Ready Indicator Red Cells (a suspension 
of red blood cells coated with murine monoclonal anti-human IgG 
molecules, 50μL) were then added to the microwell.  
These cells are captured by the antigen-antibody complexes in the 
presence of the antigen, but remain free in suspension in the absence of 
the antigen. A double centrifugation stage (30 seconds at 80 x g followed 
by 30 seconds at 170 x g) followed by a shake phase and further 
centrifugation (20 seconds at 15 x g) then forces free cells to the bottom 
of the microwell but bound cells remained as a monolayer of cells around 
the microwell.  
 
Automated reading of the microwell plate by the analyser allowed the 
distinction between the monolayer of cells, indicating a positive reaction, 
or a button of cells in the bottom of the microwell indicating a negative 
reaction (figure 2.4).  
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Figure 2.4: Reactions patterns generated by automated red cell 
antigen typing for Fya, Fyb, Jka, Jkb, S, s and k antigens 
      
                          
Screenshot showing the reaction patterns generated by the NEO 
analyser. In the Capture R Select solid phase test positive reactions are 
denoted by a layer of patient red cells coating the bottom of the well and 
negative reactions are denoted by a tight button of cells, this is in contrast 
to the reaction patterns seen in the direct agglutination testing using the 
monoclonal reagents (as shown in figure 2.3). The serological phenotype 
of the patient sample is shown in the top left hand side of the screen. 
(Picture courtesy of Caryn Conway, Immucor, personal communication). 
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2.3.3 Extended phenotyping profile result interpretation on the 
NEO® analyser 
 
A monoclonal antisera reagent profile (anti-C, Anti-c, Anti-E, anti-e, anti-
K, anti-Cw, anti-M and anti-N) was created on the IBG Immucor Galileo-
NEO® analyser (section 2.3.2, figure 2.3) along with a polyclonal antisera 
reagent profile (anti-Fya, anti-Fyb, anti-Jka, anti-Jkb, anti-S, anti-s, anti-k 
and auto control; all reagents from IBG Immucor, figure 2.4). The Galileo-
NEO® analyser provides the test result in three different formats; a “+” or 
“-“ result, a numerical value (0 to 99) and a reaction strength value (0, 1+, 
2+, 3+ and 4+). The numerical value has programmed cut-off points for 
generating the reaction strength values, which vary according to the 
antisera (see appendix 3). These cut-off points have been validated by 
the supplier and cannot be influenced by the laboratory staff operating the 
analyser. A numerical value of 23 for the monoclonal profile and 20 for 
the polyclonal profile, or below generated by the analyser is set to 
correspond to a negative result and borderline values between negative 
and the set positive value (1+ reaction) are expressed as “not 
determined” (NTD). The analyser returns an “X” in the testing well if it 
detects an insufficient volume; this could be due to insufficient sample or 
insufficient antisera and acts as an internal quality control system to 
minimise the risk of false negative results.  
 
The antisera used for the automated testing were all CE marked and 
validated for use in automated techniques, with the exception of the anti-
N (immuClone) which was CE marked only for use in tube and slide tests. 
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This validation also intended to review the effectiveness of this antiserum 
for use in the automated technique on the Galileo-NEO®. 
 
2.3.4 Quality control testing 
 
The NHSBT ten cell ID panel profile (0.8% cell suspension) in Cellstab 
preservative (item code: PR143, NHSBT, UK) with known red cell 
phenotypes (figure 2.5) was used to determine the accuracy of the 
automated phenotyping profiles prior to commencing comparative work 
with patient samples. The panel was tested on four occasions over four 
weeks to determine any intra- and inter-test variation. The panel 
contained a mixture of cells with homozygous and heterozygous 
expression of red cell antigens. The NHSBT three cell screen profile 
product (3% cell suspension) in Alsevers preservative (item code: PR122, 
NHSBT) as shown in figure 2.6), selected to include all the relevant 
antigens including homozygous and heterozygous expression of red cell 
antigens, was tested over five separate occasions to challenge the 
stability and accuracy of the antisera over an extended period. The 
NHSBT titration cell set profile (0.8% cell suspension in Cellstab, item 
code: PR407), including a two cell set with homozygous and 
heterozygous expression of red cell antigens (figure 2.7), was tested on 
two separate occasions.  
 
The purpose of quality control for red cell antigen phenotyping is to detect 
the weakest expression of the antigen, hence the requirement for 
examples of heterozygous expression of antigens. Red cells that are 
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heterozygous express both the antigen and its antithetical counterpart, for 
example Jk(a+b+). Whereas, homozygous expression is the presence of 
one antigen but not the antithetical antigen, for example Jk(a+b-).  There 
are no clear recommendations from the BCSH (BCSH 2013) on the 
requirements for quality control for phenotyping reagents, only that 
suitable positive and negative controls should be included.  In the 
absence of any commercial quality control for phenotyping reagents, with 
the exception of RhCcEe and K, the NHSBT cells were selected as they 
included heterozygous and homozygous expression of the majority of 
antigens and, thus, could provide both the positive and negative controls 
required.   
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Figure 2.5: NHSBT ten cell ID panel profile 
 
An example of an NHSBT ten cell ID panel. Panels are available in a variety of preservative media; the ID Panel in CellStab was used for quality 
control of the automated extended phenotyping technique. Antigen profiles of the red cells in the panel are denoted by a positive (+) or negative (-) 
in the table. The panel sheet supplied by the NHSBT (shown in this example) also allows for result entry in the blank section on the right hand side 
and for documentation of a DAT result at the bottom of the table. This sheet can then be retained as a worksheet within the laboratory as part patient 
result record. (Picture reproduced courtesy of NHSBT, taken from the reagent product profiles http://hospital.blood.co.uk/diagnostic-
services/reagents/product-profiles/). 
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Figure 2.6: NHSBT three cell screen profile product 
 
 
An example of an NHSBT three cell screen profile set. The product is available in different preservative media suitable for use in a 
variety of antibody screening techniques; the product in Alsevers (3% cell suspension) was used for quality control of the extended 
automated phenotyping technique. (Picture reproduced courtesy of NHSBT, taken from the reagent product profiles 
http://hospital.blood.co.uk/diagnostic-services/reagents/product-profiles/). 
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Figure 2.7:  NHSBT titration cell set profile 
 
Example of an NHSBT two cell titration set profile. This product is available for use in techniques designed to determine the strength of a red cell 
antibody by titration methods. It was selected for use as a quality control product in the validation of the extended automated phenotyping technique 
as it has a selection of red cells that are heterozygous for some of the red cell antigens which were used for determination of the performance of the 
automated technique with red cells of a weaker expression than homozygous cells. (Picture reproduced courtesy of NHSBT, taken from the reagent 
product profiles http://hospital.blood.co.uk/diagnostic-services/reagents/product-profiles/). 
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2.4 Blood Group genotyping 
 
2.4.1 DNA Extraction 
 
DNA was obtained from whole blood samples taken from 47 patients 
attending the haematology clinic for routine blood samples and who 
consented to have an additional sample taken for genetic analysis 
(ethical approval for this was obtained from the NRES Committee South 
West - Cornwall & Plymouth (MREC No. 12/SW/0251, R&D Study No. 
1301733)). The BLOODChip IDCOREXT kit funded for this research 
included 48 tests, 47 patient assays and one negative quality control 
sample. The sample size for this study group was determined by the 
funding obtained. It was not possible within the funding of the research to 
include replicates to investigate the reproducibility of the results.  
 
DNA was extracted from the whole blood samples in EDTA anticoagulant 
(2.7ml) using the Autopure LS (Qiagen, Hilden, Germany), a fully 
automated, high throughput analyser that uses PureGene chemistry 
(Qiagen). This method gently removes contaminants and inhibitors to 
enable purification of high molecular weight (100-200kb) DNA that can be 
stored for analysis.  
 
The analyser uses a red cell lysis solution (Qiagen, 15ml), part of the 
Autopure LS whole blood extraction kit (used according to manufacturer’s 
instructions) to remove the red cells from the whole blood sample and 
then uses centrifugation (3000 x g for 5 min) to produce a pellet of white 
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blood cells. The white cells are then dispersed and lysed using a cell lysis 
solution (Qiagen Autopure LS whole blood extraction kit used according 
to manufacturer’s instructions, 5ml) and the proteins precipitated (2.2ml 
Autopure protein precipitation solution, Qiagen) by mixing vigorously 
(rapid tube inversions for 5 minutes). The supernatant containing the 
DNA is then dispensed into tubes containing isopropanol (Autopure 100% 
isopropanol 6.5ml). These tubes are rotated and centrifuged (rotated 50 
times, centrifuged at 3000 x g for 5 min) to precipitate and pellet the DNA, 
the isopropanol (entire volume)  is then discarded and the DNA treated 
with 70% ethanol (Autopure 70% ethanol, 6.5ml), centrifuged (3000 x g 
for 5 min) and drained to evaporate any remaining alcohol. A DNA 
hydration solution (Autopure DNA hydration solution, 300µl) is then 
dispensed into the tubes to hydrate the DNA. Concentration and purity 
were measured using the Nanodrop ND8000 spectrophotometer 
(measured in ng/µl and ratios to indicate the purity of the samples). The 
samples were then stored at -20°C until required for testing. 
 
2.4.2 IDCOREXT test 
 
2.4.2.1 IDCOREXT Workflow 
 
The IDCOREXT protocol consists of four steps: 
 
 Amplification 
 Hybridisation/Labelling 
 Data acquisition on Luminex 
 Data analysis 
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2.4.2.2 DNA Amplification  
 
DNA preparation was undertaken in a laminar flow fume hood (Astec – 
Bioquell UK Ltd, Andover, UK). The IDCOREXT PCR master mix, 
containing the allele specific primers (product ref: 1020120100, Progenika 
Biopharma S.A), was brought to room temperature, vortexed for 10 
seconds and then spun for 10 seconds in a micro-centrifuge (13000 xg) 
before use. The HotStarTaq® DNA polymerase (Qiagen) was kept frozen 
until ready for use and then immediately prior to use the tube was flicked 
gently and spun down in a micro-centrifuge for 10 seconds. A PCR 
reaction mix was prepared using the IDCOREXT PCR master mix and 
the HotStarTaq® DNA polymerase in accordance with the quantities 
(volumes in μL) shown in table 2.1. 
 
Table 2.1:  Reagent volumes required to produce the PCR mix using 
the IDCOREXT 
Reagent volumes required to produce the PCR mix (volumes in μL) using 
the IDCOREXT PCR master mix and the HotStarTaq® DNA polymerase 
(Qiagen). Volumes are given for sample batch sizes of 1, 8, 24 and 48. 
Number of 
samples 
1 8 24 48 
IDCOREXT 
PCR master 
mix 
22.5 180 540 1080 
HotStarTaq 
DNA 
Polymerase 
(5 U/μL) 
0.5 4 12 24 
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The 47 patient samples were run in three batches for ease of sample 
preparation. A 96 well reaction plate (MicroAmp® Optical 96 well reaction 
plate, Applied Biosystems®) (ThermoFisher Scientific, Cramlington, UK) 
was used for the amplification phase. The PCR reaction mix was 
vortexed and spun rapidly for 10 seconds in a micro-centrifuge, 20μL of 
this mix was then dispensed into one well of the PCR reaction plate for 
each sample. The frozen DNA samples were brought to room 
temperature, vortexed and spun rapidly. DNA sample, 5μL, 
(concentration >10ng/μL, A260/A280 ratio in the range 1.6-1.95, as 
recommended by the package insert) was then added to the 
corresponding wells and the resulting suspension mixed gently by 
pipetting up and down. 
 
The plate was then sealed with adhesive film (Microamp® Clear adhesive 
film, Applied Biosystems®). The plate was then placed in the thermal 
cycler block (Veriti® Applied Biosystems®) with a PCR compression pad 
on the top. An amplification program was applied to the samples as 
shown in table 2.2, which resulted in the production of the biotinylated 
PCR product (Biotin labelled dCTP, included within the amplification kit). 
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Table 2.2 Amplification program details for IDCOREXT 
Program details for the amplification stages; the denaturation, annealing 
and extension phases are linked for 40 cycles and then the plates were 
kept in the thermal cycler at 4°C until ready for the hybridisation phase. 
 
 Temperature Time Cycles 
Polymerase 
Activation 
95°C 15 mins 1 
Denaturation 95°C 30 sec 40 
Annealing 60°C 30 sec 40 
Extension 72°C 80 sec 40 
Final extension 72°C 7 min 1 
Hold 4°C ∞ 1 
 
 
 
 
 
2.4.2.3 Hybridisation of amplified DNA to allele specific probes 
 
The ID-COREXT Beads Master Mix (product ref: 1020120200, Progenika 
Biopharma S.A.), a solution containing a mix of beads with allele specific 
probes attached, was brought to room temperature and vortexed 
vigorously for 30 seconds before use. The beads mix include probes 
specific for the following alleles: 
RHCE blood group: RHCE*ce; RHCE*Ce, RHCE*cE; RHCE*CE, 
RHCE*CeCW, RHCE*ceCW, RHCE*CECW, RHCE*ceAR, RHCE*CeFV, 
RHCE*CeVG , RHCE*cEFM, RHCE*ce[712G] , RHCE*ce[733G] , 
HCE*ce[733G,1006T] , RHCE*CE-D[2, 5,7]-CE, 
RHCE*cE[697G,712G,733G], RHD*r’s-RHCE*ce[733G,1006T]. 
KELL blood group: KEL*K_KPB_JSB, KEL*k_KPB_JSB, 
KEL*k_KPA_JSB, KEL*k_KPB_JSA. 
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Kidd blood group: JK*A, JK*B, JK*B_null(871C), JK*B_null(IVS5-1a). 
Duffy blood group: FY*A; FY*B, FY*B_GATA, FY*B[265T]_FY*X 
MNS blood group: GYPA*M, GYPA*N, GYPB*s, GYPB*S, GYPB*Mur, 
GYPB*deletion, GYPB*S_, null(230T) , GYPB*S_null(IVS5+5t) 
Diego blood group: DI*A, DI*B. 
Dombrock blood group: DO*A, DO*B, DO*B_HY-, DO*A_JOA 
Colton blood group: CO*A, CO*B 
Cartwright blood group: YT*A, YT*B 
Lutheran blood group: LU*A, LU*B 
 
This process was repeated before dispensing for each sample to ensure 
that the beads remained fully dispersed within the mix. ID-COREXT 
Beads Master Mix (46µL) was dispensed into relevant wells of a 96 well 
Thermowell P polycarbonate clear PCR plate (Corning, New York, USA). 
The PCR plate containing amplified DNA from patient samples was 
removed from the thermal cycler and 4μL of the PCR product was 
dispensed into the corresponding well containing the hybridisation mix; 
the resulting suspension was gently mixed by pipetting up and down. 
 
The plate was then covered with a non-adhesive sealing film (Bio-Rad 
MSA-5001 film) and placed in the thermal cycler with silicone pads. A 
program of denaturation and hybridisation was then applied to allow 
amplified DNA to attach to the specific alleles on the beads (table 2.3).  
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Table 2.3 Thermal cycler program for denaturation and hybridisation 
PCR amplicons from patient samples were hybridised to beads with allele 
specific probes was performed by denaturation at 95°C, followed by a 
hybridization phase at 52°C, the samples were then held prior to 
fluorescent labelling. 
 
 Temperature Time 
Denaturation 95°C 2 min 
Hybridisation 52°C 30min 
Hold 52°C ∞ 
 
 
 
 
 
2.4.2.4 Fluorescent labelling of hybridised DNA 
 
The SAPE (Streptavidin R-Phycoerythrin Conjugate) mixture containing 
the fluorescent marker (product ref: 000020100, Progenika Biopharma 
S.A.) and SAPE Dilution Buffer (product ref: 000020200, Progenika 
Biopharma S.A.) were brought to room temperature and the SAPE 
vortexed and spun rapidly. A labelling mix was then prepared using the 
SAPE Dilution Buffer and the SAPE reagent (volumes μL) as shown in 
table 2.4. The labelling mix was then vortexed and protected from the 
light by covering with aluminium foil.  
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Table 2.4 Fluorescent labelling mix 
The hybridised DNA attached to the allele specific beads was then 
labelled with a fluorescent mix for detection and quantification by the 
Luminex analyser. The labelling mix using the SAPE Dilution Buffer and 
the SAPE reagent (volumes μL) for different batch sizes of patient 
samples are shown in the table below.  
Number of 
samples 
1 8 24 48 
SAPE 
Dilution 
Buffer 
87 696 2088 4176 
SAPE 4.6 36.8 110.4 220.8 
 
 
 
At the 52°C hold step in the thermal cycler program (shown in table 2-3) 
the lid was opened, and the silicone pads and sealing film carefully 
removed. Labelling mix (80μL) was then dispensed into each well of the 
hybridisation plate and gently mixed by pipetting up and down. The 
samples were then immediately analysed on the Luminex X-Map® 
system. Fluorescent labelling is stated here in volumes rather than final 
concentrations, as stated in the IDCOREXT package insert, and in 
accordance with confidential, proprietary information (kit product ref: 
1020120034, Progenika Biopharma S.A.).  
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2.4.3 Luminex xMAP Analyser 
 
2.4.3.1 Luminex® X-Map system analysis 
 
 
The Luminex Gold heater block was placed on the plate holder and the 
temperature was set to 52°C to correlate with the hold temperature of the 
thermal cycler as rapid cooling of the samples could result in non-specific 
hybridisation (it is a recommendation of the Luminex assay process that 
the temperature is maintained through the process).   This was done one 
hour in advance of the labelling phase to enable the heater block to reach 
the correct temperature. 
 
Prior to analysis, the Luminex analyser was calibrated using the following 
reagents (used as per manufacturer’s instructions, Luminex® 
xPONENT® 3.1 Quick Guide, Luminex Corporation)  
 
xMAP Classification Calibrator Microspheres (CAL 1), polystyrene 
microspheres internally labelled with fluorescent dyes and intended to 
normalise the kittings for the classification channels (CL1 and CL2). 
 
xMAP Reporter Calibrator Microspheres (CAL 2), polystyrene 
microspheres internally labelled with fluorescent dyes and intended to 
normalise the analyser reporter channel (RP1) 
 
xMAP Classification Control Microspheres (CON1), polystyrene 
microspheres internally labelled with fluorescent dyes and intended to 
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verify the calibration and optical integrity for the classification channels 
and the doublet discriminator channel. 
 
xMAP Reporter Control Microspheres (CON2), polystyrene microspheres 
internally labelled with fluorescent dyes and intended to verify the 
calibration and optical integrity for the reporter channel. 
 
Batches for the sample runs were created on the Luminex® xPONENT® 
3.1 software (in accordance with the manufacturer’s instructions) using 
the Create a New Batch from an existing Protocol option in the 
batches tab. The corresponding protocol (TLMX_ID-COREXT) was then 
selected. The batch run was named and the sample identification 
numbers were manually input into the corresponding positions on the 
plate layout. 
 
A negative control was run with the sample batch, as per manufacturer’s 
recommendation. Due to the limited funding for the research it was not 
possible to include a positive control as well.  The negative control was 
performed by setting up a test reaction with molecular biology grade 
water known to be free of any DNA contamination.  
 
The Eject icon was clicked to eject the plate holder, and the hybridisation 
plate was placed into the plate holder. The Retract icon was then 
selected to place the plate holder into the analyser ready for analysis. 
The analysis process was then started, once the batch analysis had been 
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completed the data was exported as a comma separated values (csv) file 
and saved into a folder labelled with the batch name.  
 
The IDCOREXT analysis software was then used to convert the raw data 
into a report including the predicted phenotype. The analyser raw data 
includes internal quality control designed to identify any invalid results 
and prevent reporting of potentially incorrect genotypes and phenotypes. 
A “green” alert denotes a valid analysis for genotype and predicted 
phenotype. Invalid results are denoted by the following alerts: 
 Indeterminate genotype – the software is not able to assign a 
result for one or more polymorphisms. 
 Low signal intensity – the signal intensity does not fulfil the 
acceptable threshold for one or more polymorphisms. 
 Low bead count – the bead count does not reach the acceptable 
threshold for one or more polymorphisms. 
 Unknown genotype(s) and predicted phenotype(s) – a particular 
combination of SNPs is not included in the software. The genotype 
has not been previously described as associated to a phenotype. 
In this circumstance an alternative method should be used to 
confirm the genotype and serology used to predict the phenotype. 
 Invalid test – the sample analysis result is not acceptable. 
 Invalid reading – the raw data cannot be analysed by the software. 
In the event of invalid results, a report will not be generated and the 
sample(s) must be re-tested. The raw data obtained from the analysis 
can be seen in appendix 4.  
118 
 
2.5 Randomised Controlled Trial 
 
 
A total number of 60 patients were recruited to the pilot study, selected 
from patients attending the haematology out-patient clinic. The number of 
participants was calculated to provide 80% power to detect an 
acceptance rate of 85% or lower if the true acceptance rate in the 
population is 95% using a one-sided binomial test of size α = 0.05 (as 
determined with Dr Paul White (University of the West of England) and in 
accordance with Moore et al., 2011).  
 
The eligibility criteria for recruitment was that the patient was an adult 
capable of giving informed consent for inclusion into the trial, in 
accordance with the Mental Capacity Act 2005, and that there was no 
record of historic red cell antibodies on the patient’s electronic records. 
The pilot study was approved by the Cornwall and Plymouth Research 
Ethics Committee on the 5th September 2012 (MREC No.12/SW/0251 
R&D Study No. 13017733) and patient information leaflets were provided 
for all patients approached for recruitment into the trial. Recruitment 
commenced on the 9th November 2012 and the required number of 
recruits was reached by the 16th July 2014. Patients were randomly 
assigned to one of two groups; the standard care group, who had a 
standard blood group performed for ABO and RhD type and would 
receive blood matched only for ABO and RhD groups or to the 
intervention group, who, in addition to the standard care, also had their 
blood typed for Rh (CcEe) and K antigens and were flagged on the 
pathology computer system to receive blood matched for the additional 
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antigen types. Provision was made for the intervention group patients to 
receive standard blood for transfusion should there be an emergency 
situation that did not allow for additional time for the acquisition or 
matching of blood with the extra antigens. Laboratory staff was requested 
to create a comment on the pathology computer system (visible to 
laboratory staff only) in the event that matched blood could not be 
provided from the routine blood stocks in the time frame required by the 
clinical team attending the patient.  
 
Patients were assigned to the standard care or intervention group using a 
modified block randomisation technique to ensure that the groups were 
comparable in size and the total number of patients recruited amounted 
to 60. The two groups were allocated a number (1 for the standard care 
and 2 for the intervention); each number was registered on 30 separate 
pieces of paper which were then sealed into 60 individual envelopes. 
Upon recruitment of each patient an envelope was selected at random by 
a healthcare member of staff not related to the research and the 
researcher was then informed of the allocated group of the patient. If the 
patient was allocated to the intervention group the researcher then 
requested that the patient blood group sample was typed for Rh (CcEe) 
and K antigens, in addition to the standard ABO and RhD. A clinical note 
was then added to the patient electronic record on the pathology 
computer system stating the patient Rh (CcEe) and K antigen type and 
the antigen requirements of blood that would be required in the event of a 
transfusion.  
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The patients remained in the trial until it was closed on the 31st July 2015, 
at this point data were collected for each patient which included: 
 Number of patients transfused in each study group 
 Recruitment rates  
 Underlying disease condition of the patient 
 Number of units of blood transfused during the trial period 
 Number of transfusion episodes  
 Provision of matched red cell units for patients in the intervention 
group 
 Development of any red cell allo/autoantibodies  
 Length of time that the patient had been included in the trial.  
 Rh (CcEe) and K antigen type of the patient 
 Frequencies of Rh phenotypes  
This data was collated on an excel file and subjected to statistical 
analysis in order to investigate any significant differences between the 
number of units of blood transfused during the trial period, the number of 
transfusion episodes, development of any red cell allo/autoantibodies and 
the length of time that the patient had been included in the trial. 
 
Ethnicity of the patients was not included in the data collection, primarily 
because this data is not recorded in the pathology computer system as 
part of the patient demographics. It was not felt necessary to request this 
information at recruitment as part of the purpose of the pilot study was to 
review the availability of matched blood from routine stocks held in the 
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transfusion laboratory. The region served by the RD&E does not have an 
ethnically diverse population; the Exeter census profile (2011) reported 
80.49% of the population to be white British. The results of the pilot study 
could then be used to review the ease of providing matched blood from 
the current stocks, and to direct any changes that may be required to 
blood ordering and stock storage.  
 
 
2.6 STATISTICAL ANALYSIS 
 
2.6.1 Retrospective review of haematology and renal patients 
 
 
Patient information obtained from the retrospective review of 
haematology and renal transfusions, excluding any personal identifiers, 
was input into an excel spreadsheet and analysed using SPSS version 19 
(see appendices 1 and 2). Fisher’s Exact Test was used to examine 
associations between allo/autoimmunisation and categorical factors 
(gender, immunosuppression) and the independent samples t-test was 
used to examine any associations on numeric scale variables (age at first 
transfusion, number of units transfused, number of transfusion episodes).    
 
Correspondence analysis was used to investigate any associations 
between red cell antibody type (alloantibody only, allo- and autoantibody 
in combination or autoantibody only) with disease conditions within the 
haematology cohort. Correspondence analysis is a multivariate graphical 
statistical technique designed to depict associations in cross-tabulation 
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tables (Hirschfeld, 1935). The process is a decomposition of the classic 
chi-squared test of association into two orthogonal components which are 
plotted against one another; points which are close on the plot show 
positive associations. The process is a non-parametric exploratory 
depiction of potential associations and is not based on the ideas of 
statistical significance. The technique allows an exploration of 
relationships between multiple categorical variables at the same time, 
removing the need to conduct separate chi-square tests for each pair of 
variables (Sourial et al, 2010). 
 
2.6.2 Comparison of the manual and automated red cell 
phenotyping results 
 
Red cell antigen typing results obtained using serological automated 
testing were directly compared to those obtained by current manual 
techniques. Red cell antigen results obtained by serological automated 
testing using the NHSBT commercial red cell panels were compared to 
the known antigen status as recorded on the antigen profile sheets 
supplied with the panels (see figures 2.5 – 2.7). 
 
2.6.3 Comparison of the serological phenotyping and genotyping 
results 
 
Red cell antigen types obtained using the automated serological 
phenotyping techniques were directly compared to the antigen type 
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predicted by the genotyping technique, with result types being identified 
as positive or negative.  
 
2.6.4 Review of the pilot study – randomised controlled trial 
 
Patient information obtained from the pilot study involving haematology 
patients, excluding any personal identifiers, was input into an excel 
spreadsheet and analysed using SPSS version 19. Fisher’s Exact Test 
was used to examine any differences in the number of patients in the 
standard care group that received a transfusion compared to the number 
in the intervention group. The t-test was used to investigate any 
significant differences between the two groups with regard to numeric 
scale variables, time spent in trial, number of units transfused and 
number of transfusion episodes. 
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3 RETROSPECTIVE REVIEW RESULTS 
 
3.1 Introduction 
 
This study reports on a retrospective review of over 1000 patients 
admitted for at least one blood transfusion into the haematology inpatient 
ward and outpatient day case ward, and over 800 patients transfused as 
a result of renal insufficiency in a National Health Service (NHS) 
Foundation Trust hospital. The data collected for each patient included 
the total number of units of blood transfused, number of transfusion 
episodes, age at first documented transfusion, gender, diagnosis, 
intensity of treatment regime and extent of immunosuppression. A 
tabulated summary of the raw data obtained for the retrospective review 
can be seen in appendix 1 (haematology cohort) and appendix 2 (renal 
cohort).  
 
Concomitant platelet therapy and the requirement for irradiated blood 
components were used as surrogate markers for severe 
immunosuppression in the haematology patients, as historical studies 
have suggested this may result in a tolerance to alloimmunisation 
(Schonewille et al., 1999; Holohan et al., 1981; Dutcher et al., 1981; 
Asfour et al., 2004; Ramsey et al., 1989). Renal transplant was used as a 
marker for severe immunosuppression in patients transfused on the renal 
wards. Renal transplant patients are treated with life-long or long-term 
immunosuppressive drugs aimed at reducing the risk of acute graft 
rejection, often using multiple immunosuppressive agents (Lee and 
Gabardi, 2012). Immune suppression is achieved either by depleting the 
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number of lymphocytes, diverting the lymphocyte traffic or by blocking the 
lymphocyte response pathway (Hallorhan, 2004). Patients receive 
induction therapy of high dose immunosuppressives at the time of the 
transplant to prevent acute rejection (Norman and Turka, 2001; 
Hallorhan, 2004; Nashan, 2005; Terasaki and Mizutani, 2006; Cornell et 
al., 2008; Gabardi et al., 2011) followed by a lower maintenance dose 
using a combination of drugs (Gaston, 2001; Zhang, 2013). Suppression 
of the immune system in renal transplant to reduce the risk of production 
of HLA alloantibodies could also, in theory, reduce the risk of production 
of red cell antibodies in transfused renal transplant patients. 
 
The aim of this review was to identify potential risk factors and/or 
protective factors related to the production of allo and/or autoantibodies 
within these groups of chronically transfused patients. This information 
could then be used to identify an allo/autoantibody immunisation risk 
group that would benefit from extended red cell phenotyping and 
matching of blood for transfusion. Risk factors for alloimmunisation, such 
as the number of red cell transfusions (Zalpuri et al., 2012) and the 
gender of the recipient (Hoeltge et al., 1995) have already been 
suggested and, in addition, it is also known that patients who develop one 
alloantibody are more likely to produce additional antibodies following 
subsequent red cell transfusion (Schonewille et al., 1999; Fluit et al., 
1990). The identification of a high risk group destined for chronic red cell 
transfusion therapy would help to target the implementation of a strategy 
for pre-transfusion extended red cell antigen phenotyping and matching 
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of blood for transfusion in this group of patients. Such a strategy could 
have the potential to reduce the risk of alloimmunisation, in turn reducing 
the burden of additional testing for the hospital transfusion service and 
the risk of transfusion reactions in the patients. 
 
3.2 Patients with haematological malignancies 
 
A total of 1107 records of patients admitted to the haematology wards for 
transfusion were reviewed, 1006 patients for anaemia secondary to 
haematological disorders, 54 with solid organ cancer and 47 for anaemia 
secondary to other conditions (see table 3-1).  The 1107 patients 
received a total of 31,890 units of red cells during 14,013 clinical 
episodes, the average number of units transfused was 29 (SD 42.1). The 
average number of transfusion episodes was 13 (SD 17.1) and the age of 
the patients at first recorded transfusion ranged from 13 to 99 with an 
average of 72 years (SD 14.7). 
 
Of the 1107 patients, 256 (23%) either presented with, or developed, allo 
and/or autoantibodies to red cell antigens. Of the original 1107 patients 
sixty patients (5.4%) presented with allo and/or autoantibodies at the first 
recorded test, of these, 21 (1.9%) presented with an identifiable red cell 
alloantibody only. Eleven (18.3%) of the 60 patients who presented with 
red cell allo and/or autoantibodies developed additional allo and/or 
autoantibodies following transfusion.  
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A total of 1086 patients presented with no detectable red cell 
alloantibodies, 140 (12.9%) developed one or more alloantibodies post 
transfusion. The average number of units given prior to the production of 
allo/autoantibodies was 15.46 (maximum =270, minimum = 2, average = 
5.5, SD = 6.35). 
 
 
3.2.1 Antibodies and disease conditions 
 
Allo and/or autoantibodies were most commonly seen in patients with 
haemolytic anaemia (78%), aplastic anaemia (57%), Waldenström 
macroglobulinaemia (42%) and chronic lymphocytic leukaemia (39%). 
Within the disease groups chronic myeloid / monocytic leukaemia 
(CMML), myelodysplastic syndrome (MDS) and myeloproliferative 
disorder (MPD), 30% of patients were found to have allo/autoantibodies. 
In addition 30% of patients transfused for less common haematological 
conditions (shown as “other” in table 3-1), such as amyloidosis, 
sideroblastic anaemia and essential thrombocythaemia, were found to 
have allo/autoantibodies.   Allo/autoantibodies were less commonly seen 
in patients with acute lymphocytic leukaemia (0%), Hodgkin’s lymphoma 
(7%) and non-Hodgkin’s Lymphoma (16%). Table 3-1 shows the number 
of patients with allo and/or autoantibodies in relation to disease condition. 
It is important to note that in some of the groups the percentages quoted 
may be high, or low, because the patient numbers are small. 
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Table 3.1: Allo/autoantibodies and disease conditions 
A retrospective review of patients transfused within the haematology cohort (n=1107) 
was performed to investigate any associations between the risk of development of 
allo/autoantibodies and the disease status of the patient.  This table shows the total 
number of patients reviewed in each disease group, along with the number of patients in 
that group found to have allo/autoantibodies and the relative percentage.  
 
Disease Total 
number of 
patients 
Number of patients 
with 
allo/autoantibodies 
% with 
allo/autoantibodies 
Acute lymphocytic 
leukaemia 
14 0 0 
Acute myeloid leukaemia 
 
145 35 24 
Anaemia 
 
26 7 27 
Aplastic anaemia 
 
14 9 57 
Chronic 
myeloid/monocytic 
Leukaemia 
20 6 30 
Chronic lymphocytic 
leukaemia 
57 22 39 
Haemolytic anaemia 
 
9 7 78 
Hodgkin’s lymphoma 
 
29 2 7 
Lymphoma 
 
61 13 21 
Myelodysplastic 
syndrome 
 
151 45 30 
Myeloma 
 
187 33 18 
Myeloproliferative 
disorders 
 
23 7 30 
Non-Hodgkin’s 
lymphoma 
 
258 41 16 
Solid organ cancer 
 
54 10 19 
Other 
 
47 14 30 
Waldenström 
macroglobulinaemia 
12 5 42 
 
 
 
129 
 
Further analysis of the incidence of alloantibodies only, alloantibodies in 
combination with autoantibodies, and autoantibodies only, was performed 
in some of the disease conditions (Table 3-2). Correspondence analysis 
was performed to investigate any associations between disease status 
and antibody type (Figure 3.1). This demonstrated that haemolytic 
anaemia, MDS, and MPD show an association with allo and autoantibody 
in combination, whereas AML, CLL and aplastic anaemia are associated 
with autoantibody production only. Four (57.1%) of the seven immunised 
patients with haemolytic anaemia had alloantibodies in combination with 
autoantibodies. One patient with a non-autoimmune haemolytic anaemia 
developed anti-Fya and anti-Chido-Rogers. Twelve (54.5%) of the 22 
immunised patients with CLL had autoantibodies only, 9 (40.9%) 
developed autoantibodies in combination with alloantibodies and one 
patient developed an alloantibody only. Twenty six (57.8%) of the 
immunised patients with MDS had alloantibodies in combination with 
autoantibodies, 11 (24.4%) had alloantibodies only and eight (17.8%) had 
autoantibodies only. 
 
 
 
 
130 
 
Table 3.2: Red cell antibody type in relation to disease 
Analysis of red cell antibody type in relation to disease within the immunised patient group (n=256) in the haematology 
patient cohort (n=1107) was performed for a selection of disease groups. Antibody types are grouped into alloantibody only, 
allo and autoantibody in combination and autoantibody only. The total number of immunised patients in each disease group 
is represented, along with the total numbers of patients within each disease group with certain antibody types and the 
representative percentages. 
 
Disease 
Total number of 
immunised patients 
Alloantibody only Allo and autoantibody Autoantibody only 
MDS 45 11 (24.4%) 26 (57.8%) 8 (17.8%) 
AML 35 10 (28.6%) 11 (31.4%) 14 (40.0%) 
Myeloma 33 13 (39.4%) 13 (39.4%) 7 (21.2%) 
CLL 22 1 (4.5%) 9 (40.9%) 12 (54.5%) 
Lymphoma 13 4 (30.8%) 5 (38.5%) 4 (30.8%) 
Solid organ cancer 10 7 (70.0%) 3 (30.3%)                         0 (0.0%) 
Aplastic anaemia 9 2 (22.2%) 3 (33.3%) 4 (44.4%) 
Haemolytic anaemia 7 1 (14.3%) 4 (57.1%) 2 (28.6%) 
Myeloproliferative 
disorders 
7  1 (14.3%) 4 (57.1%) 2 (28.6%) 
CML/CMML 6 0 (0.0%) 3 (50.0%) 3 (50.0%) 
Waldenström 
macroglobulinaemia 
5 2 (40.0%) 1 (20.0%) 2 (40.0%) 
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Figure 3.1: Correspondence analysis of the association between 
disease types and antibody types in the Haematology cohort 
 
 
Correspondence analysis showing clusters of disease types associated 
with antibody type in the immunised patients within the haematology 
cohort (n=256). The blue squares represent the antibody type 
(alloantibody only, autoantibody only and allo and autoantibody in 
combination) and the red circles represent the disease type. The 
components (1 and 2) and the X and Y axes are derived from a process 
known as eigenvalue decomposition of the chi-square test of association. 
The “map” produced by this process will demonstrate any relationships 
between the variables by the proximity of the plotted points; haemolytic 
anaemia, MDS, and MPD show an association with allo and autoantibody 
in combination, whereas AML, CLL and aplastic anaemia are associated 
with autoantibody production only. Analysis performed by Dr Paul White, 
University of the West of England. 
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3.2.2 Antibody Specificities 
  
Of the 256 red cell antigen immunised patients, 70 (27.3%) developed 
alloantibodies only, 101 (39.4%) developed alloantibodies in combination 
with autoantibodies and 85 (33.2%) developed autoantibodies only. The 
incidence of antibody specificities is presented in figure 3.2. A total of 242 
alloantibodies were detected, of these 71 (29.3%) could not be identified. 
Of the 171 identifiable alloantibodies 114 (66.7%) were to Rh (D, C, c, E, 
e) or Kell antigens. The most common specificity was anti-E (21.5%), 
followed by anti-K (11.6%) and anti-C (7.4%). Two hundred and four 
autoantibodies were detected, 18 (8.8%) had definable specificities within 
this group auto-anti-e was the most common (61%). Autoantibody 
specificity was either confirmed at the reference laboratory (NHSBT) (11 
patients) or assigned in the transfusion laboratory based on antibody 
identification and phenotype results (7 patients). Antibodies to variant 
antigens were not excluded for any of these patients. Of the 256 red cell 
antigen immunised patients, 101 (39.2%) had alloantibodies in 
combination with autoantibodies. Of these 101 patients, 80 (79.2%) 
developed the autoantibody after the alloantibody, 8 (7.9%) developed 
the alloantibody after the autoantibody, 9 (8.9%) presented with 
alloantibody and autoantibody in combination, and 4 (3.9%) developed 
allo and autoantibody in combination following transfusion. Analysis of the 
specificities of patients with identifiable alloantibodies revealed 60 
patients with single specificity (61.6%), 28 with two alloantibodies (25%), 
11 with three antibodies (9.8%), three with four antibody specificities 
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(2.7%) and one patient who developed five separate alloantibodies 
(0.9%). 
 
Patients (n=186) who presented with, or developed autoantibodies had 
records detailing the type of antibody or complement fraction on the 
surface of their red cells. Within this group 140/186 (75.3%) were found to 
have IgG only, 17/186 (9.1%) were found to have C3d only and 29/186 
(15.6%) were found to have a combination of IgG and C3d. 
Autoantibodies of a transient nature could be demonstrated in 117 of the 
186 patients (62.9%). 
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Figure 3.2: Incidence of antibody specificities within the 
haematology cohort 
 
 
 
The incidence and specificity of allo- and autoantibodies within the immunised 
group of the haematology patient cohort (n=256). The specificity of the antibody 
is shown on the Y-axis, alloantibodies are denoted by the antigen specificity and 
autoantibodies are denoted separately. Autoantibodies showing no specificity 
were most commonly seen in this cohort of patients (n=186/256), within the 
group of autoantibodies demonstrating a red cell antigen specificity, auto anti-e 
was the most common (n=11/18). Alloantibodies to antigens within the Rh and 
Kell blood group systems were the most common (n=114/171). (AHG = Anti-
human globulin).   
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3.2.3 Antibodies and patient factors 
 
3.2.3.1 Gender and immunisation rates 
 
Of the 1107 patient records reviewed in the haematology cohort, 532 
were female and 575 were male. Analysis (Figure 3.3a) of the 
allo/autoantibody immunisation rate in males (122/575, 21.22%) and 
females (134/532, 25.19%) showed no statistical significant difference 
(Fisher’s Exact Test P=0.1340). In addition, no significant difference was 
seen in the rates in males (81/575, 14.10%) and females (90/532, 
16.92%) with alloantibodies only (Fisher’s Exact Test P=0.1310) (Figure 
3.3b).  
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Figure 3.3: Immunisation rates in males and females within the Haematology cohort 
A                      B 
                   
 
Graphs showing the allo/autoimmunisation rates in males and females in the haematology cohort (n=1107). The number of patients who did not 
demonstrate allo/autoimmunisation is denoted by the blue bar and the number with red cell allo/autoimmunisation is denoted by the red bar. 
Statistical analysis of the allo/autoantibody immunisation rate in males (122/575= 21.22%) and females (134/532 =25.19%) showed no significant 
difference (Fisher’s Exact Test P=0.1340) Figure A. In addition there was no significant difference seen in the rates in males (81/575=14.10%) and 
females (90/532=16.92%) with alloantibodies only (Fisher’s Exact Test P=0.1310) Figure B.  
 
0
100
200
300
400
500
600
700
Female Male
Gender
N
u
m
b
e
r 
o
f 
p
at
ie
n
ts
 
Patients with
allo/autoimmunisation
Patients without
allo/auto immunisation
0
100
200
300
400
500
600
700
Female Male
Gender
N
u
m
b
e
r 
o
f 
p
at
ie
n
ts
 
Alloimmunised
Non immunised
137 
 
 
 
3.2.3.2 Age and immunisation rates 
 
The age of patients receiving blood transfusions in the haematology 
cohort ranged from 13 to 99 years (n=1107). The mean age at the first 
recorded transfusion for patients with allo/autoimmunisation was 69.18 
(range 13-95 years, standard deviation (SD) 14.62) and the mean age for 
those patients without allo/autoantibodies was 69 years (range 18-99, SD 
14.73). There was no statistically significant difference between the mean 
age at first recorded transfusion and the incidence of allo/autoantibody 
immunisation (t-test P=0.8637). Further review of patients to investigate 
any relationship between age at first recorded transfusion and the 
development of alloantibodies only revealed a mean age at first recorded 
transfusion of 69.82 (SD 14.22) for those with alloimmunisation and a 
mean age of 69 (SD 14.73) for the non-immunised patients (Figures 3.4A 
and 3.4B respectively). Again, no statistical significance was 
demonstrated (t-test P= 0.5042) 
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Figure 3.4: Influence of age at first transfusion and allo/autoantibody development within the haematology cohort 
A                B 
            
 
Box-and-whiskers plots showing the minimum and maximum age at first transfusion (black line), the first quartile, median (second quartile) and third quartile. This 
figure shows the age at first recorded transfusion in patients in the haematology cohort (n=1107) with or without allo/autoantibodies (figure A) and with or without 
alloantibodies only (figure B). There was no significant difference between the mean age at first recorded transfusion and the incidence of allo/autoantibody 
immunization (mean 69.18 years, SD14.62) compared to the non-immunised group (mean = 69 years, SD14.73) (t-test P=0.8637); Figure A. Figure B shows the 
mean age at first recorded transfusion in patients with alloantibodies only (mean 69.82, SD 14.22) and those non-immunised (mean = 69, SD 14.73), no significant 
difference was seen (t-test P= 0.5042).  
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3.2.3.3 Immune suppression and incidence of immunisation 
 
Concomitant platelet support and the requirement for irradiated blood 
were used as surrogate markers for immune suppression in order to 
investigate any relationship between immune suppression and the 
incidence of immunisation to red cell antigens. In the haematology cohort 
(n=1107) 534 patients were recorded as having received concomitant 
platelet therapy, of these 123 (23.0%) patients had a recorded allo/auto 
antibody. The incidence of allo/autoantibodies in patients not receiving 
any platelet support (n=573) was 23.2%. Therefore, concomitant platelet 
therapy appeared to have no influence on the rate of allo/autoantibody 
formation (Fisher’s Exact Test P=1.00). Further analysis of patients with 
alloantibodies only revealed that 79 (14.8%) of the 534 patients receiving 
platelets were recorded as having alloantibodies and 92 (16.0%) had no 
alloantibodies, also showing no statistically significant difference 
(P=0.6750) (figures 3.5a and b respectively). 
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Figure 3.5: Influence of immune suppression (platelet requirement) on allo/autoantibody development in the 
haematology cohort 
A            B 
                                  
 
Concomitant platelet therapy was used as an indicator of immune suppression. In the haematology cohort (n=1107) 534 patients were recorded as 
having received concomitant platelet therapy, of these 123 (23.0%) patients had a recorded allo/auto antibody. The incidence of allo/autoantibodies 
in patients not receiving any platelet support (n=573) was 23.2%. Therefore, concomitant platelet therapy had no influence on the rate of 
allo/autoantibody formation (Fisher’s Exact Test P=1.00) or on the rate of alloimmunisation only (P=0.6750) (Figures A and B respectively). 
0
100
200
300
400
500
600
700
No Yes
 Platelet Therapy
N
u
m
b
e
r 
o
f 
p
at
ie
n
ts
 
Allo/auto immunised
Non immunised
0
100
200
300
400
500
600
700
No Yes
Platelet Therapy
N
u
m
b
e
r 
o
f 
p
at
ie
n
ts
 
alloimmunised
non immunised
141 
 
 
 
A total of 362 patients in the haematology cohort were given irradiated 
blood components, 91/362 (25.1%) of these patients developed an 
allo/autoantibody and 165/745 (22.2%) of patients not requiring irradiated 
blood components had allo/autoantibodies. Analysis of patients with 
alloantibodies only demonstrated an incidence 14.6% (53/362) in patients 
receiving irradiated components and 15.6% (116/745) in patients not 
receiving irradiated components.  Therefore the requirement for irradiated 
blood components appeared to have no influence on the rate of 
allo/autoantibody formation (Fisher’s Exact Test P=0.2876) or on the rate 
of alloimmunisation (P= 0.6750) (Figures 3.6a and b).  
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Figure 3.6: Influence of immunosuppression (irradiated requirement) on allo/autoantibody development in the 
haematology cohort 
A          B 
      
The allo/autoimmunisation rate in patients with a requirement for irradiated blood components was 25.1% (91/362) compared to 22.2% (165/745) 
not requiring irradiated blood components (figure A). Analysis of patients with alloantibodies only demonstrated an incidence 14.6% (53/362) of 
alloantibodies in patients receiving irradiated components and 15.6% (116/745) in patients not receiving irradiated components (Figures B).  
Therefore the requirement for irradiated blood components appeared to have no influence on the rate of allo/autoantibody formation (Fisher’s Exact 
Test P=0.2876) or on the rate of alloimmunisation (P= 0.6750).  
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3.2.3.4 Number of transfusions and incidence of immunisation 
 
 
In the haematology cohort (n=1107) the average number of transfusion 
episodes recorded over the review period for all patients was 13 (range 1-
155) and the average number of units given to the patients was 29 (range 
1-382).  
 
In the immunised group (n=256) the average number of transfusion 
episodes was 20.3 (SD 23.68), compared to an average of 10.36 (SD 
13.33) episodes in the non-immunised group (n=851), demonstrating a 
statistically significant difference in the number of transfusion episodes 
and the incidence of allo/autoimmunisation (t-test P=<0.0001) (figure 
3.7a). Further analysis of immunised patients showed a significant 
difference in the number of transfusion episodes between patients with 
alloantibodies only (average 21.57, SD 24.98) and those with allo and 
autoantibodies (average 45.95, SD 57.45 (t-test P= 0.0007), as shown in 
figure 3.7b. In addition, a significant difference was also demonstrated in 
the number of transfusion episodes in patients with allo +/- autoantibodies 
(average 23.04, SD 24.93) compared to those with autoantibodies only 
(average 13.37, SD 16.95) (t-test P= 0.0014), as shown in figure 3.7c. 
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Figure 3.7: Influence of the number of transfusion episodes on the development of all/autoantibodies in the 
haematology cohort 
A                   B                         C 
             
Box-and-whiskers plots showing the minimum and maximum numbers (black line) of transfusion episodes (figure A) (the first quartile, median 
(second quartile) and third quartile are denoted by the coloured blocks) in immunised and non-immunised patients in the haematology cohort 
(n=1107). There was a statistically significant difference (t-test P=<0.0001) in the number of transfusion episodes in the immunised group (n=256, 
average number of episodes 20.3, SD 23.68) compared to the non-immunised group (n=851 average10.36, SD 13.33) (figure A). A significant 
difference (t-test P= 0.0007), was also seen in the number of transfusion episodes in patients with alloantibodies only (average 21.57, SD 24.98) 
compared to those with allo and autoantibodies (average 45.95, SD 57.45) as shown in figure B and also between those with allo+/-autoantibody 
(average 23.04, SD 24.93) and those with an autoantibody only (average 13.37, SD 16.95) (t-test P= 0.0014) as shown in figure C. 
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Analysis of the number of red cell units transfused within the haematology 
cohort (n=1107) during the review period revealed that the number of 
units transfused ranged from 1 to 382, with an average of 29 (SD 42.1). 
The average number of red cell units given to patients in the immunised 
group (n=256) was 46.99 (SD 59.65) compared to 23.43 (SD 32.04) in 
the non-immunised group (n=851), demonstrating a statistically significant 
difference (t-test P=<0.0001), as shown in figure 3.8a. This difference 
was also seen in the number of units given in patients with allo +/- 
autoantibodies (n=171, average number of units given 54.42, SD 65.40) 
compared to those with autoantibodies only (n=85, average number of 
units given 32.72, SD 42.82) (t-test P= 0.0059), as shown in Figure 3.8b. 
 
This demonstrates that the risk of developing an allo +/- autoantibody 
increases as the number of transfusion episodes and number of red cell 
units given increases. However, the incidence of autoantibodies alone 
does not appear to be influenced by the number of transfusion episodes 
or number of units given. 
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Figure 3.8: Influence of the number of red cell units transfused on the development of allo/autoantibodies in the 
haematology cohort 
   A                                       B 
                                           
 Box-and-whiskers plots showing the minimum and maximum numbers (black line) of red cell units transfused and numbers of red cell units transfused (the first 
quartile, median (second quartile) and third quartile are denoted by the coloured blocks) in immunised and non-immunised patients in the haematology cohort 
(n=1107). The average number of red cell units given to patients in the immunised group (n=256) was 46.99 (SD59.65) compared to 23.43 (SD 32.04) in the non-
immunised group (n=851), demonstrating a statistically significant difference (t-test P=<0.0001) (figure A). The number of units given in patients with allo +/- 
autoantibodies (n=171, average number of units given 54.42, SD 65.40) compared to those with autoantibodies only (n=85, average number of units given 32.72, SD 
42.82) (t-test P= 0.0059), as shown in Figure B.                                                    
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3.2.3.5 Time between transfusions and the incidence of 
immunisation 
 
Analysis was performed on the time (in days) between transfusion 
episodes for patients within the haematology cohort (n=1107). The time 
between transfusion episodes for all patients ranged from 0 to 2882 days, 
with an average time of 107.39 (SD 220.42) days. The average time 
between transfusion episodes for the immunised patients was 113.3 (SD 
192.42) days (n=256, range 0 to 1629 days) compared to an average of 
102.5 (SD 228.22) days for non-immunised patients (n=851, range 0 to 
2882.5 days).  There was no significant difference seen in the average 
time between transfusion episodes in the two groups (t-test P=0.4925), as 
shown in figure 3.9. This suggests that the frequency at which the 
recipients are exposed to foreign red cell antigens does not influence the 
development of allo/autoantibodies. 
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Figure 3.9: Influence of the frequency of transfusion episodes on the development of allo/autoantibodies in the 
haematology cohort 
 
Box-and-whiskers plot showing the minimum and maximum (black line) number of days between transfusion episodes (the first quartile, median 
(second quartile) and third quartile are denoted by the coloured blocks) in the haematology cohort. The average time between transfusion episodes 
for the immunised patients was 113.3 (SD 192.42) days (n=256, range 0 to 1629 days) compared to an average of 102.5 (SD 228.22) days for non-
immunised patients (n=851, range 0 to 2882.5 days).   There was no significant difference seen in the average time between transfusion episodes in 
the two groups (t-test P=0.4925). 
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3.2.4 Transfusion Reactions 
 
Of the 1107 patient records reviewed within the haematology cohort, 24 
(2.17%) were investigated for a suspected transfusion reaction, giving an 
overall transfusion reaction incidence of 1 in 1328.75 units. In the 
immunised group the incidence of investigation of transfusion reactions 
was 11/256 (4.3%) compared to an incidence of 13/851 (1.5%) in the 
non-immunised group. An approximate three fold difference was seen in 
the rate of suspected transfusion reactions in the allo/auto immunised 
group compared to the non-immunised group (see table 3-3). Analysis 
using the Fisher’s Exact Test shows that the difference between the 
groups is statistically significant (P=0.0128).  
 
Patients included within the immunised group for review of suspected 
transfusion reactions were those with known red cell allo/autoantibodies 
being transfused with antigen negative and/or crossmatch compatible 
blood, not patients who had suffered a transfusion reaction as a result of 
development of antibodies subsequent to a transfusion. Therefore the 
difference between the immunised and the non-immunised group is 
suggestive that even when allo/antibodies have been detected and blood 
compatible by current in vitro methods is provided the likelihood of a 
transfusion reaction is higher if the patient has known allo/autoantibodies. 
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Table 3.3: Transfusion reactions in the haematology cohort 
The number of suspected transfusion reactions reported in the 
haematology cohort (n=1107) for immunised (patients with 
allo/autoantibodies) patients was 11/256 and those reported in non-
immunised patients was 13/851. Fisher’s Exact Test shows that the 
difference between the groups is statistically significant (P=0.0128). The 
risk of transfusion reaction was higher in the immunised group despite the 
fact that this group was transfused with blood that was deemed 
compatible by in vitro methods. 
 
 
 Total 
number of 
patients 
 
Number of 
investigated 
transfusion 
reactions 
% 
Non-
immunised 
851 13 1.5 
Immunised 
 
256 11 4.3 
Total 
 
1107 24  
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3.2.5 Cost of additional testing 
 
A total of 6914 serological tests, in addition to the standard ABO and Rh 
D group and antibody screen, were performed for the patients in the 
haematology cohort (n=1107) at a total cost of £50,262.42. A total of 358 
serological tests were performed for the non-immunised patients (n=851) 
compared to 6556 additional tests for the immunised group (n=256). A 
breakdown of the additional serological tests performed and the costs of 
the additional testing are shown in table 3-4. Test costs were calculated, 
using an in-house spreadsheet calculator (Microsoft Excel), taking into 
account reagent costs, equipment maintenance, consumables, quality 
control and staff time incurred during the financial year 2011-2012. Total 
test costs for the additional testing performed on patient samples during 
the retrospective review period were calculated using these current costs, 
although it is accepted that this is not representative of the actual costs of 
the tests performed due to changes in costs of staff salaries over the time 
period reviewed and changes in test procedures, reagents and analysers 
used. 
 
  
152 
 
Table 3.4: Cost of additional testing in the haematology cohort 
The number and cost of additional serological testing performed in 
immunised (256/1107) and non-immunised patients (851/1107) within the 
haematology cohort. The total cost of additional testing for patients with 
allo/autoantibodies was approximately 32 fold greater than that for those 
without antibodies. 
 
 Immunised group 
 
Non immunised group 
Test Number of 
tests 
Cost Number of 
tests 
Additional 
Cost 
Antibody 
identification 
panel 
2694 £19,181.28 0 0 
Direct 
Antiglobulin 
Test 
2174 £9,152.54 355 £1,494.55 
Monospecific 
Coombs test 
1279 £7,098.54 2 £11.10 
NHSBT RCI 
referral 
249 £12,474.90 0 0 
Rh CcEe type 
 
98 £426.30 0 0 
Red cell 
phenotype 
50 £209 1 £4.18 
Autoabsorption 
 
3 £44.88 0 0 
Cold agglutinin 
screen 
9 £165.15 0 0 
Total 
 
6556 £48,752.59 358 £1,509.83 
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3.3 Patients with renal insufficiency 
 
A total of 877 blood transfusion records of patients admitted to the renal 
wards for transfusion were reviewed. The 877 patients received a total of 
11822 units of red cells during 5238 clinical episodes, the average 
number of units transfused was 13.5 (SD 18.36) with a range of 1 to 246. 
The average number of transfusion episodes was 5.98 (SD 7.37) with a 
range of 1 to 67.  The age of the patients at first recorded transfusion 
ranged from 15 to 95 with an average of 68.14 years (SD 14.42). 
 
Of the 877 patients in the renal cohort, 134 (15.3%) either presented with, 
or developed, allo and/or autoantibodies to red cell antigens. Of the 
original 877 patients, 41 patients (4.7%) presented with allo and/or 
autoantibodies at the first recorded test, 27 (3.1%) of these presented 
with a red cell alloantibody only. Five (12.2%) of the 41 patients who 
presented with red cell allo and/or autoantibodies developed additional 
allo and/or autoantibodies following transfusion.  
 
A total of 850 patients presented with no detectable red cell 
alloantibodies, 33 (3.9%) of these developed one or more alloantibodies 
post transfusion  
 
The average number of units given prior to the production of 
alloantibodies was 9.66 (range 0 - 143, SD = 16.79). The average 
number of units given prior to the production of autoantibodies was 11.46 
(range 0 - 91, SD = 18.02).  
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3.3.1 Antibody Specificities 
 
Of the 134 red cell antigen immunised patients in the renal cohort, 60 
(44.78%) developed alloantibodies only, 55 (41.04%) developed 
alloantibodies in combination with autoantibodies and 19 (14.2%) 
developed autoantibodies only. The incidence of antibody specificities is 
presented in figure 3.10. A total of 147 alloantibodies were detected, of 
these 42 (28.6%) could not be identified. Of the 112 identifiable 
alloantibodies 75 (67.0%) were specific to Rh (D, C, c, E, e) or Kell 
antigens. The most common specificity was anti-E (16.3%), followed by 
anti-K (11.6%) and anti-C (11.6%). 
 
 A total of 66 autoantibodies were detected, 7/66 (10.6%) had definable 
specificities with auto-anti-e being the most common (3/7, 42.9%) (figure 
3.10). A total of 34 (25.4%) of the 134 red cell antigen immunised patients 
had alloantibodies in combination with autoantibodies. Of these patients 
six (17.6%) developed the autoantibody after the alloantibody, none 
developed the alloantibody after the autoantibody, 26 (76.5%) developed 
the alloantibody and autoantibody in combination following transfusion 
and two presented with an allo/autoantibody combination (5.9%).  
 
Analysis of the specificities of patients with identifiable alloantibodies 
revealed 38 patients with single specificity (60.3%), 18 with two 
alloantibodies (28.6%), 4 with three antibodies (6.34%) and three with 
four antibody specificities (4.76%). Sixty six patients who presented with, 
or developed autoantibodies had records detailing the type of antibody or 
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complement fraction on the surface of their red cells. Sixty one (61/66, 
92.4%) were found to have IgG only, two (2/66, 3.0%) were found to have 
C3d only and two (2/66, 3.0%) were found to have a combination of IgG 
and C3d. One patient did not have a recorded autoantibody type.  
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Figure 3.10: Incidence and specificity of allo/autoantibodies in the 
renal cohort 
 
 
 
The incidence and specificity of allo- and autoantibodies within the renal patient cohort (n= 877). 
The specificity of the antibody is shown on the Y-axis, alloantibodies are denoted by the antigen 
specificity and autoantibodies are denoted separately. Autoantibodies with no definable specificity 
were most commonly detected (n=58), along with alloantibodies reactive in Indirect Anti Human 
Globulin (AHG) tests with no definable specificity (n=42). The most commonly detected 
alloantibody was anti-E (n= 24), followed by anti-C (n=17) and anti-K (n=17). 
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3.3.2 Antibodies and patient factors 
 
3.3.2.1 Gender and immunisation rate 
 
Of the 877 records reviewed in the renal patient cohort, 339 (38.7%) were 
female and 537 (61.2%) were male. The allo/autoantibody immunisation 
rate in males was 11.7% (63/537), compared to 20.9% in females 
(71/339) demonstrating a significant difference (Fisher’s Exact Test 
P=0.0003) and indicating that females are significantly more likely to 
develop allo/autoantibodies than males in this group of patients (figure 
3.11).  
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Figure 3.11: Influence of gender on the development of 
allo/autoantibodies in the renal cohort 
 
 
 
Incidence of immunisation rates in males and females in the renal cohort 
(n=877). The incidence of immunisation in male patients was 11.7% 
(63/537) compared to an incidence rate of 20.9% (71/339) in female 
patients. A significant difference (Fisher’s Exact Test P=0.0003) was seen 
between allo/autoimmunisation rates in males and females in this group 
of patients. 
  
0
100
200
300
400
500
600
Female Male
Gender
N
u
m
b
er
 o
f 
p
at
ie
n
ts
 
immunised
non-immunised
159 
 
3.3.2.2 Age and immunisation rate 
 
In the renal cohort (n=877) the age of the patients at first recorded 
transfusion ranged from 15 to 95 years with an average of 68.14 years 
(SD14.42). Within the immunised group (n=134) the average age at first 
transfusion was 66.58 years (range 24 – 90, SD 14.70) and within the 
non-immunised group the average age was 68.42 years (range 15 – 95, 
SD 14.36). There was no significant difference between the mean age (in 
years) at first recorded transfusion in the patients with allo/autoantibodies 
and those without (t-test P=0.4599) (figure 3.12), indicating that age at 
first transfusion does not influence the incidence of immunisation. 
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Figure 3.12: Influence of age at first recorded transfusion on the 
development of allo/autoantibodies in the renal cohort 
 
 
 
Box-and-whiskers plot showing the range of age at first transfusion (black line) in the 
immunised and non-immunised patients within the renal cohort (n=877). The first and 
third quartiles and the median (second quartile) are denoted by the red and green 
blocks. The average age at first transfusion in the immunised group was 66.58 years 
(range 24 – 90, SD 14.70) and in the non-immunised group the average age was 68.42 
years (range 15 – 95, SD 14.36). No significant difference was seen between the mean 
age (in years) at first recorded transfusion in the patients with allo/autoantibodies and 
those without (t-test P=0.4599) 
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3.3.2.3 Immune suppression and immunisation rate 
 
Receipt of a renal transplant was used as a surrogate marker of immune 
suppression, within the renal cohort, in order to investigate any 
relationship between immunosuppression and immunisation rate. Forty 
seven patients within this group (n=877) had records indicating that they 
had received a renal transplant. An immunisation rate of 2.1% (7/47) was 
seen in the patients with a record of renal transplant compared to an 
immunisation rate of 15.3% (127/830) in the non-transplanted patients. 
Statistical analysis of the groups showed that there is a statistical 
significance between these rates indicating that immune suppression in 
this group of patients may have a protective effect against immunisation 
to red cell antigens (Fisher’s Exact Test P=0.0029) as shown in figure 
3.13.  
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Figure 3.13: Influence of immunosuppression on the development of 
allo/autoantibodies in the renal cohort 
 
 
 
 Comparison of the incidence of immunisation in renal patients (n=877) with and without 
recorded renal transplant, used as a surrogate marker of immune suppression. An 
immunisation rate of 2.1% (7/47) was seen in the patients with a record of renal 
transplant compared to an immunisation rate of 15.3% (127/830) in the non-transplanted 
patients. The difference in these rates is statistically significant (Fisher ’s Exact Test 
P=0.0029) 
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3.3.2.4 Number of transfusion episodes and incidence of 
immunisation 
 
The number of transfusion episodes and the number of red cell units 
transfused was reviewed for the immunised and the non-immunised 
patients in the renal cohort of patients. The average number of 
transfusion episodes across the patients in this group (n=877) was 5.98 
(range 1-67, SD 7.38). Within the immunised group (n=134), the average 
number of transfusion episodes was 9.69 (range 1-58, SD 11.53), 
compared to an average of 5.30 (range 1-67, SD 6.12) for the non-
immunised group, demonstrating a significant difference in the number of 
transfusion episodes and incidence of allo/autoimmunisation (t-test P= 
<0.0001) (figure 3.14a).  
 
The average number of red cell units transfused to all patients in the renal 
cohort (n=877) was 13.50 (range 1-246, SD 18.36). Within the immunised 
group (n=134), the average number of units was 21.85 (range 2-143, SD 
25.72), compared to an average of 11.97 (range 1-246, SD 16.26) in the 
non-immunised group (n=743), again demonstrating a significant 
difference (t-test P= <0.0001) (figure 3.14b) 
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Figure 3.14: Influence of the number of transfusion episodes and number of units transfused on the development 
of allo/autoantibodies in the renal cohort 
A          B 
                              
 
Box-and-whiskers plot showing the range (black line) of transfusion episodes and number of units given in the immunised and non-immunised patients within the 
renal cohort (n=877). The first and third quartiles and the median (second quartile) are denoted by the red and green blocks. The average number of transfusion 
episodes in the immunised group (n=134, average=9.69, SD 11.53) was significantly different to that seen in the non-immunised group (n=743, average=5.3, 
SD6.12) (figure A). Similarly, the average number of units transfused in the immunised group (n=134, average=21.85, SD25.72) was significantly different to that 
seen in the non-immunised group (n=743, average=11.97, SD 16.26) (figure B) 
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3.3.2.5 Time between transfusion and the incidence of immunisation 
 
 
Time between transfusions, in days, was reviewed for the patients within 
the renal cohort (n=877) to investigate any relationship between the 
incidence of immunisation and the time frames for transfusion of blood 
units. For all patients in this group (n=877), the time (days) between 
transfusion ranged from 0 to 2120.5 days, with an average of 136.64 (SD 
218.09). Within the immunised group (n=134) the average time between 
transfusions was 118.6 days (range 0-931.9, SD 157.65) and within the 
non-immunised group (n=743) the average was 139.5 days (range 0-
2120.5, SD 227.30), demonstrating no significant difference between the 
two groups (t-test P=0.3076) (figure 3.15). This would suggest that the 
frequency (time between transfusion) of exposure to foreign red cell 
antigens does not influence the incidence of immunisation in this group of 
patients. 
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Figure 3.15: Influence of the frequency of transfusion episodes on 
the development of allo/autoantibodies in the renal cohort 
  
 
 
 
 
Box-and-whiskers plot showing the range of time in days (black line) between transfusion 
episodes in the immunised and non-immunised patients within the renal cohort (n=877). The first 
and third quartiles and median (second quartile) are denoted by the red and green blocks. The 
average time between transfusion for the immunised group (118.6 days, range 0-931.9, SD 
157.65) was not significantly different to that seen in the non-immunised group (139.5 days, range 
0-2120.5, SD 227.30) (t-test P=0.3076)  
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3.3.3 Transfusion Reactions 
 
Of the 877 patient records reviewed within the renal cohort, 5 patients 
(0.6%) were investigated for a suspected transfusion reaction, giving an 
overall transfusion reaction incidence of 1 in 2364.4 units. An incidence of 
2.2% of patients were investigated for a suspected transfusion reaction in 
the immunised group (n=134, 3/134), compared to an incidence of 0.3% 
(n=743, 2/743) in the non-immunised group. An approximate eight fold 
difference was seen in the rate of suspected transfusion reactions in the 
allo/auto immunised group compared to the non-immunised group (see 
table 3-5). The difference between the suspected transfusion reaction 
rates between the two groups showed a significant difference (t-test 
P=0.0276), although it should be noted that the number of patients in the 
group that experienced reactions was very small. Patients included within 
the immunised group for review of suspected transfusion reactions were 
those with known red cell allo/autoantibodies being transfused with 
antigen negative and/or crossmatch compatible blood, not patients who 
had suffered a transfusion reaction as a result of development of 
antibodies subsequent to a transfusion, therefore the difference between 
the immunised and the non-immunised group is suggestive that even 
when allo/antibodies have been detected and blood compatible by current 
in vitro methods is provided the likelihood of a transfusion reaction is 
higher if the patient has known allo/autoantibodies. 
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Table 3.5: Transfusion reactions in the renal cohort 
Within the renal cohort (n=877), immunised patients (n=134) showed an 
incidence of 2.24% suspected transfusion reaction compared to just 0.3% 
in the non-immunised cohort (n=743). An approximate eight fold 
difference was seen in the rate of suspected transfusion reactions in the 
allo/auto immunised group compared to the non-immunised group. The 
risk of transfusion reaction was higher in the immunised group despite the 
fact that this group was transfused with blood that was deemed 
compatible by in vitro methods. 
 
 Total 
number of 
patients 
 
Number of 
investigated 
transfusion 
reactions 
% 
Non-
immunised 
743 2 0.27 
Immunised 134 
 
3 2.24 
Total 877 
 
5  
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3.3.4 Cost of additional testing 
 
A review was performed of the additional laboratory testing undertaken 
for the patients within the renal cohort (n=877). A total of 1919 serological 
tests, in addition to the standard ABO and Rh D group and antibody 
screen were performed for the 877 patients at a total cost of £14,604.59. 
A total of 25 additional tests costing £155.53 were performed for the non-
immunised patients (n=743) compared to 1894 additional tests and a cost 
of £13,094.76 for the immunised group (n=134). A breakdown of the 
additional serological tests performed and the costs of the additional 
testing are shown in table 3-6. The cost of testing for patients with 
allo/autoantibodies was approximately nine times greater than that for the 
non-immunised group, compared to the 32 fold difference seen within the 
haematology immunised and non-immunised cohort. Test costs were 
calculated, using an in-house spreadsheet calculator (Microsoft Excel), 
taking into account reagent costs, equipment maintenance, consumables, 
quality control and staff time incurred during the financial year 2011-2012. 
Total test costs for the additional testing performed on patient samples 
during the retrospective review period were calculated using these 
current tests costs, although it is accepted that, as discussed previously 
(section 3.2.5), there is a lack of accuracy due to estimates based on 
current costings. 
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Table 3.6: Cost of additional testing in the renal cohort 
The table shows the additional laboratory tests performed for patients 
within the renal cohort (n=877), the test type, number of tests performed 
and cost of testing is shown for the immunised and non-immunised 
groups. The costs for the additional laboratory tests required for the 
patients within the renal cohort were substantially higher for the 
immunised group (n=134) than those for the non-immunised group 
(n=743). 
 
 Immunised group 
 
Non-immunised group 
Test Number of 
tests 
Cost Number of 
tests 
Additional 
Cost 
Antibody 
identification 
panel 
962 £6,849.44 1 £7.12 
Direct 
Antiglobulin 
Test 
588 £2,475.48 21 £88.41 
Monospecific 
Coombs test 
221 £1,226.55 1 £5.55 
NHSBT RCI 
referral 
44 £2,204.40 1 £50.10 
Rh CcEe type 
 
51 £221.85 1 £4.35 
Red cell 
phenotype 
28 £117.04 0 0 
Total 
 
1894 £13,094.76 25 £155.53 
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3.4 Comparison of renal patients and haematology patients 
 
3.4.1 Gender and the incidence of immunisation 
 
Statistical analysis of the numbers of male and female patients with and 
without allo/autoantibodies treated on the haematology wards showed no 
significant differences, indicating that the sex of the patient had no 
influence on the development of allo/autoantibodies. This difference, 
however, was not replicated in the patients transfused on the renal wards. 
In order to further investigate this anomaly the rates of allo/autoantibody 
production in each of the sexes across the two disciplines were subjected 
to statistical analysis using the Fisher’s Exact Test.  
 
An immunisation rate of 21.2% was seen in the male haematology cohort 
(n=575) compared to a rate of 11.7% in the male renal cohort (n=537). 
Female patients showed an immunisation rate of 25.2% in the 
haematology cohort (n=532) and a rate of 20.9% in the renal cohort 
(n=340). A statistically significant difference was seen in the rates of 
allo/autoantibody production for males (Figure 3.16a) in the two cohorts 
(Fisher’s Exact Test, P=<0.0001), but this was not seen for females 
(Fisher’s Exact Test, P=0.1640) (Figure 3.16b). This suggests that 
females are equally likely to develop red cell all/autoantibodies whether 
they are transfused for haematological malignancies or renal insufficiency 
whereas males are less likely to produce red cell allo/autoantibodies if 
they are transfused for renal insufficiency than they are if transfused for 
haematological malignancies.  
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Figure 3.16: Comparison of the influence of gender on the development of allo/autoantibodies in the haematology 
cohort versus the renal cohort 
A                     B 
                                
 
The rates of red cell allo/autoantibody production in male patients transfused on the haematology wards (haem) (n= 575, incidence of immunisation 21.2%) and the 
renal wards (n=537, incidence of immunisation 11.7%) are shown in figure 3.16a. There is a statistically significant difference in allo/autoantibody development 
between the two groups (Fisher’s Exact Test, P=<0.0001). The immunisation rates in females within the haematology cohort (n=532, incidence 25.2%) compared to 
the rate in the renal cohort (n=339, incidence 20.9%) is shown in figure 3.16b. No significant difference in immunisation rates was seen in these groups. 
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3.4.2 Number of units transfused and immunisation rate 
 
 
Patients within the haematology cohort (n=1107) were transfused with an 
average of 28.8 units (SD 42.10) over the review period, compared to an 
average of 13.5 (SD 18.36) for the renal patients (n=877). The average 
number of red cell units transfused to immunised haematology patients 
(n=256) was 46.99 (SD 59.65), compared to an average of 21.85 (SD 
25.72) units transfused to immunised renal patients (n=134).  Non-
immunised patients in the haematology cohort (n=851) received an 
average of 23.43 (SD 32.01) units of red cells compared to an average of 
11.97 (SD 16.26) transfused to the non-immunised renal patients 
(n=743).  Analysis of the number of units transfused to patients on the 
haematology wards compared to those on the renal wards demonstrated 
that patients transfused for haematological malignancies received 
significantly more units of blood than those transfused for renal 
insufficiency irrespective of whether they had red cell allo/autoantibodies 
(figure 3.17a, t-test P value P=<0.0001) or not (figure 3.17b, t-test P value 
P=<0.0001). 
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Figure 3.17: Comparison of the number of red cell transfusions given in the haematology and renal cohorts  
A: Immunised patients                B: Non-immunised patients 
                       
Box-and-whiskers plots showing the range of number of transfusions given (black line) in the immunised and non-immunised patients within the 
haematology cohort (n=1107) and renal cohort (n=877). The first and third quartiles and the median (second quartile) are denoted by the red and 
green blocks. Immunised haematology patients received an average of 46.99 units of red cells (SD 59.65) compared to an average of 21.85 (SD 
25.72) in the immunised renal patients (figure 3.17a). In comparison, non-immunised haematology patients received an average of 23.43 units (SD 
32.01) compared to an average of 11.97 units (SD 16.26) in the renal patients (figure 3.17b). Patients transfused for haematological malignancies 
received significantly more units of blood than those transfused for renal insufficiency irrespective of whether they had red cell allo/autoantibodies 
(Figure 3.17a, t-test P value P=<0.0001) or not (Figure   3.17b, t-test P value P=<0.0001). 
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3.4.3 Age at first transfusion and incidence of immunisation 
 
The average age of patients at first transfusion in the haematology cohort 
(n=1107) was compared to that of patients within the renal cohort (n=877) 
for immunised and non-immunised patients. Non-immunised patients 
within the haematology cohort (n=851) were transfused at an average 
age of 69.18 (SD 14.7) years compared to an average of 68 years (SD 
14.4) in the renal cohort (n=743). For immunised patients the average 
age at first transfusion was 69 (SD 14.7) years for haematology patients 
(n=256) and 67 (SD 14.7) for renal patients (n=134). No statistically 
significant difference was seen in age at first transfusion within the 
immunised patients (figure 3.18a t-test P value = 0.2007) or the non-
immunised patients (figure 3.18b t-test P value = 0.1067). 
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Figure 3.18: Comparison of age at first transfusion and incidence of immunisation in the haematology and renal cohorts 
A Immunised patients                                                                           B Non-immunised patients 
                          
Box-and-whiskers plots showing the range (black line) of number of transfusions given in the immunised and non-immunised patients within the haematology 
(haem) cohort (n=1107) and renal cohort (n=877). The first and third quartiles and the median (second quartile) are denoted by the red and green blocks. 
Immunised haematology patients received the first transfusion at an average age of 69 years (SD 14.7) compared to an average age of 67 (SD 14.7) in the 
immunised renal patients (figure A). In comparison, non-immunised haematology patients received the first transfusion at an average age of 69.18 (SD 14.7) 
compared to an average age of 68 years (SD 14.4) in the renal patients (figure B). No statistically significant differences were seen in the age at first 
transfusion for either the immunised (Figure A, t-test P value P=0.207) or the non-immunised patients (Figure   B, t-test P value P=0.1067).   
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3.5 Discussion 
 
 
It is well accepted in the UK that patients with SCD and thalassaemia 
should have extended red cell antigen typing prior to transfusion, and 
should receive blood that is matched for at least Rh (CcEe) and Kell 
antigens (BCSH, 2013). This strategy has been implemented in response 
to the wealth of evidence that this group of patients have a relatively high 
alloimmunisation rate (Coles et al., 1981; Davies et al., 1986; Michail-
Merianou et al., 1987; Rosse et al., 1990; Spanos et al., 1990; Hmida et 
al., 1994; Tahhan et al., 1994; Moreira et al., 1996). Patients with SCD 
and thalassaemia require frequent transfusion support over a long period 
of time; the frequency of transfusion makes red cell antigen phenotyping 
difficult if left until after the production of a red cell alloantibody when 
transfused cells are present in the circulation. The majority of 
alloantibodies produced by these patients were found to be Rh or Kell 
system related (Davies et al., 1986; Rosse et al., 1990), hence the 
recommendation to match for these antigens prophylactically. More 
recent studies have noted that patients with SCD have high rates of 
alloimmunisation despite strategies to match for Rh and Kell antigens 
(Chou et al., 2013; Woldie et al., 2015). This may be related to ethnic 
differences between donor and recipient populations, altered RH alleles 
when the donor and recipient populations are matched, or patients 
receiving transfusions in other centres where matching does not occur. 
This information has reignited the debate regarding the benefits and cost 
effectiveness of a prophylactic matching strategy for these chronically 
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transfused patients. It has also questioned whether the introduction of 
genotyping, particularly for RH, would improve matching and reduce the 
alloimmunisation rate.   
 
Patients with haematological malignancies or renal failure are also likely 
to require frequent blood transfusion support over an extended period, 
often several years, and so it is reasonable to consider the 
implementation of such a strategy for typing and matching blood for 
transfusion in these groups of patients as well. There has been some 
debate in the literature regarding typing and matching of blood in 
chronically transfused patient groups, other than those with SCD and 
thalassaemia. Initially publications reported that prophylactic matching 
was either unnecessary or not cost effective (Blumberg et al., 1984; 
Domen and Ramirez, 1988; Schonewille et al., 1999). However, later 
studies supported this strategy in certain selected groups (Fluit et al., 
1990; Shirey et al., 2002; Schonewille et al., 2009; Kadar, 2010).  A study 
by Alves and co-workers (2012) found a relatively high rate of 
alloimmunisation in patients transfused for surgical or clinical 
emergencies. Their results suggest that a type and match strategy could 
also be beneficial for non-chronically transfused patients.  
 
To continue the debate, this retrospective study of patients who received 
blood transfusions in a UK haematology ward and a renal ward setting, 
collected and analysed data on the allo and auto-immunisation rates, 
potential risk factors and cost of additional testing, providing new 
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evidence to support a type and match strategy. The retrospective review 
found an overall alloimmunisation rate in patients transfused on the 
haematology wards of 12.9%, which is not dissimilar to the 9% found by 
Schonewille et al., (1999) and 11.8% by Fluit et al., (1990) in similar 
groups of patients. In this study alloantibodies were most commonly seen 
in patients with aplastic anaemia (35.7%), MDS (24.5%), solid organ 
cancers (18.5%), CLL (17.5%), AML (14.5%) and myeloma (13.9%). 
Other workers have found lower rates, 11% in aplastic anaemia 
(Blumberg et al., 1983) and 15% (Sanz et al., 2013) in MDS/CMML. 
Higher rates were seen in MDS by Milic and co-workers (2011), who 
found 36% alloimmunisation rate in patients who received more than 30 
units of blood and 64% in those who received more than 100 units. These 
differences may be explained by factors such as, the number of patients 
studied, the sensitivity of the antibody screening techniques and the 
transfusion policies in place. Some studies have indicated that patients 
with lymphocytic leukaemias do not develop alloantibodies (Blumberg et 
al., 1983; Blumberg et al., 1984; Fluit et al., 1990; Seyfried and Waleska, 
1990), however, both this study and that of Schonewille et al., (1999) 
have found alloimmune responses in these patients. Correspondence 
analysis of the data found in this study revealed that haemolytic anaemia, 
MDS and MPD showed an association with the development of allo and 
autoantibody, whereas CLL, AML and aplastic anaemia appeared to be 
associated with the development of autoantibodies only.   
  
180 
 
In the cohort of 877 patients transfused due to renal failure, 15.3% were 
found to have allo and/or autoantibodies, with 13% having red cell 
alloantibodies. This is slightly higher than the rates seen in a similar study 
by da Silva and co-workers (2013) who reported 7.4% of 393 patients 
with chronic kidney disease on a transplant waiting list having red cell 
alloantibodies. Sangole and Chaudhari (2013) found red cell 
alloantibodies in 25% of patients with chronic renal failure who had 
experienced transfusion reactions; however, this study involved a very 
small number of chronically transfused patients. 
 
Age appeared to have no influence on the alloimmunisation rate in either 
the haematology patients or the renal patients, a fact supported by 
Schonewille et al., (1999) and Sanz and co-workers (2013), but not by 
Seyfried and Waleska (1990) who reported that the probability of 
alloimmunisation is a quadratic function of age. A large study of patients 
and donors in the Unites States of America found the alloimmunisation 
increased with age for certain antibodies (anti-K, -Kpa, -Fya, -D, -C and –
E) and decreased with age for others (anti-Lea, -Leb, -M and -P1) 
presumably due to the inclusion of increasing numbers of women 
immunised through pregnancy and both sexes immunised through 
transfusion (Winters et al., 2001).  
 
This retrospective review reported only on adult patients, the youngest 
patients included were 13 years for the haematological cohort and 15 
years for the renal cohort. Other studies have reported much lower rates 
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of alloimmunisation in paediatric patients transfused as a result of SCD or 
thalassaemia (Spanos et al., 1990; Aygun et al., 2002), with statistically 
significant differences seen in the rate of alloimmunisation in patients 
transfused before the age of three, compared to those transfused after 
three years of age (Spanos et al., 1990). In a study of transfused patients 
awaiting kidney transplantation, which included a patient population with 
an age range of 4 to 77 years, no differences were seen in the mean age 
of the immunised group compared to the non-immunised group (da Silva 
et al., 2013). It would seem reasonable to assume that in a non-selective 
population the incidence of red cell alloantibodies increases with age but 
in transfused population this finding is not apparent after three years of 
age. 
 
In the haematological cohort, gender appeared to have no influence on 
the alloimmunisation rate, a fact supported by other studies in similar 
groups of patients (Blumberg et al., 1983; Redman et al., 1996 
Schonewille et al., 1999; Sanz et al., 2013). Within the renal cohort 
gender did appear to have an influence on the alloimmunisation rate, with 
females being more likely to produce alloantibodies. This association has 
also been reported by other groups in less selective cohorts of patients 
and/or blood donors (Hoeltge et al., 1995; Winters et al., 2001; Bauer et 
al., 2007), and is generally believed that the greater frequency of red cell 
antibodies seen in females is due to pregnancy related alloimmunisation. 
The study of renal patients by da Silva and co-workers (2013) suggested 
that the determining factor for the differences in alloimmunisation rates in 
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males and females was not only the gestations, but also due to greater 
numbers of transfusions given to females (average 7 +/- 3) compared to 
males (average 3 +/- 2.6). However, in this study of renal patients, no 
statistically significant difference was seen between the number of red 
cells transfused between males and females (average 13.51 and 13.43 
respectively t-test P value 0.9499) or the number of transfusion episodes 
(average 5.90 and 6.01 respectively, t-test P value 0.8296). Further 
analysis of the red cell immunisation rates in males and females between 
the haematological cohort and the renal cohort in this study found that 
that there was no significant difference in the rates for females (t-test P 
value 0.1640) but that there was a highly significant difference in the red 
cell immunisation rate for males (t-test P value 0.0001). This shows that 
male patients transfused for renal failure are much less likely to produce 
red cell antibodies than males transfused for haematological 
malignancies, suggesting that the disease status itself may put male 
haematology patients on an equal footing to females with regard to the 
development of red cell allo and/or autoantibodies. This apparent equality 
in red cell allo/autoimmunisation could be related to the immune 
dysregulation found in certain haematological malignancies (Barrett et al., 
2000; Maciejewski et al., 2007; Alfinito et al., 2010). Alternatively, it could 
be related purely to the fact that patients with haematological 
malignancies received, on average in this study, significantly more red 
cell transfusions over the course of their treatment than the renal patients 
(46.99 units vs 12.0 units t-test P value 0.0001 for immunised patients 
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respectively and 23.43 units vs 8.0 units t-test P value 0.0001 for non-
immunised patients). 
 
The current study found that the requirement for concomitant platelet 
therapy and irradiated blood components, used here as surrogate 
markers for intensive chemotherapy and immune suppression, did not 
influence alloimmunisation rates, while other workers have reported that 
immunosuppressed patients are less likely to produce antibodies 
(Ramsey et al., 1989; Schonewille et al., 1999; Asfour et al., 2004; Zalpuri 
et al., 2014).  It is possible that the surrogate markers used in this study 
did not identify patients whose immune suppression was of a similar state 
to those reported in the other studies. Schonewille and co-workers (1999) 
reported occurrence of antibodies in patients receiving intensive 
chemotherapy, whereas the patients studied by Asfour and co-workers 
(2004) had received bone marrow and/or peripheral blood stem cell 
transplant, and Ramsey and co-workers (1989) studied patients who 
received liver and heart transplants. The comprehensive two-centre case-
reference study by Zalpuri et al. (2014) demonstrated that exposure to 
immunosuppressives was associated with a considerably lower risk of 
alloimmunisation. Using a case controlled study they demonstrated that, 
patients taking only corticosteroids, patients taking only other 
immunosuppressants, and those taking both, had a lower 
alloimmunisation risk (adjusted Risk Ratios of 0.70 (95% CI, 0.42-1.16); 
0.51 (95% CI, 0.04-7.10) and 0.19 (95% CI, 0.07-0.53) respectively) than 
that of patients not taking any immunosuppressants (Zalpuri et al., 2014).  
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The surrogate markers used in this study were chosen because they 
were believed to be adequate markers for patients undergoing the type of 
intensive chemotherapy which would substantially suppress the immune 
system. The difference seen in this study and that of Zalpuri and co-
workers (2014) may be due to the fact that in this study it was not known 
if the immunosuppressive therapy was given before or after the 
alloimmunisation, which may have influenced the results. In addition, 
there is evidence to suggest that the transfusion of platelets can, in fact, 
increase the risk of red cell alloantibody development by inducing an 
inflammatory response in the recipient from infused cytokines (Yazer et 
al., 2009).  
 
Review of the transfused renal patients showed an apparent relationship 
between immune suppression as a result of renal transplantation and 
allo/autoimmunisation, suggesting that immune suppression may have a 
protective effect against immunisation to red cell antigens in this group of 
patients. However, the number of patients identified as having received 
renal transplants in this study was small and it was not possible to 
ascertain whether the patients had produced allo/autoantibodies prior to 
or subsequent to the transplant. 
 
The current data supports that of other studies (Sarnaik et al., 1986; Fluit 
et al., 1990; Hoeltge et al., 1995; Zalpuri et al., 2012), that the 
development of alloantibodies is related to the number of red cell 
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transfusions given; in this study both the total number of units and the 
number of transfusion episodes were related to the risk of antibody 
formation in both cohorts of patients. Antibodies were formed after an 
average of 15.46 units had been transfused in the haematology cohort, a 
figure similar to that found by Schonewille et al., (1999) and after an 
average of 9.66 units in the renal cohort.   
 
In this study a substantial proportion of alloantibodies could not be 
identified; 29.3% in the haematology cohort and 28.6% in the renal 
cohort. This is similar to the figures found by Schonewille et al., (1999), 
Redman et al., (1996) and da Silva et al., (2013) who found 22.5%, 
17.6% and 34.5%, respectively. The majority of patients formed a single 
antibody specificity (61.6% in the haematology cohort and 60.3% in the 
renal cohort) with 43 haematology patients and 25 renal patients forming 
multiple specificities, although no patients formed more than five antibody 
specificities, comparable with results found by Winters et al., (2001) in an 
American population.  
 
As in other studies (Fluit et al., 1990; Hmida et al., 1994; Redman et al., 
1996; Schonewille et al., 1999; Sanz et al., 2013; da Silva et al., 2013) 
the majority of antibodies identified were Rh and Kell related, with anti-E 
being the most common in both patients transfused for haematological 
malignancies and those transfused for renal insufficiency. Almost all red 
cell units received from the NHSBT in our institution have their Rh (CcEe) 
and K antigen status documented on the unit, making these antigens the 
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easiest to match with phenotyped patients. A strategy to type and match 
Rh (CcEe) and K antigens in chronically transfused patients with 
haematological malignancies and renal insufficiency has the potential to 
eliminate alloantibodies to these antigens and reduce the additional cost 
burdens currently seen with alloimmunised patients. 
 
The analysis of additional testing and the associated costs for the 
patients included in our retrospective review showed that immunised 
patients in the haematology cohort, in general, required approximately 19 
times the number of additional serological tests than the non-immunised 
patients, and that the increase in costs required were 32 fold. In the renal 
cohort, the additional testing for the immunised group was approximately 
75 times more than that for the non-immunised group, and the increase in 
cost was approximately nine fold. The differences in the costs between 
the groups is, in part, due to the higher number of some additional tests 
(in particular the DAT) being performed for haematology patients as part 
of routine screening for certain diseases, and regardless of immunisation 
to red cell antigens. It is likely that these figures would lead to an 
underestimation of projected figures, of both test numbers and costs, if 
used to predict cost effectiveness of a type and match program. This is 
because changes in transfusion policy throughout the study period meant 
that, in contrast to current pre-transfusion compatibility guidelines (BCSH, 
2013), tests for antibody identification, confirmatory antigen status and 
the use of elution techniques for patients with autoantibodies were 
regularly omitted from the screening process and so have not been 
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included in the costs. The costs of crossmatching red cell units for the 
immunised and non-immunised group were not included in this study, but 
would, obviously, impact on the financial burden to the hospital service as 
well. Non-immunised patients may have red cells issued for transfusion 
by electronic issue, whereas immunised patients always require 
serological crossmatching (BCSH, 2013) with the ensuing cost 
implication. 
 
A less well documented, and not completely understood, complication of 
blood transfusion is the development of red cell autoantibodies, which are 
often found in combination with alloantibodies (Shirey et al., 2002; Young 
et al., 2004; Ahrens et al., 2007) in transfused patients. The frequency of 
auto and alloimmunisation in combination varied in these studies from 
28% to 40%, not dissimilar to the figure found in this study for 
haematology patients (39.4% of immunised patients) and renal patients in 
this study (41.0% of immunised patients). In the majority of cases, in this 
study, production of the autoantibody was subsequent to production of 
the alloantibody, in accordance with results found by Sanz and co-
workers (2013), and also, in this study the autoantibodies appeared to be 
clinically insignificant. Unfortunately, throughout the study period, the 
transfusion policy within our institution did not require the use of an eluate 
kit to determine the specificity of an autoantibody appearing post 
transfusion, and so no records were available to confirm that it was not 
indicative of a delayed or acute transfusion reaction. A substantial 
proportion (75.3% of haematology patients and 92.4% of renal patients) 
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of the patients with a positive DAT had IgG demonstrable on the surface 
of their red cells; elution of these antibodies would be a useful piece of 
further work to investigate any potential specificities. However, the 
presence of the autoantibodies did not appear to increase the transfusion 
requirements of the patients, suggesting that they were not of clinical 
significance. In this study, 158 patients treated on the haematology wards 
with autoantibodies had follow up testing and, of these, 123 (77.9%) of 
the autoantibodies were transient, a phenomenon also described by 
Young and co-workers (2004). This would seem to support the theory of 
Ahrens and co-workers (2007) that the alloantibody is initially of low 
affinity (compared to the matured antibody) and so it cross reacts with 
other structures on the red cell membrane as well as the alloantigen. A 
similar phenomenon has been demonstrated in an animal model by 
Weigle (1965), who demonstrated that autoimmunity could be induced in 
rabbits by the injection of heterologous or chemically altered homologous 
thyroglobulin. Another theory that has been put forward to explain 
transfusion-induced autoantibodies is the nonexofacial polymorphism 
(NEP) hypothesis. This hypothesis is based on the theory that differences 
in red cell antigenic structures are present both on the surface of the red 
cell and within the cytoplasmic or transmembrane domains of the blood 
group molecule (Zimring et al., 2007). NEPs have been shown to exist for 
some blood group systems including Duffy (Neote et al., 1994; Mallinson 
et al., 1995; Olsson et al., 1998; Parasol et al., 1998), Kidd and Kell 
(Zimring et al., 2007). It has been demonstrated that autoreactive B cells 
specific for red cell antigens exist naturally even in the presence of a 
189 
 
functional tolerance mechanism (Murakami and Honjo 1996), and that 
they are prevented from maturing by the thymic deletion of autoreactive 
CD4+ T helper cells. Zimring and co-workers (2007) postulated that 
transfusion of red cells that have the same external red cell antigens, but 
different NEPs, could lead to non-deletion of the autoreactive T helper 
cells, leaving them available to assist the autoreactive B cells, ultimately 
leading to red cell autoantibody production. Another suggestion that has 
been put forward is that the appearance of red cell autoantibodies is due 
to the presence of lymphocytes from previous transfusions which have 
survived and produce alloantibodies that attach to the recipient red cell, 
thus mimicking an autoantibody (Petz and Garratty, 1980; Garratty, 1996; 
Petz and Garratty, 2004). 
 
The relatively high level of autoantibodies seen in the haematology cohort 
of this study, with or without associated alloantibodies, is further 
complicated by the original pathology of the patients within the study 
group. Patients with lymphoproliferative disorders are prone to the 
production of red cell autoantibodies (Kipps and Carson, 1993; Timura et 
al., 2000) due to immune dysregulation resulting from the underlying 
disease. Similarly, patients with MDS have also been shown to produce 
autoantibodies to red cell antigens (Sokol et al., 1989; Novaretti et al., 
2001) as do patients with CML (Steegmann et al., 2003). In this study the 
highest proportion of autoantibodies were found, not unexpectedly, in 
patients with haemolytic anaemia (85.7%), followed by aplastic anaemia 
(50.0%), CLL (36.8%), CML/CMML (30%), MDS (21.9%), AML (17.2%) 
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and myeloma (10.6%), compared to only 5.5% of patients with solid 
organ cancer. The levels of autoantibodies present in patients with MDS 
in this study is higher than that found by others; Sokol and co-workers 
found just 7% (Sokol et al., 1989) with other groups finding 3.7% (Martin-
Vega et al., 1988) and 8.2% (Mufti et al., 1986), however the current data 
is similar to the 21.6% found by Seitanides and co-workers (Seitanides et 
al., 1988). The higher levels in this study may be due to differences in 
sensitivity of screening techniques and/or the smaller number of patients 
included.  Red cell autoantibodies in patients with renal disease are not 
so well documented. They may be related to the immune dysregulation 
seen in ESRD, which is exacerbated by dialysis, and can result in 
inflammation caused by immunoactivation (Deschamps-Latscha and 
Chatenoud 1996; Kato et al., 2008). The relatively high rates of 
autoantibodies and alloantibodies in combination, in both the 
haematology and renal cohorts in this study, is in contrast to the rate 
(3.8%) seen in a non-selected population of red cell immunised patients 
and blood donors (Winters et al., 2001), which supports the theories that 
non-clinically significant red cell autoantibodies in combination with 
alloantibodies may be related to the disease condition. 
 
Throughout the study period, no patients in either cohort were 
documented as having suffered haemolytic transfusion reactions, either 
acute or delayed. A small percentage (2.17% of haematology patients 
and 0.57% of renal patients) of patients were investigated for suspected 
transfusion reactions, slightly higher than that found in cancer patients 
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(0.3%) by other workers (Huh and Lichtiger, 1987). This difference may 
be explained by improvements, since 1987, in the clinical observations of 
transfused patients and changes in the laboratory investigations of 
transfusion reactions. A large proportion of the reactions seen by Huh 
and Lichtiger (1987) were febrile non-haemolytic reactions, presumably 
caused by transfused white blood cells. Since November 1999, all 
allogeneic red cell units in the UK have been leucocyte depleted, the UK 
specification requires that more than 90% of manufactured leucocyte 
depleted blood components should have less than 1 x 106 leucocytes and 
more than 99% should have less than 5 x 106 leucocytes (JPAC, 2013). 
Leucocyte depletion of red cells has been demonstrated to reduce the 
incidence of febrile non-haemolytic transfusion reactions (King et al, 2004 
(b)) hence, relatively small numbers of this type of reaction would have 
been seen in this study. Review of the 11 haematology patients with allo 
and/or autoantibodies, investigated for suspected transfusion reactions in 
this study, revealed that none of these patients had developed a newly 
positive DAT or newly developed alloantibody after the transfusion, 
although no eluates were performed to confirm this. Delayed Serological 
Transfusion Reactions (DSTR), defined by the detection of a positive 
DAT and a new alloantibody specificity post transfusion, were reported as 
being a frequent finding in multiply transfused patients (Ness et al., 1990), 
although generally benign in nature and not causing clinical haemolysis, 
however, this was not seen in our patients. Introduction of the use of 
eluate testing as part of the laboratory investigation of positive DATs post 
transfusion, as recommended in the BCSH guidelines (BCSH, 2013), 
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may increase the number of regularly transfused patients diagnosed with 
DSTR in our patient population. 
 
In conclusion, this study found that patients chronically transfused for 
haematological or renal indications are at risk of alloimmunisation. The 
antibodies developed by the patients are mainly to the Rh and Kell 
antigens, which could, potentially, be reduced by a type and match 
strategy. There are considerable costs associated with the provision of 
blood in the presence of alloantibodies, and an increased risk of 
transfusion reaction for the patients. Blood units supplied by the NHSBT 
are typed for Rh and Kell antigens, and the information is visible on the 
component label, facilitating blood selection in a type and match strategy. 
However, implementation of a strategy for type and match would need a 
suitable method, within the hospital transfusion laboratory, to type patient 
samples for the corresponding antigens. The method would need to 
support a high throughput, and have a high level of automation to reduce 
the risk of error. Hospital transfusion laboratories currently use high 
throughput automation for routine blood group and antibody screening, a 
novel method for serological phenotyping on one of these platforms is 
explored in chapter 4. Alternatively, commercial assays are available for 
blood group genotyping, which could also be suitable for a hospital 
transfusion laboratory. The suitability of one of these assays is explored 
in chapter 5. Although red cell units for transfusion supplied by NHSBT 
are typed for Rh and Kell antigens, provision of matched units from the 
stocks held in a hospital transfusion laboratory could be challenging. The 
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challenges for the laboratory provision of blood are explored in the pilot 
study, detailed in chapter 6.  The high throughput assay selected to 
support a type and match strategy would also need to be cost effective. 
The costs for serological phenotyping and genotyping assays are 
explored in the relevant sections and compared in chapter 7.  
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4 AUTOMATED RED CELL PHENOTYPING 
 
4.1 Introduction 
 
Recent developments in the use of automated serological phenotyping 
techniques in the NHSBT facilities in the UK have meant that the majority 
of red cell units supplied to hospital transfusion services are now typed 
and labelled not only for ABO and RhD, but also for Rh (CcEe) and Kell 
antigens. The BCSH, however, do not recommend that hospital 
transfusion services in the UK routinely type patients for antigens other 
than ABO and RhD prior to transfusion (BCSH 2013). This is mainly due 
to the lack of automated techniques available for performing these tests 
within the hospital transfusion service setting and the risks associated 
with performing these tests manually on a large scale. Development of a 
system to perform automated red cell antigen phenotyping profiles for 
pre-transfusion patients would enable hospital transfusion services to 
prophylactically select and match blood for, at least, Rh (CcEe) and Kell 
antigens and possibly other antigens from routine blood stocks.  
 
The NEO® blood grouping analyser system (IBG Immucor) was 
implemented in the RD&E in 2011 for blood grouping, antibody screening 
and identification. The analyser also has the potential to perform rapid 
automated extended red cell phenotyping profiles including Rh (CcEeCw), 
K, Fy (a and b), Jk (a and b), M, N, S, s and k antigens. Although this 
technology has been in widespread use throughout the UK for many 
years for blood grouping, antibody screening and antibody identification, 
profiles for automated serological phenotyping have not been developed 
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or implemented for routine use. Introducing serological phenotyping to the 
system offers an opportunity for hospital transfusion services to access 
large scale, cost effective extended red cell serological phenotyping. As 
part of this study, development work was undertaken with the supplier to 
create the assay profiles on the automated system. This involved 
determination of the antisera to be used, setting the assay protocols on 
the analyser software and creating a report format.   The study aimed to 
validate the antisera for automated use using commercially available red 
cells with known antigen types. In addition,  comparability of manual red 
cell phenotyping, using a combination of techniques, and automated red 
cell phenotyping using the NEO® blood grouping analyser (IBG Immucor) 
for patient samples, was performed in accordance with BCSH guidelines 
for validation (BCSH, 2012).  
 
The study also reviewed the comparability of cost between manual and 
automated red cell phenotyping, with the aim of providing a projected cost 
for the implementation of a strategy for targeted extended red cell 
phenotyping and matching of blood for transfusion in patients with 
haematological malignancies or renal insufficiency. 
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4.2 Results of the automated phenotyping validation 
 
Automated extended red cell antigen testing on the IBG NEO® using the 
monoclonal reagents (anti-C, anti-c, anti-E, anti-e, anti-K, anti-M and anti-
N) with the commercial NHSBT ten cell profile (0.8% cell suspension in 
Cellstab), three cell profile (3% cell suspension in Alsevers) and two cell 
titration profile (0.8% cell suspension in Cellstab) over multiple occasions 
(ten cell profile n=4, three cell profile n=5 and two cell profile n=2) showed 
no failures and no discrepancies with the known red cell antigen types 
reported in the product insert. Reaction values on the IBG NEO® were 
consistently strongly positive (4+) with both homozygous and 
heterozygous expression of red cell antigens. 
 
Automated extended red cell antigen testing on the IBG NEO® with the 
polyclonal reagents (anti-Fya, anti-Fyb, anti-Jka, anti-Jkb, anti-S, anti-s and 
anti-k) with NHSBT ten cell profiles, three cell profile and two cell titration 
profile over multiple occasions (ten cell profile n=4, three cell profile n=5 
and two cell profile n=2)  showed one invalidated result with the anti-k 
reagent and one weak and undefinable (NTD) result during Jka testing. 
Following repeat testing, the invalidated result was positive and the weak 
positive result was negative, giving expected results. There were no 
discrepancies found with the known red cell antigen types reported in the 
product insert. Reaction values on the IBG NEO® were consistently 
strongly positive (4+) with homozygous and heterozygous expression of 
red cell antigens. One cell, on one occasion, produced a 3+ result with 
the anti-k reagent. The consistency of the reactions with homozygous and 
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heterozygous expression of red cell antigens is shown in table 4-1 using 
the NHSBT titration two cell profile as an example. 
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Table 4.1: Consistency of automated screening reactions with homozygous and heterozygous expression of red cell 
antigens 
The automated profiles were tested on two occasions using the NHSBT titration two cell profile to review the consistency of the reaction 
grades. The titration panel includes red cells demonstrating both homozygous (shown in green) and heterozygous (shown in red) expressions 
of red cell antigens. The antigen profiles of the cells are shown in bold type and the reaction grades are shown as negative (-) or the numerical 
value (graded 1- 4 by the analyser). On both testing occasions results for homozygous and heterozygous antigen expression were strongly 
positive (3 or 4 strength reactions).  
 
 
 C c E e Cw K M N S s Fya Fyb Jka Jkb k 
Cell 1 
antigen 
profile 
+ - + + - - - + - + - + + + + 
Cell1 – 
test 1 
4 - 4 4 - - - 4 - 4 - 4 3 4 4 
Cell 1 – 
test 2 
4 - 4 4 - - - 4 - 4 - 4 3 4 4 
Cell 2 
antigen 
profile 
+ + + + - + + + + + + + + + + 
Cell2 – 
test 1 
4 4 4 4 - 3 4 4 4 4 4 4 4 4 4 
Cell2 – 
test 2 
4 4 4 4 - 3 4 4 4 4 4 4 4 4 4 
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One hundred patient samples were selected for automated extended red 
cell antigen serological phenotyping on the IBG NEO® and comparative 
testing in the manual system. A mixed field reaction, demonstrating the 
presence of a dual population of cells with, and without, the E antigen, 
was seen with the anti-E reagent for one patient in both the automated 
and the manual testing. This type of reaction suggests interference from 
red cells from a recent blood transfusion. Following discussion with the 
patient it was confirmed that a transfusion has been performed at another 
hospital.  
 
A weak reaction was seen with the anti-Fya reagent in both the 
automated (1+ reaction strength) and the manual technique for one 
patient. This sample also produced a weakly positive (2+) result with the 
anti-S reagent in the automated profile; manual testing with anti-S 
produced a negative result. Weakly positive results are suggestive of 
interference by red cell autoantibodies, which should be identified by the 
inclusion of a control test using patient cells analysed against the patient 
plasma or a commercial neutral reagent. A DAT on the patient sample 
confirmed the presence of a weak autoantibody.  
 
A weak reaction (2+) was seen with the anti-Fyb reagent in automated 
testing in one sample, repeat testing of this sample showed a negative 
result, in accordance with the manual testing results (table 4.2). This was 
considered to be a false positive reaction generated by the analyser 
system. The cut off values for the anti-Fyb assay between the top end of 
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the “not determined” result (40.998) and the lower end of the 2+ positive 
result (50.999) are relatively tight (see appendix 3). There are a number 
of sample and/or analytical factors that may affect the value of a reaction 
within the system, these include; insufficient centrifugation of the sample, 
reagent deterioration and particles of dirt on the imaging system. These 
weak reactions seen in the initial testing with commercial cells, and again 
during patient testing were important in terms of recognition of false 
positives. In the hospital transfusion setting it is extremely important to 
reduce the risk of false positive results as these could lead to transfusion 
of incorrectly matched red cell units. The information obtained from the 
validation was used to determine the cut off values for reporting 
serological phenotyping results. It was concluded that only strongly 
positive values of 3+ and 4+ could be confidently reported as positive, 
and any results between “not determined” and 2+ would be considered 
invalid results requiring further investigation.  
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Table 4.2: Phenotyping anomalies in automated and manual assays 
Anomalous results in serological phenotyping assays were seen for three patients; patient 1 demonstrated a mixed field reaction (MF) (shown 
in green) with the anti-E reagent in manual testing and weak positive in the automated assay, patient 2 reacted weakly positive with the anti-Fya 
reagent in both the automated and manual assays, this patient also produced a weakly positive reaction with the anti-S reagent in the 
automated profile (shown in red). Patient 3 reacted weakly with the anti-Fyb reagent in the automated assay (shown in blue).  The validation 
determined that reaction strengths between 1 and 2 are suggestive of false positive results and should be invalidated.  
 Red cell antigen 
 E Fya Fyb Jka Jkb S s k 
Patient 1 manual 
assay 
MF + + + + + + + 
Patient 1 
automated assay 
NTD 4 4 4 4 4 4 4 
Patient 2 manual 
assay 
+ Weak 
positive 
+ + + - + + 
Patient 2 
automated assay  
4 1 4 4 4 2 4 4 
Patient 3 manual 
assay 
- + - + + + - + 
Patient 3 
automated assay 
(primary test) 
- 4 2 4 4  4 - 4 
Patient 3 
automated assay 
(repeat test) 
N/A 4 - 4 4 4 - 3 
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One discrepancy was seen with N typing for one patient, this sample 
repeatedly produced a negative result in automated testing using the 
immuClone anti-N and a positive result in manual testing using the 
Millipore anti-N. Confirmatory testing at the Red Cell 
Immunohaematology Laboratory at Filton NHSBT supported the positive 
result seen in the manual testing assay, and testing of the patient sample 
using the immuClone anti-N in a manual tube technique also gave a 
positive result. The discrepancy was thought possibly to be due to 
stability issues relating to sample storage time prior to testing. In addition, 
the temperature of the reagents at testing was also considered as a 
potential source of the weakened reactions (personal communication 
from Berndine Kokkelink, IBG Immucor). The performance of certain 
Immucor reagents, in particular LISS, are affected by temperature, and it 
is noted in the manufacturer’s instructions that they should be allowed to 
come to 18-20oC before use. This was not noted in the instructions for the 
phenotyping antisera. However, the anti-N reagent had not been 
validated by the supplier for automated use, and so it was reasonable to 
exclude temperature as a cause of the discrepancy. A further 12 N 
positive samples (10 M+N+ and two M-N+) were selected for stability 
testing and reagent temperature testing. These samples were repeatedly 
tested over a 10 day period; each day the samples were tested with 
reagents taken straight from refrigerated storage and again after the 
reagents had been allowed to stand at room temperature for at least 4 
hours. With the exception of one N heterozygote all other M+N+ samples 
tested gave negative results with the anti-N reagent at day 7 (figures 4.1a 
203 
 
and b). Using the manual technique, all nine of these samples were still 
strongly positive with anti-N (Millipore) at day 8. The reaction strength 
with anti-N (immuClone) in the automated technique for the nine samples 
clearly demonstrated a reduction in strength over the testing period with 
reagents taken directly from refrigerated storage and those held at room 
temperature prior to testing (figure 4.2). However, investigation of the 
potential effect of temperature of the reagents on the reaction strength 
showed no significant difference (figure 4.2) on each day of testing and 
testing was discontinued on day 8.  
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Figure 4.1: The influence of reagent temperature on the reaction strength of automated serological phenotyping 
testing 
A         B 
     
 
Reaction strengths of the automated serological phenotyping assay using monoclonal reagents over time with M+N+ and M-N+ cells using reagents 
taken from refrigerated storage (A) or used at room temperature (B). The numerical value calculated by the automated analyser is shown on the Y 
axis and the day of testing on the X axis. The majority of M+N+ cells reach the negative cut off value of 23 by day 7 regardless of the temperature of 
the reagents. 
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Figure 4.2: Influence of age of sample and temperature of reagent on the reactions strength of automated 
serological phenotyping 
A 
 
B 
  Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 Day 8 
MONOPM  82 84 77 51 46.5 36.5 25 26 
MONO 83 82.5 80 59 38.5 30.5 23.5 32.5 
P value 0.8287 0.785 0.6345 0.3974 0.4607 0.5867 0.8932 0.5711 
 
This figure (A) shows the comparison between the average numerical value for each of the nine M+N+ samples over time for serological phenotyping using reagents 
directly from refrigerated storage (MONO) and those held at room temperature prior to testing (MONOPM). The numerical value calculated by the automated 
analyser is shown on the Y axis and the day of testing on the X axis. T-test values for each paired results shown in the table (B) did not demonstrate any statistically 
significant difference, suggesting that the temperature of the reagent during use doe not influence the reaction strength of the result.  
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Manual testing for Rh (CcEe) and K, Cw, M, N took approximately 25 
minutes per patient, which included 10 minutes of staff time preparing the 
tests and reading the results. Manual testing for Fya, Fyb, Jka, Jkb, S, s 
and k required approximately 35 minutes per patient which included 10 
minutes of staff time preparing the tests and reading the results. To 
reduce the risk of error, best practice is to test one patient at a time and 
include positive and negative reagent cell controls for each anti-serum 
used (BCSH, 2013). 
 
Automated testing incurred approximately 2 minutes of staff time to load 
the reagents onto the analyser; this is independent of the number of 
patient samples tested. Preparation of samples for testing took 
approximately 2 minutes for 12 samples. The analyser is capable of 
processing three patient samples for monoclonal profiles in 28 minutes 
and three patient samples for polyclonal profiles in 50 minutes. The 
analyser is capable of processing single samples and samples in batches 
of various sizes. 
 
Overall, the repeat rate for automated extended red cell antigen 
phenotyping was 1/100 for monoclonal antibodies (anti-C, Anti-c, Anti-E, 
anti-e, anti-K, anti-M and anti-N) and 3/100 for polyclonal antibodies (anti-
Fya, anti-Fyb, anti-Jka, anti-Jkb, anti-S, anti-s and anti-k). The repeat rate 
for manual testing was 1/100 for polyclonal antisera (anti-Fya, anti-Fyb, 
anti-Jka, anti-Jkb, anti-s and anti-k). No repeat testing was required for 
manual tests performed using monoclonal antisera. 
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The frequency of red cell antigens in the tested patient samples (table 4-
3) showed percentages comparable with that reported in the literature for 
Caucasian populations (Issit and Anstee, 1998; Dean 2005; Daniels and 
Bromilow, 2010) demonstrating that the selection of samples for testing 
was representative of the mainly Caucasian population tested in our 
institution. 
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Table 4.3:  The frequency of antigens found in samples selected for validation of the automated serological 
phenotyping assays  
The frequency of antigens present in the sample population selected for validation of the automated serological phenotyping assay was 
representative of a mainly Caucasian population when compared to others studies performed in similar populations (Issitt and Anstee, 1998; Dean, 
2005; Daniels and Bromilow, 2010;).  Antigenic frequencies not stated by the reporters are denoted by NS in the table. 
Antigen C c E e K C
w
 Fy
a
 Fy
b
 Jk
a
 Jk
b
 S s M N k 
% positive in this 
study 
68.7 80.8 37.4 94.9 15.2 2.02 65.7 81.8 81.8 70.7 53.5 86.7 81.9 77.8 99 
Dean, 2005 68 80 29 98 10 NS 66 83 77 74 55 89 78 72 99 
Daniels and 
Bromilow, 2010 
 
68 81 29 98 9 NS NS NS 76 72 NS NS NS NS NS 
Issitt and Anstee, 
1998 
70 80 30 98 9 1 66 83 76.9 72.5 57 88 78 72 99.8 
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4.3 Comparison of test costs for manual and automated 
serological phenotyping  
 
Test costs were calculated for the manual and automated serological 
phenotyping assays. Staff costs were calculated at Band 5 (Agenda for 
Change, NHS pay scale 2015) pay point 20 and reagent costs were 
calculated at supplier cost 2014-2015 (excluding VAT). Costs for the 
relevant equipment maintenance were included, based on the proportion 
of tests processed on the equipment per year, and internal quality control 
costs were also included. Manual serological phenotyping assays 
performed in column agglutination tests and tube tests required 
approximately five minutes of staff time to prepare patient sample 
solutions, set up the test and quality control, and approximately five 
minutes for result interpretation and recording (table 4-4). Automated 
phenotyping took approximately 2 minutes for sample preparation and 
reagent preparation, with no time required for result interpretation and 
recording (table 4-5). Quality control costs for the manual phenotyping 
assays were based on the use of NHSBT two cell titration profile cells 
used with each assay; quality control for the automated phenotyping 
assay was based on the use of the NHSBT three cell profile in Alsevers, 
used on a monthly basis. Test costs for automated red cell antigen 
profiles processed on the NEO® analyser were considerably less than 
those for manual typing, mainly due to the reduction of staff time required 
for the process.  
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Table 4.4: Breakdown of test costs for the manual serological phenotyping assay. 
Cost per test was calculated for extended phenotyping performed in manual assays, for the antigens shown in the first column. The table shows the 
breakdown of the cost per test of the anti-serum, quality control (QC), consumables, diluent, equipment and staff time. The cost for equipment is 
allocated as a proportion of the total tests performed on the system. The total cost for an extended phenotype performed using manual assays was 
£50.46.       
 
Antigen Anti-serum cost 
per test (£) 
QC cost 
(£) 
Consumables (£) Diluent 2 (£) Equipment (£) Staff time 
(£) 
Total (£) 
Fya 0.28 0.043 1.49 0.11 0.22 2.35 4.50 
Fyb 0.19 0.043 1.49 0.11 0.22 2.35 4.40 
s 0.31 0.043 1.49 0.11 0.22 2.35 4.53 
S 1.81 0.043 0.46 NA 0.22 2.35 4.88 
Jka 0.73 0.043 1.49 0.11 0.22 2.35 4.94 
Jkb 0.37 0.043 1.49 0.11 0.22 2.35 4.59 
k 0.24 0.043 1.49 0.11 0.22 2.35 4.45 
M 0.76 0.043 0.46 NA 0.22 2.35 3.84 
N 0.76 0.043 0.46 NA 0.22 2.35 3.84 
Cw 0.94 0.043 0.46 NA 0.22 2.35 4.01 
Rh (CcEe) and K NA 0.033 3.78 0.11 0.22 2.35 6.49 
Total       50.46 
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Table 4.5: Breakdown of the test costs for the automated serological phenotyping assay 
Cost per test was calculated for extended phenotyping performed in manual assays, for the antigens shown in the first column. The 
table shows the breakdown of the cost per test of the anti-serum, quality control (QC), consumables, diluent, equipment and staff 
time. The cost for equipment is allocated as a proportion of the total tests performed on the system. The total cost for an extended 
phenotype performed by the automated method was £19.55. 
 
 
Antigen QC cost (£) Consumables (£) Liss and 
Indicator cells 
Equipment 
(£) 
Staff time (£) Total (£) 
Fya 0.05 0.24 0.028 0.66 0.07 1.40 
Fyb 0.05 0.24 0.028 0.66 0.07 1.55 
s 0.05 0.24 0.028 0.66 0.07 1.42 
S 0.05 0.24 0.028 0.66 0.07 1.42 
Jka 0.05 0.24 0.028 0.66 0.07 1.42 
Jkb 0.05 0.24 0.028 0.66 0.07 1.42 
k 0.05 0.24 0.028 0.66 0.07 1.51 
M 0.05 0.07 0.028 0.66 0.07 1.18 
N 0.05 0.01 0.028 0.66 0.07 1.09 
Cw 0.05 0.01 0 0.66 0.07 1.19 
C 0.05 0.01 0 0.66 0.07 0.97 
c 0.05 0.01 0 0.66 0.07 0.89 
E 0.05 0.01 0 0.66 0.07 0.89 
e 0.05 0.01 0 0.66 0.07 0.98 
K 0.05 0.01 0 0.66 0.07 1.15 
Neg control 0.05 0.24 0.028 0.66 0.07 1.09 
Total      19.55 
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4.4 Discussion 
 
 
The automated phenotyping profiles were demonstrated to be simple, 
robust and rapid assays for the serological testing of Rh (CcEe), K, Cw, 
M, N, Fya, Fyb, Jka, Jkb, S, s and k antigens, suitable for use in routine 
hospital transfusion service laboratories. Weakly positive reactions in the 
automated assay (reactions strengths between 1+ and 2+) were 
suggestive of false positive results and so the assay was amended to 
exclude these reactions strengths from being reported as positive.  
 
Only one discrepancy was identified during comparative testing of patient 
samples; N antigen testing of one patient sample gave repeatedly 
positive results in the manual test and negative results in the automated 
test. It was initially thought that this may have been caused by the 
automated reagent having cross reactivity with the “N” antigen.  The anti-
N reagent used in manual typing for the comparative study was a murine 
monoclonal IgG reagent (Millipore (UK) Ltd), which is stated not to react 
with the “N” antigen, when used by the recommended tube technique. 
The anti-N used in the automated typing was also a murine monoclonal 
reagent (immuClone), licensed for use in tube and slide techniques and 
was also stated not to have “N” reactivity. Consequently, the discrepancy 
between the Millipore and immuClone anti-N reagent reactivity with this 
one patient sample was discounted as being the result of cross reactivity 
with the “N” antigen in the manual tube technique, since both suppliers 
clearly state that there is no “N” reactivity with their reagents. Anecdotal 
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evidence suggested that the strength of reactivity of the anti-N reagent in 
the automated profile (verbal correspondence) may be dependent on the 
age of the sample at testing and/or the temperature of the reagents. The 
manufacturer of the immuClone anti-N used in the automated technique 
(Immucor Gamma) stated in the product insert that Ethylenediamine 
Tetraacetic Acid (EDTA) samples may be tested up to 14 days from 
collection, or until the expiry of the anticoagulant, if stored at 2 – 8oC. This 
particular sample was first tested at day 11, then at days 18 and 43. 
Review of the reaction strengths with the anti-N reagent revealed that the 
reactivity reduced from a score of 22 at day 11, 17 at day 18 and 14 at 
day 43, all giving negative qualitative results but noticeably reducing with 
age of sample. A stability study was then initiated to investigate this 
theory. It was felt that if stability of sample was an issue with anti-N 
testing, then this was most likely to affect heterozygous expression of the 
N antigen (M+N+ patients). Consequently, the stability study included 10 
samples showing heterozygous expression (M+N+) and two samples 
showing homozygous expression (M+N-). These samples were tested 
daily for up to 10 days to determine a cut-off point for sample testing. The 
stability study demonstrated that, as a general rule, the reaction strength 
with N heterozygous cells would reduce to a negative value by day 7, and 
that to achieve the acceptable 3+ or 4+ reaction strength samples should 
be tested within three days of collection. In addition, it was also 
suggested (verbal correspondence) that the temperature of the reagents 
during testing may affect the reaction strengths. To test this effect, the 
stability study was also designed to compare the reaction strengths of the 
214 
 
anti-N using reagents taken directly from refrigerated storage 2 – 8oC, 
with the reaction strengths using reagents that had reached room 
temperature. The comparison of the reaction strength between the two 
groups showed no significant difference, indicating that temperature of 
the reagents does not affect the strength of the reaction. 
 
The reason for the reduction in reaction strength of the anti-N 
(immuClone) is not clear, and would appear not to affect all N 
heterozygous cells, since one M+N+ cell remained strongly positive at 
day 10. The fact that the nine M+N+ cells, that gave negative results in 
the automated testing at day 10, still remained strongly N positive when 
tested with the anti-N (Millipore) reagent in manual testing, suggests that 
the N antigen itself is not affected by storage. Both the ImmuClone and 
the Millipore reagents are murine monoclonal reagents, and are from 
different clone lines. However, this difference was not thought to affect 
the reaction strength, since the ImmuClone reagent was found to give a 
strong positive reaction in the tube technique with the original discrepant 
sample. The reduction in reaction strength, seen with the automated 
technique over time, is possibly due to the centrifugal forces applied by 
the automated analyser, or the forces applied during the shaking step 
prior to result analysis. Although this validation demonstrated that the 
immuClone anti-N reagent is suitable for use in automated techniques, 
samples must be tested within 3 days of collection to minimise the risk of 
false negative results. 
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Automated assays are considerably cheaper than manual assays, mainly 
due to the reduction in staff time required for preparing and reading the 
assays. In addition, reactions in the automated assay are graded by the 
analyser in accordance with a computer generated algorithm, in contrast 
to the macroscopic, human eye, reading of reactions strengths in the 
manual assay which may be subject to discrepancies between individual 
staff. Thus, the automated assay has the potential to standardise results 
and reduce the risk of mis-interpretation. 
 
This validation confirmed the fact that serological phenotyping assays are 
prone to false positive results in the presence of transfused cells and 
positive DAT. As reported here, measures can be implemented to reduce 
the risk of reporting false negative results in the presence of a positive 
DAT, but challenges will inevitably remain in the presence of circulating, 
transfused red cells. Genotyping assays overcome the limitations of the 
serological assays by testing genetic material extracted from white blood 
cells in the patient sample. The red cell phenotype is then predicted from 
the genotype. Thus, genotyping assays are useful when attempting to 
antigen type regularly transfused patients and those with positive DAT. 
The following chapter aims to assess the feasibility of DNA based assays 
for use in a hospital transfusion service setting, and to compare 
phenotypes predicted by genotyping with those found in the automated 
serological assay.   
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5 BLOOD GROUP GENOTYPING 
 
 
5.1 Introduction 
 
For patients undergoing multiple transfusions, serological phenotyping 
can be complicated by the presence of transfused cells within the 
circulation (BCSH, 2013). A definitive determination of the red cell 
phenotype of the patient is not possible whilst donor cells are still present 
in the circulation, and this makes it difficult to determine whether any 
antibodies detected are alloantibodies (reacting against the donor cells) 
or autoantibodies (reacting against the patient’s own cells). This, in turn, 
leads to difficulties with selection of appropriate antigen matched blood 
for subsequent transfusions. Serological phenotyping can also be further 
complicated by the presence of antibodies bound to antigens on the 
surface of the red cells, which can lead to false positive results, if using 
polyclonal antisera. The benefits of genotyping techniques have already 
been shown in the determination of blood groups in multiply-transfused 
patients (Guelsin et al., 2010), as red cells (transfused or recipient) do not 
carry DNA, only the DNA from recipient white cells is analysed. Blood 
components in the UK are leucocyte depleted, the small amounts of white 
cell DNA transferred to the recipient during transfusion does not interfere 
with the genotyping results, and even if transfusions of non-white cell 
depleted units are given this does not appear to interfere (Rozman et al., 
2000).  
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Advances in gene cloning and sequencing of blood group genes have 
determined the molecular basis for almost all of the clinically significant 
blood group polymorphisms (Daniels, 2013). The majority of genetically 
defined blood group antigens are the result of single-nucleotide 
polymorphism (SNP) (Castilho and Junior, 2004) which give rise to the 
amino acid changes described in section 1.3.2, and determine the 
antigenic phenotype. It is this knowledge that enables the use of DNA 
based assays, which detect these SNPs, to ascertain the allelic variations 
and predict the blood group antigens expressed on the surface of the red 
cells. Information regarding the blood group systems, genotype and  
allelic variations that make up the antigens of the various blood group 
systems can be found in the ISBT blood group alleles database and the 
Erythrogene database (Möller et al., 2016).  
 
DNA techniques have also been shown to have a high concordance rate 
with serological phenotyping techniques in blood donor and patient 
samples (Karpasitou et al., 2008), although limitations are seen with null 
and/or weak phenotypes, which may be detected only by serological 
techniques (Drago et al., 2010). Knowledge of the molecular basis of null 
phenotypes and weakened expression of antigens on the red cells allows 
the inclusion of assays into the red cell antigen genotyping profiles 
designed to detect the mutations silencing the expression of the antigen. 
This allows the genotyping results to predict the red cell antigen 
phenotype with a greater level of accuracy, as the presence of the gene 
does not always lead to the presence of the antigen on the surface of the 
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red cell. The IDCOREXT assay, evaluated in this study, includes probes 
designed to detect the SNPs responsible for null phenotypes in the Kidd, 
Duffy and MNS blood group systems, thus reducing the potential for 
incorrect prediction of the presence of the red cell antigens. This study 
aimed to evaluate the applicability of this assay in a routine hospital 
transfusion service setting, as yet untested in the UK.  
 
The following subsections will focus on the genetic basis of the blood 
group antigens predicted by the BLOODChip IDCOREXT assay, table 5.1 
contains a summary of the blood group systems, genes, alleles, 
nucleotide changes associated with the allelic variations and the 
predicted amino acid changes included in the assay. The antigenic 
phenotypes predicted by the alleles assayed by the IDCOREXT test are 
shown in table 5-2. The IDCOREXT test (Progenika Biopharma S.A.) can 
be used to type allelic variants which determine the blood group antigens 
tested in the serological phenotyping section of this study (Rh (CcEe), Cw, 
Kell (K and k), Kidd (Jka and Jkb), Duffy (Fya and Fyb), M, N, S and s), 
and also includes those of other blood group systems (Diego, Dombrock, 
Colton, Yt and Lutheran systems). Information regarding the 
biochemistry, genetic basis and function of the blood group systems are 
detailed in section 1.3.2. 
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Table 5.1: Blood group system alleles detected by the BLOODChip ID COREXT assay 
Blood group systems in the Erythrogene database and ISBT Blood Group Alleles showing the system name, gene, allele, nucleotide change and predicted amino 
acid change for the blood group antigen phenotypes predicted by the BLOODChip IDCOREXT assay Key: NA = not available in ISBT database 
System name Gene  Allele (ISBT) Nucleotide change Predicted amino acid change 
Rh 
 
 
 
 
 
 
 
 
 
 
 
 
RHCE 
 
 
 
 
 
 
 
 
 
 
 
 
RHCE*01 (RHCE*ce) 
RHCE*02 (RHCE*Ce) 
 
RHCE*03 (RHCE*cE) 
RHCE*04 (RHCE*CE) 
 
RHCE*CeCW 
RHCE*ceCW 
RHCE*CECW 
RHCE*ceAR 
 
RHCE*CeFV 
RHCE*CeVG 
Wild type reference 
 
48G>C 178C>T  203A>G  
307C>T 
 
 
676G>C 
 
48G>C  150C>T  178C>A  
201A>G  203A>G  307C>T 
676G>C 
 
122A>G 
 
NA 
 
NA 
 
48G>C  712A>G  733C>G  
787A>G 800T>A  916A>G 
 
 
667G>T  697C>G  712A>G 
 
712A>G  733C>G  787A >G 
 
 
Wild type reference 
 
Trp16Cys  Leu60Ile  Asn68ser 
Pro103Ser 
 
 
Ala226Pro 
 
Trp16Cys  Leu60Ile  Asn68ser 
Pro103Ser  Ala226Pro 
 
 
Gln41Arg 
 
NA 
 
NA 
 
Trp16Cys  Met238Val  Leu245Val  
Arg263Gly  Met267Lys  Ile306Val 
 
 
Val223Phe  Gil233Glu  Met238Val 
 
 
Met238Val  Leu245Val  Arg263Gly 
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System name 
(cont.) 
Gene (cont.) Allele (ISBT) (cont.) Nucleotide change
 (cont.) 
Predicted amino acid change 
(cont.) 
Rh  RHCE*cEFM 
RHCE*ce[712G] 
RHCE*ce[733G] 
RHCE*ce[733G,1006T] 
RHCE*CE-D[2, 5, 7]-CE 
RHCE*cE[697G,712G,733G] 
RHD*r’s-RHCE*ce[733G,1006T] 
697C>G  712A>G 
 
712A>G 
 
733C>G 
 
733C>G  1006G>T 
 
307  676  712  733 1006† 
 
697C>G  712A>G  733C>G 
 
IVS3+3100G 733C>G  
1006G>T 
 
 
 
Gln233Glu  Met238Val 
 
Met238Val 
 
Leu245Val 
 
Leu245Val  Gly336Cys 
 
NA 
 
Gln233Glu  Met238Val Leu245Val 
 
Leu245Val  Gly336Cys 
 
Kell KEL 
 
KEL*k_KPB_JSB 
KEL*K_KPB_JSB 
KEL*k_KPA_JSB 
KEL*k_KPB_JSA 
578C>T 
Wild type reference 
841C>T 
1790T>C 
 
 
 
Thr193Met 
Wild type reference 
Arg281Trp 
Leu597Pro 
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System name 
(cont.) 
Gene (cont.) Allele (ISBT) (cont.) Nucleotide change (cont.) Predicted amino acid change 
(cont.) 
Kidd SLC14A1 JK*02 (JK*B) 
JK*01(JK*A) 
JK*B_null(871C) 
JK*B_null(IVS5-1a) 
 
 
 
 
Wild type reference 
838A>G 
871T>C 
1G>A in intron 5 
Wild type reference 
Asn280Asp 
Ser291Pro 
NA 
Duffy DARC FY*A; 
FY*B 
FY*B_GATA 
FY*B[265T]_FY*X 
 
 
 
125A>G 
Wild type reference 
-67T>C 
265C>T 
Asp42Gly 
Wild type reference 
NA 
Arg89Cys 
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System name 
(cont.) 
Gene (cont.) Allele (ISBT) (cont.) Nucleotide change (cont.) Predicted amino acid change 
(cont.) 
MNS GYPA 
GYPB 
GYPE 
GYPA*M 
GYPA*N 
 
GYPB*s 
GYPB*S 
GYPB*Mur 
 
GYPB*deletion 
GYPB*S_null(230T) 
GYPB*S_null(IVS5+5t) 
 
 
 
 
 
 
Wild type reference 
59C>T 71G>A  72T>G 
 
Wild type reference 
143C>T 
GYP(B1-136-Bψ137-204-
A205-229-B230-366). 
Deletion of whole gene 
230C>T 
270+5G>T 
 
Wild type reference 
Ser20Leu Gly24Glu 
 
Wild type reference 
Thr48Met 
NA 
 
NA 
Thr77Met 
Alternative splicing 
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System name 
(cont.) 
Gene (cont.) Allele (ISBT) (cont.) Nucleotide change (cont.) Predicted amino acid change 
(cont.) 
Diego SLC4A1 DI*A 
DI*B 
2561C>T 
Wildtype reference 
Pro854Leu 
Wild type reference 
Dombrock ART4 DO*A 
DO*B 
DO*B_HY 
DO*A_JO 
Wild type reference 
793A>G 
232G>T 
350C>Y 
Wild type reference 
Asn265Asp 
Gly108Val 
Thr117Ile 
Colton AQP1 CO*A 
CO*B 
 
Wild type reference 
134C>T 
Wild type reference 
Ala45Val 
Yt (Cartwright) ACHE YT*A 
YT*B 
 
Wild type reference 
1057C>A 
Wild type reference 
His353Asn 
Lutheran LU 
 
LU*A 
LU*B 
 
230G>A 
Wildtype reference 
Arg77His 
Wild type reference 
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5.1.1 Rh system CcEe 
 
RHCE encoding the various Rh (CcEe) polymorphisms is located on the 
short arm of chromosome 1 (Avent et al., 1990; Cherif-Zahar et al., 1990). 
The IDCOREXT assay includes probes for the common alleles encoding 
the C, c, E, e and Cw antigens. The alleles at the locus include RHCE*01 
(RHCE*ce), in which “c” is represented by 307C in exon 2 and “e” which 
is associated with 676G in exon 5. RHCE*C is represented by 307T in 
exon 2 and RHCE*E by 676C in exon 5. All the RHCE amplicons 
included within the IDCOREXT kit are gene-specific and so no 
amplification of RHD is expected. The CW antigen is produced as a result 
of a single nucleotide change in exon 1 (122A>G) and is usually 
associated with RHCE*Ce (Mouro et al., 1995). Rarely, Cw is associated 
with RHCE*ce and RHCE*CE, the IDCOREXT assays includes probes 
designed to detect the nucleotide change associated with all of these 
alleles. Rhnull phenotypes are identified as a result of no amplifications of 
exons 5 and 7 of RHCE.  
 
Additional alleles assayed within the IDCOREXT test in the Rh system 
include those that code for the rare V and VS antigens. VS is associated 
with a single nucleotide change 733C>G in exon 5 of RHCE*ce (Daniels, 
2013). The IDCOREXT assay includes probes designed to detect the 
VS+V+ phenotype and the VS+V- phenotype (733C>G and 1006G>T).  
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The hrS and hrB antigens are associated with partial e (Shapiro, 1960; 
Shapiro et al., 1972). These antigens are important as they may be 
lacking in some black populations, individuals may type serologically as 
e+ but make apparent anti-e. Accurate identification of individuals with 
these variant antigens is of relevance in the transfusion of patients with 
SCD (Chou and Westhoff, 2009). Allelic probes designed to detect the 
presence of these SNPs representing these phenotypes are also included 
in the IDCOREXT. 
 
5.1.2 Kell system 
 
KEL encoding the Kell antigens is located on chromosome 7 (7q33) 
(Zelinski et al., 1991; Purohit et al., 1992; Lee et al., 1993; Murphy et al., 
1993). The K/k polymorphism arises as a result of a nucleotide change, 
578C>T, within exon 10 of the KEL gene, resulting in the KEL*K (ISBT 
K*01.01) and KEL*k (ISBT K*02) alleles. Additional alleles within the Kell 
system include those that code for the antithetical antigens Kpa and Kpb 
and Jsa and Jsb.  Kpa/Kpb arises as a result of 841C>T substitution in 
exon 8 and Jsa/Jsb from a 1790T>C change in exon 17.  
 
The Kell null phenotype can result from a variety of different genetic 
events (Reid, 2009) and so it is not feasible within the IDCOREXT assay 
to include probes designed to detect the phenotype.  
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5.1.3 Kidd system 
 
The gene encoding the antigens of the Kidd system (SLC14A1) is located 
on chromosome 18 (18q11-q12) (Olives et al., 1996). The Jka/Jkb 
phenotype arises as a result of a nucleotide change 838G>A in exon 9, 
resulting in the JK*A (ISBT JK*01) and JK*B (ISBT JK*02) alleles.  
 
The rare Jk null phenotype, Jk (a-b-), can be caused as a result of one of 
two silencing mutations; a splice mutation causing skipping of exon 6, 
SLC14A1:c.471-1G>A (Lucien et al., 1998) or a T871C substitution 
predicted to disrupt a potential N-glycosylation motif (NSSNSP), 
SLC14A1:c.871T>C (Sidoux-Walter et al., 2000).  The IDCOREXT assay 
contains a probes designed to detect both of these mutations.  
 
 
5.1.4 Duffy system 
 
DARC (ISBT nomenclature or HUGO gene name ACKR1) encoding the 
Duffy system antigens is located on chromosome 1 (1q21-q22) (Mathew 
et al., 1994). The Fyb/Fya polymorphism arises as a result of a nucleotide 
change, 125A>G, in exon 2. 
 
Tournamille and co-workers (1995) have demonstrated that the Fynull 
phenotype, Fy(a-b-), commonly seen in African populations, is a result of 
disruption of a GATA motif in the Fy gene promoter (DARC:c.-67T>C). In 
addition, a weakened expression of Fyb phenotype, also known to cause 
discrepancies between genotyping and phenotyping results, (Murphy et 
al., 1997) was later found to be caused by an Arg89Cys substitution 
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(Tournamille et al., 1998), the result of a nucleotide change 265C>T in 
exon 2. The IDCOREXT assay includes probes designed to detect both 
of these changes.  
 
5.1.5 MNS system 
 
The genes encoding the MNS polymorphisms, GYPA and GYPB, are 
located on chromosome 4 (4q31.21) (Kudo and Fukuda, 1990). The third 
gene in the family, GYPE, does not encode detectable protein on the red 
cell surface, but has been shown to be involved in some gene 
rearrangements that do encode hybrid proteins (ISBT, 2017). The M/N 
polymorphism arises as a result of nucleotide changes, 59C>T, 71G>A 
and 72T>G in exon 2. The S/s polymorphism arises as a result of a single 
change, 143T>C in exon 4.  
 
Within the MNS system the alleles assayed include the U antigen, an 
antigen associated with the S-s- phenotype (Wiener et al., 1954) and Mia, 
a low frequency antigen (Levine et al., 1951). Mur and Mia antigens arise 
as a result of hybrid glycophorins (B-A-B). The GYPB*Mur allele detected 
by the IDCOREXT assay is a novel sequence derived from the composite 
exon; GYPB 5’ pseudoexon 3 and GYPA 3’ exon 3. The nucleotide 
change associated with this phenotype is GYP(B1-136-Bψ137-204-A205-
229-B230-366). 
 
The S-s-U- phenotype occurs as a result of Glycophorin B deficiency 
(Huang et al., 1987; Rahuel et al., 1991), the IDCOREXT assay includes 
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detection of the GYPB*deletion which gives rise to the S-s-U- phenotype. 
The S-s-Uvar (weakened expression of the U antigen) is associated with 
a variant Glycophorin B protein that expresses a red cell antigen known 
as the He antigen (Huang et al., 1994; Huang et al., 1995; Reid et al., 
1996; Huang et al., 1997; Storry et al., 2003). The S-s- phenotype can 
also rise as a result of mutations within GYPB, commonly within intron 5 
or caused by a nucleotide change 230C>T substitution. Probes designed 
to identify both of these are included in the IDCOREXT assay; GYPB:c. 
230C>T and GYPB:c. 270+5G>T.  
 
5.1.6 Diego system 
 
The Diego system antigens include three pairs of antithetical antigens; Dia 
and Dib, Wra and Wrb, Wu and DISK and encoded by the gene SLC4A1 
on chromosome 7 (7q12-q21) (Schofield et al., 1994).  The Dia/Dib 
polymorphism arises as a result of a nucleotide change 2561T>C in exon 
19. The IDCOREXT test includes an assay for the alleles that encode the 
Dia and Dib antigens, DI*A (ISBT DI*01) and DI*B (ISBT DI*02). 
 
 
5.1.7 Dombrock system 
 
The Dombrock system antigens are encoded by the gene ART4 gene 
located on chromosome 12 (12p13.2-12.3) (Eiberg and Mohr, 1996; 
Mauthe et al., 2000); the assay tests for alleles that encode four of these 
antigens (Doa, Dob, Hy and Joa). The Doa/Dob polymorphism arises from 
a single nucleotide change, 793A>G in exon 2, resulting in the DO*A 
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(ISBT DO*01) and DO*B (ISBT DO*02) alleles. Hy is represented by 
323G in exon 2 of DO*B and Joa by 350C in exon 2 of DO*A. 
 
5.1.8 Colton system 
 
The Colton blood group system consists of four antigens (Coa, Cob, Co3 
and Co4), the gene encoding these antigens, AQP1, is located on 
chromosome 7 (7p14) (Moon et al., 1993).. The Coa/Cob polymorphism 
arise from a single nucleotide change 134C>T in exon 1. The IDCOREXT 
assay includes probes designed to identify the alleles, CO*A and CO*B, 
responsible for the expression of the Coa and Cob phenotypes.  
 
Although Conull phenotypes exist, and some are represented by single 
nucleotide changes, they are rare and are not included in the IDCOREXT 
assay.  
 
5.1.9 Yt system 
 
The antigens of the Yt (previously known as Cartwright) system are 
encoded by the gene, ACHE, located on chromosome 7 (7q22) (Getman 
et al., 1992; Ehrlich et al., 1992). The Yta/Ytb polymorphism results from 
the nucleotide change, 1057C>A, in exon 2, giving rise to the YT*A (ISBT 
YT*01) and YT*B (ISBT YT*03) alleles. The allele responsible for the high 
frequency YTEG antigen, YT*03, is the result of a nucleotide changes, 
266G>A in exon 2.  
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5.1.10 Lutheran system 
 
The Lutheran blood group system includes 22 antigens; however the 
IDCOREXT assay includes allelic tests for just two of these antigens (Lua 
and Lub). The gene that encodes the antigens of the Lutheran blood 
group, LU, system is located on chromosome 19 (19q12-q13) (Parsons et 
al., 1997; El Nemer et al., 1997). The Lua/Lub polymorphism results from 
a single nucleotide change, 230A>G, in exon 3, resulting in the alleles, 
LU*A (ISBT LU*01) and LU*B (ISBT LU*02). The Lunull phenotype is 
extremely rare and, as such, identification is not included in the 
IDCOREXT assay.  
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Table 5.2: The red cell antigen types determined by the IDCOREXT assay. 
The IDCOREXT assay uses PCR amplification to obtain target sequences for alleles encoding red cell antigens from human blood samples. The 
human blood group systems and the alleles assayed by the test are shown in the table below, also shown are the red cell antigen types as denoted 
by their International Society of Blood Transfusion (ISBT) phenotype name. 
Blood Group System  
 
Alleles Assayed 
 
Antigens 
(ISBT Phenotype) 
 
Rh 
 
RHCE*ce; 
RHCE*Ce 
RHCE*cE; 
RHCE*CE 
RHCE*CeCW 
RHCE*ceCW 
RHCE*CECW 
RHCE*ceAR 
RHCE*CeFV 
RHCE*CeVG 
RHCE*cEFM 
RHCE*ce[712G] 
RHCE*ce[733G] 
RHCE*ce[733G,1006T] 
RHCE*CE-D[2, 5, 7]-CE 
RHCE*cE[697G,712G,733G] 
RHD*r’s-RHCE*ce[733G,1006T] 
 
C (RH:2) 
E (RH:3) 
c (RH:4) 
e (RH:5) 
CW (RH:8) 
V (RH:10) 
hrS (RH:19) 
VS (RH:20) 
hrB (RH:31) 
 
Kell 
 
KEL*K_KPB_JSB 
KEL*k_KPB_JSB 
KEL*k_KPA_JSB 
KEL*k_KPB_JSA 
 
K (KEL:1) 
k (KEL:2) 
Kpa (KEL:3) 
Kpb (KEL:4) 
Jsa (KEL:6) 
Jsb (KEL:7) 
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Blood Group System  
 
Alleles Assayed 
 
Antigens (continued) 
(ISBT Phenotype) 
 
Kidd 
 
JK*A 
JK*B 
JK*B_null(871C) 
JK*B_null(IVS5-1a) 
 
Jka (JK:1) 
Jkb (JK:2) 
 
Duffy 
 
FY*A; 
FY*B 
FY*B_GATA 
FY*B[265T]_FY*X 
 
Fya (FY:1) 
Fyb (FY:2) 
 
MNS 
 
GYPA*M 
GYPA*N 
 
GYPB*s 
GYPB*S 
GYPB*Mur 
GYPB*deletion 
GYPB*S_null(230T) 
GYPB*S_null(IVS5+5t) 
 
S (MNS:3) 
s (MNS:4) 
U (MNS:5) 
Mia (MNS:7) 
M (MNS:1) 
N (MNS:2) 
Diego 
 
DI*A 
DI*B 
 
Dia (DI:1) 
Dib (DI:2) 
 
Dombrock 
 
DO*A 
DO*B 
DO*B_HY 
DO*A_JO 
 
Doa (DO:1) 
Dob (DO:2) 
Hy (DO:4) 
Joa (DO:5) 
 
Colton CO*A 
CO*B 
 
Coa (CO:1) 
Cob (CO:2) 
 
Cartwright YT*A 
YT*B 
 
Yta (YT:1) 
Ytb (YT:2) 
 
Lutheran  
 
LU*A 
LU*B 
 
Lua (LU:1) 
Lua (LU:2) 
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5.2 Study design 
 
The IDCOREXT test allows a simultaneous multiplex reaction in a single well 
avoiding the need for running multiple separate methods in parallel. The 
results obtained from the Luminex xMAP technology are then processed using 
the IDCOREXT analysis software, converting the alleles detected into a 
genotype result which is then, in turn, used to predict the phenotype for each 
of the allelic variants interrogated by the test (see section 1.7).  
 
This study aimed to evaluate the IDCOREXT test for potential use as a high 
throughput genotyping method suitable for the hospital transfusion setting. In 
addition, this study aimed to compare the red cell phenotyping results 
obtained from blood samples taken from a selection of the patients consented 
from the Haematology Clinic and tested on the automated phenotyping 
platform, with the genotyping results obtained by the IDCOREXT test using 
DNA extracted from the same patient samples.  
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5.3 Results 
 
5.3.1 DNA extraction 
 
The concentration of DNA extracted from the whole blood samples (n=47) 
ranged from 6.03ng/μL to 812 ng/μL, the average concentration was 
184.75 ng/μL (SD 180.63) (table 5-3). The DNA concentration 
recommended for use in the IDCOREXT assay was between 10 ng/μL 
and 80 ng/μL, hence, one sample was below the recommended level.  
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Table 5.3: Concentration and quantity of DNA extracted from whole 
blood samples 
DNA was extracted from whole blood samples taken from 47 patients for 
genotyping using the IDCOREXT assay. The concentration of DNA ranged from 
6.03ng/μL to 812 ng/μL. 
Patient number DNA concentration (ng/μL) DNA quantity 
1 45.74 100 
2 26.17 100 
3 104.8 300 
4 25.58 300 
5 195.1 300 
6 175 300 
7 300.4 300 
8 6.03 300 
9 271.7 300 
10 812 300 
11 266.1 300 
12 137.7 300 
13 797 300 
14 45.97 300 
15 80.03 100 
16 64.55 300 
17 28.13 100 
18 397 300 
19 82.78 300 
20 28.78 300 
21 437.6 300 
22 411 300 
23 182.7 300 
24 25.12 300 
25 130.7 300 
26 96.24 300 
27 215.6 300 
28 95.69 300 
29 24.3 300 
30 185.9 300 
31 111.2 300 
32 71.69 300 
33 300.1 300 
34 121.3 300 
35 129.9 300 
36 297.2 300 
37 349.4 300 
38 516.2 300 
39 168.7 300 
40 47.32 300 
41 108.4 300 
42 134.8 300 
43 43.33 300 
44 124.3 300 
45 258.1 300 
46 76.06 300 
47 130 300 
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5.3.2 Cost of testing 
 
Test costs were calculated for the red cell antigen genotyping system. 
Staff costs were calculated at Band 5 (Agenda for Change, NHS pay 
scale 2015) pay point 20 and reagent costs were calculated at supplier 
cost 2014-2015 (excluding VAT). Costs for the relevant equipment 
maintenance cost per patient test were estimated, based on the number 
of patients registered as attending the Haematology or Renal wards for 
transfusion at the RD&E per year, and assuming that every patient would 
require a blood group genotype. True cost per test for the analyser 
maintenance could not be calculated as the system is not in use in our 
institution; however, estimated costs were calculated based on the 
supplier quotation. However, this may lead to over representation of the 
cost as the analyser system can also be used by other specialities, such 
as microbiology and immunology, therefore not restricted to blood group 
genotyping and, thus increasing the total throughput per year. Internal 
quality control costs were also included in the cost of the consumables. 
The total cost per patient test was estimated to be £73.66 (table 5-4).  
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Table 5.4: Cost of Blood Group genotyping 
 
The cost per test was estimated for blood group genotyping using the IDCOREXT test. All costs shown in this table are cost 
per patient sample tested. Staff time costs were estimated assuming that the testing and reporting of results would be 
performed by a band 5 Biomedical Scientist. Equipment maintenance costs were based on an assumption that all patients 
admitted for transfusion on the haematology and renal wards would require a blood group genotype test (n=1674 for the 
financial year 2014-2015).  
 
  
DNA 
extraction (£) 
IDCOREXT + 
kit (£) 
Consumables (£) Equipment 
(£) 
Staff time (£) Total cost per 
patient sample (£) 
8.95 45.00 1.50 0.87 17.34 73.66 
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5.3.3 Comparison of phenotyping and genotyping results 
 
DNA extracted from 47 patients was analysed for the presence of known 
blood group SNPs on the Luminex XMAP analyser using the IDCOREXT 
kit. Whole blood samples from each of these 47 patients had previously 
been analysed for serological phenotype using the automated 
phenotyping method (IBG Immucor) to allow comparison of the 
phenotyping result with the predicted phenotype generated by the 
genotyping result. The IDCOREXT contains assays for 49 different alleles 
that are used by the software to predict 37 red cell phenotypes. The 
report produced by the software details the blood group system, the 
alleles assayed within that system, along with the genotype result, the 
corresponding red cell antigen with their ISBT phenotype notation and the 
predicted phenotype (figure 5.2). The predicted phenotype, as interpreted 
by the software, was then used for direct comparison with the phenotypes 
reported by the automated serological phenotyping assay. The raw data 
obtained from the IDCOREXT assay are detailed in Appendix 4.  
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Figure 5.1: DNA analysis report generated by the Luminex XMAP 
analyser 
An example of the report generated by the Luminex XMAP analyser for each sample of 
DNA processed. The alleles assayed for each blood group system are shown, along 
with the genotype result, the corresponding red cell antigen (ISBT Phenotype) and the 
predicted phenotype. 
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No failures of testing were encountered and there were no discrepancies 
seen in the serological phenotyping and genotyping for Rh (CcEeCw), K, 
k, N, Fy (a and b), Jk (a and b), S and s. One discrepancy was seen in 
the M antigen status for one patient (EX1300853), this patient typed as 
M+ in serological phenotyping assays but produced an M- genotype 
(discussed further in section 5.4). One patient (EX1312673) returned a 
“not determined” result for the S antigen in the automated serological 
assay. A repeat sample could not be obtained from the patient within the 
time frame of the study, due to the death of the patient, but further review 
of the serological assay reaction value (21) showed the result to be just 
above a negative value (20.998 value for the cut off high) (see result 
interpretation cut off values in appendix 3). Therefore, the serological 
phenotyping result was suggestive of a negative result, in agreement with 
the genotyping predicted phenotype result. Full results of the comparison 
of the genotyping assay and the automated phenotyping assay can be 
seen in Table 5-5.  
 
Comparison of serological phenotype and genotype for some antigens 
predicted by the IDCOREXT assay could not be performed as there were 
no serological phenotypes performed, these include the antigens V, hrS, 
Vs and hrB of the Rh system, Kpa, Kpb, Jsa and Jsb of the Kell system, U 
and Mia of the MNS system, and antigens of the Diego, Dombrock, 
Colton, Cartwright and Lutheran system. 
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Table 5.5: Antigen phenotypes by serological analysis and genotyping 
 
Results obtained by serological phenotyping for the 47 selected patient samples are shown in black type and those predicted by genotyping are 
shown in red type. 
A single discrepancy was seen for the M antigen type for patient EX1300853 which is highlighted in yellow. 
S antigen status for patient EX1312673 was not determined by serological phenotyping methods due to undetermined consistently weak positive 
reactions (highlighted in yellow) 
 
Key: P = positive result 
        N = negative result 
        ND = not determined 
 
  Red cell antigens assayed 
Sample No C c E e Cw K Fya Fyb Jka Jkb S s M N k 
EX1305814 P P N P N P P P P N N P P N P 
  P P N P N P P P P N N P P N P 
EX1305816 N P P P N N N P N P P P P N P 
  N P P P N N N P N P P P P N P 
EX1305815 N P P N N N P N P N N P N P P 
  N P P N N N P N P N N P N P P 
EX1305817 N P P P N N P N P P P P P P P 
  N P P P N N P N P P P P P P P 
EX1300853 N P P N N N P P P P N P P P P 
  N P P N N N P P P P N P N P P 
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  Red cell antigens assayed (continued) 
Sample No C c E e Cw K Fya Fyb Jka Jkb S s M N k 
EX1300854 N P P P N N P P P P P P P N P 
  N P P P N N P P P P P P P N P 
EX1303174 N P P N N N P P N P N P P P P 
  N P P N N N P P N P N P P P P 
EX1306850 P N N P N N P N P P P P P P P 
  P N N P N N P N P P P P P P P 
EX1307336 P P P P N N N P P N P N P P P 
  P P P P N N N P P N P N P P P 
EX1307335 P N N P N N N P P P P P P P P 
  P N N P N N N P P P P P P P P 
EX1307657 P N N P N N P P P P N P P N P 
  P N N P N N P P P P N P P N P 
EX1307898 N P N P N N N P P N N P P P P 
  N P N P N N N P P N N P P P P 
EX1307899 N P P P N P P P P P P P P P P 
  N P P P N P P P P P P P P P P 
EX1308240 N P N P N N P P P N N P N P P 
  N P N P N N P P P N N P N P P 
EX1308368 P P N P N N P N P P N P P N P 
  P P N P N N P N P P N P P N P 
EX1308578 N P P P N N P P P P N P P P P 
  N P P P N N P P P P N P P P P 
EX1308762 P N N P N N N P P N P P P N P 
  P N N P N N N P P N P P P N P 
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  Red cell antigens assayed (continued) 
Sample No C c E e Cw K Fya Fyb Jka Jkb S s M N k 
EX1308909 P P P P N N P P P N N P P P P 
  P P P P N N P P P N N P P P P 
EX1308908 N P N P N N P N P N P P P P P 
  N P N P N N P N P N P P P P P 
EX1308959 P P N P N N N P N P N P P P P 
  P P N P N N N P N P N P P P P 
EX1311437 P N N P P N N P N P N P P N P 
  P N N P P N N P N P N P P N P 
EX1311438 N P P P N N P P P P P N P N P 
  N P P P N N P P P P P N P N P 
EX1311988 P P N P N P N P P P P P P P P 
  P P N P N P N P P P P P P P P 
EX1311987 P P P P N N N P P P P P P P P 
  P P P P N N N P P P P P P P P 
EX1311986 P P P P N N P P P N P P P P P 
  P P P P N N P P P N P P P P P 
EX1311989 P P N P N N P P P P P P P N P 
  P P N P N N P P P P P P P N P 
EX1312296 P P N P N N P N P N N P P N P 
  P P N P N N P N P N N P P N P 
EX1312295 P P N P N N N P N P P P P N P 
  P P N P N N N P N P P P P N P 
EX1312294 N P N P N N P P P P N P P N P 
  N P N P N N P P P P N P P N P 
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  Red cell antigens assayed (continued) 
Sample No C c E e Cw K Fya Fyb Jka Jkb S s M N k 
EX1312297 P P N P N P N P P N N P P P P 
  P P N P N P N P P N N P P P P 
EX1312311 P P N P N N N P N P N P N P P 
  P P N P N N N P N P N P N P P 
EX1312312 P N N P N N N P P P N P P P P 
  P N N P N N N P P P N P P P P 
EX1312453 N P P P N N N P P P P N P N P 
  N P P P N N N P P P P N P N P 
EX1312674 P N N P N N P N P P N P P P P 
  P N N P N N P N P P N P P P P 
EX1312673 P P N P N N N P P P ND P P P P 
  P P N P N N N P P P N P P P P 
EX1312675 P N N P P N N P N P N P N P P 
  P N N P P N N P N P N P N P P 
EX1312967 N P P P N N N P N P P P P P P 
  N P P P N N N P N P P P P P P 
EX1313154 P P N P N N P P N P P N P N P 
  P P N P N N P P N P P N P N P 
EX1313155 N P P P N N P N N P N P N P P 
  N P P P N N P N N P N P N P P 
EX1313515 N P P N N N N P P N P P N P P 
  N P P N N N N P P N P P N P P 
EX1313516 P P N P P N P P P N N P P N P 
  P P N P P N P P P N N P P N P 
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  Red cell antigens assayed (continued) 
Sample No C c E e Cw K Fya Fyb Jka Jkb S s M N k 
EX1313820 P P N P N N N P N P N P P P P 
  P P N P N N N P N P N P P P P 
EX1400171 P P N P N N N P P P N P P P P 
  P P N P N N N P P P N P P P P 
EX1400887 P P N P N N N P N P N P N P P 
  P P N P N N N P N P N P N P P 
EX1401612 P P P P N N N P P P P N P N P 
  P P P P N N N P P P P N P N P 
EX1401613 P P N P N P P P P N P P P N P 
  P P N P N N P P P N P P P N P 
EX1401737 P P P P N N P P N P P P P P P 
  P P P P N N P P N P P P P P P 
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5.4 Discussion 
 
The IDCOREXT assay was demonstrated to be a robust assay showing 
good comparison with the automated serological phenotyping assay and 
a low failure rate. A discrepancy in testing was seen with the M antigen 
type in one patient, unfortunately it was not possible within the time scale 
and funding of this project to ascertain the cause of this discrepancy. In 
addition, repeat serological testing was not possible due to the death of 
the patient.  It is unlikely that the discrepancy was caused by human 
and/or methodological error, as this would have resulted in discrepancies 
involving multiple antigens. The serological M type for this patient was 
confirmed as positive by a reference centre (NHSBT, Filton), in 
accordance with the serological phenotype determined by automated 
testing at the RD&E. Therefore the discrepancy was unlikely to be due to 
any issues affecting the performance of the anti-M used in the automated 
phenotyping assay. It is possible that the allele coding for the M antigen, 
in this particular patient, may have an alteration such that it is not 
detected by the BLOODChip IDCOREXT assay. Sequencing of the DNA 
could potentially have revealed if this was the case, however, this was not 
possible within the funding of the project. This type of discrepancy could 
result in a false negative result being reported. This would not cause 
clinically significant issues for patients within a type and match strategy 
as they would be transfused with antigen negative red cells. However, 
within the blood donor service this would have implications as the donor 
units would be erroneously reported as antigen negative and could elicit 
an immune response in a patient. 
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In a study by McBean and co-workers (2014b) it was noted that, although 
the microarray techniques are a useful tool for the determination of blood 
group genotypes, difficulties can arise as a result of a new or rare allele 
not incorporated in the assay, or a complex genetic variant. In these 
cases further analysis by sequence-based typing in specialist reference 
laboratories may elucidate the molecular basis of the unusual blood 
group phenotype (Seltsam and Doescher, 2009). McBean’s laboratory 
experience suggests that up to 5-10% of complex serological cases 
cannot be resolved by microarray genotyping, and of these, 1-2% cannot 
be resolved by sequencing (McBean et al., 2014b).  
 
Genotyping assays can also generate false positive results, where there 
is an apparently normal allele but no corresponding antigen on the red 
cells. This can be caused by silencing genes outside of the assay target 
area, as seen in “null phenotypes”. The BLOODChip IDCOREXT assay 
contains makers for well-known silencing genes, but hitherto unknown 
ones may be missed. False positive results in genotyping assays cause 
clinical issues within the transfusion service rather than the blood donor 
service, in contrast to the false negative results. A false positive result for 
a transfusion recipient in a type and match program would lead to 
selection of inappropriate red cells. Discrepancies between genotyping 
and phenotyping results may also arise if not all the alleles are known, 
and many molecular events can give rise to discrepancies. The current, 
commercially available, genotyping assays are restricted to testing for 
known SNPs, meaning that new variants will not be recognised.  
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Other studies have seen higher genotype-phenotype discrepancy rates 
than seen in this study, McBean and co-workers (2014a) found a 
discrepancy rate of 10.4% when comparing phenotyping with genotyping 
using three different genotyping platforms, the BLOODChip (Progenika), 
BeadChip (BioArray Solutions Ltd) and the HemoCarta Blood Group 
Typing Panel (Sequenom Inc.). However, it should be noted that the 
discrepancies between genotyping and phenotyping results seen in the 
McBean study and also in other studies (Drago et al., 2009; Drago et al., 
2010) were due to mutations causing weakened antigen expression or 
null phenotypes. The inclusion of markers for identification of null 
phenotypes and silencing genes within the commercial genotyping kits 
will reduce the risk of incorrect prediction of antigen phenotypes.  
 
A further limitation of the commercially available blood group genotyping 
assays is that they may be designed for a specific population (McBean et 
al., 2014b). McBean and co-workers report that the BLOODChip assay 
was designed for a European population and the BeadChip assay was 
designed for the African/America population. Neither of these assays, 
they report, are designed for the large proportion of Asian ancestry seen 
in the Australian population.  
 
The development of massively parallel sequencing (MPS) as an 
alternative approach to blood group genotyping has overcome some of 
the limitations of the commercially available microarray kits. MPS is not 
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restricted to the identification of blood group systems with known SNPs 
and, thus, allows new variant blood group antigens to be identified. MPS, 
or Next Generation Sequencing, can be used to obtain information on the 
whole genome, or restricted to whole exome or targeted gene 
sequencing. This technique is not currently commonly used for blood 
group genotyping but has been applied to resolve the genetic basis of the 
Vel antigen (Cvejic et al., 2013) and that of the low frequency orphan 
antigen SARA (McBean et al., 2014c). When looking to implement MPS, 
ethical issues should also be considered as non-blood group genetic 
information is also obtained. Methods for managing this information would 
need to be in place to ensure donor and/or patient confidentiality.  
 
One of the advantages commonly quoted for commercially available 
blood group genotyping assays is their ability to provide information on 
multiple blood group antigens for multiple patients on an automated 
platform. In addition, the automated data analysis by the system software 
removes the risk of subjective interpretation of the traditional manual 
serological assays. The validation of the automated serological assay on 
the IBG Immucor NEO® analyser system in this study demonstrates that 
serological assays can also be fully automated and provide standardised, 
non-subjective, information on a large number of blood group antigens for 
multiple patients with minimal manual input. The real advantage of the 
genotyping assays is that they can be used to obtain a predicted 
phenotype in patients who have been recently transfused and in those 
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who have a positive DAT, areas where serological assays may give 
inconsistent or incorrect results.  
 
Although DNA extraction for this study was performed by an automated 
system, the genotyping assay required substantial manual input for the 
PCR and hybridisation phases. Not only are these manual phases 
expensive in terms of labour, they also require specialist skills not 
currently used by hospital transfusion scientific staff, and they are at risk 
of errors in sample transposition and pipetting which may lead to incorrect 
results. Automation of these phases for blood group genotyping assays is 
not currently available, and it is this limitation which will hinder the 
introduction of the assays into the routine hospital laboratory setting. 
 
The evaluation of the serological and genotyping assays, as described in 
this study, have demonstrated robust, accurate systems for high 
throughput testing that have potential for use in a hospital transfusion 
setting. In particular, the automated serological assay (IBG Immucor) 
would appear to be a cost effective method that could be easily 
incorporated into a type and match program. To reduce the risk of 
inaccurate serological phenotyping results, patient samples would need 
to be tested prior to initial transfusion, or in the absence of blood 
transfusion in the previous four months. The results of the phenotyping 
assay could then be used to provide blood for transfusion that was 
matched for Rh (CcEe) and K in addition to the standard ABO/D 
matching. The introduction of a “type and match” program would have the 
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potential to reduce the risk of alloimmunisation in chronically transfused 
patients. The benefits of a type and match program have not been 
evaluated in the UK, and would require a large number of participants 
enrolled into a randomised controlled trial (RCT) to adequately address 
the research question, given the incidence of alloimmunisation in 
chronically transfused patients noted in this study.  Prior to initiation of 
such an RCT, there are other important questions that need to be 
addressed. These include recruitment rates, dropout rates and, more 
importantly, the ability of the hospital transfusion laboratories to provide 
matched blood from routine stocks. A useful precursor to an RCT is a 
pilot study, which can provide answers to some of these questions and 
identify any unforeseen issues.  A pilot study was initiated at the RD&E, 
as part of this research project, designed to provide information that could 
be used to lead into a larger RCT, and this is described in chapter 6.   
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6 PILOT STUDY-RANDOMISED CONTROLLED TRIAL 
 
6.1 Introduction 
 
 
To truly assess whether typing and matching of blood for chronically 
transfused patients would reduce the risk of the development of 
allo/autoantibodies and realise the estimated cost benefits, a randomised 
controlled trial (RCT) is required. Patients would be recruited to either a 
standard care group, receiving standard ABO and RhD matched blood or 
to an intervention group destined to receive blood additionally matched 
for Rh (CcEe) and K antigens.  This study has already demonstrated that 
the development of allo/autoantibodies occurs in around 15-25% of 
chronically transfused patients and that a relatively large number of 
transfusions are required before this effect is seen. Therefore any RCT 
designed to investigate the potential benefits of typing and matching 
blood would need large numbers of patients and would take considerable 
time to achieve. Given the number of patients with haematological and/or 
renal conditions that would be required for recruitment it is unlikely that 
this sort of RCT could be undertaken in one hospital site, but would more 
likely require a coordinated multicentre trial. 
 
A feasibility, or pilot, study is a commonly used forerunner to a large RCT, 
and is described by the National Institute for Health Research (NIHR) as 
a piece of research done before a main study to answer the question “can 
this study be done?” In this way they can be used to estimate important 
parameters that are needed to design the main study, such as standard 
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deviation of the outcome measure, which is needed in some cases to 
estimate sample size required to gain statistical power; number of eligible 
patients, willingness of participants to be randomised; willingness of 
clinicians to recruit participants; carers or other appropriate participants; 
characteristics of the proposed outcome measure. In some cases 
feasibility studies might involve designing suitable outcome 
measures; follow-up rates, response rates to questionnaires, 
adherence/compliance rates; availability of data needed or the usefulness 
and limitations of a particular database; time needed to collect and 
analyse data (NIHR guidance). Pilot studies do not necessarily need to 
be RCTs but the inclusion of a control group and randomisation allows 
the review of willingness of the subjects to be randomised which can then 
inform on the recruitment requirements of the larger trial. 
 
Pilot studies, because of their limited size, cannot provide any definite 
support for any specific therapeutic claims (Loscalzo, 2009), they cannot 
be used to evaluate safety, efficacy and effectiveness and neither do they 
provide meaningful effect size estimate for planning subsequent studies 
due to the imprecision inherent in data from small samples  (Leon et al., 
(2011); Friedman et al., 1998; Kraemer et al., 2006), however, the data 
obtained can be used to design a larger RCT and they can be useful in 
identifying any unexpected harm of the intervention early on in the course 
of its development. The ultimate aim of the larger trial should be used to 
guide the design of the pilot study and the participants or patients should 
be recruited from the same study population (Hinds and Gattuso, 1991), 
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this will enable the researchers to test those aspects of the intended 
larger trial and make any amendments in advance of embarking on any 
larger RCTs. Recruitment of trial subjects can be slower and more difficult 
than researchers imagine and many trials fail to achieve their intended 
sample size within the planned time frame (McDonald et al., 2006; Sully 
et al., 2013). Assessment of this within the pilot study may prevent issues 
developing within the larger RCT. A review of pilot studies published in 
seven major medical journals from 2000 to 2001 (Lancaster et al., 2004) 
recommended that statistical analysis of pilot studies should be either 
mainly descriptive or focus on the estimation of the sample size and that 
any results from hypothesis testing should be treated with caution. Arain 
and coworkers (2010) revisited this review between the years 2007 and 
2008 to assess whether the recommendations made by Lancaster and 
his team had produced a change in the practice of reporting pilot studies 
but found that pilot studies were still poorly reported with inappropriate 
emphasis on hypothesis testing. The review by Arain and coworkers 
found that 81% of pilot studies published reported statistics on hypothesis 
testing, they also found that only 69% of the studies included a control 
group, and although randomisation was noted in 62% of the trials, only 
20% of those were blinded randomisation. Teare and coworkers (2014) 
recommended that pilot studies include at least 35 participants per group 
(total of 70) to allow estimation of the standard deviation for a continuous 
outcome and a total of 60 to 100 recruits for trials investigating event 
rates. It is recommended that any estimation using confidence intervals 
(CI) in pilot studies should use 85% or 75% CI rather than the commonly 
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used 95% CI (Lee et al., 2014). There is no set sample size for a pilot 
study. The review by Arain and coworkers (2010) found a median number 
of 76 participants, with an interquartile range of 42-216. Generally, 
sample sizes of 30, 50 and 70 will provide 48%, 78% and 84% power to 
detect an acceptance rate of 85% or lower if the acceptance rate in the 
population is 95%, however it has been noted that the sample size is 
often related to the funding level rather than the likelihood of achieving 
the specific aims (Moore et al., 2011). 
 
With all the benefits and caveats of pilot studies in mind, a small RCT 
was designed and performed using participants from the haematology 
clinics at the RD&E. It was accepted that, given the time frame in which 
the pilot study was required to be completed, and to enable the 
participants’ sufficient time to be given blood transfusions, that only 60 
patients would be recruited to the trial. The 60 patients were randomised 
to the standard care group or to the intervention group using a modified 
block randomisation to ensure that there were equal numbers of patients 
in each group. Patients approached for recruitment into the trial were 
given information leaflets detailing the tests to be performed and the 
randomised aspect to the treatment arms (appendix 5). Patients were 
given time to read the information and encouraged to ask any questions 
regarding the trial. Specific consent forms were signed by each patient 
recruited and patients were given the option to drop out of the trial at any 
time, should they wish to do so (appendix 6). The pilot study was given 
ethical approval from the NRES Committee South West - Cornwall & 
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Plymouth (MREC No. 12/SW/0251, R&D Study No. 1301733). This is the 
first time that such a trial has been attempted in the UK.  
 
The aim of the pilot study was to review recruitment rates and dropout 
rates for the patients and also to assess the ability to supply matched 
blood for transfusion in the intervention group from routine blood stocks 
held in a hospital transfusion laboratory. The pilot study was not powered 
to investigate any differences in the rates of development of 
allo/autoantibodies between the standard care group and the intervention 
group. Nor was it powered to provide an estimate of the sample size 
required for a larger multicentre randomised controlled trial designed to 
investigate any benefits of typing and matching of blood for chronic 
transfusion. 
 
The blood stocks held at the RD&E during the time of the pilot study are 
shown in table 6.1. The red cell units were held in ABO/D specific trays 
within a walk-in cold room. There was no subdivision of ABO/D types for 
Rh or Kell antigens. Orders were made to the NHSBT for red cell stocks 
on a daily basis, no changes were made to the ordering procedure with 
respect to particular Rh antigen types. In order to locate a matching unit 
for a pilot study patient, the laboratory staff had to search the physical 
stock, there is no search function for this in the laboratory computer 
system. Alternatively, appropriate antigen negative blood could be 
ordered from the NHSBT. As such, the results of the pilot study could 
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also be used to design effective changes to the way that the stocks are 
arranged and ordered to support a type and match program.   
 
Table 6.1 Optimum stock of red cell units held in RD&E stock 
The optimum number of red cells and their ABO/D type are shown in the table 
below. A small stock of group O and A, K negative, irradiated units are held for 
patients with this special requirement. The red cell units are stored in labelled 
trays in accordance with their ABO/D type. (Table taken from the RD&E 
laboratory standard operating procedure for red cell ordering and stock 
control). 
 
Blood group Optimum Red Cell 
Stock 
Paediatric Red Cells 
O RhD Pos 30 0 
O RhD Neg 10 1  
 
A RhD Pos 30 0 
A RhD Neg 12 0 
B RhD Pos 6 0 
B RhD Neg 4 0 
AB RhD Pos 4 0 
AB RhD Neg 4 0 
O RhD Pos Irradiated K-                    4   
O RhD Neg Irradiated K-                    2  
A RhD Pos Irradiated K-                    4    
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6.2 Results of the randomised controlled pilot study 
 
A total of 60 patients were recruited to the trial between the 8th November 
2012 and the 16th July 2014. Patients were recruited from the 
haematology clinic with the only exclusions being individuals under the 
age of 18, those not capable of giving informed consent and those with a 
positive antibody screen recorded in the pathology computer system. 
Initially, recruitment was restricted to patients with haematological 
conditions considered likely to require blood transfusion, such as 
myeloma, acute and chronic leukaemias, Hodgkin’s and non-Hodgkin’s 
lymphoma, myelodysplastic and myeloproliferative disorders. However, 
using these criteria only eight patients were recruited over a seven month 
period. In order to recruit a sufficient number of patients in the time scale 
relevant to the study, the entry criteria were widened to include any 
patient attending the clinic with a confirmed haematological condition. 
Only one patient approached declined to enter the trial on the basis that 
they were alarmed by the thought of potential blood transfusions. All other 
patients approached were satisfied with the information that they were 
given regarding the trial and happy to be included.  
 
Initially 30 patients were randomised to Group 1, the standard treatment 
group, and 30 to Group 2, the intervention group. One patient in Group 2 
was found to have a positive antibody screen on initial testing and so was 
excluded from the trial. 
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6.2.1 Number of patients transfused in each study group 
 
A total of 59 patients were included in the trial, of these 19 (32.2%) were 
transfused during the trial period. A total of 13 patients received 
transfusions in the standard care group, group 1 (n=30), and four patients 
were transfused in the intervention group, group 2 (n=29). This 
demonstrates that significantly more patients in group 1 received 
transfusions than in group 2 (Fisher’s exact test p value = 0.0204) (figure 
6.1).  
 
Figure 6.1: Comparison of number of patients transfused in the pilot 
study groups 
 
 
 
Within the standard care group (group 1, n=30) 13 (43.3%) patients were 
transfused, compared to 4 (13.8%) patients in the intervention group 
(group 2, n=29). Significantly more patients in group 1 were transfused 
compared to group 1 (Fisher’s exact test p value = 0.0204). 
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6.2.2 Time spent in trial for patients in each study group 
 
 
Patients were recruited to the trial between the 8th November 2012 and 
the 16th July 2014, the trial was closed and data collected on the 31st July 
2015, consequently, in total, the trial ran over 995 days. The recruitment 
process lasted 615 days, longer than anticipated due to initial difficulties 
with the selection criteria. Over the 21 month recruitment process patients 
were accepted onto the trial at an average rate of 2.86 per month, 
however, over the first six months of the trial only seven patients were 
recruited (average 1.17 per month). At this point it was realised that 
insufficient patients would be recruited in the allocated time using the 
stringent criteria and so the criteria were relaxed, as a result of this, from 
June 2013 to November 2013 a total of 34 patients were recruited 
(average 5.67 per month) (figure 6.2). 
 
Patients in group 1 spent an average of 697.6 days (range 396 to 995 
days, SD 154.8, n=30) on the trial compared to an average of 583.7 days 
(range 380 to 994 days, SD 165.9, n=29) for patients in group 2 (figure 
6.3). Of the first 30 patients to be recruited to the trial, 21 (70%) were 
randomly assigned to group 1, this unexpectedly high number would 
account for the significant difference in length of time in the trial for 
patients in each of the groups (t-test p value = 0.0085). 
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Figure 6.2: Recruitment rates for pilot study patients 
 
Patients were recruited to the pilot study over a 21 month period (n=60). 
Slow recruitment rates in the initial six month period were thought to be 
due to strict selection criteria focussed on patients with disease 
conditions considered to be at high risk of transfusion dependence. 
Relaxation of the selection criteria and an increase in recruitment rate 
was seen from June 2013 onwards, which enabled the recruitment target 
to be achieved within the time scale of the project. 
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Figure 6.3: Comparison of the length of time spent on the trial for 
patients in the pilot study groups 
 
 
 
Box-and-whiskers plots showing the minimum and maximum numbers 
(black line) of time spent in the trial (the first quartile, mean and third 
quartile are denoted by the coloured blocks).  Patients in group 1 
(standard care group, n=30, range 396 to 995 days, SD 154.8) spent 
significantly longer on the pilot study trial than patients in group 2 
(intervention group, n=29, range 380 to 994 days, SD 165.9). T-test p 
value = 0.0085. 
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6.2.3 Comparison of the number of transfusion episodes and units 
given for patients in each study group 
 
Within the standard care group (group 1 n=30) 13 patients received blood 
transfusions and within the intervention group (group 2, n=29) four 
patients received transfusions. The average number of red cell units 
given to transfused patients in group 1 over the study period was 27.46 
(range 2 to 76, SD 26.99, n=13) and the average number of red cell units 
given the transfused patients in group 2 was 22.25 (range 1 to 71, SD 
32.71, n=4). There was no statistically significant difference seen in the 
number of red cell transfusions given to patients in each study group (t-
test p value = 0.7513) (figure 6.4). 
 
The average number of transfusion episodes within the standard care 
group (group 1) was 11.62 (range 1 to 30, SD 10.32, n=13) compared to 
an average of 10.75 (range 1 to 34, SD 15.59, n=4) in the intervention 
group (group 2), again this demonstrated no statistically significant 
difference between the two groups (t-test p value = 0.8971) (figure 6.5). 
 
Statistical analysis of the number of red cell units transfused and the 
number of transfusion episodes for the transfused patients in each of the 
study groups demonstrated that the patients in each group were well 
matched despite the majority of patients recruited during the initial 
recruitment phase, when selection for patients likely to require transfusion 
was attempted, being allocated to group 1, the standard care group. 
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Figure 6.3: Number of red cell units transfused to patients in pilot 
study 
      
 
Box-and-whiskers plots showing the minimum and maximum numbers 
(black line) of red cell units transfused (the first quartile, mean and third 
quartile are denoted by the coloured blocks) to patients in the pilot study. 
Comparison of the number of red cell units given to patients in the 
standard care group (group 1, average 27.46, range 2 to 76, SD 26.99, 
n=13) and the number given to patients in the intervention group (group 
2, average 22.25, range 1 to 71, SD 32.71, n=4) showed no significant 
difference (t-test p value = 0.7513). 
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Figure 6.4: Number of transfusion episodes for patients in the pilot 
study 
 
 
Box-and-whiskers plots showing the minimum and maximum numbers 
(black line) of transfusion episodes (the first quartile, mean and third 
quartile are denoted by the coloured blocks) experience by patients in the 
pilot study. Comparison of the number of transfusion episodes for 
patients in the standard care group (group 1, average 11.62, range 1 to 
30, SD 10.32, n=13) and those for patients in the intervention group 
(group 2, average 10.75, range 1 to 34, SD 15.59, n=4) did not 
demonstrate any statistically significant difference (t-test p value = 
0.8971). 
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6.2.4 Disease conditions in the pilot study patients 
 
 
Patients recruited to the pilot study were suffering from a wide variety of 
haematological disease conditions (figure 6.6). The standard care group 
(group 1) included a larger number of myeloma and non-Hodgkin’s 
lymphoma (NHL) patients compared to the intervention group (group 2). 
These disease conditions are considered high risk for requiring 
transfusion through the course of treatment and so, as the majority of 
patients in this phase were randomly assigned to group 1, this may have 
introduced an element of selection bias. This would explain the larger 
numbers of patients requiring transfusion within the standard care group. 
Other disease conditions expected to require blood transfusions, such as 
acute lymphocytic leukaemia (ALL), acute myeloid leukaemia (AML), 
acute pro-myelocytic leukaemia (APML), chronic lymphocytic leukaemia 
(CLL), chronic myelo-monocytic leukaemia (CMML), Hodgkin’s 
lymphoma, lymphoma, myelodysplastic syndrome (MDS) and 
myeloproliferative disease (MPD) demonstrated a relatively more even 
spread across the two study groups. Relaxation of the selection criteria 
meant that conditions unlikely to require transfusion during the course of 
the disease, such as idiopathic thrombocytopaenic purpura (ITP), 
coagulation disorders, Von Willebrand’s disease (VWD) and 
polycythaemia rubra vera (PRV) were also included in the trial groups. 
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Figure 6.5: Disease conditions in the pilot study patients 
 
A wide variety of haematological disease conditions were seen in the pilot study patients. The number of patients recruited to the standard care group (group 1) for 
each disease condition is shown on the graph as blue columns and the number of patients recruited to the intervention group (group 2) is shown by the red column. 
Key: 
AIHA = autoimmune haemolytic anaemia  CML = chronic myeloid leukaemia   MPD = myeloproliferative disorder 
ALL = acute lymphocytic leukaemia   CMML = chronic myelo-monocytic leukaemia  NHL = non-Hodgkin’s lymphoma 
AML = acute myeloid leukaemia   ET = essential thrombocythaemia   PRV = polycythaemia rubra vera 
APML = acute pro-myelocytic leukaemia   ITP = Idiopathic thrombocytopaenia purpura  VWD = Von-Willebrand’s disease 
CLL = chronic lymphocytic leukaemia   MDS = myelodysplastic syndrome 
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6.2.5 Matching red cell antigens for transfused patients in the 
intervention group 
Patients allocated to the intervention group had Rh (CcEe) and K antigen 
types performed using the automated serological method (Immuncor) and 
by the manual laboratory method (Bio-Rad). For each of these patients a 
note was added to the laboratory computer record stating the Rh (CcEe) 
and K antigen type and the corresponding antigen negative requirements 
of red cell units for transfusion. Laboratory staff was requested to record, 
on the laboratory computer system, a reason if they were unable to 
provide matched red cells for the patient for any of the transfusion 
episodes. 
 
A total of 89 red cell units were provided for the four transfused patients 
in the intervention group. Patient 1 received a total of 10 units over five 
transfusion episodes, patient 2 received 71 units over 34 episodes, 
patient 3 received seven units over three episodes and patient 4 received 
one unit on one occasion (table 6-1). 
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Table 6.2: Provision of Rh (CcEe) and K matched blood for transfused patients in the intervention group 
Four patients in the intervention group (patients allocated to receive red cells for transfusion matched with their own Rh 
(CcEe) and K types) received transfusions during the trial period. Three patients received red cell units that were matched 
with their own Rh (CcEe) and K antigen type (patient numbers 1, 3 and 4). One patient received a total of 71 units of red 
cells, of which just 20 (28.2%) were typed and matched to their Rh (CcEe) and K antigen type. 
 
Patient No Rh (CcEe) and K type Number of red cell 
units transfused 
Number of transfusion 
episodes 
% of units matched 
with Rh (CcEe) and K 
type 
1 R2r (cDE/cde) K neg 
 
10 5 100% 
2 R2R2 (cDE/cDE) K neg 
 
71 34 28.2% 
3 R1r (CDe/cde)  K neg 
 
7 3 100% 
4 R1r (CDe/cde) K neg 
 
1 1 100% 
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All four of the transfused patients were found to be negative for the K 
antigen, a phenotype shared by over 90% of the Caucasian population 
(Daniels, 2013), and as such expected to be seen in around 90% of 
donated red cells stored in a hospital blood bank stock. None of the red 
cell units transfused to any of the four patients were K positive, giving a 
matching rate of 100%. 
 
Two of the four transfused patients (patients 3 and 4)  were found to be 
positive for the C, c and e antigens and negative for the E antigen, giving 
them the mostly likely Rh type R1r (CDe/cde), a phenotype shared by 
32.68% of the English population (Daniels, 2013). Patient 3 was provided 
with seven units of blood over three transfusion episodes, and patient 4 
was provided with a single unit of blood on one occasion, the Rh (CcEe) 
type of all of the units matched with the patients Rh (CcEe) phenotype. 
 
Patient 1 was found to be positive for the c, E and e Rh antigens and 
negative for the C antigen, giving a most likely Rh type R2r (cDE/cde), a 
phenotype shared by 10.97% of the English population (Daniels, 2013). 
This patient was provided with 10 units of blood over five transfusion 
episodes, all of the units provided carried the same Rh antigens as the 
patient. 
 
Patient 2 was found positive for the c and E antigens and negative for the 
C and e antigens, giving a most likely Rh type of R2R2 (cDE/cDE), a 
phenotype shared with just 1.99% of the English population (Daniels, 
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2013). This patient required a total of 71 units of blood over 34 
transfusion episodes during the trial period, the laboratory were only able 
to provide 20 units of blood that matched this patient’s Rh (CcEe) 
phenotype. On four occasions a reason was given to explain the lack of 
matched blood; it was noted that there were no units in stock that 
matched. No reason was noted for the remainder of the transfusion 
episodes. 
 
 
The Rh (CcEe) and K types of all the patients recruited to the trial were 
elucidated using the automated extended serological assay (table 6-2). 
The most likely phenotypes of the patients are shown in both Fisher-Race 
(CDE) terminology (Fisher, cited in Race, 1944) and Wiener’s Rh-Hr 
(Wiener, 1943). The D antigen status of the patients was determined 
using two commercial reagents; NOVACLONE™ anti-D blend (IgM D175-
2 and IgG D145, IE4) and ImmuClone® IgM (derived from cell line RUM 
1). The assays were performed using the standard D typing assay on the 
NEO® analyser (Immucor).  
 
The R1r (CDe/cde) phenotype was the most common Rh type seen in the 
patients recruited to the pilot study (21/59, 35.6%), R2r was seen in nine 
patients (15.2%), R1R1 in nine patients (15.2%), R1R2 in eight patients 
(13.6%), rr in 7 patients (11.9%) and R2R2 in five patients (8.5%) (Figure 
6.7). The R1R1 phenotype is shared by 17.68% of the English population, 
R1R2 by 11.87%, and rr by 15.10% (Daniels, 2013), should the pilot 
study patients sharing these phenotypes have required a transfusion the 
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provision of blood should not have proved difficult from routine stocks 
given the frequency of phenotypes. 
  
273 
 
Table 6.3: Rh and K types of patients recruited to the pilot study 
Rh and K antigen status was determined using the automated extended serological assay for all the patients recruited to the pilot 
study. In the table below antigen status is denoted as positive (P) or negative (N) for the antigens C, c, E, e and K, assayed using 
the extended automated serological phenotyping assay, the D antigen status was determined using two anti-D clones via the 
standard automated assay (NEO®analyser, Immucor). The most likely Rh phenotype is shown in both Fisher-Race and Wiener’s 
terminologies.  
 
Patient 
number 
Trial 
Group 
Antigens Probable phenotype 
  C c E e K  Fisher-Race Wiener 
1 1 P P N P P CDe/cde R1r 
2 1 N P P P N cDE/cde R2r 
3 1 N P P N N cDE/cDE R2R2 
4 1 N P P N N cDE/cDE R2R2 
5 1 P N N P N CDe/CDe R1R1 
6 1 P P P P N CDe/cDE R1R2 
7 1 P N N P N CDe/CDe R1R1 
8 1 P N N P N CDe/CDe R1R1 
9 1 N P N P N cde/cde rr 
10 1 N P P P P cDE/cde R2r 
11 1 N P N P N cde/cde rr 
12 1 N P P P N cDE/cde R2r 
13 1 P N N P N CDe/CDe R1R1 
14 1 N P N P N cde/cde rr 
15 1 P P N P N CDe/cde R1r 
16 1 N P P P N cDE/cde R2r 
17 1 P P P P N CDe/cDE R1R2 
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Patient 
number 
Trial 
Group 
Antigens Probable phenotype (continued) 
  C c E e K  Fisher-Race Wiener 
18 1 P P N P N CDe/cde R1r 
19 1 P P N P N CDe/cde R1r 
20 1 P P N P N CDe/cde R1r  
21 1 N P N P N cde/cde rr 
22 1 P P N P N CDe/cde R1r 
23 1 N P P P N cDE/cde R2r 
24 1 P N N P N CDe/CDe R1R1 
25 1 P P N P N CDe/cde R1r 
26 1 P P N P N CDe/cde R1r 
27 1 P P N P P CDe/cde R1r 
28 1 P P N P N CDe/cde R1r 
29 1 N P N P N cde/cde rr 
30 1 N P P N N cDE/cDE R2R2 
31 2 N P P P N cDE/cde R2r 
32 2 N P P P N cDE/cde R2r 
33 2 N P P N N cDE/cDE R2R2 
34 2 P P N P N CDe/cde R1r 
35 2 P P P P N CDe/cDE R1R2 
36 2 P N N P N CDe/CDe R1R1 
37 2 P P N P P CDe/cde R1r 
38 2 P P P P N CDe/cDE R1R2 
39 2 P P N P P CDe/cde R1r 
40 2 P N N P N CDe/CDe R1R1 
41 2 N P P P N cDE/cde R2r 
42 2 P P N P N CDe/cde R1r 
43 2 N P P P N cDE/cde R2r 
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Patient 
number 
Trial 
Group 
Antigens Probable phenotype (continued) 
  C c E e K  Fisher-Race Wiener 
44 2 N P P N N cDE/cDE R2R2 
45 2 P P N P N CDe/cde R1r 
46 2 P P N P N CDe/cde R1r 
47 2 P P N P N CDe/cde R1r 
48 2 P P P P N CDe/cDE R1R2 
49 2 P P P P N CDe/cDE R1R2 
50 2 P N N P N CDe/CDe R1R1 
51 2 P N N P N CDe/CDe R1R1 
52 2 P P N P N CDe/cde R1r 
53 2 P P P P N CDe/cDE R1R2 
54 2 P P N P N CDe/cde R1r 
55 2 P P P P N CDe/cDE R1R2 
56 2 N P N P N cde/cde rr 
57 2 N P N P N cde/cde rr 
58 2 P P N P N CDe/cde R1r 
59 2 P P N P P CDe/cde R1r 
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Figure 6.6: Frequencies of Rh phenotypes in patients recruited to 
the pilot study 
 
 
The graph shows the frequencies of the Rh phenotypes of the patients 
recruited to the pilot study (group 1, the standard care group (n=30) and 
group 2, the intervention group (n=29)) denoted using the Wiener 
terminology. The most common phenotype seen was the R1r (35.6%), 
other phenotypes were seen with the following frequencies; R2r (15.2%), 
R1R1 (15.2%), R1R2 (13.6%), rr (11.9%) with R2R2 (8.5%) being the least 
common.   
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6.3 Discussion 
 
The pilot study demonstrated that patients responded well to the 
recruitment process and the information that was provided regarding the 
trial, with only one patient declining to participate. The recruitment 
process itself, however, was slow, particularly when selection was limited 
to patients with diagnoses anticipated to require transfusion support. 
Recruitment increased when the selection criteria were relaxed to include 
patients with any disease condition. However, the number of patients in 
each group that actually received a transfusion was low, particularly in the 
intervention group where only 13.8% (4/29) of the patients received a 
transfusion. Comparison of the number of red cell units transfused and 
the number of transfusion episodes for the transfused patients in the 
standard care group and the intervention group demonstrated that 
patients were well matched in each group. The pilot study was not 
powered to investigate any differences in the rate of antibody 
development in the groups and it was noted that no patients in either 
group developed an allo- or autoantibody as a result of the red cell 
transfusions given. 
 
No patients requested to drop out of the trial, suggesting that recruitment 
to a larger multi-centre trial would not pose significant issues, however, 
two patients died during the course of the trial. When estimating 
participant numbers for a multi-centre randomised controlled trial to 
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investigate the benefit of a typing and matching strategy for patients with 
haematological conditions or renal insufficient, it should be remembered 
that these patients have serious conditions and that the death rate in the 
study groups may be high. In addition, the pilot study showed low rates of 
transfusion in patients recruited to the trial. This was mainly attributed to a 
relaxation of the selection criteria in order to recruit sufficient patients in a 
relatively short space of time. In order to undertake a larger RCT, 
powered to detect any significant differences in antibody development 
rates in patients given standard care compared to those given antigen 
matched units, it would be preferable to maintain a stricter selection 
criteria based on haematological disease conditions considered most 
likely to require transfusion support. 
 
Randomisation is a technique well known and extensively used in clinical 
trials to prevent selection bias during the recruitment of subjects to the 
trial and also reduce the risk of accidental bias during the data analysis 
(Rosenberger and Lachin, 2015). It also allows the use of probability 
theory to investigate the likelihood of chance as a source for any 
differences seen in the end outcome of the trial. Randomisation is 
particularly useful for the investigation of different treatment or 
intervention regimes; whether one particular treatment is better than 
another, no worse than another or equivalent. Randomisation has the 
benefit of ensuring that subjects have an equal chance of being allocated 
to one group or another and that the groups are balanced with respect to 
known, and unknown, confounding or prognostic variables and are an 
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essential tool for testing the efficacy of a treatment (Suresh, 2011). If 
randomisation is not used at the start of a clinical trial then the influence 
of imbalance that is introduced needs to be controlled for in the analysis 
of the results in order to produce an unbiased result (Kalish and Begg, 
1985; Fleiss et al., 2003), using techniques such as analysis of 
covariance (ANCOVA) or multivariate ANCOVA. Randomisation is 
essential to ensure that the treatment effects are reviewed appropriately. 
Clinical trials that been set up with unclear or inadequate randomisation 
have been reported to over-estimate the treatment effects by up to 40% 
(Schulz and Grimes, 2002a). In order to further reduce the potential for 
selection bias during the randomisation process, allocation concealment 
can be used, a technique which shields the researcher from the 
knowledge of the group to which subject will be allocated. 
 
There are different types of randomisation that can be used for clinical 
trials; simple randomisation, block randomisation, stratified randomisation 
and covariate adaptive randomisation. Simple randomisation involves a 
single sequence of random assignments, which can be achieved by a 
process as simple as flipping a coin or rolling a dice. This technique is 
useful in clinical trials involving large numbers of subjects (200 or more) 
but can result in unequal numbers between the groups in trials involving 
smaller numbers of subjects (Altman and Bland, 1999a). In order to 
attempt to equalise the number of subjects being allocated to each group, 
block randomisation can be used, the total number of subjects required 
for the trial is broken down into smaller blocks with pre-determined group 
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assignments which has the effect of keeping the subject numbers similar 
at all times (Frane, 1998; Altman and Bland, 1999b). The downside to 
block randomisation is that it can introduce some bias as the groups 
could then have imbalances as the subjects are recruited, such as gender 
or disease type inequalities (Pocock and Simon, 1975) and it can harm 
the unpredictability of treatment assignments (Schulz and Grimes, 
2002b). Reduction of the bias effects that simple or block randomisation 
may introduce within trial groups can be achieved by using stratified 
randomisation. This technique requires that any covariates that need to 
be controlled within the trial are identified prior to the selection process 
and can then be applied to each participant. This approach to 
randomisation can prove difficult in clinical trials where subjects are 
recruited on an individual basis or if there are numerous covariates that 
need to be controlled (Weir and Lees, 2003). In clinical trials involving 
small to moderate numbers of subjects, covariate adaptive randomisation 
can be used, where recruits are assigned to one of the treatment groups 
with reference to any covariates and also assignments of previous 
recruits allowing balance of a large number of covariates (Kalish and 
Begg, 1985; Hu et al., 2014). 
 
The randomisation technique used to allocate patients to the standard 
care or the intervention group in this pilot study resulted in an unexpected 
bias towards the standard care group for the first 30 patients recruited. 
This meant that patients in the standard care group spent significantly 
longer on the trial than patients in the intervention group. To reduce the 
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risk of this occurring in a larger RCT, a block or stratified randomisation 
approach should be utilised. Stratified randomisation would allow control 
of the important variables, gender and disease condition, whilst ensuring 
that patients in each study group have equality in the length of time on 
the trial. 
 
This pilot study demonstrated issues with provision of antigen matched 
blood from routine stocks held in a hospital transfusion laboratory for 
patients with rarer Rh (CcEe) phenotypes. NHSBT blood centres test and 
distribute blood donated from a very wide geographical area, as such the 
blood stocks held within a hospital transfusion laboratory should 
represent the distribution of phenotypes in that general population. Thus, 
provision of matched blood for patients with common phenotypes such as 
K negative and the Rh type R1r should be relatively easy, whereas 
provision of matched blood for the less common Rh phenotype, R2R2, is 
more difficult. This is supported by a study by Klapper and coworkers 
(2010) using a virtual type and match strategy which demonstrated that 
blood units could be provided from routine stocks for over 90% of 
requests if providing K and Rh matches. ABO blood group type will also 
impact on the provision of matched blood from routine stock; patients with 
blood type O will only be able to received matched blood from the stock 
of group O, whereas patients of blood type A are able to receive matched 
blood of type A or O, increasing the probability of finding matching blood 
within the stocks held, and patients of blood type AB can receive donor 
blood of type O, A, B or AB, further increasing the likelihood of finding a 
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match in the stock fridge. Patient 2 in this pilot study was of group O type, 
as well as being a less common R2R2 Rh type; this meant that selection 
of matched blood was restricted to the stocks of group O RhD positive. 
Patients with haematological diseases or renal insufficiency rarely 
present with emergency requirement for blood transfusion and so this 
should allow laboratory staff time to order blood of the appropriate Rh 
(CcEe) and K antigen type for specific patients from the NHSBT. A good 
communication system between the haematology/renal clinics and the 
laboratory, with regard to patients with transfusion requirement, 
adherence to protocols ensuring that transfusion samples are sent to the 
laboratory two working days in advance of transfusion, would help 
laboratories ensure that they have appropriately matched units of blood in 
the stock fridge ready for the patients.   Ethnic disparity between the 
donor pool and patient population would need to be taken into account 
when making changes to the blood stock inventory control and ordering 
system to support a type and match strategy. Some Rh types show 
disparity, such as R1 which is more common in White than Black 
populations, and R0 which is more common in Blacks than Whites 
(Daniels, 2013). Ethnic disparity was not considered to impact on the 
provision of blood in this pilot study, and no issues were noted with 
provision of blood, by the NHSBT, of any particular Rh phenotype. 
Improvements in provision of matched blood by the laboratory could be 
achieved simply by rearranging the way that the units are stocked and 
setting optimum numbers of each phenotype for blood ordering.  
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The results of the retrospective review noted an alloimmunisation rate of 
approximately 67% for Rh and Kell alloantibodies for both the renal and 
the haematology cohort. The pilot study demonstrates that a type and 
match strategy for Rh and Kell antigens could be implemented to reduce 
the alloimmunisation rate. Changes would be needed to the blood stock 
arrangement and the ordering procedure to ensure that sufficient 
numbers of each phenotype were available. There would be no cost 
implications for phenotyping the red cell unit, for Rh and Kell, as this is 
performed at the NHSBT; however, there are cost implications for typing 
the patients which need to be explored (see chapter 7).  
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7 COST ANALYSIS 
 
7.1 Introduction 
 
This study has shown that the implementation of extended automated 
serological phenotyping, or genotyping, assays prior to transfusion in 
patients with disease conditions likely to require chronic transfusion 
support, followed by matching of blood for, at least, Rh (CcEe) and K 
antigens, has the potential to reduce the risk of development of red cell 
antibodies. However, the cost of implementation of these assays needs to 
be assessed and balanced against the potential savings that could be 
realised if the development of red cell antibodies were to be prevented. 
This study has also shown that both the extended automated serological 
phenotyping assay (NEO® analyser Immucor) and the BLOODChip 
IDCOREXT genotyping assay are robust and reliable techniques for the 
identification of red cell antigens within the hospital transfusion service 
setting. The cost effectiveness of both of these assays was assessed 
using the data regarding additional laboratory testing collected as part of 
the retrospective review. This is the first time that a cost analysis for a 
prospective type and match program has been performed in the UK.  
 
 
7.2 Automated extended serological phenotyping 
 
The total cost of additional laboratory testing incurred by the immunised 
patients in the haematology cohort (n=256/1107) was £48,752.59 (see 
section 3.2.5). In addition to this cost, each unit of blood for transfusion in 
this group of patients required compatibility testing by IAT assay, a test 
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calculated to cost £3.81/unit (RD&E 2014 cost) based on compatibility 
testing (crossmatching) by IAT in Column Agglutination (Bio-Rad) by a 
Band 5 Biomedical Scientist at pay point 20 (Agenda for Change, NHS 
2015). During the retrospective review of the transfusion needs of the 
haematology patients, data was not collected on the type of crossmatch 
assay performed for each unit transfused for patients with red cell 
antibodies and so it is not possible to give accurate costs for compatibility 
testing for the immunised group in this patient cohort. However, using the 
average number of units transfused to the immunised group (n=256), 
46.99 units, and the 2014 cost for compatibility testing (£3.81), a total 
cost of £45,711.87 can be estimated for this group for compatibility 
testing. This figure is likely to be an overestimate as the majority of 
patients in the immunised group developed red cell antibodies following 
transfusion and so, initially, provision of blood would not have required 
serological crossmatch by IAT. Additional laboratory testing performed for 
the immunised patients in the retrospective review amounted to 
£48,752.59, this figure, plus the estimated cost of compatibility testing, 
gives a total cost of £94,464.46 for laboratory tests performed over the 
review period. This gives a cost per head for the immunised haematology 
patients (n=256) of approximately £369.00. Additional testing for the non-
immunised patients in the haematology cohort (n= 851) amounted to a 
total of £1,509.83. Again, using a cost for compatibility testing based on 
the average number of units given to patients in this group (23.43 units) 
and the 2014 cost for provision of blood without serological compatibility 
testing by IAT (electronic issue, £0.47/unit), it can be estimated that this 
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group incurred a total cost of £9,371.30 for compatibility testing. This 
figure, together with the additional testing figure, gives a total of 
£10,881.13 for the non-immunised patients, equating to a cost per head 
of £12.79/patient. Overall, the cost of provision of blood (additional testing 
plus compatibility testing) for the entire haematology cohort (n=1107) can 
be estimated at £105,345.59, giving a cost per head of £95.16 per 
patient.  
 
Within the renal cohort (n=877) the immunised group (n=134) incurred 
additional testing costs of £13,094.76 and the non-immunised group 
(n=743) incurred a cost of £155.53. Using the average number of units 
transfused to patients in each group (21.85 and 11.97 respectively) and 
the cost of provision of blood by IAT crossmatch for the immunised 
patients (£3.81/unit) and electronic issue (£0.47/unit) the total cost for 
provision of blood for the immunised patients amounted to approximately 
£24,250.06 and £4,180.04 for the non-immunised patients. The cost per 
head for immunised renal patients can be estimated at £180.97 and for 
non-immunised patients at £5.62, the overall cost per head for the entire 
renal cohort (n=877) is estimated at £32.41 per patient. 
 
Automated extended serological phenotyping for Rh (CcEe), K, M, N and 
Cw antigens cost £9.43 per patient and for Jka, Jkb, Fya, Fyb, S, s and k 
antigens the cost amounted to £10.14 per patient, giving a cost per head 
of £19.57 per patient. Both figures are considerably less than the current 
£95.16 per head for the haematology cohort and £32.41 per head for the 
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renal cohort for blood provision. This suggests that extended automated 
serological phenotyping for all haematology or renal patients could be 
justified if the patient phenotype could then be used to match blood for 
transfusion and reduce the risk of allo and/or auto-immunisation to red 
cell antigens. This is particularly relevant for the typing and matching of 
Rh (CcEe) and K antigens, for which donor blood is automatically typed. 
Automated serological phenotyping for Rh (CcEe) and K antigens only 
would amount to £5.97 per patient, this is significantly less than the cost 
per head estimated for the immunised haematology and renal patients 
(£369.0 and £180.97 respectively) and, furthermore, less than the 
estimated cost per head for the non-immunised patients in the 
haematology cohort (£12.79) and similar to the cost per head for the non-
immunised renal patients (£5.62). 
 
 Manual extended serological phenotyping, at a total cost of £50.46 per 
head, could be justified on a cost basis for haematology patients (cost per 
head for immunised and non-immunised estimated at £95.16), but not for 
renal patients (cost per head for immunised and non-immunised 
estimated at £32.41). As for automated serological phenotyping, test cost 
for manual Rh (CcEe) and K antigen testing (estimated at £6.49 per 
patient) would appear to be a cost effective option if it could be 
demonstrated that matching blood for transfusion for these antigens 
prevents antibody production. However, the risks of manual testing on 
this scale would need to be carefully considered if this approach was 
used.  
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7.1 Genotyping Assay 
 
The cost per patient test for the IDCOREXT test was estimated at £73.66. 
On a cost basis alone, this technique could be justified for all patients with 
haematological conditions prior to initial transfusion, but not for renal 
patients. This technique, however, required equipment that is not 
currently used in hospital transfusion services, such as extraction hoods, 
thermocyclers and the Luminex XMap analyser. The initial set up costs of 
introducing these systems into a routine hospital transfusion laboratory 
and the staff training required would also need to be taken into account.  
Costs for equipment may be kept to a minimum if other disciplines within 
the hospital, such as microbiology or immunology, were to share the 
equipment, but this may mean that the different aspects of sample 
preparation and analysis may take place in geographically separate areas 
of the hospital.  
 
7.2 Cost comparison of serological phenotyping and 
genotyping techniques 
Pre-transfusion phenotyping, in conjunction with a strategy for matching 
for the Rh (CcEe) and K antigens, appears to be a cost effective option 
when comparing the estimated cost per head for provision of blood for 
immunised patients (£369 for haematology patients and £180.97 for renal 
patients) with the cost per test for serological phenotyping for the Rh 
(CcEe) and K antigens (£5.97 for automated technique) (Table 7-1). The 
assumption being that serological phenotype prior to transfusion 
combined with a type and match strategy would reduce risk of 
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alloantibody development and associated costs with subsequent 
transfusions. Pre-transfusion genotyping appears to be cost effective but 
is less easy to justify in clinical practice as described in section 7.1. 
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Table 7.1: Cost effectiveness of serological phenotyping and genotyping techniques 
The estimated current costs for the provision of blood for immunised haematology and renal patients per head (standard practice 
column), which includes the additional testing required once the patient has developed a red cell allo/autoantibody is considerably 
higher than that for pre-transfusion phenotyping or genotyping. Pre-transfusion phenotyping, or genotyping, combined with a 
strategy for matching for the Rh (CcEe) and K antigens, both appear to be a cost effective options with the assumption that such a 
strategy would prevent the development of antibodies against these antigens.  
 
Standard practice Phenotype for Rh (CcEe) and K antigens Extended genotype 
Haematology cohort Renal cohort 
Automated serological 
phenotyping 
Manual serological 
phenotyping Genotyping 
Immunised 
Non-
immunised Immunised 
Non-
immunised       
£369.00 £12.79 £180.97 £5.62 £5.97 £6.49 £73.66 
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7.3 Discussion 
 
The additional costs incurred for the provision of blood for patients who 
have developed atypical red cell allo/auto-antibodies are considerably 
higher than the cost for provision of blood for patients without antibodies, 
in both the haematology cohort and the renal cohort. There is potential to 
reduce this financial burden by the introduction of high throughput 
methods of red cell antigen testing and then matching of blood for 
transfusion in these chronically transfused patients. Manual and 
automated serological red cell antigen phenotyping techniques are useful 
methods which can be easily incorporated into routine hospital 
transfusion laboratories. Manual techniques have disadvantages in that 
they are labour intensive, making them expensive and also introducing 
human error risks in the sample preparation, testing, interpretation and 
reporting stages. Automated readers, interfacing to laboratory computer 
systems and automated interpretation could eliminate some of these risks 
but would incur costs for computer upgrades and equipment, if not 
already used within the laboratory. Automated serological testing, as 
validated in this study, has been shown to be a robust and cost effective 
alternative to current manual systems. Interfacing to laboratory computer 
systems may incur additional one-off costs, but this would facilitate the 
high throughput testing required to antigen type large numbers of patients 
by eliminating the need for manual transcription of results.  
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The main disadvantage of serological testing, manual or automated, is 
that it cannot be used for recently transfused patients due to circulating 
donor cells. This would not be an issue if the hospital transfusion service 
chose to adopt the approach of automated serological red cell antigen 
typing for all haematology and renal patients prior to initial transfusion, 
but would restrict the use of the technique if used only for patients post 
development of red cell antibodies. In addition, serological techniques, 
manual and automated, using polyclonal anti-sera, such as those used in 
the detection of antigens in the Kidd, Duffy, and Ss systems cannot be 
used for patients with red cell autoantibodies due to the risk of false 
positive results (BCSH, 2013). Again, if used prior to the initial transfusion 
for haematology and renal patients this would not pose a significant 
issue, but the considerable numbers of patients with autoantibodies seen 
in both patient cohorts (186/1107 (16.8%) for haematology patients and 
74/877 (8.4%) for renal patients) would restrict the use of the technique if 
only implemented post development of antibodies. Genotyping 
techniques, however, offer a flexible solution to red cell antigen typing 
that can be used for red cell antigen typing using samples from patients 
post-transfusion and from those with red cell autoantibodies (Guelsin et 
al., 2010).  
 
The potential reduction of costs for additional antibody identification tests 
and serological crossmatching could not be realised unless red cell 
antigen typing, serological phenotyping or genotyping, was implemented 
prior to initial transfusion and the blood provided for transfusion was 
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matched for, at least, the Rh (CcEe) and K antigens. Such a strategy 
could significantly reduce the current costs for provision of blood for 
patients within the haematology and renal cohorts, if the development of 
red cell antibodies to these antigens was prevented. The inclusion of 
extended phenotyping techniques, to include red cell antigens within the 
Jk, Fy, and Ss systems, would increase the initial costs for phenotyping. 
Matching of blood for these antigens is more complex, primarily because 
donor blood units are not automatically typed for these antigens but also 
because attempting to match at this secondary level reduces the 
likelihood of finding matched units within the routine blood stocks held by 
the hospital transfusion laboratory. 
 
In addition, other benefits to patients could be realised, such as reduction 
in delays in provision of blood and a reduced risk of transfusion reactions. 
Individualising patient care in this way also has the potential to improve 
the patient journey, particularly for patients with haematological and renal 
diseases whose care and treatment can be prolonged and emotionally 
challenging.  
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8 FINAL DISCUSSION AND CONCLUSIONS 
 
In order to implement a strategy of red cell antigen typing and matching of 
blood for transfusion the hospital transfusion service requires a cost-
effective, robust, high throughput method for extended red cell 
phenotyping, or genotyping, of patient samples prior to transfusion. 
Current methods in hospital transfusion services for red cell antigen 
testing are serological, mainly manual, or, at least, require a selection of 
techniques for determination of individual antigen status. This results in a 
cumbersome, costly system with all the inherent risks of manual testing 
and manual input of results, which is then reserved for patient groups 
where there is a national requirement for pre-transfusion testing, namely 
the sickle cell disease and thalassaemia groups (BCSH, 2013).  
 
Red cell antigen typing of patients red cells following production of an 
alloantibody is generally limited to testing only for the implicated red cell 
antigen, requiring a local decision regarding typing and matching for 
further antigens (BCSH, 2013). Decisions need to be made in conjunction 
with risk assessment, taking into account the limitations with the manual 
testing system, costs, and the amount of staff time required to perform 
extended typing. This study demonstrated that automated extended 
serological red cell antigen typing using the IBG Immucor NEO® analyser 
is a robust, cost effective method suitable for high throughput activity 
within a hospital transfusion service setting, giving the laboratory access 
to a robust assay for extended antigen typing. The method also lends 
itself to the addition of an electronic interface from the analyser to the 
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hospital LIM system, removing the requirement for manual input of results 
and reducing the risk of error. The automated system has built in quality 
control to ensure that sufficient antisera and patient red cells are added to 
the reaction mixture, a feature that is difficult to control using a manual 
system where such judgments are made by macroscopic reading. Testing 
of the automated system demonstrated that strongly positive reactions 
are produced for heterozygous and homozygous antigen expression in 
both commercial control cells (NHSBT red cell antigen cells) and patient 
red cells. Red cell antigen typing using polyclonal antisera in the gel 
column agglutination manual techniques employed in this study did not 
demonstrate comparable differences in heterozygous and homozygous 
antigen expression reaction strengths. It is possible to automate gel 
column agglutination tests for red cell antigen typing and it would be 
interesting to perform a further comparative study between the IBG 
Immucor extended red cell antigen profiles and similar profiles created on 
an automated column agglutination analyser.  Weakly positive results 
demonstrated in this study in the automated system were shown to be 
false positives; although the numbers involved were small the specificity 
of the automated system could be further improved by instructing the 
analyser to invalidate any weak reaction (1+ or 2+ reaction strengths).  
 
The automated system created for testing in this study included an auto 
control (patient red cells tested against a non-reactive reagent, designed 
to identify non-specific agglutination) as part of the polyclonal antisera 
testing profile to minimise the risk of false positive results due to a 
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positive DAT. Only one patient in the study group proved to have a 
positive DAT, which was identified due to weakly positive reactions in 
both the automated and manual systems, not by the auto control included 
in the automated profile. Further testing of a larger number of DAT 
positive patients in the automated system is necessary to demonstrate 
that inclusion of the auto control will identify DAT positive patients 
effectively. In addition, invalidation of weakly positive results will also 
reduce the risk of reporting false positive results. The monoclonal reagent 
testing profile (anti-C, anti-c, anti-E, anti-e, anti-K, anti-Cw, anti-M and 
anti-N) created on the IBG Immucor analyser did not include an auto 
control, this was not felt to be a necessary addition as, if this profile was 
included as part of pre-transfusion testing, the sample would also be ABO 
and D typed by the same analyser, a test profile that already includes an 
auto control.  
 
There are currently no commercial quality control samples available 
specifically for extended red cell antigen typing profiles in automated 
systems. Whole blood quality control cells are available for use in the IBG 
Immucor automated systems (WBCorQC), although these were tested 
and found to be useful for internal quality control of the automated Rh 
(CcEe) and K antisera, they are pooled cells and, as such, cannot be 
used for internal quality control of the remaining antisera. The NHSBT 2 
cell profile (3% suspension in Alsevers) is marketed for alloantibody 
detection but was found to be suitable as an internal quality control 
system for the extended red cell antigen typing profiles in this study. 
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However, these cells are not supplied in tubes compatible with use on the 
analyser and therefore had to be transferred into suitable tubes, 
introducing a potential source of error and removing the potential for any 
audit trail and reagent expiry date control on the analyser. To further 
improve the use and marketability of the IBG Immucor extended red cell 
antigen typing profiles the production of red cell controls, containing cells 
with negative red cell antigen expression and, preferably, cells expressing 
heterozygous red cell antigens should be explored. Another improvement 
to the automated extended red cell antigen phenotyping profiles would be 
the replacement of the current polyclonal reagents (anti-Fya, -Fyb, -Jka, -
Jkb, -S, -s and –k) with monoclonal reagents. Not only would this reduce 
the cost of testing but it would also allow the use of the reagents on 
samples from patients with a positive DAT, currently one of the major 
limitations of this assay. 
 
Test costs for automated red cell antigen typing profiles were found to be 
considerably cheaper than those for performing the same tests by manual 
methods in our institution. In addition, the reduction in staff time required 
for performing the automated profiles make this an attractive method for 
extended red cell antigen typing in a hospital transfusion service setting. 
However, the inclusion of internal quality control material for the 
automated system also needs to be taken into account; decisions would 
need to be made at a local level as to the frequency of reagent quality 
control and the source of the material until such time as commercial cells 
become available.  
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If one makes the assumption that typing and matching of blood for 
transfusion for Rh (CcEe) and K antigens would eliminate alloantibodies 
to Rh C, c, E, e and K, using patient numbers from the retrospective 
study patient group (haematology patients), use of such a strategy would 
have eliminated the production of Rh and Kell antibodies in 78 of the 
1107 patients. Using the average number of antibody identification panels 
performed for the retrospective review patients with red cell alloantibodies 
(14.25), the total cost of antibody identification panels performed for the 
78 patients was £7,913.88. If all 1107 patients included in the 
retrospective review of haematology patients had been tested using the 
monoclonal reagent testing profile the total cost would have amounted to 
£9,232.38. Inclusion of costs for crossmatching  (£3.81 per unit) for each 
unit transfused for the 78 patients with Rh related or K antibodies, based 
on an average of 46.99 units given to immunised patients in this cohort, 
gives a total of £13,964.49. The total cost of antibody identification panels 
and crossmatching for the 78 patients in the haematology cohort with Rh 
related or K antibodies is estimated at £21,878.37, compared to a cost of 
£9,232.38 for performing an automated extended phenotyping profile 
including Rh (CcEe), K, M, N and Cw antigens for all the haematology 
patients in the cohort. Making the assumption that pre-transfusion 
phenotyping and matching of blood for Rh (CcEe) and K could prevent 
the production of antibodies against these antigens, makes, in theory, 
pre-transfusion phenotyping using an automated assay, a cost effective 
system for patients with haematological conditions.  
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To realise the cost benefits of introducing a pre-transfusion phenotyping 
strategy, particularly tying for Rh (CcEe) and K antigens, for patients with 
haematological conditions at most risk of developing an allo/autoantibody 
is recommended, this would include patients with haemolytic anaemia, 
aplastic anaemia, Waldenström macroglobulinaemia, chronic lymphocytic 
leukaemia, chronic myelo-monocytic leukaemia, acute myeloid 
leukaemia, myelodysplastic syndrome and myeloproliferative disease, 
shown to be high risk for antibody development in this study.  The high 
proportion of antibodies to Rh and Kell antigens seen in patients in both 
the haematology cohort (66.7% of alloantibodies) and in the renal cohort 
(67.0%) would support the implementation of a typing and matching of 
blood for transfusion strategy for these antigens. Restriction of this 
strategy to female patients within the renal cohort could further improve 
the cost effectiveness of pre-transfusion antigen typing and matching of 
blood, as females in this cohort were seen to have a greater risk of 
antibody development than males. 
 
Implementation of pre-transfusion testing for all patients, prior to the 
primary transfusion, using the polyclonal reagent testing profile (Jka, Jkb, 
Fya, Fyb, S, s, k antigens) is less easy to justify on a cost basis alone, 
even if restricted to the patients at most risk of development of 
allo/autoantibodies. However, it could be considered a useful addition to 
the hospital transfusion service repertoire of tests for patients following 
the production of a red cell alloantibody for those patients not on a regular 
transfusion regime. It could also be useful, and possibly cost effective, for 
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those hospital transfusion services dealing with more substantial numbers 
of sickle cell disease and Thalassaemia patients than those seen in our 
institution.  
 
The use of serological phenotyping methods is limited in the presence of 
autoantibodies and not recommended if the patient has been recently 
transfused due to interference by transfused red cells (BCSH, 2013). In 
these cases the phenotype may be predicted using genotyping methods 
(BCSH, 2013). In this study red cell antigen status predicted by the 
BLOODChip IDCOREXT blood group genotyping technique showed a 
high correlation with the serological antigen status in the 47 patients 
tested. In addition, the IDCOREXT included assays covering a wider 
range of red cell antigens than that covered by the automated serological 
assay. Although typing and matching of blood for all antigens detected by 
the genotyping system is not currently possible, the additional information 
provided is useful in the event of the patient developing alloantibodies 
post transfusion. 
 
The IDCOREXT technique was simple to use, with a low failure rate and 
high concordance with phenotyping results. However, the DNA 
preparation phases are manual and labour intensive, and, as such, do not 
currently lend them to the hospital transfusion setting where staff may not 
be specialised in genetic techniques and the risk of error makes manual 
testing undesirable. The advent of platforms with integrated DNA 
extraction and real-time PCR, such as those used for microbiological 
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assays (Riedlinger et al., 2010; Le Guern et al., 2012; Dalpke et al., 
2012), may mean that these types of specialised tests can be transferred 
into the routine service setting of the hospital transfusion laboratory. The 
cost of blood group genotyping is also currently prohibitive for routine 
use, the cost per test of the IDCOREXT assay alone is approximately £47 
with the additional costs for DNA extraction, amplification, staff time and 
analyser costs pushing the total cost to around £73 per patient. 
Consequently, this type of assay is currently reserved for chronically 
transfused patients with multiple antibodies. As DNA testing in general 
becomes more mainstream and automated, it is likely that the costs will 
reduce and, in the future, this may succeed serological phenotyping as 
the routine test for pre-transfusion typing and matching strategies and 
confirmatory testing for patients with red cell antibodies. 
 
In the future, the potential for next generation sequencing (NGS), or 
massively parallel sequencing, is being explored as current methods 
detecting SNPs will only detect known blood group genotypes whereas 
NGS will detect unknown ones as well (Altayar et al., 2013). NGS also 
allows for very high throughput testing making it ideal for the testing of 
donated blood. The use of NGS has been suggested as a potential 
platform to accurately characterise the blood group phenotypes in 
patients with sickle cell disease, particularly those in the African American 
population who have a high RH allelic diversity (Reid et al., 2014). 
 
302 
 
Treatment of patients with haematological conditions using allogeneic 
bone marrow, or stem cell, transplants may introduce a further 
complication if a strategy for red cell antigen typing and matching of blood 
for transfusion is implemented. Allogeneic bone marrow transplant (BMT) 
replaces the recipient haemopoetic cells with those taken from a healthy 
donor. This technique has been in use for over 20 years and is mainly 
used as a treatment for leukaemias, lymphoproliferative disorders, solid 
tumours and some non-malignant disorders (EBMT, 2011). The 
conditioning regimes available, designed to eliminate malignant disease 
(Gyurkocza and Sandmaier, 2014), should also eradicate immune system 
cells in the bone marrow of the recipient, leaving the recipient immune 
suppressed and tolerant to any foreign red cell antigens introduced by the 
transplant. However, there are reports of recipient antibodies being 
detected many months, and even years after the transplant (Sparkes et 
al., 1979; Witherspoon et al., 1978; Korver et al., 1987; Van Tol et al., 
1996; Ang et al., 1997) suggesting that some recipient plasma cells may 
survive the conditioning regime and exist long term. Izumi and co-workers 
(2003) report an interesting case of a patient with pre-existing 
alloantibodies to Rh E and c antigens, the patient received a bone 
marrow transplant from an Rh E+ c+ donor and then suffered from 
chronic persistent haemolytic anaemia, with positive DAT and IAT 
present, for approximately 20 months after the BMT (Izumi et al., 2003).  
Implementation of red cell antigen typing and matching of blood for 
transfusion for patients prior to, during and after allogeneic bone marrow 
transplantation would require special attention to the red cell phenotype 
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of the recipient, donor and that of the blood selected for transfusion at the 
various stages of the transplant.  
 
The pilot study performed suggested that recruitment to a larger, multi-
centre RCT would not pose any real issues, however care would need to 
be taken with the estimate of the number of recruits to the trial as the 
death rate of patients in the pilot study is suggestive of a relatively high 
mortality rate in this cohort. Also, the recruitment process would need to 
include selection for patients considered most likely to require blood 
transfusion in the course of their disease treatment as demonstrated in 
this study, such as myeloma, MDS, MPD, acute and chronic leukaemias, 
to ensure that sufficient blood transfusions were performed in patients 
within each arm of the study. Adequate numbers of patients would need 
to be recruited to ensure that the trial was powered to investigate 
differences in the rate of development of allo/autoantibodies in patients 
receiving standard care and those receiving antigen matched blood. An 
estimate of the sample size required for a two arm, binary, superiority trial 
designed with a 90% power, which would allow a sample size large 
enough to be reasonably confident of demonstrating that one of the 
treatment arms is superior to the other, can be achieved using a power 
calculator (Sealed Envelope, 2012). In such a trial the binary outcome 
would have two measures, chronically transfused patients develop Rh 
and Kell related antibodies or they do not develop antibodies. An estimate 
of the percentage “success” in the control group and the intervention 
group need to be established. In this scenario, given that approximately 
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25% of chronically transfused haematology patients in the retrospective 
review developed allo/autoantibodies and 67% of the alloantibodies were 
Rh or K related antibodies, an estimate of 16.75% of patients in the 
control arm (non matched blood) would make antibodies, compared to 
0% in the intervention group (given RhCcEe and K matched blood). Using 
the power calculator 106 patients (53 in each arm) would be required to 
have a 90% chance of detecting, as significant at the 5% level, a 
decrease in the primary outcome measure from 16.75% in the control 
group to 0% in the intervention group. However, it is prudent to proceed 
cautiously when determining sample size to reduce the risk of under 
powering the trial and being unable to make conclusions from the data.  
 
The pilot study revealed issues with availability of antigen matched blood 
for the less common phenotypes, these issues could be overcome by 
improving communication between the haematology/renal clinic and the 
laboratory and early pre-transfusion sample taking, giving laboratory staff 
sufficient time to order red cell units with appropriate antigen types. Re-
design of stock holding could also facilitate supply of matched units; in 
this pilot study no changes were made to the way that blood units are 
stored in the blood stock fridge. Current local practice is to store units 
according to ABO and RhD group, a small stock of c, E and K negative 
(group O and A) are held separately, but there is no further separation of 
blood according to Rh and Kell antigen types. Further separation of the 
blood units could enable easier identification of matching units, which is 
currently performed by searching through the units, and provide the basis 
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for an optimum order level for antigen negative units to ensure there are 
always matching units available, even for patients with the rarer Rh types.  
 
In conclusion, implementation of a strategy for red cell antigen typing and 
matching of blood for transfusion in patients with haematological 
conditions and renal insufficiency would appear to be an achievable and 
beneficial objective. This is supported by a recent study which showed a 
significantly lower rate of alloimmunisation of haematology patients who 
were phenotyped and matched for Rh/K antigens compared to a group 
who only received matched red cells after developing an antibody (Baia 
et al, 2015). An automated platform for rapid, cost effective high 
throughput extended serological red cell antigen typing, using the 
Immucor NEO® analyser system, has been demonstrated to be suitable 
for use in hospital transfusion services, with the potential for development 
of electronic transfer of results to the host Laboratory Information 
Management System (LIMS), which would allow hospital transfusion 
services to implement a type and match strategy encompassing large 
numbers of patients. The feasibility of introducing a method for blood 
group genotyping into a routine hospital transfusion service setting has 
also been assessed. Although the manual aspects of blood group 
genotyping would appear to preclude this assay from the majority of 
hospital transfusion laboratories, it remains a valuable tool for reference 
laboratories. Advances in automated genotyping techniques may see 
these assays being used in hospital transfusion laboratories in the near 
future. Cost analysis of the serological phenotyping assay used in this 
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research has demonstrated that this technique is cost effective if used 
within a type and match program for Rh (CcEe) and K antigens. The 
assay for extended serological phenotyping for other blood group 
systems, assessed in this research was not found to be cost effective for 
a type and match program. However, this assay is a valuable tool in the 
hospital transfusion laboratory for serological phenotyping for non-
chronically transfused patients with alloantibodies, and has considerable 
advantages over manual techniques. The small pilot study performed 
demonstrated that a type and match program for Rh (CcEe) and K 
antigens can be achieved using the automated serological phenotyping 
assay for chronically transfused patients. Patients can be provided with 
matched blood from routine blood stocks held in the laboratory, but 
provision could be improved with changes to the stock ordering and 
holding arrangements. In addition, assurance of correct matching of blood 
could be improved by the addition of algorithms within the LIMS. The pilot 
study has also demonstrated that a large scale, multi-centre, randomised 
controlled trial could be conducted in the UK to investigate the potential of 
a typing and matching approach in reducing the risk of allo and/or 
autoantibody production and decreasing the cost of laboratory testing in 
these patient cohorts. The retrospective review of chronically transfused 
patients demonstrated that these cohorts of patients are at risk of 
development of alloantibodies, particularly to the Rh and Kell blood group 
systems. A prospective type and match program has the potential to 
reduce the transfusion complications for these patients and also reduce 
the cost of provision of blood for the health service.  
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The results of this research have been utilised to implement a type and 
match program and drive the changes required within the hospital 
transfusion service at the RD&E to ensure that the program is robust and 
successful. Patients have been enrolled on the program from January 
2017. The automated serological phenotyping system has been 
introduced within the laboratory and the LIMS has been upgraded to 
incorporate information on the patient antigen status. All new 
haematology, renal, oncology and paediatric oncology patients are typed 
for Rh (CcEe) and K antigens prior to first transfusion, patients are 
identified by the laboratory staff based on the location and/or clinical 
details provided on the test request form. Previously transfused patients, 
with no red cell antibodies and with no evidence of transfusion within four 
months are also included on the program. The LIM system has also been 
upgraded to include an algorithm for cross checking the patient antigen 
requirements (included in the computer records as “antigen negative” and 
detailing the RH (CcEe) and K antigen for which the patient is negative) 
against the “antigen negative” status of the red cell unit selected for 
transfusion by the laboratory staff. The computer system allows an 
override if there is a mis-match in the antigen negative status of the unit 
and the patient, for cases of emergency transfusion when matched units 
cannot be supplied from the routine stock. The antigen matching 
algorithm is also included in the interface for red cell units dispensed from 
the remote allocation fridges, a system which does not include interaction 
from the laboratory staff. The blood stock storage arrangements have 
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been altered to allow red cell units to be stored in individual trays with the 
Rh (CcEe) and K antigen status clearly marked to enable easy and swift 
identification by laboratory staff. Changes have also been made to the 
blood stock ordering process to ensure that sufficient stock of each 
RhCcEe and K typed units are available. 
 
A preliminary review of the data showed that, during the 12 month period, 
273 patients were identified by the laboratory staff as being in a high risk 
group for chronic transfusion. None of the patients had alloantibodies and 
all were suitable for serological phenotype with no record of transfusion 
within the preceding four months. Of the 273 patients included in the type 
and match program, only 175 were transfused (64.1%), suggesting that 
identification of patients could be improved. A study by Lin and co-
workers (2017) investigating the impact of prophylactic Rh and K antigen 
matching in patients with MDS also noted challenges in identification of 
patients. In their study the identification of patients was performed by the 
clinical staff and communicated to the transfusion laboratory, they noted 
that only 62% of patients that should have received matched blood were 
phenotyped. In contrast, in our institution, the identification of patients is 
performed by laboratory staff and this would appear to lead to excess of 
phenotyping. Further work is planned within the RD&E to address this 
issue. Over the study period the patients (n=175) were transfused a total 
of 773 (range 1 – 50, average 4.4) units of red cells. No cases were noted 
where matching could not be achieved. At the end of the study period 
(December 2017) no patients had developed antibodies to Rh or K 
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antigens, however, 2 patients had developed anti-Jka. This is a significant 
reduction compared to the alloimmunisation rate noted in the 
retrospective review of chronically transfused haematology patients (1.1% 
compared to 12.9%) (see chapter 3). The study by Lin and co-workers 
(2017) also noted no alloimmunisation to Rh and K antigens for patients 
receiving matched blood, but noted a 6% alloimmunisation rate for non-
Rh/K alloimmunisation rate. This difference could be explained by the fact 
that the patients in their study were transfused over a longer time frame 
(3 years compared to 1 year) and received more red cell units (median 39 
units) compared to the RD&E patients (median 2 units). It is accepted that 
a type and match strategy for Rh (CcEe) and K antigens cannot eliminate 
alloimmunisation to non-Rh/K antigens. However, the fact that two 
patients at the RD&E developed anti-Jka after exposure to a small 
number of units (one patient received 1 unit and the other received 4 
units) has prompted consideration for the inclusion of typing and 
matching for Jka and Jkb antigens into the program.  
 
The cost of serological phenotyping for the RD&E patients amounted to 
£1629.81. As a crude measure of cost effectiveness, the costs for 
antibody identification and serological crossmatching were compared for 
the same time period before and after implementation of the program. 
The reduction in additional testing post implementation of the program 
resulted in savings of £1728.3, although it should be noted that this may 
also be affected by other factors, such as changes in the patient 
population and a general reduction in blood usage. 
310 
 
 
In conclusion, a type and match strategy would appear to be both 
achievable, in terms of service provision, and beneficial, in terms of 
laboratory workload, cost effectiveness and patient alloimmunisation rate 
for patients likely to require long-term transfusion support.  
 
  
311 
 
 
9 REFERENCES 
 
Abdelrazik, A. M., Elshafie, S. M., El Said, M. N., Ezzat Ahmed, G. M., Al-
Gamil, A.-K. A., El Nahhas, M. G. M. and Sady, A. A. B. (2016), Study of 
red blood cell alloimmunization risk factors in multiply transfused 
thalassemia patients: role in improving thalassemia transfusion practice in 
Fayoum, Egypt. Transfusion, 56: 2303–2307. 
 
Agenda for Change NHS pay scale. NHS employers 
http://www.nhsemployers.org/case-studies-and-
resources/2017/03/agenda-for-change-pay-scales-and-points-april-2017 
(website accessed 20.1.2018)  
 
Ahrens, N., Pruss, A., Kahne, A., Kieswewetter, H. and Salama, A. 
Coexistence of autoantibodies and alloantibodies to red blood cells due to 
transfusion. Transfusion 2007; 47, 813-816. 
 
Altayar, M., Halawani, A., Kiernan, M., Reynolds, A., Kaushik, N., 
Madgett, T. and Avent, N. Next Generation Sequencing based 
genotyping of Duffy, Kidd and ABO blood group genes. Transfusion 
Medicine 2013; 23, 62-63. 
 
Alfinito, F., Sica, N., Luciano, L., Della Pepa R., Palladino, C., Ferrara, I., 
Giani, U., Ruggiero, G. and Terrazzano, G. Immune dysregulation and 
312 
 
dyserythropoesis in the myelodysplastic syndromes. British Journal of 
Haematology 2010; 148, 90-98.  
 
Altman, D. and Bland, J. How to randomize. British Medical Journal 
1999a; 319, 703-704. 
 
Altman, D. and Bland, J. Statistics notes. Treatment allocation in 
controlled trials: why randomise? British Medical Journal 1999b; 318, 
1209. 
 
Alves, V., Martins, P., Soares, S., Araújo, G., Schmidt, L., Costa, S., 
Langhi, D. and Moraes-Souza, H. (2012). Alloimmunization screening 
after transfusion of red blood cells in a prospective study. Revista 
Brasileira de Hematologia E Hemoterapia, 34, 206–211.  
 
Ang, H., Apperley, J. and Ward, K. Persistence of antibody to human 
parvovirus B19 after allogeneic bone marrow transplantation: role of prior 
recipient immunity. Blood 1997; 89, 4646-4651. 
 
Arain, M., Campbell, M., Cooper, C. and Lancaster, G. What is a pilot or 
feasibility study? A review of current practice and editorial policy. BioMed 
Central Medical Research Methodology 2010; 10, 67. 
 
Arber, D., Orazi, A., Hasserjian, R., Thiele, J., Borowitz, M., Le Beau, M., 
Bloomfield, C., Cazzola, M. and Vardiman, J. The 2016 revision to the 
313 
 
World Health Organization classification of myeloid neoplasms and acute 
leukemia. Blood 2016; 127, 2391-2405. 
 
Asfour, M., Narvios, A. and  Lichtiger B. Transfusion of RhD-Incompatible 
Blood Components in RhD-Negative Blood Marrow Transplant 
Recipients.    Medscape General Medicine. 2004; 6, 22. 
 
Astor, B., Muntner, P., Levin, A., Eustace, J. and Coresh, J. Association 
of kidney function with anaemia. The Third National Health and Nutrition 
Examination Survey (1988-1994). Archives of Internal Medicine 2002, 
162, 1401-1408. 
 
Avent, N., Ridgwell, K., Tanner, M. and Anstee, D. cDNA cloning of a 30 
kDa erythrocyte membrane protein associated with Rh (Rhesus) blood-
group-antigen expression. Biochemical Journal. 1990; 271, 821-815. 
 
Avent, N., Martinez, A., Flegel, W., Olsson, M., Scott, M., Nogues, N., 
Pisacka, M., Daniels, G., van der Schoot, E., Muniz-Diaz, E., Madgett, T., 
Storrey, J., Beiboer, S., Maaskant-van Wijk, P., von Zabern, I., Jiminez, 
E., Tejedor, D., Lopez, M., Camacho, E., Cheroutre, G., Hacker, A., 
Jinoch, P., Svobodova, I. and de Haas, M. The BloodGen project: 
towards mass scale comprehensive genotyping of blood donors in the 
European Union and beyond. Transfusion 2007; 47, 405-465. 
 
314 
 
Avent, N. Large-scale blood group genotyping – clinical implications. 
British Journal of Haematology 2009; 144, 3-13. 
 
Aygun, B., Padmanabhan, S., Paley, C. and Chandrasekaran, V. Clinical 
significance of red cell alloantibodies in sickle cell patients who received 
transfusions. Transfusion 2002; 42, 37-43. 
 
Baia, F., Correia, F., Alves, B., Martinez, F., Koch, C., Carneiro, A. and 
Araujo. Phenotyping Rh/Kell and risk of alloimmunization in 
haematological patients. Transfusion Medicine 2015; 26, 34-38. 
 
Barrett, J., Saunthararajah, Y. and Molldrem, J. Myelodysplastic 
syndrome and Aplastic Anaemia: distinct entities or diseases linked by a 
common pathophysiology? Seminars in Hematology 2000; 37, 15-29. 
 
Bauer, M., Wiersum-Osselton, J., Schipperis, M., Vandenbroucke, J. and 
Briet, E. Clinical predictors of alloimmunisation after red blood cell 
transfusion. Transfusion 2007; 47, 2066-2071. 
 
BCSH Working Party of the British Committee for Standards in 
Haematology Blood Transfusion Task Force. Guidelines for pre-
transfusion compatibility procedures in blood transfusion laboratories. 
Transfusion Medicine 2013; 23, 3-35. 
 
315 
 
BCSH Validation and Qualification, including change control, for hospital 
transfusion laboratories. Transfusion Medicine 2012; 22, 5-43. 
 
Beauregard, P and Blajchman, M. Haemolytic and pseudo-haemolytic 
transfusion reactions and the clinical conditions that mimic them. 
Transfusion Medicine Reviews 1994; 8, 184-199. 
 
Belhacene, N., Maulon, L., Guerin, S., Ehrland, J., Colin, Y., Cartron, J. 
and Auberger, P. Differential expression of the Kell blood group and 
CD10 antigens: two related membrane metallopeptidases during 
differentiation of K562 cells by phorbol ester and hemin. Federation of 
American Societies for Experimental Biology 1998; 12, 531-539. 
 
 
Bennet, J., Catovsky, D., Daniel, M., Flandrin, G., Galton, D., Gralnick, H. 
and Sultan, C. Proposal for the classification of the acute leukaemias. 
British Journal of Haematology, 1976; 33, 452-459. 
 
 
Blumberg, N., Peck, K., Ross, K. and Avila, E. Immune response to 
chronic red blood cell transfusion. Vox Sanguinis 1983; 44, 212-217. 
 
Blumberg, N., Ross, K., Avila, E. and Peck, K. Should chronic transfusion 
be matched for antigens other than ABO and Rh0 (D)? Vox Sanguinis 
1984; 47, 205-208. 
 
316 
 
Brugnara, C. and Eckardt, K. Hematologic aspects of kidney disease. In 
Taal MW, ed. Brenner and Rector’s The Kidney. 9th ed. Philadelphia: 
Saunders; 2011: 2081-2120. 
 
Cartwright, R., Gilman, E. and Gurney, K. Time trends in incidence of 
haematological malignancies and related conditions. British Journal of 
Haematology 1999; 106, 281-295. 
 
Castilho, L. and Pellegrino Júnior, J. Blood group genotyping. Revista 
Brasileira de Hematologia e Hemoterapia 2004; 26, 135-140. 
 
Champlin, R. and Gale, R. Acute myelogenous leukaemia: recent 
advances in therapy. Blood 1987, 69, 1551-1562. 
 
Chan, J., Banks, P., Cleary, M., Delsol, G., De Wolf-Peeters, C., Falini, 
B., Gatter, K., Grogan, T., Harris, N., Isaacson, P., Jaffe, E., Knowles, D., 
Mason, D., Muller-Hermelink, H-K., Pileri, S., Prirs, M., Ralfkiaer, E., 
Stein, H. and Warnke, R.  A proposal for classification of lymphoid 
neoplasms (by the International Lymphoma Study Group). Histopathology 
1994; 25, 517-536. 
 
Chan, J., Banks, P., Cleary, M., Delsol, G., De Wolf-Peeters, C., Falini, 
B., Gatter, K., Grogan, T., Harris, N., Isaacson, P., Jaffe, E., Knowles, D., 
Mason, D., Muller-Hermelink, H., Pileri, S., Piris, M., Ralfkiaer, E., Stein, 
H. and Warnke, R. A revised European-American classification of 
317 
 
lymphoid neoplasms proposed by the International Lymphoma Study 
Group. A summary version. American Journal of Clinical Pathology 1995; 
103, 543-560. 
 
Cherif-Zahar, B., Bloy, C., Le Van Kim, C., Blanchard, D., Bailly, P., 
Hermand, P., Salmon, C., Cartron. J. and Colin, Y.   Molecular cloning of 
protein structure of a human blood group Rh polypeptide. Proceedings of 
the National Academy of Sciences 1990; 87, 6243-6247. 
 
Chou, S. and Westhoff, C. Molecular biology of the Rh system: clinical 
considerations for transfusion in sickle cell disease. American Society of 
Hematology Education Book 2009; 1, 178-184. 
 
Chou, S., Jackson, T., Vege, S., Smith-Whitley, K., Friedman, D. and 
Westhoff, C. High prevalence of red cell alloimmunization in sickle cell 
disease despite transfusion for Rh-matched minority donors. Blood 2013; 
122, 1062-1071. 
 
Churchill, D., Taylor, D., Cook, R., La Plante, P., Barre, P., Cartier, P., 
Fay, W., Goldstein, M., Jindal., K. and Mandin, H. Canadian 
Hemodialysis Morbidity Study. American Journal of Kidney Disease 1992; 
19, 214-234. 
 
Coles, S., Klein, H. and Holland, P. Alloimmunisation in two 
multitransfused patient populations. Transfusion 1981; 21, 462-466. 
318 
 
 
Cook, I. Primary rhesus immunization of male volunteers. British Journal 
of Haematology 1971; 20, 369-75. 
 
Coombs, R.R.A., Mourant, A.E. and Race, R.R., 1945. Detection of Weak 
and “Incomplete” Rh Agglutinins: A New Test. In Rhesus haemolytic 
disease (pp. 88-88). Springer Netherlands. 
 
Coombs, R., Mourant, A. and Race, R. A new test for detection of weak 
and “incomplete” Rh agglutinins. British Journal of Experimental 
Pathology 1945(b); 26: 255-266. 
 
Cornell, L., Smith, R. and Colvin, R. Kidney transplantation: mechanisms 
of rejection and acceptance. Annual Review of Pathology 2008; 3, 189-
220. 
 
Court-Brown, W. and Doll, R. Adult Leukaemia Trends in mortality in 
relation to aetiology. British Journal of Medicine 1959; 1, 1063-1069. 
 
Cvejic, A., Haer-Wigman, L., Stephens, J., Kostadima, M., Smethurst, P., 
Frontini, M., van den Akker, E., Bertone, P., Bielczyk-Maczyńska, E., 
Farrow, S., Fehrmann, R., Gray, A., de Haas, M., Haver, V., Jordan, G., 
Karjalainen, J., Kerstens, H., Kiddle, G., Lloyd-Jones, H., Needs, M., 
Poole, J., Ait Soussan, A., Rendon, A., Rieneck, K., Sambrook, J., 
Schepers, H., Silljé, H., Sipos, B., Swinkels, D., Tamuri, A., Verweij, N., 
319 
 
Watkins, N., Westra, H-J., Stemple, D., Franke, L., Soranzo, N., 
Stunnenberg, H., Goldman, N., van der Harst, P., van der Schoot, C., 
Ouwehand, W. and Albers, C. SMIM1 underlies the Vel blood group and 
influences red blood cell traits. Nature Genetics 2013; 45, 542-545. 
 
Dalpke, A., Hofko, M. and Zimmerman, S. Comparison of the BD Max 
Methicillin-Resistant Staphylococcus Aureus (MRSA) Assay and the BD 
GeneOhm MRSA Achromopeptidase Assay with Direct- and Enriched-
Culture Techniques Using Clinical Specimens for Detection of MRSA. 
Journal of Clinical Microbiology 2012; 50, 3365-3367. 
 
Daniels, G., Fletcher, A., Garratty, G., Jørgensen, J., Judd, W., Levene, 
C., Lomas-Francis, C., Moulds, J. J., Moulds, J.M., Overbeeke, M., Reid, 
M., Rouger, P., Scott, M., Sistonen, P., Smart, E., Tani, Y., Wendel, S. 
and Zelinski, T. Blood group terminology 2004: from the International 
Society of Blood Transfusion committee on terminology for red cell 
surface antigens. Vox Sanguinis 2004; 87, 304-316. 
 
Daniels, G. Human Blood Groups. Third Edition 2013. Wiley-Blackwell. 
 
Daniels, G. and Bromilow, I. Essential Guide to Blood Groups. Second 
Edition 2010. Wiley-Blackwell.  
 
Da Silva, S., Ferriera, G., da Silva, S., Alves, T., Ribeiro, I., Ribeiro, T. 
and Cavalcante, M. Red blood cell and leukocyte alloimmunisation in 
320 
 
patients awaiting kidney transplantation. Revista Brasileira de 
Hematologia e Hemoterapia 2013; 35, 185-188. 
 
Davies, S., McWilliam, A., Hewitt, P., Devenish, A. and Brozovic, M. Red 
cell alloimmunization in sickle cell disease. British Journal of 
Haematology 1986; 63, 241-245. 
 
Dean, L. Blood Groups and Red Cell Antigens. Bethesda (MD): National 
Centre for Biotechnology Information (US); 2005. 
(http://www.ncbi.nlm.nih.gov/books/NBK2261/ Accessed 26.02.13). 
 
Denomme, G. and Van Oene, M. High-throughput multiplex single-
nucleotide polymorphism analysis for red cell and platelet antigen 
genotypes. Transfusion 2005; 45, 660-666. 
 
Deschamps-Latscha, B. and Chatenoud, L. T cells and B cells in Chronic 
Renal Failure. Seminars in Nephrology 1996; 16, 183-191. 
 
Dombret, H. and Gardin, C. An update of current treatments for adult 
acute myeloid leukaemia. Blood 2016; 127, 53-61. 
 
Domen, R. and Ramirez, G. Red Cell Alloimmunization in Chronic Renal 
Failure Patients Undergoing Hemodialysis. Nephron 1988; 48, 284-285. 
 
321 
 
Drago, F., Karpasitou, K. and Poli, F. Microarray beads for Identifying 
Blood Group Single Nucleotide Polymorphisms. Transfusion Medicine 
and Hemotherapy 2009; 36, 157-160. 
 
Drago, F., Karpasitou, K., Spinardi, L., Crespiatico, L., Scalamogna, M. 
and Poli, F. A Microsphere-Based Suspension Array for Blood Group 
Molecular Typing: An Update. Transfusion Medicine and Hemotherapy 
2010; 37, 336-338. 
 
Drüeke, T. Hyporesponsiveness to recombinant human erythropoietin. 
Nephrology Dialysis Transplantation 2001, 16, 25-28. 
 
 
Dutcher, J., Schiffer, C., Aisner, J. and Wiernik, P. Long term follow up 
patients with leukaemia receiving platelet transfusions: identification of a 
large group of patients who do not become alloimmunized. Blood 1981; 
58, 1007-1011. 
 
European Group for Blood and Marrow Transplantation (EBMT). Annual 
report 2011: 
(https://www.ebmt.org/Contents/Resources/Library/Annualreport/Docume
nts/Annual%20Report%2011%20EBMT%20vertical_Website.pdf 
accessed 01/06/2016). 
 
Eiberg, H. and Mohr, J. Dombrock blood group (DO): assignment to 
chromosome 12p. Human Genetics 1996; 98, 518-521. 
322 
 
 
El Nemer, W., Rahuel, C., Colin, Y., Gane, P., Cartron, J. and Le Van 
Kim, C. Organization of the Human LU Gene and Molecular Basis of the 
Lua/Lub Blood Group Polymorphism. Blood 1997; 89, 4608-4616. 
 
Endeward, V., Cartron, J-P. and Gros, G. RhAG protein of the Rhesus 
complex is a CO2 channel in the human red cell membrane. FASEB 
Journal (The official journal of the Federation of American Societies for 
Experimental Biology) 2008; 22, 64-73. 
 
Ehrlich, G., Viegas-Pequignot, E., Ginzberg, D., Sindel, L., Soreq, H. and 
Zakut, H. Mapping the Human Acetylcholinesterase Gene to 
Chromosome 7q22 by Fluorescent in situ Hybridization Coupled with 
Selective PCR Amplification from a Somatic Hybrid Cell Panel and 
Chromosome-Sorted DNA Libraries. Genomics 1992; 13, 1192-1197. 
 
Erslev, A. Humoral regulation of red cell production. Blood 1953; 8, 349-
357. 
 
Exeter Census Profile 2011. Devon County Council 
http://www.devon.gov.uk/census_profile-exeter.pdf (accessed 
29/01/2018). 
 
323 
 
Ferlay, J., Autier, P., Boniol, M., Haenue, M., Colombet, M. and Boyle, P. 
Estimates of cancer incidence and mortality in Europe 2006. Annals of 
Oncology 2007, 18, 581-592. 
 
Finning, K., Bhandari, R., Sellers, F., Revelli, N., Villa, M. A., Muñiz-Díaz, 
E., and Nogués, N. (2016). Evaluation of red blood cell and platelet 
antigen genotyping platforms (ID CORE XT/ID HPA XT) in routine clinical 
practice. Blood Transfusion, 14, 160–167.  
 
Fleiss, J., Levin, B. and Park, M. A statistical method for rates and 
proportion. How to randomize. Third edition. Hobohan NJ. John Wiley 
and Sons, 2003. 
 
Fluit, C., Kunst, V. and Drenthe-Schonk, A. Incidence of red cell 
antibodies after multiple blood transfusion. Transfusion 1990; 30, 532-
535. 
 
Frane, J. A method of biased coin randomisation, its implementation and 
validation. Drug Information Journal 1998; 32, 423-432. 
 
Freda, V, Gorman, J., Pollack, W., Robertson, J., Jennings, E. and 
Sullivan, J. Prevention of Rh isoimmunization: progress report of the 
clinical trial in mothers. Journal of the American Medical Association 
1967; 199, 390-4. 
 
324 
 
Friedman, L., Furberg, C. and DeMets, D. Fundamentals of Clinical Trials 
3. New York: Springer; 1998. 
 
Frohn, C., Dumbgen, L., Brand, J., Gorg, S., Luhm, J. and Kirchner, H. 
Probability of anti-D development in D- patients receiving D+ RBCs. 
Transfusion 2003; 43, 893-8. 
 
Gabardi, S., Martin, S., Roberts, K. and Grafais, M. Induction 
immunosuppressive therapies in renal transplantation. American Journal 
of Health System Pharmacy 2011; 68, 211-218. 
 
Garratty, G. Novel mechanisms for immune destruction of circulating 
autologous cells. In: Silberstein LE, editor. Autoimmune disorders of 
blood. Bethesda: American Association of Blood Banks; 1996, 79-114. 
 
Garratty, G. Autoantibodies induced by blood transfusion. Transfusion 
2004; 44, 5-9. 
 
Gassner, C., Meyer, S., Frey, B. and Vollmert, C. Matrix-assisted laser 
desorption/ionisation, time-of-flight mass spectrometry-based blood group 
genotyping – the alternative approach. Transfusion Medicine Reviews 
2013; 27, 2-9. 
 
325 
 
Gaston, R. Maintenance immunosuppression in the renal transplant 
recipient: an overview. American Journal of Kidney Diseases. 2001; 38, 
S25-S35. 
 
Gerrard-Marchant, R., Hamlin Lennart, K., Rilke, F. and Stansfield, A.  
Classification of NHL. Lancet 1974; ii, 406-409. 
 
Getman, D., Eubanks, J., Camp, S., Evans, G. and Taylor, P. The Human 
Gene Encoding Acetylcholinesterase Is Located on the Long Arm of 
Chromosome 7. American Journal of Human Genetics 1992; 52, 170-
177. 
 
Goldman, M., Nogués, N. and Castilho, L. An overview of the Progenika 
ID CORE XT: an automated genotyping platform based on a fluidic 
microarray system. Immunohaematology 2015; 31, 62-68. 
 
Grais, M. Mortality and Morbidity from Leukaemia and Aleukaemia in 
Specific Countries. Bulletin of the World Health Organisation 1962; 25, 
683- 688. 
 
 
Guelsin, G., Sell, A., Castilho, L., Masaki, V., Melo, F., Hashimotot, N., 
Higa, T., Hirle, L. and Visentainer, J. Benefits of Blood Group Genotyping 
in Multi-Transfused Patients from the South of Brazil. Journal of Clinical 
Laboratory Analysis 2010; 24, 311-316. 
 
326 
 
Gunson, H., Stratton, F., Cooper, D. and Rawlinson, V. Primary 
immunization of Rh-negative volunteers. British Medical Journal 1970; 1, 
593-5. 
 
Gyurkocza, B. and Sandmaier, B. Conditioning regimens for 
hematopoietic cell transplantation: one size does not fit all. Blood 2014; 
124, 344-353. 
 
Hallorhan, P. Immunosuppressive drugs for kidney transplantation. New 
England Journal of Medicine 2004; 351, 2715-2719. 
 
Harris, N., Jaffe, E., Stein, H., Banks, P., Chan, J., Cleary, M., Delsol, G., 
De Woolf-Peeters, C., Falini, B., Gatter, K., Grogan, T., Isaacson, P., 
Knowles, D., Mason, D., Muller-Hermelink, H., Pileri, S., Piris, M., 
Ralfkiaer, E. and Warnke, R. A revised European-American classification 
of lymphoid neoplasms: a proposal from the International Lymphoma 
Study Group. Blood 1994; 84, 1361-1392. 
 
Hashmi, G., Shariff, T., Seul, M., Vissavajjhala, P., Hue-Roye, K., 
Charles-Pierre, D., Lomas-Francis, C., Chaudhuri, A. and Reid, M. A 
flexible array format for large scale rapid blood group DNA typing. 
Transfusion 2005; 45, 680-688. 
 
Hashmi, G., Shariff, T., Zhang, Y., Cristobal., J., Chau, C., Seul, M., 
Vissavajjhala, P., Baldwin, C., Hue-Roye, K., Charles-Pierre, D., Lomas-
327 
 
Francis, C. and Reid, M. Determination of 24 minor red blood cell 
antigens for more than 2000 blood donors by high-throughput DNA 
analysis. Transfusion 2007; 47, 736-747. 
 
Heddle, N., Soutar, R., O’Hoski, P., Singer, J., McBride, J., Ali, M. and 
Kelton, J. A prospective study to determine the frequency and clinical 
significance of alloimmunization post-transfusion. British Journal of 
Haematology 1995; 91, 1000-5. 
 
Hendrickson, J., Desmarets, M., Deshpande, S., Chadwick, T., Hillyer, C., 
Roback, J. and Zimring, J. Recipient inflammation affects the frequency 
and magnitude of immunization to transfused red cells. Transfusion 2006; 
46, 1526-1536.  
 
Hinds, P. and Gattuso, J. From pilot work to a major study in cancer 
nursing research. Cancer Nursing 1991; 14, 132-135. 
 
Hirschfeld, H. A connection between correlation and contingency. 
Proceedings of the Cambridge Philosophical Society 1935; 31, 520-524. 
 
Hmida, S., Mojaat, N., Maamar, M., Bejaoui, M., Mediouni, M. and 
Boukef, K. Red cell alloantibodies in patients with haemoglobinopathies. 
Nouvelle Revue Francaise d’Hematologie 1994; 36, 363-366. 
 
328 
 
Hoeltge, G., Domen, R., Rybicki, L. and Schaffer, P. Multiple Red Cell 
Transfusions and Alloimmunization: Experience With 6996 Antibodies 
Detected in a Total of 159 262 patients from 1985 to 1993. Archives of 
Pathology and Laboratory Medicine 1995; 119, 42-5. 
 
Holohan, T., Terasaki, P. and Deisseroth, A. Suppression of Transfusion 
Related Alloimmunization in Intensively Treated Cancer Patients. Blood 
1981; 58, 122-128. 
 
Huang, C-H., Johe, K., Moulds, J., Siebert, P., Fukuda, M. and 
Blumenfeld, O. δ glycophorin (glycophorin B) gene deletion in two 
individuals homozygous for the S-s-U- blood group phenotype. Blood 
1987; 70, 1830-1835. 
 
Huang, C-H., Reid, M. and Blumenfeld, O. Remodelling of the 
Transmembrane Segment in Human Glycophorin by Aberrant RNA 
Splicing. Journal of Biological Chemistry 1994; 269, 10804-18012. 
 
Huang, C-H. and Blumenfeld, O. MNSs blood groups and major 
glycophorins: Molecular basis for allelic variation. In: Cartron, J-P, 
Rouger, P. eds. Molecular basis of human blood group antigens. New 
York: Plenum Press 1995, 153-188. 
 
Huang, C-H., Blumenfeld, O., Reid, M., Chen, Y., Daniels, G. and Smart, 
E. Alternative Splicing of a Novel Glycophorin Allele GPHe(GL) 
329 
 
Generates Two Protein Isoforms in the Human Erythrocyte Membrane. 
Blood 1997; 90, 391-397. 
 
Hu, F., Hu, Y., Ma, Z. and Rosenberger, W. Adaptive randomization for 
balancing over covariates. WIREs Computational Statistics 2014; 6, 288-
303. 
 
Huh, Y. and Lichtiger, B. Transfusion Reactions in Patients with Cancer. 
American Journal of Clinical Pathology 1987; 87, 253-257. 
 
Human Genome Organisation: Gene Nomenclature Committee 
http://www.genenames.org/cgi-bin/genefamilies/set/454 (accessed 
04/12/2015). 
 
Isacke, C. and Horton, M. The Adhesion Molecule Facts Book, Edition 2. 
Academic Press. London. 2000. 
 
Ishikura, H., Endo, J., Saito, Y., Kosaka, Y., Matsuo, S., Nagasue, N., 
Nakamura, T., Tsunematsu, T., Miyazaki, T. and Matsumoto, H. Graft 
versus host antibody reaction causing a delayed hemolytic anaemia after 
blood transfusion. Blood 1993; 82, 3222-3. 
 
Issitt, P. and Anstee, D. Applied Blood Group Serology. Fourth Edition, 
1998. Montgomery Scientific Publications. Durham, North Carolina, USA. 
 
330 
 
Izumi, N., Fuse, I., Furukawa, T., Uesugi, Y., Tsuchiyama, J., Toba, K., 
Togashi, K., Yamada, K., Ohtake, S., Saitoh, Y., Yanagisawa, N. and 
Aizawa, Y. Long-term production of pre-existing alloantibodies to E and c 
after allogeneic BMT in a patient with aplastic anemia resulting in delayed 
hemolytic anemia. Transfusion 2003; 43, 241-245.  
 
Jacobson, L., Goldwasser, E., Fried, W. and Plzak, L. Role of the kidney 
in erythropoiesis. Nature 1957; 179, 633-634. 
 
JPAC - Joint United Kingdom (UK) Blood Transfusion and Tissue 
Transplantation Services Professional Advisory Committee. 
transfusionguidelines.org (www.transfusionguidelines.org.uk/transfusion-
handbook accessed 03.04.2015). Transfusion Handbook 5th ed. Jan 
2014. 
 
JPAC - Joint United Kingdom (UK) Blood Transfusion and Tissue 
Transplantation Services Professional Advisory Committee. 
transfusionguidelines.org. Guidelines for the Blood Transfusion Services 
in the United Kingdom 8th edition, 2013.  
 
Juji, T, Kano, K. and Milgrom, F. Mixed agglutination with platelets. 
International Archives of Allergy. 1972; 42, 474-484. 
 
331 
 
Kadar, J. Impact of phenotype-matched red cell transfusions on the long 
term blood supply of patients under hematolooncologic outpatient care. 
Vox Sanguinis 2010, 99, 465-465. 
 
Kalish, L. and Begg, G. Treatment allocation methods in clinical trials; a 
review. Statistics in Medicine 1985; 4, 129-144. 
 
Karpasitou, K., Drago, F., Crespiatico, L., Paccapelo, C., Truglio, F., 
Frison, S., Scalamogna, M and Poli, F. Blood group genotyping for 
Jka/Jkb, Fya/Fyb, S/s, K/k, Kpa/Kpb, Jsa/Jsb, Coa/Cob and Lua/Lub with 
microarray beads. Transfusion 2008; 48, 505-512. 
 
Kato, S., Chmielewski, M., Honda, H., Pecoits-Filho, R., Matsuo, S., 
Yazawa, Y., Tranaeus, A., Stenvinkel, P. and Lindholm, B. Aspects of 
immune dysfunction in end stage renal disease. Clinical Journal of the 
American Society of Nephrology 2008; 3, 1526-1533. 
 
King, L., Kozono, D. and Agre, P. From structure to disease: the evolving 
tale of aquaporin biology. Nature Reviews Molecular Cell Biology 2004 
(a); 5, 687-698. 
 
King, K., Shirey, R., Thoman, S., Benson-Kennedy, D., Tanz, W. and 
Ness, P. Universal leukoreduction decreases the incidence of febrile 
nonhemolytic reactions to RBCs. Transfusion 2004 (b); 44, 25-29. 
 
332 
 
Kipps, T. and Carson, D. Autoantibodies in Chronic Lymphocytic 
Leukaemia and Related Systemic Autoimmune Diseases. Blood 1993; 
81, 2475-2487. 
 
Klapper, E., Zhang, Y., Figueroa, P., Ness, P., Stubbs, J., Abumuhor, I., 
Bailey, J., Epperson, L., Tauscher, C., Enriquez, E., Hashmi, G. and Seul, 
M. Towards extended phenotype matching: a new operational paradigm 
for the transfusion service. Transfusion 2010; 50, 536-546. 
 
Korver, K., de Lange, G., van den Burgh, R., Schellekens, P. and van 
Loghem, E. Lymphoid chimerism after allogeneic bone marrow 
transplantation. Y-chromatin staining of peripheral T and B lymphocytes 
and allotyping of serum immunoglobulins. Transplantation 1987; 44, 643-
650. 
 
Kościelak, J. The Hypothesis on Function of Glycosphingolipids and ABO 
Blood Groups Revisited. Neurochemical Research 2012; 37, 1170-1184.  
 
Kraemer, H., Mintz, J., Noda, A., Tinklenberg, J. and Yesavge, J. Caution 
regarding the use of pilot studies to guide power calculations for study 
proposals. Archives of General Psychiatry 2006; 63, 484-489. 
 
Kudo, S. and Fukuda, M. Identification of a Novel Human Glycophorin, 
Glycophorin E, by Isolation of Genomic Clones and Complementary DNA 
333 
 
Clones Utilizing Polymerase Chain Reaction. Journal of Biological 
Chemistry 1990; 265, 1102-1110. 
 
Lancaster, G., Dodd, S. and Williamson, P. Design and analysis of pilot 
studies: recommendations for good practice. Journal of Evaluation in 
Clinical Practice 2004; 10, 307-312. 
 
Lapierre, Y., Rigal, D., Adam, J., Josef, D., Meyer, F., Greber, S. and 
Drot, C. The gel test: a new way to detect red cell antigen-antibody 
reactions. Transfusion 1990; 30, 109-113. 
 
Laundy, R., Karamatic Crew, V., Davies, H., Harris, C., Baglow, L., 
Walser, P. and Thornton, N. A novel high incidence antigen in the Yt 
blood group system. Transfusion Medicine 2017; 27, 19-20. 
 
Lee, E., Whitehead, A., Jacques, R. and Julious, S. The statistical 
interpretation of pilot trials: should significance thresholds be 
reconsidered? BioMed Central; Medical Research Methodology 2014; 14, 
41. 
 
Lee, R-A and Gabardi, S. Current trends in immunosuppressive therapies 
for renal transplant recipients. American Journal of Health-System 
Pharmacy 2012; 69, 1961-1975. 
 
334 
 
Lee, S., Zambas, E., Marsh, W. and Redman, C. The Human Kell Blood 
Group Gene Maps to Chromosome 7q33 and its Expression Is Restricted 
to Erythroid Cells. Blood 1993; 81, 2804- 2809. 
 
 
Le Guern, R., Herwegh, S., Grandbastien, B., Courcol, R. and Wallet, F. 
Evaluation of a new molecular test, the BD Max Cdiff, for detection of 
toxigenic Clostridium difficile in fecal samples. Journal of Clinical 
Microbiology 2012; 50, 3089-3090. 
 
Leon, A., Davis, L. and Kraemer, H. The role and interpretation of pilot 
studies in clinical research. Journal of Psychiatric Research 2011; 45, 
626-629. 
 
Levine, P., Stock, A., Kuhmichel, A. and Bronikovsky, N. A new human 
blood factor of rare incidence in the general population. Proceedings of 
the Society of Experimental Biology 1951; 77, 402-403.  
 
Lin, Y., Saskin, A., Wells, R., Lenis, M., Mamedov, A., Callum, J. and 
Buckstein, R. Prophylactic RhCE and Kell antigen matching: impact on 
alloimmunization in transfusion-dependent patients with myelodysplastic 
syndromes. Vox Sanguinis 2017; 112, 79-86. 
 
Loscalzo, J. Pilot trials in clinical research: of what value are they? 
Circulation 2009; 119, 1694-1696 
335 
 
 
 
Lucien, N., Sidoux-Walter, F., Olives, B., Moulds, J., Le Pennec, P-Y., 
Cartron, J-P. and Bailly, P. Characterization of the Gene Encoding the 
Human Kidd Blood Group/Urea Transporter Protein. Evidence for splice 
site mutations in Jknull individuals. Journal of Biological Chemistry 1998; 
273, 12973-12980. 
 
Lukes, R. and Butler, J. The pathology of the nomer data of HD. Cancer 
Research, 1986; 26, 1077-1081. 
 
Maciejewski, J., O’Keefe, C., Gondek, L. and Tiu, R. Immune mediated 
bone marrow failure syndromes of progenitor and stem cells: molecular 
analysis of cytotoxic T cell clones. Fiolia Histochemica et Cytochemica 
2007; 45, 5-14. 
 
Makins, G. Injuries to the Blood Vessels. In History of the Great War 
Medical Services. Surgery of the War London, 1922, 2, 170-296. His 
Majesty’s Stationery Office, London. 
 
 
Mallinson, G., Soo, K., Schall, T., Pisacka, M. and Anstee, D. Mutations 
in the erythrocyte chemokine receptor (Duffy) gene: the molecular basis 
of the Fya/Fyb antigens and identification of a deletion in the Duffy gene of 
an apparently healthy individual with the Fy(a-b-) phenotype. British 
Journal of Haematology 1995; 90, 823-829. 
336 
 
 
Marini, A-M., Urrestarazu, A., Beauwens, R. and Andre, B. The Rh 
(Rhesus) blood group polypeptides are related to NH4
+ transporters. 
Trends in Biochemical Sciences 1997; 22, 460-461. 
 
Martin-Vega, C., Massuet, L., Julia, A.    Autoimmune Haemolytic 
anaemia (AIHA) in Myelodysplastic Syndromes (MS). In: Proceedings of 
the XX congress of the International Society of Blood Transfusion in 
association with the British Blood Transfusion Society. London 1988. 
Manchester: British Blood Transfusion Society, 1988; 81-81. 
 
Master, S., Ong, M. and Mansour, R. Blood Transfusion in Adult Patients 
with Sickle Cell Disease: Incidence of Alloimmunization. Blood 2016; 
128:2459. 
 
Mathew, S., Chaudhuri, A., Murty, V. and Pogo, A. Confirmation of Duffy 
blood group antigen locus (FY) at 1q22-q23 by fluorescence in situ 
hybridization. Cytogenetic and Cell Genetics 1994; 67, 68-68. 
 
Mauthe, J., Coghlan, G. and Zelinski, T. Confirmation of the Assignment 
of the Dombrock Blood Group Locus (DO) to chromosome 12p: 
Narrowing the Boundaries to 12p 12.3 – p13.2). Vox Sanguinis 2000; 79, 
53-56. 
 
337 
 
McBean, R., Hyland, C. and Flower, R. Molecular genotyping platforms 
for blood group antigen prediction. Pathology 2014a; 46, S87. 
 
McBean, R., Hyland, C. and Flower, R. Approaches to Determination of a 
Full Profile of Blood Group Genotypes: Single Nucleotide Variant 
Mapping and Massively Parallel Sequencing. Computational and 
Structural Biotechnology Journal 2014b; 11, 147-151. 
 
McBean, R., Hyland, C., Roscioli, T. and Flower, R. The low frequency 
SARAH blood group antigen: evidence for new MNS antigen. Vox 
Sanguinis. 2014c; 107, 17-17. 
 
McDonald, A., Knight, R., Campbell, M., Entwistle, V., Grant, A., Cook, J., 
Elbourne, D., Francis, D., Garcia, J., Roberts, I. and Snowdon, C. What 
influences recruitment to randomised controlled trials? A review of trials 
funded by two UK funding agencies. BioMed Central; Trials 2006; 7, 9. 
 
Mental Capacity Act 2005 (legislation.gov.uk) accessed 16/10/2015. 
 
Michail-Merianou, V., Phamphili-Panousophoulou, L., Piperi-Lowes, L., 
Pelegrinis, E. and Karaklis, A. Alloimmunization to red cell antigens in 
Thalassaemia: comparative study of usual versus better-match 
transfusion programmes. Vox Sanguinis 1987; 52, 95-98. 
 
Mikhail, A., Shrivastava, R. and Richardson, D. Anaemia of CKD. UK 
Renal Association, 5th edition, 2009-2012, Final Version 2010. 
338 
 
 
Milic, M., Webb, G. and Bowen, D. 344 Single centre experience of 
transfusion-dependent MDS demonstrates a high frequency of allo-
antibody formation in heavily transfused patients. Leukemia Research 
2011, 35, S138. 
 
Mohanram, A., Zhang, Z., Shahinfar, S., Keane, W., Brenner, B. and 
Toto, R. Anemia and end-stage renal disease in patients with type 2 
diabetes and nephropathy. Kidney International 2004; 66, 1131-1138. 
 
Möller, M., Jöud, M., Storry, J., and Olsson, M. L. Erythrogene: a 
database for in-depth analysis of the extensive variation in 36 blood 
group systems in the 1000 Genomes Project. Blood Advances, 2016; 
1:240-249. https://doi.org/10.1182/bloodadvances.2016001867 
(accessed 26/01/2018). 
 
Moncharmont, P., Barday, G. and Meyer, F. Red blood cell 
alloimmunisation in 18 to 50-year old transfused women: a 3-year study. 
Blood Transfusion 2015; 13, 345-346. 
 
 
Montpetit, A., Phillips, M., Mongrain, I., Lemieux, R. and St-Louis, M. 
High-throughput molecular profiling of blood donors for minor red blood 
cell and platelet antigens. Transfusion 2006; 46, 841-848. 
 
339 
 
Moon, C., Preston, G., Griffin, C., Jabs, E. and Agre, P. The human 
aquaporin-CHIP gene. Structure, organization, and chromosomal 
localization. Journal of Biological Chemistry 1993; 268, 15772-15778. 
 
Moore, C., Carter, R., Nietert, P. and Stewart, P. Recommendations for 
Planning Pilot Studies in Clinical and Translational Research. Clinical and 
Translational Science 2011; 4, 332-337. 
 
Moreira, G., Bordin, J., Kuroda, A. and Kerbauy, J. Red blood cell 
alloimmunization in sickle cell disease: The influence of racial and 
antigenic pattern differences between donors and recipients in Brazil. 
American Journal of Hematology 1996; 52, 197-200. 
 
Mouro, I., Colin, Y., Sistonen, P., Le Pennec, P., Cartron, J. and Le Van 
Kim, C. Molecular basis of the RhCW (Rh8) and RhCX (Rh9) blood group 
specificities. Blood 1995; 86, 1196-1201. 
 
Mufti, G., Figes, A., Hamblin, T. Oscier, D. and Copplestone, J.   
Immunological abnormalities in the myelodysplastic syndromes. I. Serum 
immunoglobulins and autoantibodies. British Journal of Haematology 
1986; 63, 143-147. 
 
Murakami, M. and Honjo, T. Anti-red blood cell autoantibody transgenic 
mice: murine model of autoimmune hemolytic anemia. Seminars in 
Immunology 1996; 8, 3-9. 
340 
 
 
Murphy, M., Morrison, N., Miles, J., Fraser, R., Spurr, N. and Boyd, E. 
Regional chromosomal assignment of the Kell blood group locus (KEL) to 
chromosome 7q33-q35 by fluorescence in situ hybridization: evidence for 
the polypeptide nature of antigenic variation. Human Genetics 1993; 91, 
585-588. 
 
Murphy, M., Templeton, L., Fleming, J., Ferguson, M., Peterkin, M. and 
Fraser, R. Comparison of the Fyb status as determined serologically and 
genetically. Transfusion Medicine 1997; 7, 135-141.  
 
Murphy, M., Pamphilon, D and Heddle, N. Practical Transfusion 
Medicine. 4th edition 2013. Wiley-Blackwell. 
 
Nashan, B. Antibody Induction Therapy in Renal Transplant Patients 
Receiving Calcineurin-Inhibitor Immunosuppressive Regimens: A 
Comparative Review. BioDrugs 2005; 19, 39-46. 
 
National Comparative Audit of Blood Transfusion (NCABT). Audit of the 
use of blood in adult medicine – Part 1 2011. www.hospital.blood.co.uk 
(accessed 03.04.2015). 
 
National Comparative Audit Reports (NCABT)– National Survey Red Cell 
Use – 2014 (http://hospital.blood.co.uk/audits/national-comparative-
audit/national-comparative-audit-reports/) accessed 01/12/2017. 
341 
 
 
Neote, K., Mak, J., Kolakowski, L. and Schall, T. Functional and 
Biochemical Analysis of the Cloned Duffy Antigen: Identity With the Red 
Blood Cell Chemokine Receptor. Blood 1994; 84, 44-52. 
 
Ness, P., Shirey, R., Thoman, S. and Buck, S. The differentiation of 
delayed serologic and hemolytic transfusion reactions: incidence, long-
term serologic findings, and clinical significance. Transfusion 1990; 30, 
688-693. 
 
NICE 2003; Improving Outcomes in Haematological Cancers. The 
Manual. National Institute for Clinical Excellence. 
(https://www.nice.org.uk/guidance/ng47/evidence/improving-outcomes-in-
haematological-cancers-the-manual-2487893581) accessed 18/04/2018 
 
NICE 2011; Anaemia management in people with chronic kidney disease. 
www.publications.nice.org.uk/anaemia-management-in-people-with-
chronic-kidney-disease-cg114 (accessed 07.03.2014). 
 
NIH National Institute of Diabetes and Digestive and Kidney Diseases 
(http://www.niddk.nih.gov/health-information/health-topics/kidney-
disease/anemia-in-kidney-disease-and-dialysis/Pages/facts.aspx 
accessed 16/04/2016). 
 
342 
 
National Institute for Health Research: Guidance Feasibility and Pilot 
studies (www.nets.nihr.ac.uk/glossary) accessed 17/10/2015. 
 
Norman, D. and Turka, L. Primer on transplantation. 2nd ed. Mt Laurel NJ: 
American Society of Transplantation 2001; 85-102. 
 
Novaretti, M., Sopelete, C., Velloso, E., Rosa, M., Dorlhiac-Llacer, P. and 
Chamone, D. Immunohematological findings in myelodysplastic 
syndrome. Acta Haematologica 2001; 105, 1-6. 
 
Office for National Statistics. Cancer Statistics Registrations, England: 
2012; 
(https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocial
care/conditionsanddiseases/bulletins/cancerregistrationstatisticsengland/
2014-06-19) Accessed 25/12/2017. 
 
Olives, B., Martial, S., Mattei, M-G., Matassi, G., Rousselet, G., Ripoche, 
P., Cartron, J. and Bailly, P.    Molecular characterization of a new urea 
transporter in the human kidney. FEBS Letters 1996; 386, 156-160. 
 
Olsson, M., Smythe, J., Hansson, C., Poole, J., Mallinson, G., Jones, J., 
Avent, N. and Daniels, G. The Fy(x) phenotype is associated with a 
missense mutation in the Fy(b) allele predicting Arg89Cys in the Duffy 
glycoprotein. British Journal of Haematology 1998; 103, 1184-1191. 
 
343 
 
Olujohungbe, A., Hambleton, I., Stephens, L., Serjeant, B. and Serjeant, 
G. Red cell antibodies in patients with homozygous sickle cell disease: a 
comparison of patients in Jamaica and the United Kingdom. British 
Journal of Haematology 2001; 113, 661-665. 
 
Parasol, N., Reid, M., Rios, M., Castilho, L., Harari, I. and Kosower, N. A 
Novel Mutation in the Coding Sequence of the FY*B Allele of the Duffy 
Chemokine Receptor Gene Is Associated With an Altered Erythrocyte 
Phenotype. Blood 1998; 92, 2237-2243. 
 
Parsons, S., Mallinson, G., Daniels, G., Green, C., Smythe, J. and 
Anstee, D.    Use of Domain-Deletion Mutants to Locate Lutheran Blood 
Group Antigens to Each of the Five Immunoglobulin Superfamily 
Domains of the Lutheran Glycoprotein: Elucidation of the Molecular Basis 
of the Lua/Lub and the Aua/Aub Polymorphisms. Blood 1997; 88, 4219-
4225. 
 
Plapp, F., Sinor, L., Rachel, J., Beck, M., Coenen, W. and Bayer, W. A 
Solid Phase Antibody Screen. American Journal of Clinical Pathology 
1984; 82, 719-721. 
 
Petz, L. and Garratty, G. Acquired Immune Hemolytic Anemias. New 
York: Churchill Livingstone, 1980:331-337. 
 
344 
 
Petz, L. and Garratty, G. Immune Hemolytic Anemias. 2nd Edition. 
Philadelphia: Churchill Livingstone, 2004. 
 
Pocock, S. and Simon, R. Sequential treatment assignment with 
balancing for prognostic factors in the controlled clinical trial. Biometrics, 
1975; 31, 103-115. 
 
Pruenster, M. and Rot, A. Throwing light on DARC. Biochemical Society 
Transactions 2006; 34, 1005-1008. 
 
Priyadarshi, A. and Shapiro, J. Erythropoietin resistance in the treatment 
of anaemia of chronic renal failure. Seminars in Dialysis, 2006; 19, 273-
278. 
 
Purohit, K., Weber, J., Ward, L. and Keats, B. The Kell blood group locus 
is close to the cystic fibrosis locus on chromosome 7. Human Genetics 
1992; 89, 457-458. 
 
Race, R. An “Incomplete” Antibody in Human Serum. Nature 1944; 153, 
771-772. 
 
Rahuel, C., London, J., Vignal, A., Ballas, S. and Cartron, J-P. 
Erythrocyte Glycophorin B Deficiency May Occur by Two Distinct Gene 
Alterations. American Journal of Hematology 1991; 37, 57-58. 
 
345 
 
Ramsey, G. and Larson, P. Loss of red cell alloantibodies over time. 
Transfusion 1988; 28, 162-165. 
 
Ramsey, G., Hahn, L., Cornell, F., Boczkowski, D.,  Staschak, S.,  Clark, 
R.,  Hardesty, R., Griffith, B. and Starzl, T. Low rate of Rhesus 
immunization from Rh-incompatible blood transfusions during liver and 
heart transplant surgery. Transplantation 1989; 47, 993-995 
 
Redman, M., Regan, F. and Contreras, M. A Prospective Study of the 
Incidence of Red Cell Allo-Immunisation following Transfusion. Vox 
Sanguinis 1996; 71, 216-220. 
 
Reid, M. Applications and Experience with PCR-Based Assays to Predict 
Blood Group Antigens. Transfusion Medicine and Hemotherapy 2009; 36, 
168-178. 
 
Reid, M., Storry, J., Ralph, H., Blumenfeld, O. and Huang, C-H.   
Expression and quantitative variation of the low-incidence blood group 
antigen He on some S-s- red cells. Transfusion 1996; 36, 719-724. 
 
Reid, M., Halter-Hipsky, C., Hue-Roye, K. and Hoppe, C. Genomic 
analyses of RH alleles to improve transfusion therapy in patients with 
sickle cell disease. Blood Cells Molecules and Diseases 2014; 54, 195-
202. 
 
346 
 
Renoud, K., Barracchini, K., Byrne, K., Adams, S., Pickett, A., Caruccio, 
L. and Stroncek, D. KEL6 and KEL7 genotyping with sequence-specific 
primers. Transfusion 2006; 46, 1510-1514. 
 
Reverberi, R. The persistence of red cell alloantibodies. Blood 
Transfusion 2008; 4, 225-234. 
 
Ribeiro, S., Costa, E., Belo, L., Reis, F. and Santos-Silva, A. rh EPO for 
the Treatment of Erythropoietin Resistant Anemia in Hemodialysis 
Patients – Risks and Benefits. Hemodialysis 2013; 
(http://www.intechopen.com/books/hemodialysis accessed 02/05/2016). 
 
Riedlinger, J., Beqaj, S., Milish, M., Young, S., Smith, R., Dodd, M., 
Hankerd, R., Lebar, W. and Newton, D. Multicenter evaluation of the BD 
Max GBS assay for detection of group B streptococci in prenatal vaginal 
and rectal screening swab specimens from pregnant women. Journal of 
Clinical Microbiology 2010; 48, 4239-4241. 
 
Robertson, O. Transfusion with preserved red blood cells. British Medical 
Journal 1918; 1, 691-695. 
 
Rolih, S., Eisinger, R., Moheng, M., Dean, W. and Eatz, R. Solid Phase 
Adherence Assays: Alternatives to Conventional Blood Bank Tests. 
Laboratory Medicine 1985; 16, 766-770. 
 
347 
 
Rosenberger, W. and Lachin, J., 2016. Randomization in clinical trials: 
theory and practice. John Wiley & Sons. 
 
Rosse, W., Gallagher, D., Kinney, T. Castro, O., Dosik, H., Moohr, J., 
Wang, W. and Levy, P. Transfusion and alloimmunization in sickle cell 
disease. Blood 1990; 76, 1431-1437. 
 
Royal College of Obstetricians and Gynaecologists. Red Cell Antibodies 
during Pregnancy, the Management of Women with (Green-top 
Guidelines No 65) May 2014. https://www.rcog.org.uk/en/guidelines-
research-services/guidelines/gtg65/ (accessed 25/01/2018). 
 
Rozman, P., Dovc, T. and Gassner, C. Differentiation of autologous ABO, 
RHD, RHCE, KEL, JK and FY blood group genotypes by analysis of 
peripheral blood samples of patients who have recently received multiple 
transfusions. Transfusion 2000; 40, 936-942. 
 
Sangole, V. and Chaudhury, D. Alloimmunisation of Red Blood Cells in 
Multitransfused Patients. International Journal of Health Sciences and 
Research 2013; 3, 39-41. 
 
Sanquin Blood 
Supplyhttp://www.sanquin.nl/en/research/departments/transfusion-
medicine/randomized-clinical-trials/ (accessed 11.2.13). 
 
348 
 
Sanz, C., Nomdedeu, M., Belkaid, M., Martinez, I., Nomdedeu, B. and 
Pereira, A. Red blood cell alloimmunization in transfused patients with 
myelodysplastic syndrome or chronic myelomonocytic leukaemia. 
Transfusion 2013; 53, 710-715. 
 
Sarnaik, S., Schornack, J. and Lusher, J. The incidence of development 
of irregular red cell antibodies in patients with sickle cell anemia. 
Transfusion 1986; 26, 249-252. 
 
Schofield, A., Martin, P., Spillett, D. and Tanner, M. The structure of the 
human red blood cell anion exchanger (EPB3, AE1, band 3) gene. Blood 
1994; 84, 2000-2012. 
 
Schonewille, H., Haak, H. and Van Zijl, A. Alloimmunization after blood 
transfusion in patients with hematologic and oncologic diseases. 
Transfusion 1999; 39, 763-771. 
 
Schonewille, H., Rene, R., De Vries, P. and Brand, A. Alloimmune 
response after additional red blood cell antigen challenge in immunized 
hematooncology patients. Transfusion 2009; 49, 453-457. 
 
Schonewille, H., Honohan, A., van der Watering, L., Hudig, F., te 
Boekhorst, P., Koopman-van Gemert, A. and Brand, A. Incidence of 
alloantibody formation after ABO-D or extended matched red blood cell 
349 
 
transfusions: a randomized trial (MATCH study). Transfusion 2016; 56, 
311-320. 
 
Schulz, K and Grimes, D.  Allocation concealment in randomised trials: 
defending against deciphering. Lancet 2002a; 359, 614-618. 
 
Schulz, K and Grimes, D.  Unequal group size in randomised trials: 
guarding against guessing. Lancet 2002b; 359, 966-970. 
 
Sealed Envelope Ltd. 2012. Power calculator for binary outcome 
superiority trial. [Online] Available from: 
https://www.sealedenvelope.com/power/binary-superiority/ [Accessed 
Nov 14 2016]. 
 
Seitanides, B., Antonopoulou, A. and Karabelis, A.  Immunological 
abnormalities in myelodysplastic syndrome. Journal of Clinical Pathology 
1988; 41, 922-923. 
 
Seltsam, A. and Doescher, A. Sequence-Based Typing of Human Blood 
Groups. Transfusion Medicine and Hemotherapy 2009; 36, 204-212. 
 
Serious Hazards of Transfusion (SHOT) annual report 2014 
www.shotuk.org (accessed 21/05/2016). 
 
350 
 
Serious Hazards of Transfusion (SHOT) annual report 2016. 
https://www.shotuk.org/wp-content/uploads/SHOT-Report-
2016_web_11th-July.pdf (accessed 25/01/2018). 
 
Seyfried, H. and Walewska, I. Analysis of immune response to red blood 
cell antigens in multitransfused patients with different diseases. Materia 
Medica Polona 1990; 22, 21-5. 
 
Shapiro, M. Serology and genetics of a new blood factor: hrs. Journal of 
Forensic Medicine 1960; 7, 96-105. 
 
Shapiro, M., Le Roux, M. and Brink, S. Serology and genetics of a new 
blood factor: hr B. Haematologia 1972; 6, 121-128. 
 
Shirey, R., Boyd, J., Parwani, A., Tanz, W., Ness, P. and King, K. 
Prophylactic antigen‐matched donor blood for patients with warm 
autoantibodies: an algorithm for transfusion management. Transfusion, 
2002; 42, 1435-1441. 
 
Sidoux-Walter, F., Lucien, N. and Olives, B. At Physiological Expression 
Levels the Kidd Blood Group/Urea Transporter Protein Is Not a Water 
Channel. Journal of Biological Chemistry 1999; 274, 30228-30235. 
 
Sidoux-Walter, F., Lucien, N., Nissinen, R., Sistonen, P., Henry, S., 
Moulds, J., Cartron, J-P. and Bailly, P. Molecular heterogeneity of the 
351 
 
Jknull phenotype: expression analysis of the Jk (S291P) mutation found in 
Finns. Blood 2000; 96, 1566-1573. 
 
Spanos, T., Karageorga, M., Ladis, V., Peristeri, J., Hatziliami, A. and 
Kattamis, C.  Red cell alloantibodies in patients with thalassaemia. Vox 
Sanguinis 1990; 58, 50-55. 
 
Sparkes, R., Sparkes, M. and Gale, R. Immunoglobulin synthesis 
following allogeneic bone marrow transplantation in man. Conversion to 
donor allotype. Transplantation 1979; 27, 212-213. 
 
Springer, G., Horton, R. and Forbes, M. Origin of anti-human blood group 
B agglutinins in White Leghorn chicks. Journal of Experimental Medicine 
1959a; 110, 221-244. 
 
Springer, G., Horton, R. and Forbes, M. Origin of antihuman blood group 
B agglutinins in germfree chicks. Annals of the New York Academy of 
Sciences 1959b; 78, 272-275. 
 
Springer, G. and Horton, R. Blood group isoantibody stimulation in man 
by feeding blood group-active bacteria. Journal of Clinical Investigation 
1969; 48, 1280-1291. 
 
352 
 
Sokol, R., Hewitt, S. and Brooker, D. Erythrocyte autoantibodies, 
autoimmune haemolysis, and myelodysplastic syndrome. Journal of 
Clinical Pathology 1989; 42, 1088-1091. 
 
Solal-Celigny, P., Vazeux, R., Vroclans, M., Amar, M., Herrera, A., 
Bernard, J. and Boivin, P. Positive Coombs tests in acute leukaemia. 
British Journal of Haematology 1984; 57, 563-569. 
 
Sourial, N., Wolfson, C., Zhu, B., Quail, J., Fletcher, J., Karunananthan, 
S., Bandeen-Roches, K., Beland, F. and Bergman, H. Correspondence 
analysis is a useful tool to uncover the relationships among categorical 
variables. Journal of Clinical Epidemiology 2010; 63, 638-646. 
 
Stainsby, D., Jones, H., Asher, D., Atterbury, C., Boncinelli, A., Brant, L., 
Chapman, C., Davison, K., Gerrard, R., Gray, A., Knowles, S., Love, E., 
Milkins, C., McClelland, D., Norfolk, D., Soldan, K., Taylor, C., Revill, J., 
Williamson, L. and Cohen, H. Serious Hazards of transfusion: a decade 
of hemovigilance in the UK. Transfusion Medicine Reviews 2006; 20, 
273-282. 
 
Starr, D. Blood: An epic history of medicine and commerce. 1999; Little 
Brown and Company, London. 
 
 
Steegmann, J., Requena, M., Martin-Regueira, P., De La Cámara, R., 
Casado, F., Salvanés, F. and Fernández Rañada, J. High incidence of 
353 
 
autoimmune alterations in chronic myeloid leukemia patients treated with 
interferon-alpha. American Journal of Hematology 2003; 72, 170-176. 
 
Storry, J., Reid, M., Fetics, S. and Huang, C-H. Mutations in the GYPB 
exon 5 drive the S-s-U+var phenotype in persons of African descent: 
implications for transfusion. Transfusion 2003; 43, 1738-1747. 
 
Strumia, M. and McGraw, J. The Development of Plasma Preparations 
for Transfusions. Annals of  Internal Medicine 1941; 15, 80-88.  
 
Sully, B., Julious, S. and Nicholl, J. A reinvestigation of recruitment to 
randomised, controlled, multicenter trials: a review of trials funded by two 
UK funding agencies. Trials 2013; 14, 166. 
 
Suresh, K. An overview of randomization techniques: An unbiased 
assessment of outcome in clinical research. Journal of Human 
Reproductive Sciences 2011; 4, 8-11. 
 
Swerdlow, S., Campo, E., Harris, N., Jaffe, E., Pileri, S., Stein, H., Thiele, 
J. and Vardiman, J., 2008. WHO Classification of Tumors of 
Hematopoietic and Lymphoid Tissues 4th Ed. (2008). IARC Publications. 
 
Swerdlow, S., Campo, E., Pileri, S., Harris, N., Stein, H., Siebert, R., 
Advani, R., Ghielmini, M., Salles, G.,  Zelenetz, A. and Jaffe, E. The 2016 
354 
 
revision of the World Health Organization classification of lymphoid 
neoplasms. Blood 2016; 127, 2375-2390. 
 
Tahhan, H., Holbrook, C., Braddy, L., Brewer, L. and Christie, J. Antigen-
matched donor blood in the transfusion management of patients with 
sickle cell disease. Transfusion 1994; 34, 562-569. 
 
Tanner, M. Molecular and cellular biology of the erythrocyte anion 
exchanger (AE1). Seminars in Hematology 1993; 30, 34-57. 
 
Teare, M., Dimairo, M., Shephard, N., Hayman, A., Whitehead, A. and 
Walters, S. Sample size requirements to estimate key design parameters 
from external pilot randomised controlled trials: a simulation study. 
BioMed Central; Trials 2014; 15, 264. 
 
Terasaki, P. and Mizutani, K. Antibody Mediated Rejection: Update 2006. 
Clinical Journal of the American Society of Nephrology 2006; 1, 400-403. 
 
 
The International Society of Blood Transfusion Red Cell Immunogenetics 
and Blood Group Terminology Working Party. 
http://www.isbtweb.org/working-parties/red-cell-immunogenetics-and-
terminology (accessed 03/12/2015). 
 
355 
 
Timura, G., Duman, A., Ongut, G. and Saka, O.  The Significance of 
Autoantibodies in Non-Hodgkin’s Lymphoma. Leukemia and Lymphoma. 
2000; 40, 119-122. 
 
Tournamille, C., Colin, Y., Cartron, J-P. and Le Van Kim, C. Disruption of 
a GATA motif in the Duffy gene promoter abolishes erythroid expression 
in Duffy-negative individuals. Nature Genetics 1995; 10, 224-228. 
 
Tournamille, C., Le Van Kim, C., Gane, P., Le Pennec, P., Roubinet, F., 
Babinet, J., Cartron, J-P. and Colin, Y. Arg89Cys substitution results in 
very low membrane expression of the Duffy antigen/receptor for 
chemokines in Fyx individuals. Blood 1998; 92, 2147-2156. 
 
Türkmen, T., Qiu, D., Cooper, N., Sachs, U. J., Wößmann, W., Schranz, 
D., Zimmer, K.-P., Ehrhardt, H., Hackstein, H. and Bein, G. (2017), Red 
blood cell alloimmunization in neonates and children up to 3 years of age. 
Transfusion, 57: 2720–2726. 
 
Van den Berghe, H. Morphologic, immunologic and cytogenetic (MIC) 
working classification of the acute myeloid leukaemias. British Journal of 
Haematology 1988; 68, 487-494. 
 
Van der Putten, K., Braam, B., Jie, K. and Gaillard, C. Mechanisms of 
Disease: erythropoietin resistance in patients with both heart and kidney 
failure. Nature Clinical Practice Nephrology 2008; 4, 47-57. 
356 
 
 
 
van Tol, M., Gerritsen, E., de Lange, G., van Leeuwen, A., Jol-van der 
Zijde, C., Oudeman-Gruber, N., de Vries, E., Radl, J. and Vossen, J. The 
origin of IgG production and homogeneous IgG components after 
allogeneic bone marrow transplantation. Blood 1996; 87, 818-826. 
 
Viitala, J. and Järnefelt, J. The red cell surface revisited. Trends in 
Biochemical Sciences 1985; 10, 392-395. 
 
Wagner, F., Flegel, W., Bittner, R. and Döscher, A. Molecular typing for 
blood group antigens within 40 min by direct polymerase chain reaction 
from plasma or serum. British Journal of Haematology 2017; 176, 814-
821.  
 
Walter, C. and Murphy, W. A closed gravity technique for the preservation 
of whole blood in ACD solution utilizing plastic equipment. Surgery, 
Gynecology & Obstetrics 1952; 94, 687-692. 
 
Weigle, W. The induction of autoimmunity in rabbits following injection of 
heterologous or altered homologous thyroglobulin. Journal of 
Experimental Medicine 1965; 121, 289-308. 
 
Weir, C and Lees, K. Comparison of stratification and adaptive methods 
for treatment allocation in an acute stroke clinical trial. Statistics in 
Medicine 2003; 22, 705-726. 
357 
 
 
Wiener, A. Genetic Theory of the Rh Blood Types. Experimental Biology 
and Medicine 1943, 54, 316-319. 
 
Wiener, A., Unger, L. and Cohen, L. Distribution and heredity of blood 
factor U. Science 1954; 119, 734-735. 
 
Westhoff, C. The structure and function of the Rh antigen complex. 
Seminars in Hematology, 2007; 44, 42-50. 
 
Westhoff, C. and Shaz, B. Kell and Kidd Blood Group Systems. 
Transfusion Medicine and Haemostasis (second edition) 2013. 
https://www.sciencedirect.com/topics/immunology-and-microbiology/kell-
antigen-system (accessed 11/02/2018). 
 
Winters, J., Pineda, A., Gorden, L., Bryant, S., Melton, J., Vamvakas, E. 
and Moore, S. RBC alloantibody specificity and antigen potency in 
Olmstead County, Minnesota. Transfusion 2001; 41, 1413-1420. 
 
Witherspoon, R., Schanfield, M., Storb, R., Thomas, E. and Giblett, E. 
Immunoglobulin production of donor origin after bone marrow 
transplantation for acute leukemia or aplastic anemia. Transplantation 
1978; 26, 407-408. 
 
358 
 
Woldie, I., Swerdlow, P., Bluth, M., Mohammad, U., Landolfi, E., 
Chaudrhy, S., Dyson, G. and O’Malley, B. Lifetime risk and 
characterization of red blood cell alloimmunization in chronically 
transfused patients with sickle cell disease. International Journal of Blood 
Transfusion and Immunohematology 2015; 5, 1-5. 
 
Woodrow, J and Donohoe, W. Rh-immunization by Pregnancy: Results of 
a Survey and Their Relevance to Prophylactic Therapy. British Medical 
Journal 1968; 4, 139-144. 
 
Yazer, M., Triulzi, D., Shaz, B., Kraus, T. and Zimring, J. Does a febrile 
reaction to platelets predispose recipients to red blood cell 
alloimmunization? Transfusion 2009; 49, 1070-1075. 
 
Zhu, X., Rivera, A., Golub, M., Peng, J., Sha, Q., Wu, X., Song, X., 
Kumarathasan, P., Ho, M., Redman, C. and Lee, S. Changes in red cell 
ion transport, reduced intratumoral neovascularization, and some mild 
motor function abnormalities accompany targeted disruption of the Mouse 
Kell gene (Kel). American Journal of Hematology 2009; 84, 492-498. 
 
Young, P., Uzielbo, A., Trulock, E., Lublin, D. and Goodnough, L. 
Autoantibody formation after alloimmunization: are blood transfusions a 
risk factor for autoimmune hemolytic anemia? Transfusion 2004; 44, 67 – 
72. 
 
359 
 
Yu, Y-B., Gau, J-P., You, J-Y., Chern, H-H., Chau, W-K., Tzeng, C-H., 
Ho, C-H. and Hsu, H-C. Cost-effectiveness of postremission intensive 
therapy in patients with acute leukaemia. Annals of Oncology 2007; 18, 
529-534. 
 
Zalpuri, S., Zwaginga, J., Cessie, S. Elhuis, J., Schonewille, H. and Van 
der Bom, J.   Red-blood-cell alloimmunization and number of red-blood-
cell transfusions. Vox Sanguinis 2012; 102, 144-149. 
 
Zalpuri, S., Evers, D., Zwaginga, J., Schonewille, H., de Vooght, K., le 
Cessie, S. and van der Bom, J. Immunosuppressants and 
alloimmunisation against red blood cell transfusions. Transfusion 2014; 
54, 1981-1987. 
 
Zelinski, T., Coghlan, G., Myal, Y., Shiu, R., Phillips, S., White, L. and 
Lewis, M.   Genetic linkage between the Kell blood group system and 
prolactin –inducible protein loci: provisional assignment of KEL to 
chromosome 7. Annals of Human Genetics 1991; 55, 137-140. 
 
Zhang, R. Modern Immunosuppressive Therapy in Kidney 
Transplantation. Open Journal of Organ Transplant Surgery 2013; 3, 22-
31. 
 
360 
 
Zheng, Y. and Maitta, R. Alloimmunisation rates of sickle cell disease 
patients in the United States differ from those in other geographical 
regions. Transfusion Medicine 2016; 26, 225-230. 
 
Zimring, J., Spitalnik, S., Roback, J. and Hillyer, C. Transfusion induced 
autoantibodies and differential immunogenicity of blood group antigens: a 
novel hypothesis. Transfusion 2007; 47, 2189-2196. 
 
 
1 | A p p e n d i x  
 
10 APPENDICES 
10.1 Appendix 1: Raw data for retrospective review of haematology cohort 
 
Key: N = No    M=Male 
 Y = Yes                 F=Female 
  
  
Diagnosis 
No. units 
transfused 
Alloimmunised 
at admission 
Alloimmunised 
post 
transfusion Gender 
No. 
transfusion 
episodes 
Age at first 
recorded 
transfusion 
Platelet 
requirement 
Irradiated 
requirement 
Anaemia of chronic disease 53 N N M 24 81 N N 
AIHA 17 N Y F 7 27 N N 
AIHA 49 N Y F 23 85 N N 
AIHA 4 N N M 1 66 N N 
AIHA 13 Y Y F 4 50 N N 
AIHA 7 N Y F 3 70 N Y 
AIHA 35 N Y F 14 60 N N 
AIHA 9 Y Y F 4 86 N N 
AITL 6 N Y M 3 81 Y Y 
AITL 15 Y Y M 7 74 Y Y 
ALL 3 N N F 1 44 Y N 
ALL 8 N N F 3 66 Y N 
ALL 11 N N F 6 72 Y N 
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Diagnosis 
No. units 
transfused 
Alloimmunised 
at admission 
Alloimmunised 
post 
transfusion Gender 
No. 
transfusion 
episodes 
Age at first 
recorded 
transfusion 
Platelet 
requirement 
Irradiated 
requirement 
ALL 46 N N F 20 54 Y Y 
ALL 38 N N M 12 38 Y Y 
ALL 27 N N F 12 75 Y N 
ALL 84 N N F 38 55 Y Y 
ALL 3 N N M 2 72 Y N 
ALL 92 N N M 43 41 Y Y 
ALL 35 N N M 17 23 Y N 
ALL 17 N N F 8 51 Y N 
ALL 8 N N M 4 84 N N 
ALL 76 N N M 31 66 Y N 
ALL 52 N N M 25 66 Y N 
AML 2 Y Y M 1 81 N Y 
AML 2 N N F 1 67 Y N 
AML 5 N N F 2 79 Y N 
AML 6 N N F 4 86 Y N 
AML 8 N N F 4 52 Y Y 
AML 9 N N M 3 80 N N 
AML 9 N N F 4 76 Y N 
AML 10 N N F 4 88 N N 
AML 11 N N F 4 62 Y N 
AML 11 N N M 5 51 Y Y 
AML 12 N Y F 6 71 Y N 
AML 14 N N M 7 60 Y N 
AML 17 N N M 7 55 Y Y 
AML 20 N N M 10 78 Y N 
AML 22 N N F 8 91 Y N 
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Diagnosis 
No. units 
transfused 
Alloimmunised 
at admission 
Alloimmunised 
post 
transfusion Gender 
No. 
transfusion 
episodes 
Age at first 
recorded 
transfusion 
Platelet 
requirement 
Irradiated 
requirement 
AML 23 N N M 10 76 Y N 
AML 25 N N F 11 69 Y N 
AML 28 Y Y M 13 79 Y Y 
AML 28 N N M 12 51 Y Y 
AML 30 N N M 16 37 Y Y 
AML 30 N N M 14 36 Y N 
AML 32 N N M 15 46 Y Y 
AML 35 N N M 15 37 Y Y 
AML 36 N N M 15 57 Y Y 
AML 37 N Y F 18 63 Y Y 
AML 37 N Y M 17 32 Y Y 
AML 41 N N F 15 73 Y N 
AML 43 N Y M 20 56 Y Y 
AML 47 N Y F 22 39 Y Y 
AML 48 N N M 23 69 Y N 
AML 59 N N F 28 71 Y N 
AML 61 N Y F 26 49 Y Y 
AML 64 N Y M 29 54 Y Y 
AML 64 N Y M 32 49 Y Y 
AML 64 N Y M 22 68 Y Y 
AML 66 N Y F 33 60 Y Y 
AML 73 N Y F 35 82 N N 
AML 75 N Y M 30 19 Y Y 
AML 79 N N F 36 56 Y Y 
AML 85 N N M 43 74 N N 
AML 168 N N F 79 51 Y Y 
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Diagnosis 
No. units 
transfused 
Alloimmunised 
at admission 
Alloimmunised 
post 
transfusion Gender 
No. 
transfusion 
episodes 
Age at first 
recorded 
transfusion 
Platelet 
requirement 
Irradiated 
requirement 
AML 53 N Y M 26 42 Y Y 
AML 51 N Y F 24 52 Y Y 
AML 144 N Y F 67 71 Y Y 
AML 14 N N F 7 73 N N 
AML 53 N N F 25 74 Y N 
AML 75 N Y M 34 63 Y Y 
AML 32 N N M 15 40 Y Y 
AML 8 N N F 4 89 N N 
AML 18 N N F 9 80 Y N 
AML 22 N N F 9 75 Y N 
AML 56 N N M 26 64 Y Y 
AML 52 N N F 26 50 Y Y 
AML 44 N N F 18 60 Y Y 
AML 13 N N M 6 62 Y Y 
AML 8 N N M 4 80 Y N 
AML 14 N N F 6 86 N N 
AML 80 N N F 35 64 Y Y 
AML 33 N N M 14 24 Y Y 
AML 31 N N F 15 57 Y N 
AML 4 N N F 2 55 N N 
AML 30 N N F 13 93 Y N 
AML 12 N N F 6 58 Y Y 
AML 15 N N M 7 82 N N 
AML 6 N Y F 3 74 N N 
AML 6 N N M 3 85 Y N 
AML 70 N N M 34 67 Y N 
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Diagnosis 
No. units 
transfused 
Alloimmunised 
at admission 
Alloimmunised 
post 
transfusion Gender 
No. 
transfusion 
episodes 
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transfusion 
Platelet 
requirement 
Irradiated 
requirement 
AML 79 N N M 34 67 Y N 
AML 13 N N M 5 61 Y N 
AML 14 N N M 6 76 N N 
AML 25 N N F 13 49 Y Y 
AML 80 N Y F 33 67 Y N 
AML 94 N Y M 46 56 Y Y 
AML 53 N Y F 25 56 Y Y 
AML 94 N N M 39 81 Y N 
AML 89 N N F 43 63 Y Y 
AML 42 N Y F 18 59 Y N 
AML 33 N N M 16 34 Y Y 
AML 17 N N M 7 67 Y N 
AML 39 N N M 18 78 N N 
AML 44 N N M 19 77 Y N 
AML 30 N Y F 13 65 Y N 
AML 22 N N M 10 61 Y Y 
AML 112 N N F 54 52 Y Y 
AML 34 N N F 16 75 Y N 
AML 33 N N M 16 70 Y N 
AML 85 N N F 42 54 Y Y 
AML 42 N N M 21 71 Y N 
AML 39 N N F 18 55 Y Y 
AML 69 N N F 29 30 N Y 
AML 41 N N F 19 24 Y Y 
AML 53 N Y F 25 51 Y Y 
AML 28 N N M 10 76 Y Y 
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transfusion 
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Irradiated 
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AML 27 N N F 12 74 Y Y 
AML 31 N N M 17 64 Y N 
AML 18 N N F 9 83 Y N 
AML 10 N N F 4 83 Y N 
AML 33 N N M 15 45 Y Y 
AML 44 N N M 21 89 Y N 
AML 21 N N M 10 70 Y N 
AML 68 N N M 30 73 N N 
AML 10 N N F 5 76 Y Y 
AML 29 N N F 14 75 Y N 
AML 28 N N M 13 65 Y N 
AML 54 N N M 25 69 Y N 
AML 10 N N F 4 72 N N 
AML 35 N N F 17 54 Y N 
AML 52 N N M 25 59 Y Y 
AML 22 N N M 11 81 Y N 
AML 157 N Y M 72 58 Y N 
AML 104 Y Y F 53 66 Y Y 
AML 40 N Y M 18 66 Y N 
AML 15 N N F 6 84 Y N 
AML 28 N N M 11 74 Y N 
AML 10 N N F 6 63 Y Y 
AML 10 N N F 4 48 Y Y 
AML 42 N N F 21 67 Y Y 
AML 166 N N M 63 71 Y N 
AML 4 N N F 2 69 Y N 
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Irradiated 
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AML 18 N Y F 8 60 N N 
AML 51 N N M 21 75 Y N 
AML 38 N N F 17 60 Y Y 
AML 4 N N F 2 70 Y N 
AML 53 N N F 24 54 Y Y 
AML 115 N N M 47 59 Y Y 
AML 26 N N M 9 84 Y N 
AML 23 N N F 12 58 Y N 
AML 27 N Y F 14 72 Y N 
AML 62 N N M 30 73 Y Y 
AML 61 N Y F 26 73 Y Y 
AML 88 N N M 39 67 Y Y 
AML 2 N N M 1 78 N N 
AML 18 N N F 9 65 Y Y 
AML 43 N N F 21 18 Y N 
AML 36 N N F 17 74 Y N 
AML 50 N Y M 23 61 Y Y 
AML 36 N Y M 17 81 Y N 
AML 31 N N M 13 68 Y Y 
AML 2 N N F 1 79 Y N 
AML 22 N N F 11 61 Y N 
AML 20 N Y F 10 75 Y N 
AML 28 N N F 14 76 Y Y 
AML 36 N N F 16 66 Y N 
AML 48 N Y F 23 84 Y N 
AML 65 N N F 29 69 Y N 
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Platelet 
requirement 
Irradiated 
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AMML 8 N N M 4 85 Y N 
AMYLOID 4 N N F 2 48 N N 
AMYLOID 47 N N M 10 31 Y Y 
AMYLOID 72 N Y F 36 55 N N 
AMYLOID 4 N N F 2 49 N N 
ANAEMIA 7 N N F 2 45 N N 
ANAEMIA 80 N Y M 53 42 N N 
ANAEMIA 60 N N M 21 71 N N 
ANAEMIA 2 N N F 1 62 N N 
ANAEMIA 6 N N F 3 41 N N 
ANAEMIA 32 N Y F 13 74 N N 
ANAEMIA 2 N N F 1 48 N N 
ANAEMIA 4 N N F 2 74 N N 
ANAEMIA 5 N N F 2 59 N N 
ANAEMIA 34 N N F 13 71 N N 
ANAEMIA 19 N N M 7 79 N N 
ANAEMIA 6 N N M 2 80 N N 
ANAEMIA 2 N N F 1 99 N N 
ANAEMIA 9 N N F 4 83 N N 
ANAEMIA 2 N N M 1 83 N N 
ANAEMIA 2 N N F 1 40 N Y 
ANAEMIA 6 N N F 3 81 N N 
ANAEMIA 16 N N F 8 73 N N 
APLASTIC 15 N N F 10 22 Y Y 
APLASTIC 19 N Y F 9 87 Y N 
APLASTIC 36 N Y M 14 26 Y Y 
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Platelet 
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APLASTIC 63 N Y F 31 86 Y N 
APLASTIC 107 N Y M 52 57 Y Y 
APLASTIC 26 N N M 13 27 Y N 
APLASTIC 10 N N M 3 80 N N 
APLASTIC 68 N Y F 30 27 Y Y 
APLASTIC 4 N N M 2 64 N Y 
APLASTIC 93 N Y F 44 58 N N 
APLASTIC 9 N N F 4 33 N N 
APLASTIC 88 N Y F 43 69 Y N 
APLASTIC 57 N Y F 29 79 Y N 
APLASTIC 9 Y Y M 4 53 N N 
APML 15 N N M 7 44 Y Y 
Autoimmune Neutropenia 6 N N F 3 80 N N 
B-Cell Lymphoma 26 N N M 12 67 Y N 
Cancer (solid organ) 5 N N M 2 71 N N 
Cancer (solid organ) 7 N Y F 3 60 N N 
Cancer (solid organ) 7 N N F 2 80 N N 
Cancer (solid organ) 7 N N F 4 36 N N 
Cancer (solid organ) 7 N N F 4 49 Y Y 
Cancer (solid organ) 8 Y Y M 3 53 N N 
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Cancer (solid organ) 8 N N F 2 54 N N 
Cancer (solid organ) 9 N N F 4 49 N N 
Cancer (solid organ) 11 N Y F 5 45 N N 
Cancer (solid organ) 12 N Y F 5 79 N N 
Cancer (solid organ) 23 N N M 10 82 N N 
Cancer (solid organ) 25 N N M 11 85 N N 
Cancer (solid organ) 35 N N F 14 46 N N 
Cancer (solid organ) 5 N N F 2 53 N N 
Cancer (solid organ) 5 N N M 2 82 N N 
Cancer (solid organ) 8 N N M 4 68 Y N 
Cancer (solid organ) 16 N N F 7 56 N N 
Cancer (solid organ) 20 N N F 9 35 N N 
Cancer (solid organ) 11 N N M 6 85 Y N 
Cancer (solid organ) 7 N N F 2 52 N N 
Cancer (solid organ) 14 N N M 6 66 N N 
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transfusion 
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Cancer (solid organ) 3 N N F 2 65 N N 
Cancer (solid organ) 2 N N M 1 63 N N 
Cancer (solid organ) 8 N Y F 3 45 N N 
Cancer (solid organ) 32 Y Y F 12 65 N N 
Cancer (solid organ) 6 N N M 3 87 N N 
Cancer (solid organ) 2 N N F 1 59 N N 
Cancer (solid organ) 2 N N F 1 48 N N 
Cancer (solid organ) 2 N N F 1 63 N N 
Cancer (solid organ) 5 N N M 2 75 N N 
Cancer (solid organ) 2 N N F 1 75 N N 
Cancer (solid organ) 25 N N M 10 77 N N 
Cancer (solid organ) 3 N N F 1 75 N N 
Cancer (solid organ) 4 N N M 2 77 N N 
Cancer (solid organ) 23 N Y F 9 63 N N 
Cancer (solid organ) 10 N N F 3 31 N N 
12 | A p p e n d i x  
 
Diagnosis 
No. units 
transfused 
Alloimmunised 
at admission 
Alloimmunised 
post 
transfusion Gender 
No. 
transfusion 
episodes 
Age at first 
recorded 
transfusion 
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Irradiated 
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Cancer (solid organ) 2 N N F 1 61 Y N 
Cancer (solid organ) 2 N N F 1 51 N N 
Cancer (solid organ) 9 N N M 4 74 N N 
Cancer (solid organ) 6 N N F 3 66 Y N 
Cancer (solid organ) 2 N N F 1 49 N N 
Cancer (solid organ) 19 N N M 9 76 N N 
Cancer (solid organ) 25 N N M 10 74 N N 
Cancer (solid organ) 21 N N F 9 70 N N 
Cancer (solid organ) 17 N N M 8 61 N N 
Cancer (solid organ) 12 N N M 6 75 N N 
Cancer (solid organ) 19 N Y M 9 51 Y M 
Cancer (solid organ) 54 N Y M 20 80 N N 
Cancer (solid organ) 14 N Y M 7 69 Y N 
Cancer (solid organ) 13 N N M 6 72 Y N 
Cancer (solid organ) 6 N N F 3 82 N N 
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Cancer (solid organ) 23 N N M 8 75 N N 
Cancer (solid organ) 6 N N F 3 69 N N 
Cancer (solid organ) 14 N N M 7 89 N N 
CLL 2 N N M 1 78 N Y 
CLL 2 N N F 1 74 N N 
CLL 4 N N F 1 53 Y N 
CLL 6 N Y F 3 88 N N 
CLL 6 N N F 3 84 N N 
CLL 6 N N M 3 78 Y N 
CLL 7 N N M 3 91 Y N 
CLL 10 N N F 3 84 N N 
CLL 11 N N M 4 85 N N 
CLL 16 N Y M 6 72 N Y 
CLL 17 N N M 9 90 Y N 
CLL 21 N Y M 10 93 Y N 
CLL 65 N N F 27 78 Y N 
CLL 22 N N F 11 65 N Y 
CLL 11 N N M 5 93 N N 
CLL 5 N N M 2 84 N Y 
CLL 10 N N M 5 82 N N 
CLL 10 N N F 5 63 Y Y 
CLL 12 N N M 6 71 N Y 
CLL 7 N N F 3 86 N N 
CLL 11 Y Y M 4 75 Y Y 
CLL 1 N N F 1 91 N N 
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CLL 8 N Y F 3 88 N N 
CLL 7 N N M 3 78 N Y 
CLL 15 Y Y F 7 75 N N 
CLL 36 N Y M 15 68 Y Y 
CLL 44 N N M 20 63 Y Y 
CLL 8 N Y F 4 67 N N 
CLL 39 N N M 19 71 Y Y 
CLL 212 N Y M 87 68 Y Y 
CLL 16 N N M 8 77 N Y 
CLL 18 N Y M 5 70 Y Y 
CLL 30 N Y M 15 69 Y Y 
CLL 6 N N M 3 86 N N 
CLL 14 Y Y M 6 72 N Y 
CLL 2 N N M 1 91 N Y 
CLL 5 Y Y M 2 83 N N 
CLL 6 N N M 3 86 N Y 
CLL 11 N Y M 5 73 N Y 
CLL 34 N Y M 17 76 Y N 
CLL 4 Y Y F 2 83 N N 
CLL 9 N N M 4 83 N N 
CLL 12 Y Y F 5 78 N N 
CLL 3 Y Y F 1 87 N N 
CLL 10 N Y M 4 79 N Y 
CLL 2 N N M 1 68 N Y 
CLL 4 Y Y M 2 66 N N 
CLL 10 N N F 5 79 N Y 
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CLL 11 N N F 4 74 Y Y 
CLL 18 N Y F 9 89 N N 
CLL 19 N N M 7 69 Y Y 
CLL 52 N N M 24 75 Y Y 
CLL 46 Y Y F 18 62 N Y 
CLL 4 N N M 2 81 N N 
CLL 33 N N M 17 64 Y Y 
CLL 19 N N M 11 92 N N 
CLL 9 N N M 4 76 N N 
CML 24 N N F 11 85 N N 
CML 45 N N M 20 61 Y Y 
CML 22 N Y F 10 73 N N 
CML 7 N N F 3 73 N N 
CML 9 N N M 3 74 Y N 
CML 10 N Y F 4 86 N N 
CML 44 N Y F 19 74 N N 
CML 10 N N M 5 39 Y Y 
CML 2 Y Y M 1 62 N N 
CML 40 N N F 22 63 Y Y 
CML 4 N N F 2 73 N N 
CMML 2 N N F 1 66 Y N 
CMML 5 N N F 2 90 N N 
CMML 37 N N M 25 73 Y N 
CMML 37 N N M 16 82 Y N 
CMML 28 N Y M 12 70 N N 
CMML 63 N N M 29 76 Y N 
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CMML 18 N N M 7 70 Y N 
CMML 11 N Y M 36 77 N N 
CMML 20 N N M 10 70 N N 
Cold Haemagglutinin Diease 12 Y Y F 6 73 N N 
Cold Haemagglutinin Diease 2 Y Y M 1 76 N N 
CRF 6 N N F 2 75 N N 
CRF 12 N Y M 6 83 N N 
CRF 32 N Y F 13 74 N N 
CRF 28 N N F 9 86 N N 
CRF 22 N N F 10 76 N N 
CRF 6 N N M 2 80 N N 
CRF 23 N Y F 9 81 N N 
Diamond Blackfan Anaemia 382 N Y F 147 13 N N 
Diffuse large B –cell 
lymphoma 36 N N M 17 59 Y Y 
Essential thrombocythaemia  4 N N M 2 73 N N 
Essential thrombocythaemia  8 N N M 4 85 N N 
Essential thrombocythaemia  6 N N M 2 75 Y N 
Essential thrombocythaemia  40 N N F 15 79 Y N 
Essential thrombocythaemia  4 N N M 2 68 N N 
Essential thrombocythaemia  5 N N F 2 74 N N 
F IX DEF 13 N N M 5 77 Y N 
Haemolytic anaemia 19 N Y F 7 76 N N 
Hairy cell leukaemia 2 N N M 1 60 N Y 
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transfusion 
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Hairy cell leukaemia 14 N N M 7 68 N Y 
Hairy cell leukaemia 6 N N M 3 66 N Y 
Hairy cell leukaemia 6 N N M 3 79 Y Y 
Hairy cell leukaemia 2 N Y M 1 76 N Y 
Hodgkin's lymphoma 2 N N F 1 32 N Y 
Hodgkin's lymphoma 2 N N F 1 22 N Y 
Hodgkin's lymphoma 4 N N F 3 36 Y Y 
Hodgkin's lymphoma 5 N N F 2 76 N Y 
Hodgkin's lymphoma 6 N N F 3 34 N Y 
Hodgkin's lymphoma 6 N N M 3 21 Y Y 
Hodgkin's lymphoma 6 N N F 3 26 N Y 
Hodgkin's lymphoma 10 N N F 6 63 N Y 
Hodgkin's lymphoma 13 N N M 6 37 Y Y 
Hodgkin's lymphoma 2 N N F 1 93 N Y 
Hodgkin's lymphoma 5 N N F 2 31 N Y 
Hodgkin's lymphoma 13 N N M 6 74 N Y 
Hodgkin's lymphoma 8 N N M 4 54 N Y 
Hodgkin's lymphoma 8 N N M 4 63 N Y 
Hodgkin's lymphoma 4 N N M 2 63 N Y 
18 | A p p e n d i x  
 
Diagnosis 
No. units 
transfused 
Alloimmunised 
at admission 
Alloimmunised 
post 
transfusion Gender 
No. 
transfusion 
episodes 
Age at first 
recorded 
transfusion 
Platelet 
requirement 
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Hodgkin's lymphoma 4 N N M 2 59 N Y 
Hodgkin's lymphoma 2 N N F 1 81 N Y 
Hodgkin's lymphoma 10 N N M 5 85 N Y 
Hodgkin's lymphoma 10 N N F 5 70 Y Y 
Hodgkin's lymphoma 10 N N M 5 77 N Y 
Hodgkin's lymphoma 6 N N F 3 67 N Y 
Hodgkin's lymphoma 30 Y Y M 15 41 Y Y 
Hodgkin's lymphoma 19 N N M 9 72 N N 
Hodgkin's lymphoma 6 N N M 3 81 N Y 
Hodgkin's lymphoma 2 N N F 1 52 N Y 
Hodgkin's lymphoma 2 N N F 1 70 N Y 
Hodgkin's lymphoma 4 N N F 2 68 N N 
Hodgkin's lymphoma 4 N N M 2 29 Y Y 
Hodgkin's lymphoma 50 N Y F 24 56 Y Y 
ITP 8 N N M 2 68 Y N 
ITP 9 Y Y M 4 69 Y N 
ITP 4 N Y F 2 82 N N 
ITP 19 N N M 6 84 N N 
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ITP 4 N N F 2 72 Y N 
ITP 6 N N M 2 64 Y N 
ITP 4 N N M 2 82 N N 
LEA 4 N N F 2 97 N N 
Lymphoma 2 Y Y M 1 86 Y N 
Lymphoma 2 N N M 1 81 N N 
Lymphoma 2 N N F 1 87 N N 
Lymphoma 3 N N F 1 26 N N 
Lymphoma 5 N N M 3 45 Y Y 
Lymphoma 8 N N M 4 59 Y Y 
Lymphoma 10 N N M 5 75 Y N 
Lymphoma 12 N Y M 6 77 N N 
Lymphoma 17 N N M 8 68 Y Y 
Lymphoma 20 N N M 10 81 Y N 
Lymphoma 21 Y Y M 8 46 Y Y 
Lymphoma 28 N N M 11 63 Y Y 
Lymphoma 30 N N F 13 62 Y Y 
Lymphoma 20 N N M 10 70 Y Y 
Lymphoma 15 N N F 8 79 N N 
Lymphoma 6 N N M 3 51 Y N 
Lymphoma 5 N N M 2 62 N N 
Lymphoma 6 N N M 3 74 Y N 
Lymphoma 6 N N M 3 69 N N 
Lymphoma 25 N N M 12 61 N Y 
Lymphoma 20 Y Y F 8 70 N Y 
Lymphoma 12 N N M 5 87 Y N 
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Lymphoma 4 N N F 2 79 N N 
Lymphoma 7 N N F 3 87 N N 
Lymphoma 12 N N F 6 57 Y N 
Lymphoma 3 N N F 2 78 N N 
Lymphoma 11 N N F 7 64 Y Y 
Lymphoma 10 N N F 5 86 N N 
Lymphoma 3 Y Y M 1 82 N N 
Lymphoma 22 N N F 11 18 Y Y 
Lymphoma 4 Y Y F 2 71 N N 
Lymphoma 58 N Y M 24 43 Y Y 
Lymphoma 13 N N F 5 59 N N 
Lymphoma 4 N N M 2 56 Y Y 
Lymphoma 13 N N F 6 69 N N 
Lymphoma 2 N N M 1 69 Y N 
Lymphoma 51 N Y M 23 83 N Y 
Lymphoma 4 N N F 2 76 N N 
Lymphoma 4 N N M 2 79 N Y 
Lymphoma 4 N N F 2 67 Y Y 
Lymphoma 4 N N F 2 87 N Y 
Lymphoma 13 N Y M 6 82 N N 
Lymphoma 2 N N M 1 70 N N 
Lymphoma 4 N N F 2 78 N N 
Lymphoma 21 N N F 10 61 N Y 
Lymphoma 28 N N F 14 67 N N 
Lymphoma 4 N N F 2 85 N N 
Lymphoma 6 N Y F 3 70 N N 
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Lymphoma 4 N N F 2 87 Y N 
Lymphoma 10 Y Y F 5 84 N N 
Lymphoma 2 N N M 1 82 Y N 
Lymphoma 19 N N M 8 63 N Y 
Lymphoma 18 N N M 9 67 Y Y 
Mantle cell lymphoma 2 N N M 1 62 Y Y 
MDS 5 N Y F 2 94 N N 
MDS 5 N N M 2 86 N N 
MDS 8 N N F 3 80 N N 
MDS 8 N N F 3 48 N N 
MDS 8 N N M 2 93 N N 
MDS 8 N N F 4 53 Y Y 
MDS 13 N Y M 6 85 Y Y 
MDS 13 N N F 6 85 N N 
MDS 14 N N F 7 85 Y N 
MDS 21 N N M 6 80 Y N 
MDS 25 N N M 10 67 Y N 
MDS 30 N Y M 14 84 Y N 
MDS 35 N N F 46 90 N N 
MDS 39 N Y M 18 95 N N 
MDS 41 N N F 14 76 N N 
MDS 43 N N F 19 77 N N 
MDS 59 N N M 23 82 Y N 
MDS 67 N N F 32 86 N N 
MDS 70 N N M 27 73 Y N 
MDS 74 N N F 33 85 Y N 
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MDS 80 N N F 42 89 Y N 
MDS 114 N Y M 48 67 Y N 
MDS 184 N Y F 61 88 N N 
MDS 209 N N F 75 72 Y N 
MDS 256 N Y F 94 25 N N 
MDS 310 N Y F 101 75 Y N 
MDS 338 N N M 120 69 Y N 
MDS 183 N N F 77 73 N Y 
MDS 7 N N F 3 85 N N 
MDS 8 N N M 4 97 Y N 
MDS 15 N N F 6 86 N N 
MDS 15 N Y F 6 73 Y N 
MDS 53 N N M 23 68 Y Y 
MDS 28 N N M 12 89 N N 
MDS 16 N N F 8 71 N N 
MDS 16 N N F 7 86 Y N 
MDS 12 N N M 6 71 Y N 
MDS 19 N N F 10 74 N N 
MDS 6 N N F 3 72 N N 
MDS 4 N N M 2 80 N N 
MDS 92 N N M 37 82 N N 
MDS 30 N N F 15 80 N Y 
MDS 109 N N M 51 74 Y N 
MDS 40 N Y M 16 76 N N 
MDS 45 N N M 22 85 Y N 
MDS 63 N N M 30 77 N N 
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MDS 50 N N M 23 68 N Y 
MDS 32 N N F 10 59 N N 
MDS 2 N N F 1 88 N N 
MDS 18 Y Y M 9 81 Y N 
MDS 7 N N M 3 85 N N 
MDS 58 N N M 25 76 Y N 
MDS 135 N N F 55 80 N N 
MDS 2 N N F 1 71 N Y 
MDS 111 N N F 54 83 N N 
MDS 94 N Y F 36 80 N N 
MDS 61 N N F 21 74 N N 
MDS 38 N N M 19 65 Y N 
MDS 37 N N M 18 50 Y Y 
MDS 24 N N F 12 82 Y N 
MDS 32 N N F 15 87 N N 
MDS 224 N N M 87 62 Y N 
MDS 66 N Y M 30 79 N N 
MDS 143 N Y M 58 72 Y N 
MDS 119 N N M 40 79 N N 
MDS 10 N N M 5 73 N N 
MDS 15 Y Y F 7 82 N Y 
MDS 94 N N M 38 88 N N 
MDS 20 N N M 8 68 N N 
MDS 49 N N M 19 67 Y N 
MDS 332 N Y M 155 69 Y Y 
MDS 20 N N M 9 81 N N 
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MDS 67 N N M 28 68 N N 
MDS 51 N N M 23 78 N Y 
MDS 28 N N F 11 80 Y N 
MDS 4 N N M 2 96 Y N 
MDS 32 N N F 14 27 Y N 
MDS 7 N N F 4 71 N N 
MDS 6 N N M 3 83 Y Y 
MDS 60 N Y M 27 84 N N 
MDS 287 N N M 124 76 Y N 
MDS 43 N N M 15 88 N N 
MDS 10 N N M 5 78 N N 
MDS 45 N Y M 22 83 Y N 
MDS 226 N Y M 81 60 Y Y 
MDS 3 N N M 1 81 Y N 
MDS 21 N N M 10 75 Y N 
MDS 35 N N F 14 82 N N 
MDS 6 N N M 2 85 N N 
MDS 33 N Y M 17 91 N N 
MDS 10 N N M 4 82 N N 
MDS 83 N N M 31 86 N N 
MDS 14 N N M 7 65 N N 
MDS 11 N N M 6 42 Y N 
MDS 33 N Y M 16 79 N N 
MDS 29 N Y M 13 76 Y N 
MDS 119 N N F 60 75 N Y 
MDS 69 N Y M 25 90 N N 
25 | A p p e n d i x  
 
Diagnosis 
No. units 
transfused 
Alloimmunised 
at admission 
Alloimmunised 
post 
transfusion Gender 
No. 
transfusion 
episodes 
Age at first 
recorded 
transfusion 
Platelet 
requirement 
Irradiated 
requirement 
MDS 19 N N M 6 57 Y N 
MDS 16 N Y M 7 74 N N 
MDS 53 N N F 24 78 Y N 
MDS 52 N Y M 22 78 N N 
MDS 70 N Y F 25 84 Y N 
MDS 38 N N M 19 92 N N 
MDS 47 N N M 21 72 N N 
MDS 35 N Y M 16 79 Y N 
MDS 2 N N M 1 85 Y N 
MDS 18 N N M 9 81 Y N 
MDS 32 N N F 14 88 Y N 
MDS 14 N N F 6 80 N N 
MDS 61 N Y M 27 67 Y N 
MDS 21 N N F 7 77 Y N 
MDS 34 N Y M 17 74 Y N 
MDS 124 N N M 60 81 Y N 
MDS 9 N N M 5 87 N N 
MDS 5 N N F 2 82 N N 
MDS 19 N N M 9 89 N N 
MDS 52 N Y F 24 74 Y N 
MDS 24 N Y M 14 76 N N 
MDS 22 N N M 11 83 Y N 
MDS 166 N Y F 59 85 N N 
MDS 30 Y Y M 15 70 Y N 
MDS 29 N N M 15 74 Y N 
MDS 11 N N F 5 73 Y Y 
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Diagnosis 
No. units 
transfused 
Alloimmunised 
at admission 
Alloimmunised 
post 
transfusion Gender 
No. 
transfusion 
episodes 
Age at first 
recorded 
transfusion 
Platelet 
requirement 
Irradiated 
requirement 
MDS 14 N N M 7 85 N N 
MDS 20 N Y F 7 80 N N 
MDS 140 N Y F 63 87 Y N 
MDS 12 N N M 6 85 N N 
MDS 10 N N F 5 75 N N 
MDS 4 N N F 2 66 N N 
MDS 154 Y Y F 62 84 N N 
MDS 14 N Y F 5 75 Y N 
MDS 119 N Y M 45 89 N N 
MDS 21 N N M 9 84 Y N 
MDS 69 N Y F 29 63 Y Y 
MDS 11 N N M 5 88 N N 
MDS 25 N Y F 11 65 N N 
MDS 16 N Y M 6 81 N Y 
MDS 32 N Y F 16 81 N N 
MDS 5 N N F 2 63 Y N 
MDS 6 N N M 3 83 N N 
MDS 8 N N M 3 79 N N 
MDS 179 N Y F 70 84 Y N 
MDS 7 N N F 3 78 N N 
MDS 17 N N F 4 77 Y N 
MDS 110 N N M 39 90 N N 
MDS 8 N N M 5 93 N N 
MDS 10 N N F 4 80 N N 
MDS 22 N Y M 10 69 Y Y 
MDS 62 N N M 27 90 N N 
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Diagnosis 
No. units 
transfused 
Alloimmunised 
at admission 
Alloimmunised 
post 
transfusion Gender 
No. 
transfusion 
episodes 
Age at first 
recorded 
transfusion 
Platelet 
requirement 
Irradiated 
requirement 
MDS/AML 11 N Y M 5 77 Y N 
MF 14 N N M 5 81 N N 
MF 202 N Y M 83 69 Y Y 
MF 17 N N F 8 67 Y N 
MF 12 N N M 5 82 Y N 
MF 80 N N M 37 68 N N 
MF 33 Y Y F 11 80 N N 
MF 10 N N F 5 82 N N 
MF 17 N N F 11 72 Y N 
MF 34 N N F 17 72 N N 
MF 3 N N M 1 52 N N 
MF 4 N N M 2 83 N N 
MF 132 Y Y M 46 77 N N 
MF 24 Y Y F 12 74 N N 
MF 73 N N M 28 64 Y N 
MF 134 N Y F 61 61 Y N 
MF 26 N N M 10 66 Y N 
MF 18 Y Y F 8 61 Y Y 
MF 151 N N F 53 73 N N 
MF 48 N N F 24 59 N N 
MPD 55 Y Y M 22 52 Y Y 
MPD 33 N N F 11 64 N N 
MPD 11 N N M 4 84 N N 
MPD 6 N N F 3 74 N N 
Myeloma 2 N Y M 1 66 Y Y 
Myeloma 2 N N M 1 58 Y Y 
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Diagnosis 
No. units 
transfused 
Alloimmunised 
at admission 
Alloimmunised 
post 
transfusion Gender 
No. 
transfusion 
episodes 
Age at first 
recorded 
transfusion 
Platelet 
requirement 
Irradiated 
requirement 
Myeloma 2 N N M 2 76 N N 
Myeloma 2 N N M 1 81 N N 
Myeloma 3 N N F 1 80 N N 
Myeloma 3 N N M 1 58 Y Y 
Myeloma 4 N N F 2 71 N N 
Myeloma 4 N N M 2 88 N N 
Myeloma 4 N N M 2 61 N Y 
Myeloma 4 N N M 2 75 Y N 
Myeloma 4 N N M 2 89 N N 
Myeloma 4 N N M 2 56 N N 
Myeloma 4 N N F 2 82 N N 
Myeloma 4 N N F 2 75 N N 
Myeloma 4 N N F 2 54 Y Y 
Myeloma 4 N N M 11 64 Y Y 
Myeloma 6 N Y F 3 82 N N 
Myeloma 6 N N F 3 74 N N 
Myeloma 6 N N F 3 65 N N 
Myeloma 6 N N F 3 55 Y Y 
Myeloma 7 N N M 3 58 Y Y 
Myeloma 8 N N M 4 64 Y Y 
Myeloma 8 N N F 3 85 N N 
Myeloma 9 Y Y F 4 76 N N 
Myeloma 9 N Y F 3 84 N N 
Myeloma 9 N N F 4 83 N N 
Myeloma 10 N Y F 5 60 Y Y 
Myeloma 10 N Y M 5 61 Y Y 
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Diagnosis 
No. units 
transfused 
Alloimmunised 
at admission 
Alloimmunised 
post 
transfusion Gender 
No. 
transfusion 
episodes 
Age at first 
recorded 
transfusion 
Platelet 
requirement 
Irradiated 
requirement 
Myeloma 10 N N F 5 86 N N 
Myeloma 10 N N F 5 57 Y Y 
Myeloma 11 N Y F 6 75 N N 
Myeloma 12 N N F 6 61 Y Y 
Myeloma 12 N N F 6 51 Y Y 
Myeloma 12 N N M 7 72 Y N 
Myeloma 14 N N M 6 49 N Y 
Myeloma 16 N Y F 8 68 Y N 
Myeloma 16 N N M 7 78 Y N 
Myeloma 19 N N F 8 62 N Y 
Myeloma 20 Y Y M 11 56 Y Y 
Myeloma 20 N N F 9 75 Y N 
Myeloma 20 N N F 10 65 Y N 
Myeloma 21 N Y F 10 53 Y Y 
Myeloma 22 N Y M 10 71 Y N 
Myeloma 22 N N M 10 48 Y N 
Myeloma 23 N N F 10 75 N N 
Myeloma 23 N N M 11 68 N N 
Myeloma 24 N N F 10 70 Y N 
Myeloma 25 N N F 11 69 Y N 
Myeloma 26 N N F 12 89 N N 
Myeloma 26 N N F 14 93 N N 
Myeloma 29 N N M 14 62 Y N 
Myeloma 33 N N M 15 60 Y Y 
Myeloma 33 N N M 15 78 N N 
Myeloma 35 N Y F 20 75 Y N 
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No. units 
transfused 
Alloimmunised 
at admission 
Alloimmunised 
post 
transfusion Gender 
No. 
transfusion 
episodes 
Age at first 
recorded 
transfusion 
Platelet 
requirement 
Irradiated 
requirement 
Myeloma 35 N N F 6 61 Y N 
Myeloma 37 N N F 19 78 Y N 
Myeloma 37 N N M 16 83 Y N 
Myeloma 40 N N F 17 84 N N 
Myeloma 41 N Y M 16 71 N N 
Myeloma 47 N N M 22 74 Y N 
Myeloma 52 N N M 27 58 Y Y 
Myeloma 53 N Y F 35 52 Y Y 
Myeloma 55 N N M 21 61 Y Y 
Myeloma 56 N N F 26 50 Y Y 
Myeloma 57 N N F 24 78 N N 
Myeloma 66 N N F 32 49 Y N 
Myeloma 66 N N M 32 51 Y Y 
Myeloma 67 N N F 25 63 N N 
Myeloma 76 N N F 37 56 Y Y 
Myeloma 83 N N M 42 62 Y Y 
Myeloma 98 N N M 35 82 N N 
Myeloma 180 N Y M 81 48 Y Y 
Myeloma 23 N N F 11 70 Y N 
Myeloma 3 N N F 1 76 N N 
Myeloma 15 N N F 8 94 N N 
Myeloma 17 N N F 9 68 Y Y 
Myeloma 21 N N F 9 50 Y Y 
Myeloma 4 N N M 2 78 N N 
Myeloma 57 N N F 27 57 Y N 
Myeloma 4 N N F 2 63 N N 
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Diagnosis 
No. units 
transfused 
Alloimmunised 
at admission 
Alloimmunised 
post 
transfusion Gender 
No. 
transfusion 
episodes 
Age at first 
recorded 
transfusion 
Platelet 
requirement 
Irradiated 
requirement 
Myeloma 12 N N F 6 77 N N 
Myeloma 21 N N M 11 69 N N 
Myeloma 4 N N F 2 62 Y Y 
Myeloma 21 N N F 9 80 Y N 
Myeloma 4 N N M 2 72 N N 
Myeloma 21 N Y F 10 49 Y Y 
Myeloma 16 N N M 8 48 Y Y 
Myeloma 130 N N M 49 80 Y N 
Myeloma 13 N Y F 5 83 N N 
Myeloma 12 N N M 6 64 Y Y 
Myeloma 8 N N M 4 75 N N 
Myeloma 8 N N M 4 62 Y N 
Myeloma 106 N N F 51 70 N N 
Myeloma 3 N N F 1 82 N N 
Myeloma 48 N N F 20 72 Y N 
Myeloma 39 N Y M 18 76 N N 
Myeloma 26 N N M 12 56 Y Y 
Myeloma 51 N N M 21 68 Y Y 
Myeloma 14 N N F 7 68 Y Y 
Myeloma 11 N N F 6 71 N N 
Myeloma 8 N N F 4 79 N N 
Myeloma 124 N Y F 61 49 Y Y 
Myeloma 29 N N F 14 74 N N 
Myeloma 4 N N M 2 81 N N 
Myeloma 169 N N F 64 75 Y N 
Myeloma 27 N N F 14 71 N N 
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Diagnosis 
No. units 
transfused 
Alloimmunised 
at admission 
Alloimmunised 
post 
transfusion Gender 
No. 
transfusion 
episodes 
Age at first 
recorded 
transfusion 
Platelet 
requirement 
Irradiated 
requirement 
Myeloma 2 N N M 1 81 N N 
Myeloma 51 N N M 26 78 N N 
Myeloma 55 Y Y F 34 52 Y Y 
Myeloma 13 N Y F 6 84 N N 
Myeloma 4 N N M 2 80 N N 
Myeloma 39 N N F 19 78 Y N 
Myeloma 36 N N M 16 60 Y Y 
Myeloma 7 N N M 4 63 N N 
Myeloma 43 N N M 20 57 Y Y 
Myeloma 134 N N M 66 50 Y Y 
Myeloma 6 N N M 3 79 N N 
Myeloma 23 N N F 11 84 N N 
Myeloma 2 N N M 1 75 Y N 
Myeloma 37 N N M 16 70 N N 
Myeloma 8 N N M 4 65 N N 
Myeloma 2 N N F 1 66 Y Y 
Myeloma 4 N N F 2 83 N N 
Myeloma 13 N N M 6 83 N N 
Myeloma 19 N N M 10 82 N N 
Myeloma 23 N N F 11 65 N N 
Myeloma 10 N N F 5 87 N N 
Myeloma 19 N Y M 9 79 N N 
Myeloma 95 N N M 47 59 Y Y 
Myeloma 3 N N F 2 79 N N 
Myeloma 14 N N F 5 78 N N 
Myeloma 10 N N M 6 84 N N 
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Diagnosis 
No. units 
transfused 
Alloimmunised 
at admission 
Alloimmunised 
post 
transfusion Gender 
No. 
transfusion 
episodes 
Age at first 
recorded 
transfusion 
Platelet 
requirement 
Irradiated 
requirement 
Myeloma 6 N N M 3 82 N N 
Myeloma 4 N N F 2 78 N N 
Myeloma 60 N Y F 25 74 N N 
Myeloma 3 N N M 1 70 Y N 
Myeloma 73 N N F 37 52 Y Y 
Myeloma 11 N N M 5 69 N N 
Myeloma 21 N Y F 8 78 N N 
Myeloma 2 N N M 1 71 N N 
Myeloma 50 N N M 21 66 Y Y 
Myeloma 4 N N F 2 83 N N 
Myeloma 6 N N M 3 87 N N 
Myeloma 19 N N M 9 73 N N 
Myeloma 127 N Y M 59 78 Y N 
Myeloma 32 N N M 14 50 Y Y 
Myeloma 33 N Y M 14 51 Y Y 
Myeloma 13 N N M 5 88 N N 
Myeloma 2 N N M 1 78 N N 
Myeloma 53 N Y M 25 76 N N 
Myeloma 11 N N M 5 45 Y Y 
Myeloma 2 N N M 1 85 N N 
Myeloma 32 N N M 16 68 N N 
Myeloma 10 N N M 5 86 N Y 
Myeloma 19 N N F 5 82 Y N 
Myeloma 17 N Y F 8 67 N N 
Myeloma 7 N N F 3 83 Y N 
Myeloma 5 N N M 2 65 Y Y 
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Diagnosis 
No. units 
transfused 
Alloimmunised 
at admission 
Alloimmunised 
post 
transfusion Gender 
No. 
transfusion 
episodes 
Age at first 
recorded 
transfusion 
Platelet 
requirement 
Irradiated 
requirement 
Myeloma 2 N N M 1 72 N N 
Myeloma 37 N N F 18 64 N N 
Myeloma 27 N N M 13 74 N N 
Myeloma 8 N N F 4 60 N N 
Myeloma 24 N Y F 11 69 Y Y 
Myeloma 177 Y Y F 67 79 N N 
Myeloma 10 N N M 5 70 N N 
Myeloma 208 N N M 67 76 Y N 
Myeloma 4 N N F 2 87 N N 
Myeloma 39 N N M 18 71 N N 
Myeloma 8 N N F 3 86 N N 
Myeloma 6 N N F 3 80 N N 
Myeloma 10 N N M 6 60 N N 
Myeloma 112 N N M 42 84 Y N 
Myeloma 38 N Y M 16 69 N N 
Myeloma 2 N N M 1 67 Y Y 
Myeloma 40 N N F 16 88 N N 
Myeloma 56 N N M 24 54 Y Y 
Myeloma 8 N N M 3 68 Y Y 
Myeloma 50 N Y F 23 74 N N 
Myeloma 8 N N M 4 74 N N 
Myeloma 41 N Y M 21 54 Y Y 
Myeloma 10 N N M 6 65 Y N 
Myeloma 4 N N M 2 77 Y N 
Myeloma 29 N N F 14 57 Y Y 
Myeloma 70 N N M 33 62 Y Y 
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Diagnosis 
No. units 
transfused 
Alloimmunised 
at admission 
Alloimmunised 
post 
transfusion Gender 
No. 
transfusion 
episodes 
Age at first 
recorded 
transfusion 
Platelet 
requirement 
Irradiated 
requirement 
Myeloma 2 N N M 1 80 N N 
Myeloma 6 N N M 3 81 N N 
NHL 2 N N M 1 69 N N 
NHL 2 N N M 2 62 N N 
NHL 2 N N M 1 41 Y Y 
NHL 2 N N F 1 56 N N 
NHL 3 N N F 1 66 N N 
NHL 4 N Y M 2 90 N N 
NHL 4 N N F 2 73 Y N 
NHL 4 N N M 4 74 N N 
NHL 4 N N F 2 83 N N 
NHL 4 N N F 2 45 Y Y 
NHL 4 N N F 2 82 N N 
NHL 4 N N F 2 64 N N 
NHL 4 N N F 2 67 N N 
NHL 4 N N M 2 39 N N 
NHL 5 N N M 2 34 Y Y 
NHL 5 N N F 2 68 N N 
NHL 6 N N M 3 72 Y Y 
NHL 6 N N M 2 79 Y N 
NHL 6 N N F 3 75 Y N 
NHL 6 N N F 3 56 N Y 
NHL 7 N N M 3 74 Y N 
NHL 8 N Y F 4 71 Y N 
NHL 8 N Y F 2 75 Y Y 
NHL 8 N N M 4 70 Y Y 
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Diagnosis 
No. units 
transfused 
Alloimmunised 
at admission 
Alloimmunised 
post 
transfusion Gender 
No. 
transfusion 
episodes 
Age at first 
recorded 
transfusion 
Platelet 
requirement 
Irradiated 
requirement 
NHL 8 N N M 4 75 N N 
NHL 8 N N M 4 45 Y Y 
NHL 9 N N M 6 62 N N 
NHL 9 N N M 4 78 Y N 
NHL 10 N Y F 5 79 Y Y 
NHL 10 N N M 5 59 N N 
NHL 10 N N M 5 80 N N 
NHL 10 N N F 5 81 N N 
NHL 10 N N M 4 64 Y Y 
NHL 10 N N M 5 54 Y Y 
NHL 11 N N F 6 52 Y Y 
NHL 12 N N M 6 77 Y Y 
NHL 13 N N F 7 75 Y Y 
NHL 13 N N M 6 74 N N 
NHL 13 N N M 5 61 N N 
NHL 15 N N M 7 78 Y Y 
NHL 16 N N M 8 68 Y N 
NHL 16 N N F 7 54 Y N 
NHL 16 N N F 8 21 Y Y 
NHL 19 N N F 7 59 Y Y 
NHL 19 N N F 11 62 Y N 
NHL 20 N Y M 11 67 Y Y 
NHL 20 N N M 9 53 Y Y 
NHL 20 N N M 9 73 Y Y 
NHL 21 N Y M 10 80 N Y 
NHL 23 N N M 12 23 Y N 
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Diagnosis 
No. units 
transfused 
Alloimmunised 
at admission 
Alloimmunised 
post 
transfusion Gender 
No. 
transfusion 
episodes 
Age at first 
recorded 
transfusion 
Platelet 
requirement 
Irradiated 
requirement 
NHL 24 N Y F 13 60 Y Y 
NHL 25 N N M 11 25 Y Y 
NHL 27 N N M 11 38 Y Y 
NHL 29 N N F 12 46 Y Y 
NHL 32 N N M 13 64 Y N 
NHL 35 N N F 17 67 N Y 
NHL 35 N N M 16 81 Y Y 
NHL 36 N N M 16 74 Y Y 
NHL 37 N N M 19 54 Y Y 
NHL 38 N N M 15 45 Y Y 
NHL 39 N Y F 19 67 Y Y 
NHL 39 N N M 18 63 Y Y 
NHL 40 N N M 19 57 Y Y 
NHL 46 N N M 8 47 Y N 
NHL 59 N Y F 31 61 Y Y 
NHL 91 N N M 37 84 N N 
NHL 117 N N F 53 58 Y Y 
NHL 31 N N M 16 73 Y Y 
NHL 4 N N M 2 72 N N 
NHL 16 N N F 8 70 N Y 
NHL 10 N N F 5 74 Y N 
NHL 6 N N M 3 89 N Y 
NHL 12 N N F 6 78 N Y 
NHL 2 N N F 1 93 N N 
NHL 12 N N M 6 73 N Y 
NHL 6 N N F 3 87 N N 
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Diagnosis 
No. units 
transfused 
Alloimmunised 
at admission 
Alloimmunised 
post 
transfusion Gender 
No. 
transfusion 
episodes 
Age at first 
recorded 
transfusion 
Platelet 
requirement 
Irradiated 
requirement 
NHL 38 Y Y F 19 64 N Y 
NHL 2 N N M 1 74 N N 
NHL 61 N Y F 27 70 N N 
NHL 8 N N F 4 68 Y N 
NHL 5 N N F 3 84 N N 
NHL 14 N N M 6 61 N N 
NHL 4 N N M 2 76 N Y 
NHL 15 N N M 7 73 Y Y 
NHL 13 N N F 5 73 N N 
NHL 12 N N F 5 79 N N 
NHL 7 Y Y F 4 80 Y Y 
NHL 4 N N F 2 77 N N 
NHL 4 N N M 2 51 N N 
NHL 25 N N M 11 88 Y N 
NHL 15 N N F 7 61 Y Y 
NHL 3 N N M 2 75 N N 
NHL 4 N N F 2 81 N N 
NHL 29 N N M 15 73 Y N 
NHL 23 N N F 10 56 Y Y 
NHL 10 N N M 5 84 N N 
NHL 5 N N M 2 89 N N 
NHL 34 N Y M 16 70 Y N 
NHL 63 N Y M 26 68 Y Y 
NHL 37 N N M 14 57 Y Y 
NHL 6 N N M 3 68 Y N 
NHL 16 N N F 8 67 Y N 
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Diagnosis 
No. units 
transfused 
Alloimmunised 
at admission 
Alloimmunised 
post 
transfusion Gender 
No. 
transfusion 
episodes 
Age at first 
recorded 
transfusion 
Platelet 
requirement 
Irradiated 
requirement 
NHL 17 N N M 8 60 Y Y 
NHL 15 N N M 7 71 Y Y 
NHL 5 N N M 2 61 Y Y 
NHL 10 N N M 5 58 N N 
NHL 59 N N M 27 56 Y Y 
NHL 26 N N F 13 78 N N 
NHL 24 N N M 11 59 Y Y 
NHL 30 N Y M 15 78 N N 
NHL 4 N N F 2 54 N Y 
NHL 6 N N M 3 84 N N 
NHL 3 N N F 1 87 Y N 
NHL 2 N N M 1 78 N Y 
NHL 17 Y Y F 7 76 N N 
NHL 8 N N F 4 65 N Y 
NHL 2 N N M 1 80 N N 
NHL 16 N N M 8 65 N Y 
NHL 2 N N F 1 71 N Y 
NHL 8 N N F 4 94 N N 
NHL 8 N N F 4 65 Y N 
NHL 6 N N M 3 72 N N 
NHL 5 Y Y F 3 74 Y Y 
NHL 10 N N M 5 29 Y Y 
NHL 4 N N F 2 71 N N 
NHL 2 N N F 1 80 N N 
NHL 24 N N F 11 89 N N 
NHL 2 N N M 1 78 Y N 
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Diagnosis 
No. units 
transfused 
Alloimmunised 
at admission 
Alloimmunised 
post 
transfusion Gender 
No. 
transfusion 
episodes 
Age at first 
recorded 
transfusion 
Platelet 
requirement 
Irradiated 
requirement 
NHL 13 N N M 5 65 Y Y 
NHL 25 N Y M 12 60 Y N 
NHL 2 N N M 1 42 Y N 
NHL 17 N N M 9 50 Y N 
NHL 13 N N F 7 77 N Y 
NHL 9 N N F 5 61 Y Y 
NHL 14 N N M 6 48 Y Y 
NHL 10 N Y F 4 43 N Y 
NHL 49 N N F 21 63 Y Y 
NHL 4 N N M 2 59 Y Y 
NHL 7 N N F 4 83 N N 
NHL 7 N N M 3 79 N N 
NHL 17 N N M 6 87 N N 
NHL 18 N Y F 7 79 N N 
NHL 2 N N M 1 36 Y Y 
NHL 20 N N F 10 65 Y Y 
NHL 4 N N M 2 71 N N 
NHL 10 N N M 5 73 N Y 
NHL 13 N N F 6 63 N N 
NHL 2 N N F 1 81 N N 
NHL 11 N N M 5 66 Y Y 
NHL 26 N N M 11 59 Y Y 
NHL 20 N N M 10 63 Y Y 
NHL 8 N N F 4 60 Y Y 
NHL 2 N N F 1 78 Y N 
NHL 24 N N F 9 32 Y N 
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Diagnosis 
No. units 
transfused 
Alloimmunised 
at admission 
Alloimmunised 
post 
transfusion Gender 
No. 
transfusion 
episodes 
Age at first 
recorded 
transfusion 
Platelet 
requirement 
Irradiated 
requirement 
NHL 15 N Y M 7 72 N N 
NHL 5 N N F 2 75 N N 
NHL 14 N N M 6 65 Y Y 
NHL 6 N N F 3 69 Y Y 
NHL 6 N N F 3 62 N N 
NHL 63 N N F 27 54 Y Y 
NHL 10 N N M 5 96 N N 
NHL 16 N N M 8 63 Y Y 
NHL 4 N N M 2 49 N N 
NHL 27 Y Y F 10 71 Y Y 
NHL 2 N N F 1 69 N N 
NHL 17 N Y F 6 83 N N 
NHL 96 N Y F 47 65 N N 
NHL 16 N N M 8 52 Y N 
NHL 63 N Y F 22 63 Y Y 
NHL 12 N N F 6 61 N N 
NHL 10 N N M 5 65 Y Y 
NHL 6 N N F 3 64 N N 
NHL 13 N N F 6 80 N N 
NHL 2 N N M 1 42 Y Y 
NHL 15 Y Y M 6 76 Y N 
NHL 41 Y Y F 8 53 Y N 
NHL 2 N N M 1 77 N N 
NHL 6 N N M 3 75 N N 
NHL 4 N N F 2 92 Y N 
NHL 6 N N M 3 91 N N 
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No. units 
transfused 
Alloimmunised 
at admission 
Alloimmunised 
post 
transfusion Gender 
No. 
transfusion 
episodes 
Age at first 
recorded 
transfusion 
Platelet 
requirement 
Irradiated 
requirement 
NHL 46 N Y F 23 88 N N 
NHL 12 Y Y M 5 87 N N 
NHL 6 Y Y F 3 77 N N 
NHL 6 N N M 3 78 N N 
NHL 10 N N F 5 49 Y Y 
NHL 2 N N M 1 76 N N 
NHL 55 Y Y M 24 60 N N 
NHL 2 N N F 1 79 N N 
NHL 6 N N M 3 38 Y Y 
NHL 8 N N M 4 72 Y N 
NHL 8 Y Y M 4 65 N N 
NHL 16 N N F 8 76 N N 
NHL 18 N Y F 9 74 N N 
NHL 18 N N F 7 75 Y N 
NHL 70 N N F 27 55 Y Y 
NHL 4 N N F 2 46 N N 
NHL 10 Y Y M 5 79 N N 
NHL 7 N N M 3 65 Y N 
NHL 9 N N F 4 50 N N 
NHL 8 N N M 4 71 N N 
NHL 8 N N F 4 67 N N 
NHL 2 N N M 1 78 N N 
NHL 54 N N M 24 68 Y Y 
NHL 8 N N F 3 82 Y N 
NHL 4 N N F 2 35 N N 
NHL 2 N N F 1 55 N N 
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No. units 
transfused 
Alloimmunised 
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Alloimmunised 
post 
transfusion Gender 
No. 
transfusion 
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Age at first 
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transfusion 
Platelet 
requirement 
Irradiated 
requirement 
NHL 85 N N M 39 61 Y Y 
NHL 8 N N F 4 75 N N 
NHL 33 N N M 12 59 Y Y 
NHL 4 N N F 2 77 N N 
NHL 16 N Y M 7 63 N N 
NHL 2 N N F 1 69 N N 
NHL 14 N N M 7 77 Y Y 
NHL 47 N N F 22 76 N N 
NHL 2 N N F 1 79 N N 
NHL 2 N N F 1 48 Y Y 
NHL 26 N N M 4 67 Y Y 
NHL 14 N N F 7 77 Y Y 
NHL 45 N N M 22 40 Y Y 
NHL 11 N N M 5 81 N N 
NHL 2 N N F 1 72 N N 
NHL 42 N N M 18 40 Y Y 
NHL 4 N N M 2 66 N Y 
NHL 4 N N M 2 70 N N 
NHL 4 N N F 2 78 N N 
NHL 13 N N M 6 67 Y Y 
NHL 4 N N F 2 67 N Y 
NHL 20 N N F 7 72 N Y 
NHL 13 N N M 6 54 Y Y 
NHL 20 N Y M 10 62 Y Y 
NHL 11 Y Y M 4 69 N N 
NHL 10 N N M 4 74 N N 
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Diagnosis 
No. units 
transfused 
Alloimmunised 
at admission 
Alloimmunised 
post 
transfusion Gender 
No. 
transfusion 
episodes 
Age at first 
recorded 
transfusion 
Platelet 
requirement 
Irradiated 
requirement 
NHL 25 N N M 12 67 Y N 
NHL 4 N N M 2 89 N N 
NHL 6 N N M 4 86 N N 
NHL 14 N Y M 6 80 N Y 
NHL 67 N N M 33 82 Y N 
NHL 2 N N M 1 73 N N 
NHL 2 N N M 1 67 N N 
NHL 27 N Y M 13 81 Y Y 
NHL 14 N N F 7 76 Y Y 
NHL 16 N Y M 5 62 Y Y 
NHL 31 N N F 16 85 Y N 
NHL 44 N N M 18 77 N Y 
NHL 12 N N M 6 63 Y N 
NHL 33 N N M 15 52 Y N 
NHL 11 N N F 5 64 Y N 
NHL 129 N N F 57 27 Y Y 
NHL 4 N N F 2 64 N N 
NHL 6 N N F 3 72 N N 
NHL 2 N N F 1 83 N Y 
NHL 2 N N F 1 74 Y N 
NHL 2 N N M 1 69 N N 
NHL 2 N N F 1 79 N N 
NHL 4 N N M 2 80 Y N 
NHL 12 Y Y F 6 78 Y Y 
NHL 89 N N M 37 66 N Y 
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Diagnosis 
No. units 
transfused 
Alloimmunised 
at admission 
Alloimmunised 
post 
transfusion Gender 
No. 
transfusion 
episodes 
Age at first 
recorded 
transfusion 
Platelet 
requirement 
Irradiated 
requirement 
NHL + AIHA 93 N Y F 34 56 Y Y 
NHL 4 Y Y M 2 81 N N 
Pancytopaenia 9 N N F 4 54 Y N 
Pancytopaenia 30 N N F 10 72 Y N 
Pancytopaenia 4 N N F 2 76 N N 
Pancytopaenia 5 N N M 2 36 Y N 
Pernicious anaemia 102 N N F 28 71 N N 
Post transplant 
lymphomprofilerative disease 6 N N F 3 24 N N 
PRV 17 N N F 8 74 N N 
PVR 9 N N F 4 70 N N 
Rheumatoid arthritis 14 Y Y M 4 69 N N 
Sideroblastic Anaemia 5 N N M 2 72 N N 
Sideroblastic Anaemia 244 N Y M 104 66 N N 
Sideroblastic Anaemia 76 N N F 28 87 N N 
Sideroblastic Anaemia 124 N Y F 41 77 N N 
Sideroblastic Anaemia 54 N Y M 26 88 N N 
Sideroblastic Anaemia 98 N N F 39 79 N N 
T cell prolymphocytic 
leukaemia 68 N N M 28 69 Y Y 
46 | A p p e n d i x  
 
Diagnosis 
No. units 
transfused 
Alloimmunised 
at admission 
Alloimmunised 
post 
transfusion Gender 
No. 
transfusion 
episodes 
Age at first 
recorded 
transfusion 
Platelet 
requirement 
Irradiated 
requirement 
T-cell leukaemia 45 N Y M 22 71 N N 
Thalassaemia 381 Y Y M 127 25 N N 
TTP 11 N Y F 3 30 Y N 
TTP 3 Y Y F 1 20 N N 
VWD 2 N N M 1 52 N N 
WM 32 N Y M 16 71 N Y 
WM 2 N N F 1 78 Y N 
WM 42 Y Y F 19 61 Y Y 
WM 20 N N F 12 70 Y N 
WM 23 Y Y F 11 75 N Y 
WM 7 N N F 3 65 N N 
WM 39 N Y F 16 77 N N 
WM 21 N Y F 9 73 Y Y 
WM 15 N N F 8 91 N Y 
WM 4 N N M 2 80 Y Y 
WM 16 N N F 8 75 Y Y 
WM 89 N N M 41 71 Y Y 
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10.2 Appendix 2: Raw data for retrospective review of renal cohort 
 
Key:  AKI = Acute kidney injury 
 ARF = Acute renal failure 
 CKD = Chronic kidney disease 
 CRF = Chronic renal failure 
 ESRF = End stage renal failure 
 Y =Yes 
 N = No 
 M =Male 
 F = Female 
 
Diagnosis 
No 
units 
given  
Alloimmunised 
at admission 
Alloimmunised 
post 
transfusion 
Autoimmunised 
at admission 
Autoimmunised 
post transfusion Gender 
No. 
Episodes 
Age at first 
transfusion Transplant 
AKI 94 N N N N M 43 87 N 
AKI 7 N N N N M 3 40 N 
AKI 3 N N N N F 1 65 N 
AKI 2 N N N N M 1 85 N 
AKI 2 N N N N F 1 66 N 
AKI 2 N N N N F 1 80 N 
AKI 8 N N N N M 3 79 N 
ARF 30 N N N N F 14 36 Y 
ARF 2 N N N N F 1 54 N 
ARF 4 N N N N F 2 60 N 
ARF 29 N N N N M 13 80 N 
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Diagnosis 
No 
units 
given  
Alloimmunised 
at admission 
Alloimmunised 
post 
transfusion 
Autoimmunised 
at admission 
Autoimmunised 
post transfusion Gender 
No. 
Episodes 
Age at first 
transfusion Transplant 
ARF 6 N N N N M 3 83 N 
ARF 3 N N N N F 1 71 N 
ARF 6 N N N N M 3 84 N 
ARF 3 N N N N F 1 76 N 
ARF 4 N N N N M 1 77 N 
ARF 6 N N N N M 2 75 N 
ARF 4 N N N N M 2 81 N 
ARF 10 N N N N M 5 77 N 
ARF 4 N N N N F 2 68 N 
ARF 20 N N N N F 9 53 N 
ARF 2 N N N N F 1 63 N 
ARF 2 N N N N F 1 41 N 
ARF 14 N N N N F 6 72 N 
ARF 14 N N N N M 6 61 N 
ARF 1 N N N N F 1 81 N 
ARF 4 N N N N M 2 78 N 
ARF 5 N N N N F 2 67 N 
ARF 7 N N N N F 4 66 N 
ARF 15 N N N N M 6 82 N 
ARF 5 N N N N F 2 74 N 
ARF 2 N N N N M 1 87 N 
ARF 2 N N N N M 1 76 N 
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Diagnosis 
No 
units 
given  
Alloimmunised 
at admission 
Alloimmunised 
post 
transfusion 
Autoimmunised 
at admission 
Autoimmunised 
post transfusion Gender 
No. 
Episodes 
Age at first 
transfusion Transplant 
ARF 5 N N N N F 2 56 N 
ARF 13 N N N N M 5 93 N 
ARF 2 N N N N M 1 76 N 
ARF 17 N N N N M 7 67 N 
ARF 44 N N N N F 13 44 N 
ARF 2 N N N N F 1 66 N 
ARF 10 N N N N F 4 82 N 
ARF 4 N N N N M 2 89 N 
ARF 8 N N N N M 3 31 N 
ARF 6 N N N N M 3 69 N 
ARF 2 N N N N M 2 69 N 
ARF 18 N N N N M 8 76 N 
ARF 2 N N N N M 1 83 N 
ARF 4 N N N N F 2 22 N 
ARF 2 N N N N F 1 62 N 
ARF 3 N N N N M 1 74 N 
ARF 4 N N N N M 2 83 N 
CKD 2 N N N N M 1 63 N 
CKD 4 N N N N M 2 76 N 
CKD 47 N N N N M 13 72 N 
CKD 2 N N N N F 1 73 N 
CKD 2 N N N N M 1 62 N 
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Diagnosis 
No 
units 
given  
Alloimmunised 
at admission 
Alloimmunised 
post 
transfusion 
Autoimmunised 
at admission 
Autoimmunised 
post transfusion Gender 
No. 
Episodes 
Age at first 
transfusion Transplant 
CKD 2 N N N N F 1 46 N 
CKD 4 N N N N F 2 75 N 
CKD 74 N N N N M 35 70 N 
CKD 2 N N N N M 1 69 N 
CKD 8 N N N N M 4 52 N 
CKD 2 N N N N M 1 88 N 
CKD 2 N N N N F 1 75 N 
CKD 4 N N N N M 2 76 N 
CKD 10 N N N N M 4 66 N 
CKD 14 N N N N M 7 91 N 
CKD 4 N N N N F 2 24 N 
CKD 16 N N N N M 8 72 N 
CKD 2 N N N N F 1 87 N 
CKD 8 N N N N F 4 63 N 
CKD 16 N N N N F 7 76 N 
CKD 36 N N N N F 14 75 N 
CKD 4 N N N N M 2 85 N 
CKD 25 N N N N M 13 69 N 
CKD 2 N N N N M 1 69 N 
CKD 2 N N N N M 1 55 N 
CKD 2 N N N N F 1 84 N 
CKD 6 N N N N M 3 80 N 
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Diagnosis 
No 
units 
given  
Alloimmunised 
at admission 
Alloimmunised 
post 
transfusion 
Autoimmunised 
at admission 
Autoimmunised 
post transfusion Gender 
No. 
Episodes 
Age at first 
transfusion Transplant 
CKD 9 N N N N M 5 68 N 
CKD 2 N N N N M 1 74 N 
CKD 14 N N N N F 7 79 N 
CKD 9 N N N N F 3 76 N 
CKD 5 N N N N M 2 73 N 
CKD 2 N N N N M 1 73 N 
CKD 4 N N N N M 2 52 N 
CKD 4 N N N N M 2 77 N 
CKD 12 N N N N M 6 52 N 
CKD 10 N N N N M 5 87 N 
CKD 44 N N N N M 16 95 N 
CKD 6 N N N N M 3 65 N 
CKD 13 N N N N F 6 55 N 
CKD 16 N N N N M 5 65 N 
CKD 39 N N N N F 20 59 N 
CKD 2 N N N N M 1 54 N 
CKD 9 N N N N M 4 71 N 
CKD 12 N N N N M 5 71 N 
CKD 9 N N N N M 4 63 N 
CKD 5 N N N N F 2 79 N 
CKD 16 N N N N M 8 83 N 
CKD 6 N N N N M 3 52 N 
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Diagnosis 
No 
units 
given  
Alloimmunised 
at admission 
Alloimmunised 
post 
transfusion 
Autoimmunised 
at admission 
Autoimmunised 
post transfusion Gender 
No. 
Episodes 
Age at first 
transfusion Transplant 
CKD 8 N N N N F 4 80 N 
CKD 15 N N N N M 8 71 N 
CKD 9 N Y N Y M 4 69 N 
CKD 2 Y Y Y Y F 1 43 N 
CKD 14 N Y N Y F 7 65 N 
CKD 98 N Y N Y F 40 55 N 
CKD 25 Y Y Y Y M 13 74 N 
CRF 29 N N N N F 13 59 N 
CRF 3 N N N N M 1 37 Y 
CRF 3 N N N N F 1 44 Y 
CRF 7 N N N N M 3 39 Y 
CRF 9 N N N N M 5 43 Y 
CRF 48 N N N N M 22 55 Y 
CRF 26 N N N N M 13 15 Y 
CRF 4 N N N N F 2 57 Y 
CRF 21 N N N N M 9 57 Y 
CRF 2 N N N N F 1 69 Y 
CRF 12 N N N N M 5 57 Y 
CRF 12 N N N N F 5 32 Y 
CRF 7 N N N N M 3 39 Y 
CRF 22 N N N N F 11 67 Y 
CRF 8 N N N N M 4 28 Y 
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Diagnosis 
No 
units 
given  
Alloimmunised 
at admission 
Alloimmunised 
post 
transfusion 
Autoimmunised 
at admission 
Autoimmunised 
post transfusion Gender 
No. 
Episodes 
Age at first 
transfusion Transplant 
CRF 11 N N N N M 4 45 Y 
CRF 2 N N N N M 1 63 Y 
CRF 2 N N N N M 1 19 Y 
CRF 5 N N N N M 2 41 Y 
CRF 31 N N N N M 19 37 Y 
CRF 12 N N N N F 6 54 Y 
CRF 8 N N N N F 3 38 Y 
CRF 6 N N N N M 3 51 Y 
CRF 5 N N N N M 2 70 Y 
CRF 5 N N N N M 3 34 Y 
CRF 15 N N N N M 7 45 Y 
CRF 2 N N N N F 1 70 Y 
CRF 22 N N N N F 8 32 Y 
CRF 5 N N N N M 3 64 Y 
CRF 8 N N N N M 4 33 Y 
CRF 2 N N N N F 1 49 Y 
CRF 2 N N N N M 1 60 Y 
CRF 22 N Y N N M 7 42 Y 
CRF 143 N Y N N M 54 45 Y 
CRF 4 N Y N N M 2 38 Y 
CRF 4 N Y N N M 2 65 Y 
CRF 8 N Y N N M 4 60 Y 
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Diagnosis 
No 
units 
given  
Alloimmunised 
at admission 
Alloimmunised 
post 
transfusion 
Autoimmunised 
at admission 
Autoimmunised 
post transfusion Gender 
No. 
Episodes 
Age at first 
transfusion Transplant 
CRF 9 N Y N Y M 4 44 Y 
CRF 6 N Y N N M 3 48 Y 
CRF 3 N N N N M 2 84 N 
CRF 2 N N N N F 1 74 N 
CRF 13 N N N Y M 6 53 N 
CRF 4 N N N N M 2 71 N 
CRF 4 N N N N F 2 45 N 
CRF 8 N N N N F 3 39 N 
CRF 5 N N N N F 3 69 N 
CRF 5 N N N N F 2 82 N 
CRF 3 N N N N M 2 91 N 
CRF 10 N N N N F 4 63 N 
CRF 4 N N N N F 2 81 N 
CRF 2 N N N N F 1 68 N 
CRF 7 N N N N F 3 74 N 
CRF 7 N N N N M 4 53 N 
CRF 12 N N N N M 5 65 N 
CRF 20 N N N N F 9 77 N 
CRF 2 N N N N M 1 82 N 
CRF 11 N N N N M 4 80 N 
CRF 5 N N N N M 2 55 N 
CRF 7 N N N N M 3 73 N 
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Diagnosis 
No 
units 
given  
Alloimmunised 
at admission 
Alloimmunised 
post 
transfusion 
Autoimmunised 
at admission 
Autoimmunised 
post transfusion Gender 
No. 
Episodes 
Age at first 
transfusion Transplant 
CRF 21 N N N N M 9 78 N 
CRF 32 N N N N F 14 58 N 
CRF 11 N N N N M 5 79 N 
CRF 3 N N N N M 1 81 N 
CRF 3 N N N N F 2 59 N 
CRF 3 N N N N M 1 84 N 
CRF 6 N N N N M 3 65 N 
CRF 14 N N N N M 4 65 N 
CRF 4 N N N N M 1 88 N 
CRF 12 N N N N M 5 68 N 
CRF 4 N N N N M 2 71 N 
CRF 3 N N N N M 1 66 N 
CRF 7 N N N N M 3 84 N 
CRF 10 N N N N F 4 80 N 
CRF 2 N N N N M 1 75 N 
CRF 2 N N N N M 1 82 N 
CRF 6 N N N N F 2 84 N 
CRF 3 N N N N M 1 72 N 
CRF 6 N N N N M 2 83 N 
CRF 7 N N N N M 4 76 N 
CRF 11 N N N N M 5 79 N 
CRF 6 N N N N F 2 32 N 
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Diagnosis 
No 
units 
given  
Alloimmunised 
at admission 
Alloimmunised 
post 
transfusion 
Autoimmunised 
at admission 
Autoimmunised 
post transfusion Gender 
No. 
Episodes 
Age at first 
transfusion Transplant 
CRF 17 N N N N M 6 83 N 
CRF 34 N N N N F 13 46 N 
CRF 4 N N N N M 1 70 N 
CRF 3 N N N N F 1 61 N 
CRF 5 N N N N M 3 79 N 
CRF 7 N N N N M 3 78 N 
CRF 4 N N N N M 2 81 N 
CRF 2 N N N N M 1 77 N 
CRF 8 N N N N F 2 66 N 
CRF 6 N N N N M 3 80 N 
CRF 6 N N N N M 3 56 N 
CRF 2 N N N N M 1 54 N 
CRF 6 N N N N M 3 87 N 
CRF 2 N N N N M 1 42 N 
CRF 8 N N N N F 4 52 N 
CRF 246 N N N N M 67 75 N 
CRF 2 N N N N M 1 49 N 
CRF 2 N N N N M 1 75 N 
CRF 2 N N N N F 1 58 N 
CRF 27 N N N N M 14 42 N 
CRF 22 N N N N M 8 73 N 
CRF 4 N N N N M 2 66 N 
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Diagnosis 
No 
units 
given  
Alloimmunised 
at admission 
Alloimmunised 
post 
transfusion 
Autoimmunised 
at admission 
Autoimmunised 
post transfusion Gender 
No. 
Episodes 
Age at first 
transfusion Transplant 
CRF 6 N N N N M 2 83 N 
CRF 8 N N N N M 3 59 N 
CRF 10 N N N N F 4 76 N 
CRF 6 N N N N M 3 89 N 
CRF 3 N N N N F 2 68 N 
CRF 7 N N N N M 3 76 N 
CRF 10 N N N N M 4 64 N 
CRF 66 N N N N F 26 47 N 
CRF 2 N N N N F 1 70 N 
CRF 17 N N Y Y F 8 76 N 
CRF 2 N N N N M 1 81 N 
CRF 31 N N N N F 15 68 N 
CRF 12 N N N N F 6 71 N 
CRF 21 N N N N F 9 67 N 
CRF 8 N N N N M 4 60 N 
CRF 9 N N N N M 4 78 N 
CRF 4 N N N N M 3 82 N 
CRF 13 N N N N F 6 35 N 
CRF 4 N N N N F 2 68 N 
CRF 7 N N N N M 4 76 N 
CRF 75 N N N Y M 36 65 N 
CRF 15 N N Y Y M 6 76 N 
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Diagnosis 
No 
units 
given  
Alloimmunised 
at admission 
Alloimmunised 
post 
transfusion 
Autoimmunised 
at admission 
Autoimmunised 
post transfusion Gender 
No. 
Episodes 
Age at first 
transfusion Transplant 
CRF 13 N N N N F 5 70 N 
CRF 10 N N N N M 5 78 N 
CRF 5 N N N N M 2 75 N 
CRF 10 N N N N F 4 54 N 
CRF 16 N N N N F 8 63 N 
CRF 16 N N N N M 7 88 N 
CRF 24 N N Y Y M 9 81 N 
CRF 46 N N N N M 18 83 N 
CRF 12 N N N N F 6 55 N 
CRF 56 N N N N M 24 54 N 
CRF 5 N N N N F 2 73 N 
CRF 6 N N N N F 3 51 N 
CRF 11 N N N N M 4 82 N 
CRF 62 N N N N F 28 53 N 
CRF 11 N N N N M 5 75 N 
CRF 24 N N N N M 9 77 N 
CRF 19 N N N N M 9 67 N 
CRF 50 N N N N M 21 57 N 
CRF 25 N N N N M 11 65 N 
CRF 21 N N N N F 10 74 N 
CRF 2 N N N N M 1 65 N 
CRF 18 N N N N M 9 66 N 
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Diagnosis 
No 
units 
given  
Alloimmunised 
at admission 
Alloimmunised 
post 
transfusion 
Autoimmunised 
at admission 
Autoimmunised 
post transfusion Gender 
No. 
Episodes 
Age at first 
transfusion Transplant 
CRF 25 N N N N M 9 80 N 
CRF 4 N N N N M 2 73 N 
CRF 3 N N N N M 2 82 N 
CRF 6 N N N N M 2 78 N 
CRF 6 N N Y Y M 3 85 N 
CRF 18 N N N N F 9 77 N 
CRF 10 N N N N M 4 78 N 
CRF 2 N N N N M 1 72 N 
CRF 4 N N N N F 2 83 N 
CRF 14 N N N N M 6 60 N 
CRF 38 N N N N M 18 61 N 
CRF 162 N N N N M 34 76 N 
CRF 3 N N N N M 1 84 N 
CRF 2 N N N N M 1 73 N 
CRF 12 N N N N M 6 78 N 
CRF 6 N N N N F 3 71 N 
CRF 10 N N N N M 4 84 N 
CRF 9 N N N N M 3 72 N 
CRF 3 N N N N M 1 65 N 
CRF 12 N N N N F 4 56 N 
CRF 21 N N N N F 4 79 N 
CRF 10 N N N N M 4 72 N 
60 | A p p e n d i x  
 
Diagnosis 
No 
units 
given  
Alloimmunised 
at admission 
Alloimmunised 
post 
transfusion 
Autoimmunised 
at admission 
Autoimmunised 
post transfusion Gender 
No. 
Episodes 
Age at first 
transfusion Transplant 
CRF 2 N N N N F 1 78 N 
CRF 16 N N N N F 7 71 N 
CRF 2 N N N N M 1 84 N 
CRF 5 N N N N M 2 32 N 
CRF 2 N N N N M 1 75 N 
CRF 2 N N Y Y M 1 66 N 
CRF 13 N N N N M 6 61 N 
CRF 2 N N N N M 1 80 N 
CRF 9 N N N N M 4 79 N 
CRF 13 N N N N M 6 48 N 
CRF 5 N N N N F 2 55 N 
CRF 5 N N N N F 3 56 N 
CRF 3 N N N N F 1 75 N 
CRF 4 N N N N F 2 63 N 
CRF 2 N N N N F 1 72 N 
CRF 5 N N N N F 2 79 N 
CRF 31 N N N N F 13 75 N 
CRF 17 N N N N F 7 65 N 
CRF 2 N N N N M 1 77 N 
CRF 8 N N N N F 4 72 N 
CRF 3 N N N N M 1 67 N 
CRF 2 N N N N M 1 83 N 
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Diagnosis 
No 
units 
given  
Alloimmunised 
at admission 
Alloimmunised 
post 
transfusion 
Autoimmunised 
at admission 
Autoimmunised 
post transfusion Gender 
No. 
Episodes 
Age at first 
transfusion Transplant 
CRF 3 N N N N M 2 79 N 
CRF 41 N Y N Y M 16 71 N 
CRF 5 Y Y N N F 2 62 N 
CRF 15 N Y N N F 7 74 N 
CRF 21 N Y N N F 11 24 N 
CRF 9 N Y N N F 5 73 N 
CRF 12 Y Y N Y M 6 79 N 
CRF 2 Y Y N N M 1 82 N 
CRF 4 N Y N N M 2 58 N 
CRF 3 N Y N N F 1 82 N 
CRF 78 Y Y N Y F 37 67 N 
CRF 36 N Y N Y M 11 77 N 
CRF 12 N Y N N F 5 80 N 
CRF 3 Y Y N N F 1 81 N 
CRF 7 N Y N N F 3 84 N 
CRF 6 Y Y Y Y F 3 76 N 
CRF 16 N Y N N F 7 68 N 
CRF 4 N Y N N F 2 90 N 
CRF 22 N Y N N F 9 43 N 
CRF 40 N Y N N M 18 49 N 
CRF 14 N Y N Y M 6 43 N 
CRF 3 N Y N N M 2 69 N 
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Diagnosis 
No 
units 
given  
Alloimmunised 
at admission 
Alloimmunised 
post 
transfusion 
Autoimmunised 
at admission 
Autoimmunised 
post transfusion Gender 
No. 
Episodes 
Age at first 
transfusion Transplant 
CRF 12 N Y N Y F 6 44 N 
CRF 23 N Y N N F 9 81 N 
CRF 5 Y Y N Y F 2 76 N 
CRF 10 N Y N Y M 4 77 N 
CRF 8 N Y N N M 4 73 N 
CRF 8 Y Y N Y F 3 80 N 
CRF 7 N Y N Y M 3 86 N 
CRF 12 N Y N N M 6 76 N 
CRF 103 N Y N N F 51 65 N 
CRF 13 Y Y N Y M 4 73 N 
CRF 107 N Y N N F 58 69 N 
CRF 25 N Y N Y F 11 68 N 
CRF 42 N Y N Y M 18 63 N 
CRF 10 N Y N Y F 5 63 N 
CRF 4 Y Y Y Y F 2 62 N 
CRF 10 N N N N F 5 79 N 
CRF 3 N N N N M 1 49   
ESRF 37 N N N Y F 17 34 N 
ESRF 18 N N N Y M 8 68 N 
ESRF 37 N N N N M 18 53 N 
ESRF 5 N N N N M 2 38 Y 
ESRF 14 N N N N M 6 38 Y 
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Diagnosis 
No 
units 
given  
Alloimmunised 
at admission 
Alloimmunised 
post 
transfusion 
Autoimmunised 
at admission 
Autoimmunised 
post transfusion Gender 
No. 
Episodes 
Age at first 
transfusion Transplant 
ESRF 13 N N N N M 8 55 Y 
ESRF 15 N N N N M 7 54 Y 
ESRF 10 N N N N M 5 60 Y 
ESRF 27 N N N N F 12 29 Y 
ESRF 13 N N N N M 7 62 Y 
ESRF 5 N N N N F 2 78 N 
ESRF 8 N N N N F 4 56 N 
ESRF 7 N N N N F 3 78 N 
ESRF 2 N N N N M 1 91 N 
ESRF 6 N N N N M 3 59 N 
ESRF 7 N N N N M 3 78 N 
ESRF 22 N N N N M 10 80 N 
ESRF 18 N N N N M 9 76 N 
ESRF 14 N N N N M 7 73 N 
ESRF 12 N N N N M 5 61 N 
ESRF 21 N N N N F 10 50 N 
ESRF 10 N N N N M 5 72 N 
ESRF 4 N N N N M 2 71 N 
ESRF 4 N N N N F 2 76 N 
ESRF 2 N N N N F 1 35 N 
ESRF 10 N N N N F 5 69 N 
ESRF 27 N N N N F 13 76 N 
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Diagnosis 
No 
units 
given  
Alloimmunised 
at admission 
Alloimmunised 
post 
transfusion 
Autoimmunised 
at admission 
Autoimmunised 
post transfusion Gender 
No. 
Episodes 
Age at first 
transfusion Transplant 
ESRF 2 N N N N F 1 76 N 
ESRF 10 N N N N F 5 67 N 
ESRF 2 N N N N F 1 73 N 
ESRF 13 N N N N F 6 75 N 
ESRF 20 N N N N F 9 67 N 
ESRF 7 N N N N F 3 64 N 
ESRF 14 N N N N F 6 79 N 
ESRF 18 N N N N F 8 74 N 
ESRF 31 N N N N F 15 48 N 
ESRF 8 N N N N F 4 81 N 
ESRF 2 N N N N F 1 79 N 
ESRF 16 N N N N F 8 58 N 
ESRF 83 N N N N M 36 73 N 
ESRF 22 N N N N F 11 58 N 
ESRF 25 N N N N M 9 77 N 
ESRF 7 N N N N M 4 69 N 
ESRF 19 N N N N M 9 38 N 
ESRF 22 N N N N M 11 60 N 
ESRF 26 N N N N M 11 74 N 
ESRF 19 N N N N F 7 70 N 
ESRF 18 N N N N F 8 46 N 
ESRF 5 N N N N F 3 62 N 
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Diagnosis 
No 
units 
given  
Alloimmunised 
at admission 
Alloimmunised 
post 
transfusion 
Autoimmunised 
at admission 
Autoimmunised 
post transfusion Gender 
No. 
Episodes 
Age at first 
transfusion Transplant 
ESRF 73 N N N N M 27 75 N 
ESRF 4 N N N N M 2 78 N 
ESRF 6 N N N N M 3 81 N 
ESRF 2 N N N N M 1 80 N 
ESRF 9 N N N N M 4 65 N 
ESRF 4 N N N N F 2 80 N 
ESRF 6 N N N N F 3 81 N 
ESRF 19 N N N N F 10 34 N 
ESRF 19 N N N Y M 9 73 N 
ESRF 6 N N N N F 3 41 N 
ESRF 2 N N N N F 1 77 N 
ESRF 10 N N N N M 5 52 N 
ESRF 30 N N N N M 11 65 N 
ESRF 7 N N N N M 4 78 N 
ESRF 13 N N N N M 6 73 N 
ESRF 4 N N N N M 2 84 N 
ESRF 2 N N N N M 1 50 N 
ESRF 2 N N N N F 1 73 N 
ESRF 18 N N N Y M 8 78 N 
ESRF 24 N N N N M 10 45 N 
ESRF 11 N N N N M 5 37 N 
ESRF 6 N N N N M 3 72 N 
66 | A p p e n d i x  
 
Diagnosis 
No 
units 
given  
Alloimmunised 
at admission 
Alloimmunised 
post 
transfusion 
Autoimmunised 
at admission 
Autoimmunised 
post transfusion Gender 
No. 
Episodes 
Age at first 
transfusion Transplant 
ESRF 6 N N N N M 2 70 N 
ESRF 8 N N N N M 3 71 N 
ESRF 24 N N N N M 12 74 N 
ESRF 8 N N N N M 4 78 N 
ESRF 9 N N N N F 5 82 N 
ESRF 2 N N N N M 1 68 N 
ESRF 3 N N N N M 1 84 N 
ESRF 5 N N N N M 2 62 N 
ESRF 7 N N N N F 3 75 N 
ESRF 8 N N N N M 4 52 N 
ESRF 9 N N N N F 4 72 N 
ESRF 4 N N N N F 2 65 N 
ESRF 30 N N N N M 15 66 N 
ESRF 28 N N N N M 13 67 N 
ESRF 10 N N N N F 4 79 N 
ESRF 2 N N N N M 2 75 N 
ESRF 31 N N N N M 14 18 N 
ESRF 2 N N N N F 1 76 N 
ESRF 4 N N N N M 2 70 N 
ESRF 14 N N N N F 5 77 N 
ESRF 7 N N N N M 3 69 N 
ESRF 8 N N N N M 4 72 N 
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Diagnosis 
No 
units 
given  
Alloimmunised 
at admission 
Alloimmunised 
post 
transfusion 
Autoimmunised 
at admission 
Autoimmunised 
post transfusion Gender 
No. 
Episodes 
Age at first 
transfusion Transplant 
ESRF 3 N N N N M 1 80 N 
ESRF 10 N N N N F 5 69 N 
ESRF 12 N N N N M 6 53 N 
ESRF 2 N N N N M 1 70 N 
ESRF 12 N N N N F 6 75 N 
ESRF 3 N N N N M 1 89 N 
ESRF 19 N N N N M 9 69 N 
ESRF 25 N N N N M 13 62 N 
ESRF 15 N N N N M 7 82 N 
ESRF 16 N N N N M 8 70 N 
ESRF 8 N N N N M 4 85 N 
ESRF 12 N N N N M 6 80 N 
ESRF 5 N N N N M 2 71 N 
ESRF 20 N N N N F 9 81 N 
ESRF 69 N N N N M 34 60 N 
ESRF 19 N N N Y F 5 79 N 
ESRF 2 N N N N F 1 83 N 
ESRF 3 N N N N M 1 65 N 
ESRF 6 N N N N M 3 78 N 
ESRF 9 N N N N M 4 61 N 
ESRF 5 N N N N M 3 66 N 
ESRF 12 N N N N M 6 88 N 
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Diagnosis 
No 
units 
given  
Alloimmunised 
at admission 
Alloimmunised 
post 
transfusion 
Autoimmunised 
at admission 
Autoimmunised 
post transfusion Gender 
No. 
Episodes 
Age at first 
transfusion Transplant 
ESRF 8 N N N N M 4 82 N 
ESRF 14 N N N N F 5 77 N 
ESRF 4 N N N N M 2 66 N 
ESRF 6 N N N N M 3 81 N 
ESRF 12 N N N N F 7 79 N 
ESRF 4 N N N N F 2 74 N 
ESRF 4 N N N N F 2 90 N 
ESRF 21 N N N N F 10 54 N 
ESRF 2 N N N N M 1 81 N 
ESRF 4 N N N N M 2 64 N 
ESRF 2 N N N N M 1 78 N 
ESRF 16 N N N N F 7 51 N 
ESRF 5 N N N N F 2 81 N 
ESRF 20 N N N N M 8 59 N 
ESRF 2 N N N N M 1 82 N 
ESRF 10 N N N N M 5 79 N 
ESRF 2 N N N N M 1 84 N 
ESRF 2 N N N N M 1 83 N 
ESRF 21 N N N N M 11 74 N 
ESRF 2 N N N N F 1 86 N 
ESRF 10 N N N N M 5 74 N 
ESRF 15 N N N N M 8 70 N 
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Diagnosis 
No 
units 
given  
Alloimmunised 
at admission 
Alloimmunised 
post 
transfusion 
Autoimmunised 
at admission 
Autoimmunised 
post transfusion Gender 
No. 
Episodes 
Age at first 
transfusion Transplant 
ESRF 4 N N N N M 2 78 N 
ESRF 2 N N N N M 1 63 N 
ESRF 10 N N N N M 5 76 N 
ESRF 2 N N N N M 1 85 N 
ESRF 2 N N N N F 1 86 N 
ESRF 8 N N N N M 4 72 N 
ESRF 2 N N N N M 1 78 N 
ESRF 23 N N N N F 10 58 N 
ESRF 6 N N N N F 3 83 N 
ESRF 6 N N N N F 3 76 N 
ESRF 2 N N N N F 1 79 N 
ESRF 6 N N N N F 3 82 N 
ESRF 3 N N N N M 1 75 N 
ESRF 8 N N N N M 4 46 N 
ESRF 9 N N N N M 5 62 N 
ESRF 4 N N N N M 2 71 N 
ESRF 10 N N N N M 5 75 N 
ESRF 21 N N N N M 10 42 N 
ESRF 11 N N N N M 5 78 N 
ESRF 14 N N N N F 7 71 N 
ESRF 6 N N N N M 3 78 N 
ESRF 2 N N N N M 1 87 N 
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Diagnosis 
No 
units 
given  
Alloimmunised 
at admission 
Alloimmunised 
post 
transfusion 
Autoimmunised 
at admission 
Autoimmunised 
post transfusion Gender 
No. 
Episodes 
Age at first 
transfusion Transplant 
ESRF 11 N N N N F 6 73 N 
ESRF 2 N N N N M 2 76 N 
ESRF 20 N N N N F 10 75 N 
ESRF 2 N N N N M 1 71 N 
ESRF 12 N N N N M 6 77 N 
ESRF 19 N N N N M 9 62 N 
ESRF 12 N N N N M 4 84 N 
ESRF 4 N N N N M 2 73 N 
ESRF 11 N N N N M 4 82 N 
ESRF 13 N N N N F 4 56 N 
ESRF 5 N N N N M 2 86 N 
ESRF 2 N N N N F 1 67 N 
ESRF 8 N N N N M 5 79 N 
ESRF 4 N N N N F 2 53 N 
ESRF 3 N N N N M 1 87 N 
ESRF 8 N N N N M 4 85 N 
ESRF 10 N N N N F 5 70 N 
ESRF 6 N N N N M 3 76 N 
ESRF 6 N N N N M 3 74 N 
ESRF 8 N N N N F 4 78 N 
ESRF 12 N N N N M 6 82 N 
ESRF 10 N N N N M 6 48 N 
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Diagnosis 
No 
units 
given  
Alloimmunised 
at admission 
Alloimmunised 
post 
transfusion 
Autoimmunised 
at admission 
Autoimmunised 
post transfusion Gender 
No. 
Episodes 
Age at first 
transfusion Transplant 
ESRF 8 N N N N M 4 78 N 
ESRF 9 N N N N F 4 71 N 
ESRF 33 N N N N M 16 88 N 
ESRF 6 N N N N F 3 73 N 
ESRF 25 N N N N F 12 61 N 
ESRF 8 N N N N M 4 55 N 
ESRF 4 N N N N M 2 76 N 
ESRF 2 N N N N F 1 75 N 
ESRF 7 N N N N M 3 81 N 
ESRF 36 N N N N M 17 65 N 
ESRF 8 N N N N M 4 91 N 
ESRF 4 N N N N M 2 84 N 
ESRF 4 N N N N M 2 89 N 
ESRF 23 N N N N F 11 77 N 
ESRF 17 N N N N F 7 51 N 
ESRF 14 N N N N F 3 65 N 
ESRF 2 N N N N M 1 78 N 
ESRF 2 N N N N M 1 75 N 
ESRF 2 N N N N F 1 83 N 
ESRF 12 N N N N M 7 75 N 
ESRF 7 N N N N M 3 61 N 
ESRF 4 N N N N F 2 17 N 
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Diagnosis 
No 
units 
given  
Alloimmunised 
at admission 
Alloimmunised 
post 
transfusion 
Autoimmunised 
at admission 
Autoimmunised 
post transfusion Gender 
No. 
Episodes 
Age at first 
transfusion Transplant 
ESRF 2 N N N N F 1 86 N 
ESRF 6 N N N N M 3 75 N 
ESRF 8 N N N N M 4 70 N 
ESRF 14 N N N N M 5 54 N 
ESRF 10 N N N N M 5 72 N 
ESRF 14 N N N N M 5 79 N 
ESRF 6 N N N N M 3 79 N 
ESRF 16 N N N N M 9 61 N 
ESRF 54 N N N N M 17 49 N 
ESRF 4 N N Y Y M 2 77 N 
ESRF 4 N N N N F 2 64 N 
ESRF 19 N N N N F 9 70 N 
ESRF 2 N N N N M 1 83 N 
ESRF 5 N N N N M 2 74 N 
ESRF 5 N N N N M 2 65 N 
ESRF 6 N N N N M 2 76 N 
ESRF 6 N N N N M 3 78 N 
ESRF 27 N N N N M 11 37 N 
ESRF 8 N N N N F 4 80 N 
ESRF 31 N N N N F 16 44 N 
ESRF 6 N N N N F 3 76 N 
ESRF 2 N N N N F 1 70 N 
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Diagnosis 
No 
units 
given  
Alloimmunised 
at admission 
Alloimmunised 
post 
transfusion 
Autoimmunised 
at admission 
Autoimmunised 
post transfusion Gender 
No. 
Episodes 
Age at first 
transfusion Transplant 
ESRF 2 N N N N F 1 75 N 
ESRF 4 N N N N M 2 67 N 
ESRF 26 N N N N F 13 60 N 
ESRF 5 N N N N F 3 64 N 
ESRF 7 N N N N F 3 76 N 
ESRF 2 N N N N M 1 86 N 
ESRF 6 N N N N F 3 79 N 
ESRF 8 N N N N F 4 75 N 
ESRF 3 N N N N M 2 79 N 
ESRF 13 N N N N M 6 77 N 
ESRF 25 N N N N M 12 53 N 
ESRF 23 N N N N F 10 65 N 
ESRF 18 N N N N M 9 84 N 
ESRF 5 N N N N M 2 87 N 
ESRF 2 N N N N M 1 80 N 
ESRF 132 N N N N F 58 70 N 
ESRF 6 N N N N F 3 53 N 
ESRF 6 N N N N M 3 76 N 
ESRF 6 N N N N M 3 75 N 
ESRF 9 N N N N M 4 81 N 
ESRF 5 N N N N M 3 58 N 
ESRF 22 N N N N M 11 82 N 
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Diagnosis 
No 
units 
given  
Alloimmunised 
at admission 
Alloimmunised 
post 
transfusion 
Autoimmunised 
at admission 
Autoimmunised 
post transfusion Gender 
No. 
Episodes 
Age at first 
transfusion Transplant 
ESRF 14 N N N N F 9 85 N 
ESRF 2 N N N N F 1 88 N 
ESRF 8 N N N N M 4 57 N 
ESRF 4 N N N N M 2 79 N 
ESRF 4 N N N N F 2 73 N 
ESRF 6 N N N N M 3 46 N 
ESRF 6 N N N N M 3 80 N 
ESRF 4 N N N N M 2 75 N 
ESRF 6 N N N N M 3 78 N 
ESRF 9 N N N N M 4 51 N 
ESRF 2 N N N N M 1 72 N 
ESRF 2 N N N N M 1 87 N 
ESRF 28 N N N Y F 13 58 N 
ESRF 3 N N N N F 2 60 N 
ESRF 6 N N N N M 3 83 N 
ESRF 4 N N N N F 2 67 N 
ESRF 2 N N N N M 1 25 N 
ESRF 27 N N N N M 14 72 N 
ESRF 4 N N N N F 2 74 N 
ESRF 17 N N N N F 9 70 N 
ESRF 8 N N N N M 4 46 N 
ESRF 16 N N N N M 9 62 N 
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Diagnosis 
No 
units 
given  
Alloimmunised 
at admission 
Alloimmunised 
post 
transfusion 
Autoimmunised 
at admission 
Autoimmunised 
post transfusion Gender 
No. 
Episodes 
Age at first 
transfusion Transplant 
ESRF 7 N N N N F 4 85 N 
ESRF 2 N N N N M 1 66 N 
ESRF 28 N N N N M 13 52 N 
ESRF 5 N N N N F 2 47 N 
ESRF 54 N N N N M 24 68 N 
ESRF 11 N N N N F 4 83 N 
ESRF 7 N N N N M 3 61 N 
ESRF 7 N N N N M 3 64 N 
ESRF 2 N N N N M 1 82 N 
ESRF 6 N N N N M 3 75 N 
ESRF 19 N N N N M 9 55 N 
ESRF 8 N N N N M 4 52 N 
ESRF 7 N N N N M 3 63 N 
ESRF 21 N N N N M 9 52 N 
ESRF 8 N N N N F 4 75 N 
ESRF 4 N N N N F 2 73 N 
ESRF 27 N N N N M 4 57 N 
ESRF 35 N N N N F 18 59 N 
ESRF 3 N N N N F 2 50 N 
ESRF 18 N N N N F 9 69 N 
ESRF 3 N N N N M 1 82 N 
ESRF 14 N N N N M 6 76 N 
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Diagnosis 
No 
units 
given  
Alloimmunised 
at admission 
Alloimmunised 
post 
transfusion 
Autoimmunised 
at admission 
Autoimmunised 
post transfusion Gender 
No. 
Episodes 
Age at first 
transfusion Transplant 
ESRF 19 N N N N M 9 23 N 
ESRF 12 N N N N F 7 64 N 
ESRF 22 N N N N M 10 68 N 
ESRF 4 N N N N M 3 65 N 
ESRF 20 N N N N F 11 52 N 
ESRF 20 N N N N M 9 57 N 
ESRF 4 N N N N M 2 56 N 
ESRF 29 N N N N M 13 67 N 
ESRF 11 N N N N M 6 46 N 
ESRF 31 N N N N F 12 82 N 
ESRF 4 N N N N M 1 71 N 
ESRF 15 N N N N M 7 71 N 
ESRF 6 N N N N M 3 82 N 
ESRF 5 N N N N M 2 39 N 
ESRF 12 N N N N M 5 65 N 
ESRF 17 N N N N M 9 66 N 
ESRF 7 N N N N F 3 71 N 
ESRF 16 N N N N M 6 77 N 
ESRF 6 N N N N F 3 70 N 
ESRF 14 N N N N M 6 41 N 
ESRF 9 N N N N F 4 77 N 
ESRF 2 N N N N M 1 87 N 
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Diagnosis 
No 
units 
given  
Alloimmunised 
at admission 
Alloimmunised 
post 
transfusion 
Autoimmunised 
at admission 
Autoimmunised 
post transfusion Gender 
No. 
Episodes 
Age at first 
transfusion Transplant 
ESRF 15 N N N N M 8 81 N 
ESRF 17 N N N N F 7 72 N 
ESRF 21 N N N N M 10 67 N 
ESRF 46 N N N N M 24 63 N 
ESRF 16 N N N N F 8 66 N 
ESRF 7 N N N N M 3 79 N 
ESRF 17 N N N N M 8 50 N 
ESRF 7 N N N N M 3 69 N 
ESRF 9 N N N N M 4 82 N 
ESRF 8 N N N N F 4 87 N 
ESRF 7 N N N N M 3 69 N 
ESRF 2 N N N N M 1 80 N 
ESRF 49 N N N N M 21 72 N 
ESRF 5 N N N N M 2 75 N 
ESRF 9 N N N N F 4 58 N 
ESRF 3 N N N N M 2 75 N 
ESRF 4 N N N N M 2 49 N 
ESRF 19 N N N N M 8 40 N 
ESRF 16 N N N N M 8 68 N 
ESRF 6 N N N N F 3 85 N 
ESRF 22 N N N N F 10 71 N 
ESRF 11 N N N N F 5 82 N 
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Diagnosis 
No 
units 
given  
Alloimmunised 
at admission 
Alloimmunised 
post 
transfusion 
Autoimmunised 
at admission 
Autoimmunised 
post transfusion Gender 
No. 
Episodes 
Age at first 
transfusion Transplant 
ESRF 3 N N N N M 1 83 N 
ESRF 10 N N N N F 4 77 N 
ESRF 25 N N N N M 11 76 N 
ESRF 16 N N N N F 7 85 N 
ESRF 34 N N N N F 17 67 N 
ESRF 10 N N N N M 6 65 N 
ESRF 10 N N N N F 4 47 N 
ESRF 37 N N N N M 18 61 N 
ESRF 2 N N N N M 1 74 N 
ESRF 3 N N N N M 1 63 N 
ESRF 37 N N N N M 16 70 N 
ESRF 51 N N N N M 19 83 N 
ESRF 14 N N N N M 6 39 N 
ESRF 2 N N N N M 7 69 N 
ESRF 12 N N N N M 5 80 N 
ESRF 29 N N N N M 10 58 N 
ESRF 14 N N N N F 7 87 N 
ESRF 8 N N N N M 4 84 N 
ESRF 10 N N N N M 5 56 N 
ESRF 15 N N N N F 6 75 N 
ESRF 14 N N N N M 7 78 N 
ESRF 11 N N N N M 6 84 N 
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Diagnosis 
No 
units 
given  
Alloimmunised 
at admission 
Alloimmunised 
post 
transfusion 
Autoimmunised 
at admission 
Autoimmunised 
post transfusion Gender 
No. 
Episodes 
Age at first 
transfusion Transplant 
ESRF 34 N N N N F 10 60 N 
ESRF 3 N N N N F 1 78 N 
ESRF 26 N N N N F 10 79 N 
ESRF 10 N N N N F 5 69 N 
ESRF 27 N N N N M 10 77 N 
ESRF 100 N N N N M 44 36 N 
ESRF 12 N N N N F 5 35 N 
ESRF 5 N N N N M 2 82 N 
ESRF 10 N N N N F 5 80 N 
ESRF 13 N N N N M 5 83 N 
ESRF 8 N N N N F 3 77 N 
ESRF 8 N N N N M 4 66 N 
ESRF 28 N N N N F 11 73 N 
ESRF 6 N N N N F 3 78 N 
ESRF 14 N N N N M 6 84 N 
ESRF 10 N N N N M 5 81 N 
ESRF 27 N N N N M 12 64 N 
ESRF 17 N N N N F 9 37 N 
ESRF 6 N N N N F 3 26 N 
ESRF 4 N N N N F 2 78 N 
ESRF 4 N N N Y M 2 77 N 
ESRF 18 N N N N F 9 51 N 
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Diagnosis 
No 
units 
given  
Alloimmunised 
at admission 
Alloimmunised 
post 
transfusion 
Autoimmunised 
at admission 
Autoimmunised 
post transfusion Gender 
No. 
Episodes 
Age at first 
transfusion Transplant 
ESRF 4 N N N N M 2 70 N 
ESRF 16 N N N N F 5 81 N 
ESRF 15 N N N N F 7 82 N 
ESRF 5 N N N N M 2 59 N 
ESRF 7 N N N N M 3 79 N 
ESRF 8 N N N N M 3 80 N 
ESRF 2 N N N N M 1 79 N 
ESRF 6 N N N N F 4 63 N 
ESRF 10 N N N N M 5 69 N 
ESRF 6 N N N N M 3 60 N 
ESRF 12 N N N N M 6 73 N 
ESRF 4 N N N N M 2 72 N 
ESRF 14 N N N N M 8 69 N 
ESRF 19 N N N N M 9 73 N 
ESRF 28 N N N N M 13 28 N 
ESRF 9 N N N N M 4 64 N 
ESRF 2 N N N N M 1 86 N 
ESRF 30 N N N N M 14 68 N 
ESRF 14 N N N N M 6 44 N 
ESRF 34 N N N N M 13 78 N 
ESRF 17 N N N N F 9 56 N 
ESRF 31 N N N N F 26 46 N 
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Diagnosis 
No 
units 
given  
Alloimmunised 
at admission 
Alloimmunised 
post 
transfusion 
Autoimmunised 
at admission 
Autoimmunised 
post transfusion Gender 
No. 
Episodes 
Age at first 
transfusion Transplant 
ESRF 82 N N N Y M 35 76 N 
ESRF 2 N N N N M 1 79 N 
ESRF 31 N N N Y M 14 71 N 
ESRF 14 N N N N M 6 72 N 
ESRF 5 N N N N M 2 71 N 
ESRF 15 N N N N M 6 82 N 
ESRF 10 N N N N M 4 70 N 
ESRF 18 N N N N F 8 61 N 
ESRF 25 N N N N M 10 76 N 
ESRF 2 N N N N F 1 86 N 
ESRF 2 N N N N F 1 67 N 
ESRF 10 N N N N F 4 67 N 
ESRF 26 N N N Y F 13 73 N 
ESRF 16 N N N N M 7 66 N 
ESRF 18 N N N N M 9 68 N 
ESRF 32 N N N N F 7 82 N 
ESRF 5 N N N N M 2 44 N 
ESRF 2 N N N N F 1 71 N 
ESRF 11 N N N N M 5 30 N 
ESRF 8 N N N N M 4 83 N 
ESRF 8 N N N N M 4 77 N 
ESRF 22 N N N N M 9 53 N 
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Diagnosis 
No 
units 
given  
Alloimmunised 
at admission 
Alloimmunised 
post 
transfusion 
Autoimmunised 
at admission 
Autoimmunised 
post transfusion Gender 
No. 
Episodes 
Age at first 
transfusion Transplant 
ESRF 4 N N N N F 2 61 N 
ESRF 8 N N N N M 4 80 N 
ESRF 3 N N N N F 1 64 N 
ESRF 2 N N N N M 1 43 N 
ESRF 2 N N N N M 1 52 N 
ESRF 7 N N N N M 4 77 N 
ESRF 4 N N N N M 2 80 N 
ESRF 9 N N N N M 4 63 N 
ESRF 2 N N N N M 1 79 N 
ESRF 29 N N N N F 16 77 N 
ESRF 11 N N N N F 5 80 N 
ESRF 5 N N N N M 2 85 N 
ESRF 6 N N N N M 2 77 N 
ESRF 25 N N N N M 3 65 N 
ESRF 2 N N N N F 1 80 N 
ESRF 38 N N N N F 18 57 N 
ESRF 5 N N N N M 2 72 N 
ESRF 3 N N N N M 1 87 N 
ESRF 5 N N N N M 2 80 N 
ESRF 22 N N N Y M 11 77 N 
ESRF 35 N N N N F 17 73 N 
ESRF 2 N N N N F 1 82 N 
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Diagnosis 
No 
units 
given  
Alloimmunised 
at admission 
Alloimmunised 
post 
transfusion 
Autoimmunised 
at admission 
Autoimmunised 
post transfusion Gender 
No. 
Episodes 
Age at first 
transfusion Transplant 
ESRF 2 N N N N F 1 86 N 
ESRF 2 N N N N M 1 75 N 
ESRF 6 N N N N M 2 82 N 
ESRF 10 N N N N M 5 76 N 
ESRF 11 N N N N F 5 77 N 
ESRF 2 N N N N M 1 87 N 
ESRF 13 N N N N F 6 49 N 
ESRF 8 N N N N F 4 80 N 
ESRF 2 N N N N F 1 73 N 
ESRF 6 N N N N M 3 82 N 
ESRF 7 N N N N F 3 92 N 
ESRF 19 N N N N M 9 75 N 
ESRF 14 N N N N M 7 77 N 
ESRF 14 N N N N M 7 79 N 
ESRF 3 N N N N F 1 40 N 
ESRF 3 N N N N M 1 73 N 
ESRF 63 N Y N Y M 29 67 N 
ESRF 5 N Y N Y F 2 62 N 
ESRF 73 Y Y Y Y F 36 52 N 
ESRF 13 N Y N N F 6 33 N 
ESRF 4 Y Y N N F 2 83 N 
ESRF 31 Y Y N N F 12 71 N 
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Diagnosis 
No 
units 
given  
Alloimmunised 
at admission 
Alloimmunised 
post 
transfusion 
Autoimmunised 
at admission 
Autoimmunised 
post transfusion Gender 
No. 
Episodes 
Age at first 
transfusion Transplant 
ESRF 4 Y Y N N F 2 49 N 
ESRF 11 N Y N Y F 5 49 N 
ESRF 4 N Y N Y M 2 80 N 
ESRF 8 N Y N N F 4 81 N 
ESRF 2 Y Y N N M 1 84 N 
ESRF 12 N Y N Y M 5 65 N 
ESRF 6 N Y N Y M 3 61 N 
ESRF 2 Y Y N N F 1 77 N 
ESRF 40 N Y N N F 18 63 N 
ESRF 36 N Y N N M 15 71 N 
ESRF 10 N Y N N M 4 72 N 
ESRF 2 N Y N N F 1 59 N 
ESRF 22 N Y N Y M 10 36 N 
ESRF 33 N Y N Y F 16 62 N 
ESRF 16 Y Y N N M 7 79 N 
ESRF 2 Y Y N N F 1 74 N 
ESRF 119 N Y N Y M 53 78 N 
ESRF 34 N Y N N F 17 52 N 
ESRF 17 N Y N N F 7 43 N 
ESRF 22 N Y N N M 9 39 N 
ESRF 5 N Y N N M 2 73 N 
ESRF 18 N Y N N F 8 75 N 
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Diagnosis 
No 
units 
given  
Alloimmunised 
at admission 
Alloimmunised 
post 
transfusion 
Autoimmunised 
at admission 
Autoimmunised 
post transfusion Gender 
No. 
Episodes 
Age at first 
transfusion Transplant 
ESRF 20 N Y N N F 10 47 N 
ESRF 15 N Y N Y F 7 72 N 
ESRF 25 N Y N Y F 12 60 N 
ESRF 12 N Y N N F 5 82 N 
ESRF 6 N Y N N F 3 83 N 
ESRF 6 Y Y N Y F 2 85 N 
ESRF 2 N Y N N F 1 65 N 
ESRF 10 N Y N Y F 5 89 N 
ESRF 6 N Y N Y M 3 72 N 
ESRF 11 N Y N N M 5 38 N 
ESRF 101 N Y N Y M 45 77 N 
ESRF 8 N Y N N F 4 76 N 
ESRF 61 N Y N Y M 29 77 N 
ESRF 8 N Y Y Y F 4 77 N 
ESRF 12 N Y N Y F 5 77 N 
ESRF 11 N Y N Y F 5 75 N 
ESRF 22 N Y N N M 11 51 N 
ESRF 48 N Y N Y F 19 31 N 
ESRF 12 N Y N N M 4 53 N 
ESRF 12 N Y N Y F 6 81 N 
ESRF 50 N Y N N F 20 78 N 
ESRF 10 N Y N N M 4 66 N 
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Diagnosis 
No 
units 
given  
Alloimmunised 
at admission 
Alloimmunised 
post 
transfusion 
Autoimmunised 
at admission 
Autoimmunised 
post transfusion Gender 
No. 
Episodes 
Age at first 
transfusion Transplant 
ESRF 37 Y Y N N F 14 86 N 
ESRF 24 N Y N N F 11 69 N 
ESRF 4 Y Y Y Y F 2 80 N 
ESRF 13 N Y N Y F 6 63 N 
ESRF 22 Y Y N Y M 11 65 N 
ESRF 23 N Y N N M 10 79 N 
ESRF 11 Y Y N Y M 5 61 N 
ESRF 57 N Y N N F 20 80 N 
ESRF 16 N Y N Y M 6 60 N 
ESRF 18 N Y N Y F 6 65 N 
ESRF 31 N Y N Y M 14 58 N 
ESRF 9 Y Y Y Y F 4 54 N 
ESRF 2 Y Y N N F 1 80 N 
ESRF 12 Y Y Y Y F 4 25 N 
ESRF 6 Y Y Y Y M 3 80 N 
HUS 6 N N N N M 3 26 N 
NHL 5 N Y N Y M 3 82 N 
Pyelonephritis 5 N N N N M 2 37 N 
Pyelonephritis 19 N N N N M 9 75 N 
Wegener 
granulomatosis 5 N N N N M 3 65 N 
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Diagnosis 
No 
units 
given  
Alloimmunised 
at admission 
Alloimmunised 
post 
transfusion 
Autoimmunised 
at admission 
Autoimmunised 
post transfusion Gender 
No. 
Episodes 
Age at first 
transfusion Transplant 
Wegener 
granulomatosis 5 N N N N F 2 57 N 
Wegener 
granulomatosis 5 N N N N M 2 46 N 
Wegener 
granulomatosis 12 N N N N M 5 69 N 
Wegener 
granulomatosis 39 N N N N M 12 74 N 
Wegener 
granulomatosis 12 N N N N M 6 76 N 
Wegener 
granulomatosis 5 N N N N M 2 57 N 
Wegener 
granulomatosis 7 N N N N F 3 56 N 
Wegener 
granulomatosis 4 N N N N M 2 64 N 
Wegener 
granulomatosis 7 N N N N M 3 71 N 
Wegener 
granulomatosis 4 N N N N F 2 82 N 
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10.3 Appendix 3: Programmed cut off values for the serological phenotyping profiles on the NEO analyser 
 
 
 
Antiserum Cut off low Cut off high Antiserum Cut off low Cut off high
Negative 0.000 23.998 Negative 0.000 23.998
Not determined 23.999 27.998
Positive (1+) 27.999 35.998
Positive (2+) 35.999 50.998
Positive (3+) 75.999 80.998 Positive (3+) 50.999 80.998
Postive (4+) 80.999 99.999 Postive (4+) 80.999 99.999
Negative 0.000 23.998 Negative 0.000 23.998
Positive (3+) 75.999 80.998 Positive (3+) 50.999 80.998
Postive (4+) 80.999 99.999 Postive (4+) 80.999 99.999
Negative 0.000 23.998 Negative 0.000 23.000
Positive (3+) 75.999 80.998 Positive (3+) 75.999 80.998
Postive (4+) 80.999 99.999 Postive (4+) 80.999 99.999
Negative 0.000 23.998 Negative 0.000 23.998
Positive (2+) 35.999 50.998
Positive (3+) 75.999 80.998 Positive (3+) 50.999 80.998
Postive (4+) 80.999 99.999 Postive (4+) 80.999 99.999
Not determined 23.999 35.998
Not determined 23.999 75.998
Not determined 23.999 50.998
Anti-E
Anti-e
Anti-K
Not determined 23.999 75.998
Not determined 23.999 75.998
Not determined 23.999 75.998
Not determined 23.999 75.998
Anti-Cw
Anti-M
Anti-N
Anti-C
Anti-c
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Antiserum Cut off low Cut off high Antiserum Cut off low Cut off high
Negative 0.000 20.998 Negative 0.000 20.998
Not determined 20.999 40.998 Not determined 20.999 40.998
Positive (1+) 40.999 50.998 Positive (1+) 40.999 50.998
Positive (2+) 50.999 72.998 Positive (2+) 50.999 72.998
Positive (3+) 72.999 90.998 Positive (3+) 72.999 90.998
Postive (4+) 90.999 99.999 Postive (4+) 90.999 99.999
Negative 0.000 20.998 Negative 0.000 20.998
Not determined 20.999 40.998 Not determined 20.999 40.998
Positive (1+) 40.999 50.998 Positive (1+) 40.999 50.998
Positive (2+) 50.999 72.998 Positive (2+) 50.999 72.998
Positive (3+) 72.999 90.998 Positive (3+) 72.999 90.998
Postive (4+) 90.999 99.999 Postive (4+) 90.999 99.999
Negative 0.000 20.998 Negative 0.000 20.998
Not determined 20.999 40.998 Not determined 20.999 40.998
Positive (1+) 40.999 50.998 Positive (1+) 40.999 50.998
Positive (2+) 50.999 72.998 Positive (2+) 50.999 72.998
Positive (3+) 72.999 90.998 Positive (3+) 72.999 90.998
Postive (4+) 90.999 99.999 Postive (4+) 90.999 99.999
Negative 0.000 20.998 Negative 0.000 20.998
Not determined 20.999 40.998 Not determined 20.999 40.998
Positive (1+) 40.999 50.998 Positive (1+) 40.999 50.998
Positive (2+) 50.999 72.998 Positive (2+) 50.999 72.998
Positive (3+) 72.999 90.998 Positive (3+) 72.999 90.998
Postive (4+) 90.999 99.999 Postive (4+) 90.999 99.999
Anti-Jkb Control Negative
Anti-Fya Anti-S
Anti-Fyb Anti-s
Anti-Jka Anti-k
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10.4 Appendix 4: Raw data for genotyping results 
 
 
 
Symbol Sample CSV 
Blood 
Group 
System Alleles Assayed Genotype Result 
Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green Unknown1 
New Batch 
4_20140514_125813.csv Rh RHCE*ce RHCE*cE C (RH:2) 0 
Green Unknown1 
New Batch 
4_20140514_125813.csv   RHCE*Ce   E (RH:3) + 
Green Unknown1 
New Batch 
4_20140514_125813.csv   RHCE*cE   c (RH:4) + 
Green Unknown1 
New Batch 
4_20140514_125813.csv   RHCE*CE   e (RH:5) 0 
Green Unknown1 
New Batch 
4_20140514_125813.csv   RHCE*CeCW   CW (RH:8) 0 
Green Unknown1 
New Batch 
4_20140514_125813.csv   RHCE*ceCW   V (RH:10) 0 
Green Unknown1 
New Batch 
4_20140514_125813.csv   RHCE*CECW   hrS (RH:19) + 
Green Unknown1 
New Batch 
4_20140514_125813.csv   RHCE*ceAR   VS (RH:20) 0 
Green Unknown1 
New Batch 
4_20140514_125813.csv   RHCE*CeFV   hrB (RH:31) 0 
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green Unknown1 
New Batch 
4_20140514_125813.csv   RHCE*CeVG       
Green Unknown1 
New Batch 
4_20140514_125813.csv   RHCE*cEFM       
Green Unknown1 
New Batch 
4_20140514_125813.csv   RHCE*ce[712G]       
Green Unknown1 
New Batch 
4_20140514_125813.csv   RHCE*ce[733G]       
Green Unknown1 
New Batch 
4_20140514_125813.csv   RHCE*ce[733G,1006T]       
Green Unknown1 
New Batch 
4_20140514_125813.csv   RHCE*CE-D[2, 5, 7]-CE       
Green Unknown1 
New Batch 
4_20140514_125813.csv   RHCE*cE[697G,712G,733G]       
Green Unknown1 
New Batch 
4_20140514_125813.csv   
RHD*r’s-
RHCE*ce[733G,1006T]       
Green Unknown1 
New Batch 
4_20140514_125813.csv Kell KEL*K_KPB_JSB KEL*k_KPB_JSB K (KEL:1) 0 
Green Unknown1 
New Batch 
4_20140514_125813.csv   KEL*k_KPB_JSB   k (KEL:2) + 
Green Unknown1 
New Batch 
4_20140514_125813.csv   KEL*k_KPA_JSB   Kpa (KEL:3) 0 
Green Unknown1 
New Batch 
4_20140514_125813.csv   KEL*k_KPB_JSA   Kpb (KEL:4) + 
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green Unknown1 
New Batch 
4_20140514_125813.csv       Jsa (KEL:6) 0 
Green Unknown1 
New Batch 
4_20140514_125813.csv       Jsb (KEL:7) + 
Green Unknown1 
New Batch 
4_20140514_125813.csv Kidd JK*A JK*A, JK*B Jka (JK:1) + 
Green Unknown1 
New Batch 
4_20140514_125813.csv   JK*B   Jkb (JK:2) + 
Green Unknown1 
New Batch 
4_20140514_125813.csv   JK*B_null(IVS5-1a)       
Green Unknown1 
New Batch 
4_20140514_125813.csv   JK*B_null(871C)       
Green Unknown1 
New Batch 
4_20140514_125813.csv Duffy FY*A FY*A, FY*B Fya (FY:1) + 
Green Unknown1 
New Batch 
4_20140514_125813.csv   FY*B   Fyb (FY:2) + 
Green Unknown1 
New Batch 
4_20140514_125813.csv   FY*B_GATA       
Green Unknown1 
New Batch 
4_20140514_125813.csv   FY*B[265T]_FY*X       
Green Unknown1 
New Batch 
4_20140514_125813.csv MNS GYPA*M GYPA*N M (MNS:1) 0 
Green Unknown1 
New Batch 
4_20140514_125813.csv   GYPA*N   N (MNS:2) + 
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green Unknown1 
New Batch 
4_20140514_125813.csv   GYPB*S GYPB*s S (MNS:3) 0 
Green Unknown1 
New Batch 
4_20140514_125813.csv   GYPB*s   s (MNS:4) + 
Green Unknown1 
New Batch 
4_20140514_125813.csv   GYPB*S_null(IVS5+5t)   U (MNS:5) + 
Green Unknown1 
New Batch 
4_20140514_125813.csv   GYPB*S_null(230T)   Mia (MNS:7) 0 
Green Unknown1 
New Batch 
4_20140514_125813.csv   GYPB*deletion       
Green Unknown1 
New Batch 
4_20140514_125813.csv   GYPB*Mur       
Green Unknown1 
New Batch 
4_20140514_125813.csv Diego DI*A DI*B Dia (DI:1) 0 
Green Unknown1 
New Batch 
4_20140514_125813.csv   DI*B   Dib (DI:2) + 
Green Unknown1 
New Batch 
4_20140514_125813.csv Dombrock DO*A DO*A, DO*B Doa (DO:1) + 
Green Unknown1 
New Batch 
4_20140514_125813.csv   DO*B   Dob (DO:2) + 
Green Unknown1 
New Batch 
4_20140514_125813.csv   DO*B_HY-   Hy (DO:4) + 
Green Unknown1 
New Batch 
4_20140514_125813.csv   DO*A_JOA-   Joa (DO:5) + 
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green Unknown1 
New Batch 
4_20140514_125813.csv Colton CO*A CO*A Coa (CO:1) + 
Green Unknown1 
New Batch 
4_20140514_125813.csv   CO*B   Cob (CO:2) 0 
Green Unknown1 
New Batch 
4_20140514_125813.csv Cartwright YT*A YT*A Yta (YT:1) + 
Green Unknown1 
New Batch 
4_20140514_125813.csv   YT*B   Ytb (YT:2) 0 
Green Unknown1 
New Batch 
4_20140514_125813.csv Lutheran LU*A LU*B Lua (LU:1) 0 
Green Unknown1 
New Batch 
4_20140514_125813.csv   LU*B   Lub (LU:2) + 
Green Unknown2 
New Batch 
4_20140514_125813.csv Rh RHCE*ce RHCE*ce, RHCE*cE C (RH:2) 0 
Green Unknown2 
New Batch 
4_20140514_125813.csv   RHCE*Ce   E (RH:3) + 
Green Unknown2 
New Batch 
4_20140514_125813.csv   RHCE*cE   c (RH:4) + 
Green Unknown2 
New Batch 
4_20140514_125813.csv   RHCE*CE   e (RH:5) + 
Green Unknown2 
New Batch 
4_20140514_125813.csv   RHCE*CeCW   CW (RH:8) 0 
Green Unknown2 
New Batch 
4_20140514_125813.csv   RHCE*ceCW   V (RH:10) 0 
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green Unknown2 
New Batch 
4_20140514_125813.csv   RHCE*CECW   hrS (RH:19) + 
Green Unknown2 
New Batch 
4_20140514_125813.csv   RHCE*ceAR   VS (RH:20) 0 
Green Unknown2 
New Batch 
4_20140514_125813.csv   RHCE*CeFV   hrB (RH:31) + 
Green Unknown2 
New Batch 
4_20140514_125813.csv   RHCE*CeVG       
Green Unknown2 
New Batch 
4_20140514_125813.csv   RHCE*cEFM       
Green Unknown2 
New Batch 
4_20140514_125813.csv   RHCE*ce[712G]       
Green Unknown2 
New Batch 
4_20140514_125813.csv   RHCE*ce[733G]       
Green Unknown2 
New Batch 
4_20140514_125813.csv   RHCE*ce[733G,1006T]       
Green Unknown2 
New Batch 
4_20140514_125813.csv   RHCE*CE-D[2, 5, 7]-CE       
Green Unknown2 
New Batch 
4_20140514_125813.csv   RHCE*cE[697G,712G,733G]       
Green Unknown2 
New Batch 
4_20140514_125813.csv   
RHD*r’s-
RHCE*ce[733G,1006T]       
Green Unknown2 
New Batch 
4_20140514_125813.csv Kell KEL*K_KPB_JSB KEL*k_KPB_JSB K (KEL:1) 0 
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green Unknown2 
New Batch 
4_20140514_125813.csv   KEL*k_KPB_JSB   k (KEL:2) + 
Green Unknown2 
New Batch 
4_20140514_125813.csv   KEL*k_KPA_JSB   Kpa (KEL:3) 0 
Green Unknown2 
New Batch 
4_20140514_125813.csv   KEL*k_KPB_JSA   Kpb (KEL:4) + 
Green Unknown2 
New Batch 
4_20140514_125813.csv       Jsa (KEL:6) 0 
Green Unknown2 
New Batch 
4_20140514_125813.csv       Jsb (KEL:7) + 
Green Unknown2 
New Batch 
4_20140514_125813.csv Kidd JK*A JK*A, JK*B Jka (JK:1) + 
Green Unknown2 
New Batch 
4_20140514_125813.csv   JK*B   Jkb (JK:2) + 
Green Unknown2 
New Batch 
4_20140514_125813.csv   JK*B_null(IVS5-1a)       
Green Unknown2 
New Batch 
4_20140514_125813.csv   JK*B_null(871C)       
Green Unknown2 
New Batch 
4_20140514_125813.csv Duffy FY*A FY*A, FY*B Fya (FY:1) + 
Green Unknown2 
New Batch 
4_20140514_125813.csv   FY*B   Fyb (FY:2) + 
Green Unknown2 
New Batch 
4_20140514_125813.csv   FY*B_GATA       
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green Unknown2 
New Batch 
4_20140514_125813.csv   FY*B[265T]_FY*X       
Green Unknown2 
New Batch 
4_20140514_125813.csv MNS GYPA*M GYPA*M M (MNS:1) + 
Green Unknown2 
New Batch 
4_20140514_125813.csv   GYPA*N   N (MNS:2) 0 
Green Unknown2 
New Batch 
4_20140514_125813.csv   GYPB*S GYPB*S, GYPB*s S (MNS:3) + 
Green Unknown2 
New Batch 
4_20140514_125813.csv   GYPB*s   s (MNS:4) + 
Green Unknown2 
New Batch 
4_20140514_125813.csv   GYPB*S_null(IVS5+5t)   U (MNS:5) + 
Green Unknown2 
New Batch 
4_20140514_125813.csv   GYPB*S_null(230T)   Mia (MNS:7) 0 
Green Unknown2 
New Batch 
4_20140514_125813.csv   GYPB*deletion       
Green Unknown2 
New Batch 
4_20140514_125813.csv   GYPB*Mur       
Green Unknown2 
New Batch 
4_20140514_125813.csv Diego DI*A DI*B Dia (DI:1) 0 
Green Unknown2 
New Batch 
4_20140514_125813.csv   DI*B   Dib (DI:2) + 
Green Unknown2 
New Batch 
4_20140514_125813.csv Dombrock DO*A DO*A Doa (DO:1) + 
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green Unknown2 
New Batch 
4_20140514_125813.csv   DO*B   Dob (DO:2) 0 
Green Unknown2 
New Batch 
4_20140514_125813.csv   DO*B_HY-   Hy (DO:4) + 
Green Unknown2 
New Batch 
4_20140514_125813.csv   DO*A_JOA-   Joa (DO:5) + 
Green Unknown2 
New Batch 
4_20140514_125813.csv Colton CO*A CO*A Coa (CO:1) + 
Green Unknown2 
New Batch 
4_20140514_125813.csv   CO*B   Cob (CO:2) 0 
Green Unknown2 
New Batch 
4_20140514_125813.csv Cartwright YT*A YT*A Yta (YT:1) + 
Green Unknown2 
New Batch 
4_20140514_125813.csv   YT*B   Ytb (YT:2) 0 
Green Unknown2 
New Batch 
4_20140514_125813.csv Lutheran LU*A LU*B Lua (LU:1) 0 
Green Unknown2 
New Batch 
4_20140514_125813.csv   LU*B   Lub (LU:2) + 
Green Unknown3 
New Batch 
4_20140514_125813.csv Rh RHCE*ce RHCE*cE C (RH:2) 0 
Green Unknown3 
New Batch 
4_20140514_125813.csv   RHCE*Ce   E (RH:3) + 
Green Unknown3 
New Batch 
4_20140514_125813.csv   RHCE*cE   c (RH:4) + 
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green Unknown3 
New Batch 
4_20140514_125813.csv   RHCE*CE   e (RH:5) 0 
Green Unknown3 
New Batch 
4_20140514_125813.csv   RHCE*CeCW   CW (RH:8) 0 
Green Unknown3 
New Batch 
4_20140514_125813.csv   RHCE*ceCW   V (RH:10) 0 
Green Unknown3 
New Batch 
4_20140514_125813.csv   RHCE*CECW   hrS (RH:19) + 
Green Unknown3 
New Batch 
4_20140514_125813.csv   RHCE*ceAR   VS (RH:20) 0 
Green Unknown3 
New Batch 
4_20140514_125813.csv   RHCE*CeFV   hrB (RH:31) 0 
Green Unknown3 
New Batch 
4_20140514_125813.csv   RHCE*CeVG       
Green Unknown3 
New Batch 
4_20140514_125813.csv   RHCE*cEFM       
Green Unknown3 
New Batch 
4_20140514_125813.csv   RHCE*ce[712G]       
Green Unknown3 
New Batch 
4_20140514_125813.csv   RHCE*ce[733G]       
Green Unknown3 
New Batch 
4_20140514_125813.csv   RHCE*ce[733G,1006T]       
Green Unknown3 
New Batch 
4_20140514_125813.csv   RHCE*CE-D[2, 5, 7]-CE       
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green Unknown3 
New Batch 
4_20140514_125813.csv   RHCE*cE[697G,712G,733G]       
Green Unknown3 
New Batch 
4_20140514_125813.csv   
RHD*r’s-
RHCE*ce[733G,1006T]       
Green Unknown3 
New Batch 
4_20140514_125813.csv Kell KEL*K_KPB_JSB KEL*k_KPB_JSB K (KEL:1) 0 
Green Unknown3 
New Batch 
4_20140514_125813.csv   KEL*k_KPB_JSB   k (KEL:2) + 
Green Unknown3 
New Batch 
4_20140514_125813.csv   KEL*k_KPA_JSB   Kpa (KEL:3) 0 
Green Unknown3 
New Batch 
4_20140514_125813.csv   KEL*k_KPB_JSA   Kpb (KEL:4) + 
Green Unknown3 
New Batch 
4_20140514_125813.csv       Jsa (KEL:6) 0 
Green Unknown3 
New Batch 
4_20140514_125813.csv       Jsb (KEL:7) + 
Green Unknown3 
New Batch 
4_20140514_125813.csv Kidd JK*A JK*B Jka (JK:1) 0 
Green Unknown3 
New Batch 
4_20140514_125813.csv   JK*B   Jkb (JK:2) + 
Green Unknown3 
New Batch 
4_20140514_125813.csv   JK*B_null(IVS5-1a)       
Green Unknown3 
New Batch 
4_20140514_125813.csv   JK*B_null(871C)       
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green Unknown3 
New Batch 
4_20140514_125813.csv Duffy FY*A FY*A, FY*B Fya (FY:1) + 
Green Unknown3 
New Batch 
4_20140514_125813.csv   FY*B   Fyb (FY:2) + 
Green Unknown3 
New Batch 
4_20140514_125813.csv   FY*B_GATA       
Green Unknown3 
New Batch 
4_20140514_125813.csv   FY*B[265T]_FY*X       
Green Unknown3 
New Batch 
4_20140514_125813.csv MNS GYPA*M GYPA*M, GYPA*N M (MNS:1) + 
Green Unknown3 
New Batch 
4_20140514_125813.csv   GYPA*N   N (MNS:2) + 
Green Unknown3 
New Batch 
4_20140514_125813.csv   GYPB*S GYPB*s S (MNS:3) 0 
Green Unknown3 
New Batch 
4_20140514_125813.csv   GYPB*s   s (MNS:4) + 
Green Unknown3 
New Batch 
4_20140514_125813.csv   GYPB*S_null(IVS5+5t)   U (MNS:5) + 
Green Unknown3 
New Batch 
4_20140514_125813.csv   GYPB*S_null(230T)   Mia (MNS:7) 0 
Green Unknown3 
New Batch 
4_20140514_125813.csv   GYPB*deletion       
Green Unknown3 
New Batch 
4_20140514_125813.csv   GYPB*Mur       
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green Unknown3 
New Batch 
4_20140514_125813.csv Diego DI*A DI*B Dia (DI:1) 0 
Green Unknown3 
New Batch 
4_20140514_125813.csv   DI*B   Dib (DI:2) + 
Green Unknown3 
New Batch 
4_20140514_125813.csv Dombrock DO*A DO*B Doa (DO:1) 0 
Green Unknown3 
New Batch 
4_20140514_125813.csv   DO*B   Dob (DO:2) + 
Green Unknown3 
New Batch 
4_20140514_125813.csv   DO*B_HY-   Hy (DO:4) + 
Green Unknown3 
New Batch 
4_20140514_125813.csv   DO*A_JOA-   Joa (DO:5) + 
Green Unknown3 
New Batch 
4_20140514_125813.csv Colton CO*A CO*A Coa (CO:1) + 
Green Unknown3 
New Batch 
4_20140514_125813.csv   CO*B   Cob (CO:2) 0 
Green Unknown3 
New Batch 
4_20140514_125813.csv Cartwright YT*A YT*A Yta (YT:1) + 
Green Unknown3 
New Batch 
4_20140514_125813.csv   YT*B   Ytb (YT:2) 0 
Green Unknown3 
New Batch 
4_20140514_125813.csv Lutheran LU*A LU*B Lua (LU:1) 0 
Green Unknown3 
New Batch 
4_20140514_125813.csv   LU*B   Lub (LU:2) + 
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green Unknown4 
New Batch 
4_20140514_125813.csv Rh RHCE*ce RHCE*ce, RHCE*Ce C (RH:2) + 
Green Unknown4 
New Batch 
4_20140514_125813.csv   RHCE*Ce   E (RH:3) 0 
Green Unknown4 
New Batch 
4_20140514_125813.csv   RHCE*cE   c (RH:4) + 
Green Unknown4 
New Batch 
4_20140514_125813.csv   RHCE*CE   e (RH:5) + 
Green Unknown4 
New Batch 
4_20140514_125813.csv   RHCE*CeCW   CW (RH:8) 0 
Green Unknown4 
New Batch 
4_20140514_125813.csv   RHCE*ceCW   V (RH:10) 0 
Green Unknown4 
New Batch 
4_20140514_125813.csv   RHCE*CECW   hrS (RH:19) + 
Green Unknown4 
New Batch 
4_20140514_125813.csv   RHCE*ceAR   VS (RH:20) 0 
Green Unknown4 
New Batch 
4_20140514_125813.csv   RHCE*CeFV   hrB (RH:31) + 
Green Unknown4 
New Batch 
4_20140514_125813.csv   RHCE*CeVG       
Green Unknown4 
New Batch 
4_20140514_125813.csv   RHCE*cEFM       
Green Unknown4 
New Batch 
4_20140514_125813.csv   RHCE*ce[712G]       
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green Unknown4 
New Batch 
4_20140514_125813.csv   RHCE*ce[733G]       
Green Unknown4 
New Batch 
4_20140514_125813.csv   RHCE*ce[733G,1006T]       
Green Unknown4 
New Batch 
4_20140514_125813.csv   RHCE*CE-D[2, 5, 7]-CE       
Green Unknown4 
New Batch 
4_20140514_125813.csv   RHCE*cE[697G,712G,733G]       
Green Unknown4 
New Batch 
4_20140514_125813.csv   
RHD*r’s-
RHCE*ce[733G,1006T]       
Green Unknown4 
New Batch 
4_20140514_125813.csv Kell KEL*K_KPB_JSB 
KEL*K_KPB_JSB, 
KEL*k_KPB_JSB K (KEL:1) + 
Green Unknown4 
New Batch 
4_20140514_125813.csv   KEL*k_KPB_JSB   k (KEL:2) + 
Green Unknown4 
New Batch 
4_20140514_125813.csv   KEL*k_KPA_JSB   Kpa (KEL:3) 0 
Green Unknown4 
New Batch 
4_20140514_125813.csv   KEL*k_KPB_JSA   Kpb (KEL:4) + 
Green Unknown4 
New Batch 
4_20140514_125813.csv       Jsa (KEL:6) 0 
Green Unknown4 
New Batch 
4_20140514_125813.csv       Jsb (KEL:7) + 
Green Unknown4 
New Batch 
4_20140514_125813.csv Kidd JK*A JK*A Jka (JK:1) + 
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green Unknown4 
New Batch 
4_20140514_125813.csv   JK*B   Jkb (JK:2) 0 
Green Unknown4 
New Batch 
4_20140514_125813.csv   JK*B_null(IVS5-1a)       
Green Unknown4 
New Batch 
4_20140514_125813.csv   JK*B_null(871C)       
Green Unknown4 
New Batch 
4_20140514_125813.csv Duffy FY*A FY*A, FY*B Fya (FY:1) + 
Green Unknown4 
New Batch 
4_20140514_125813.csv   FY*B   Fyb (FY:2) + 
Green Unknown4 
New Batch 
4_20140514_125813.csv   FY*B_GATA       
Green Unknown4 
New Batch 
4_20140514_125813.csv   FY*B[265T]_FY*X       
Green Unknown4 
New Batch 
4_20140514_125813.csv MNS GYPA*M GYPA*M M (MNS:1) + 
Green Unknown4 
New Batch 
4_20140514_125813.csv   GYPA*N   N (MNS:2) 0 
Green Unknown4 
New Batch 
4_20140514_125813.csv   GYPB*S GYPB*s S (MNS:3) 0 
Green Unknown4 
New Batch 
4_20140514_125813.csv   GYPB*s   s (MNS:4) + 
Green Unknown4 
New Batch 
4_20140514_125813.csv   GYPB*S_null(IVS5+5t)   U (MNS:5) + 
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green Unknown4 
New Batch 
4_20140514_125813.csv   GYPB*S_null(230T)   Mia (MNS:7) 0 
Green Unknown4 
New Batch 
4_20140514_125813.csv   GYPB*deletion       
Green Unknown4 
New Batch 
4_20140514_125813.csv   GYPB*Mur       
Green Unknown4 
New Batch 
4_20140514_125813.csv Diego DI*A DI*B Dia (DI:1) 0 
Green Unknown4 
New Batch 
4_20140514_125813.csv   DI*B   Dib (DI:2) + 
Green Unknown4 
New Batch 
4_20140514_125813.csv Dombrock DO*A DO*A, DO*B Doa (DO:1) + 
Green Unknown4 
New Batch 
4_20140514_125813.csv   DO*B   Dob (DO:2) + 
Green Unknown4 
New Batch 
4_20140514_125813.csv   DO*B_HY-   Hy (DO:4) + 
Green Unknown4 
New Batch 
4_20140514_125813.csv   DO*A_JOA-   Joa (DO:5) + 
Green Unknown4 
New Batch 
4_20140514_125813.csv Colton CO*A CO*A Coa (CO:1) + 
Green Unknown4 
New Batch 
4_20140514_125813.csv   CO*B   Cob (CO:2) 0 
Green Unknown4 
New Batch 
4_20140514_125813.csv Cartwright YT*A YT*A Yta (YT:1) + 
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green Unknown4 
New Batch 
4_20140514_125813.csv   YT*B   Ytb (YT:2) 0 
Green Unknown4 
New Batch 
4_20140514_125813.csv Lutheran LU*A LU*B Lua (LU:1) 0 
Green Unknown4 
New Batch 
4_20140514_125813.csv   LU*B   Lub (LU:2) + 
Green Unknown5 
New Batch 
4_20140514_125813.csv Rh RHCE*ce RHCE*cE C (RH:2) 0 
Green Unknown5 
New Batch 
4_20140514_125813.csv   RHCE*Ce   E (RH:3) + 
Green Unknown5 
New Batch 
4_20140514_125813.csv   RHCE*cE   c (RH:4) + 
Green Unknown5 
New Batch 
4_20140514_125813.csv   RHCE*CE   e (RH:5) 0 
Green Unknown5 
New Batch 
4_20140514_125813.csv   RHCE*CeCW   CW (RH:8) 0 
Green Unknown5 
New Batch 
4_20140514_125813.csv   RHCE*ceCW   V (RH:10) 0 
Green Unknown5 
New Batch 
4_20140514_125813.csv   RHCE*CECW   hrS (RH:19) + 
Green Unknown5 
New Batch 
4_20140514_125813.csv   RHCE*ceAR   VS (RH:20) 0 
Green Unknown5 
New Batch 
4_20140514_125813.csv   RHCE*CeFV   hrB (RH:31) 0 
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green Unknown5 
New Batch 
4_20140514_125813.csv   RHCE*CeVG       
Green Unknown5 
New Batch 
4_20140514_125813.csv   RHCE*cEFM       
Green Unknown5 
New Batch 
4_20140514_125813.csv   RHCE*ce[712G]       
Green Unknown5 
New Batch 
4_20140514_125813.csv   RHCE*ce[733G]       
Green Unknown5 
New Batch 
4_20140514_125813.csv   RHCE*ce[733G,1006T]       
Green Unknown5 
New Batch 
4_20140514_125813.csv   RHCE*CE-D[2, 5, 7]-CE       
Green Unknown5 
New Batch 
4_20140514_125813.csv   RHCE*cE[697G,712G,733G]       
Green Unknown5 
New Batch 
4_20140514_125813.csv   
RHD*r’s-
RHCE*ce[733G,1006T]       
Green Unknown5 
New Batch 
4_20140514_125813.csv Kell KEL*K_KPB_JSB KEL*k_KPB_JSB K (KEL:1) 0 
Green Unknown5 
New Batch 
4_20140514_125813.csv   KEL*k_KPB_JSB   k (KEL:2) + 
Green Unknown5 
New Batch 
4_20140514_125813.csv   KEL*k_KPA_JSB   Kpa (KEL:3) 0 
Green Unknown5 
New Batch 
4_20140514_125813.csv   KEL*k_KPB_JSA   Kpb (KEL:4) + 
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green Unknown5 
New Batch 
4_20140514_125813.csv       Jsa (KEL:6) 0 
Green Unknown5 
New Batch 
4_20140514_125813.csv       Jsb (KEL:7) + 
Green Unknown5 
New Batch 
4_20140514_125813.csv Kidd JK*A JK*A Jka (JK:1) + 
Green Unknown5 
New Batch 
4_20140514_125813.csv   JK*B   Jkb (JK:2) 0 
Green Unknown5 
New Batch 
4_20140514_125813.csv   JK*B_null(IVS5-1a)       
Green Unknown5 
New Batch 
4_20140514_125813.csv   JK*B_null(871C)       
Green Unknown5 
New Batch 
4_20140514_125813.csv Duffy FY*A FY*A Fya (FY:1) + 
Green Unknown5 
New Batch 
4_20140514_125813.csv   FY*B   Fyb (FY:2) 0 
Green Unknown5 
New Batch 
4_20140514_125813.csv   FY*B_GATA       
Green Unknown5 
New Batch 
4_20140514_125813.csv   FY*B[265T]_FY*X       
Green Unknown5 
New Batch 
4_20140514_125813.csv MNS GYPA*M GYPA*N M (MNS:1) 0 
Green Unknown5 
New Batch 
4_20140514_125813.csv   GYPA*N   N (MNS:2) + 
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green Unknown5 
New Batch 
4_20140514_125813.csv   GYPB*S GYPB*s S (MNS:3) 0 
Green Unknown5 
New Batch 
4_20140514_125813.csv   GYPB*s   s (MNS:4) + 
Green Unknown5 
New Batch 
4_20140514_125813.csv   GYPB*S_null(IVS5+5t)   U (MNS:5) + 
Green Unknown5 
New Batch 
4_20140514_125813.csv   GYPB*S_null(230T)   Mia (MNS:7) 0 
Green Unknown5 
New Batch 
4_20140514_125813.csv   GYPB*deletion       
Green Unknown5 
New Batch 
4_20140514_125813.csv   GYPB*Mur       
Green Unknown5 
New Batch 
4_20140514_125813.csv Diego DI*A DI*B Dia (DI:1) 0 
Green Unknown5 
New Batch 
4_20140514_125813.csv   DI*B   Dib (DI:2) + 
Green Unknown5 
New Batch 
4_20140514_125813.csv Dombrock DO*A DO*A Doa (DO:1) + 
Green Unknown5 
New Batch 
4_20140514_125813.csv   DO*B   Dob (DO:2) 0 
Green Unknown5 
New Batch 
4_20140514_125813.csv   DO*B_HY-   Hy (DO:4) + 
Green Unknown5 
New Batch 
4_20140514_125813.csv   DO*A_JOA-   Joa (DO:5) + 
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green Unknown5 
New Batch 
4_20140514_125813.csv Colton CO*A CO*A Coa (CO:1) + 
Green Unknown5 
New Batch 
4_20140514_125813.csv   CO*B   Cob (CO:2) 0 
Green Unknown5 
New Batch 
4_20140514_125813.csv Cartwright YT*A YT*A Yta (YT:1) + 
Green Unknown5 
New Batch 
4_20140514_125813.csv   YT*B   Ytb (YT:2) 0 
Green Unknown5 
New Batch 
4_20140514_125813.csv Lutheran LU*A LU*B Lua (LU:1) 0 
Green Unknown5 
New Batch 
4_20140514_125813.csv   LU*B   Lub (LU:2) + 
Green Unknown6 
New Batch 
4_20140514_125813.csv Rh RHCE*ce RHCE*ce, RHCE*cE C (RH:2) 0 
Green Unknown6 
New Batch 
4_20140514_125813.csv   RHCE*Ce   E (RH:3) + 
Green Unknown6 
New Batch 
4_20140514_125813.csv   RHCE*cE   c (RH:4) + 
Green Unknown6 
New Batch 
4_20140514_125813.csv   RHCE*CE   e (RH:5) + 
Green Unknown6 
New Batch 
4_20140514_125813.csv   RHCE*CeCW   CW (RH:8) 0 
Green Unknown6 
New Batch 
4_20140514_125813.csv   RHCE*ceCW   V (RH:10) 0 
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green Unknown6 
New Batch 
4_20140514_125813.csv   RHCE*CECW   hrS (RH:19) + 
Green Unknown6 
New Batch 
4_20140514_125813.csv   RHCE*ceAR   VS (RH:20) 0 
Green Unknown6 
New Batch 
4_20140514_125813.csv   RHCE*CeFV   hrB (RH:31) + 
Green Unknown6 
New Batch 
4_20140514_125813.csv   RHCE*CeVG       
Green Unknown6 
New Batch 
4_20140514_125813.csv   RHCE*cEFM       
Green Unknown6 
New Batch 
4_20140514_125813.csv   RHCE*ce[712G]       
Green Unknown6 
New Batch 
4_20140514_125813.csv   RHCE*ce[733G]       
Green Unknown6 
New Batch 
4_20140514_125813.csv   RHCE*ce[733G,1006T]       
Green Unknown6 
New Batch 
4_20140514_125813.csv   RHCE*CE-D[2, 5, 7]-CE       
Green Unknown6 
New Batch 
4_20140514_125813.csv   RHCE*cE[697G,712G,733G]       
Green Unknown6 
New Batch 
4_20140514_125813.csv   
RHD*r’s-
RHCE*ce[733G,1006T]       
Green Unknown6 
New Batch 
4_20140514_125813.csv Kell KEL*K_KPB_JSB KEL*k_KPB_JSB K (KEL:1) 0 
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green Unknown6 
New Batch 
4_20140514_125813.csv   KEL*k_KPB_JSB   k (KEL:2) + 
Green Unknown6 
New Batch 
4_20140514_125813.csv   KEL*k_KPA_JSB   Kpa (KEL:3) 0 
Green Unknown6 
New Batch 
4_20140514_125813.csv   KEL*k_KPB_JSA   Kpb (KEL:4) + 
Green Unknown6 
New Batch 
4_20140514_125813.csv       Jsa (KEL:6) 0 
Green Unknown6 
New Batch 
4_20140514_125813.csv       Jsb (KEL:7) + 
Green Unknown6 
New Batch 
4_20140514_125813.csv Kidd JK*A JK*B Jka (JK:1) 0 
Green Unknown6 
New Batch 
4_20140514_125813.csv   JK*B   Jkb (JK:2) + 
Green Unknown6 
New Batch 
4_20140514_125813.csv   JK*B_null(IVS5-1a)       
Green Unknown6 
New Batch 
4_20140514_125813.csv   JK*B_null(871C)       
Green Unknown6 
New Batch 
4_20140514_125813.csv Duffy FY*A FY*B Fya (FY:1) 0 
Green Unknown6 
New Batch 
4_20140514_125813.csv   FY*B   Fyb (FY:2) + 
Green Unknown6 
New Batch 
4_20140514_125813.csv   FY*B_GATA       
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green Unknown6 
New Batch 
4_20140514_125813.csv   FY*B[265T]_FY*X       
Green Unknown6 
New Batch 
4_20140514_125813.csv MNS GYPA*M GYPA*M M (MNS:1) + 
Green Unknown6 
New Batch 
4_20140514_125813.csv   GYPA*N   N (MNS:2) 0 
Green Unknown6 
New Batch 
4_20140514_125813.csv   GYPB*S GYPB*S, GYPB*s S (MNS:3) + 
Green Unknown6 
New Batch 
4_20140514_125813.csv   GYPB*s   s (MNS:4) + 
Green Unknown6 
New Batch 
4_20140514_125813.csv   GYPB*S_null(IVS5+5t)   U (MNS:5) + 
Green Unknown6 
New Batch 
4_20140514_125813.csv   GYPB*S_null(230T)   Mia (MNS:7) 0 
Green Unknown6 
New Batch 
4_20140514_125813.csv   GYPB*deletion       
Green Unknown6 
New Batch 
4_20140514_125813.csv   GYPB*Mur       
Green Unknown6 
New Batch 
4_20140514_125813.csv Diego DI*A DI*B Dia (DI:1) 0 
Green Unknown6 
New Batch 
4_20140514_125813.csv   DI*B   Dib (DI:2) + 
Green Unknown6 
New Batch 
4_20140514_125813.csv Dombrock DO*A DO*B Doa (DO:1) 0 
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green Unknown6 
New Batch 
4_20140514_125813.csv   DO*B   Dob (DO:2) + 
Green Unknown6 
New Batch 
4_20140514_125813.csv   DO*B_HY-   Hy (DO:4) + 
Green Unknown6 
New Batch 
4_20140514_125813.csv   DO*A_JOA-   Joa (DO:5) + 
Green Unknown6 
New Batch 
4_20140514_125813.csv Colton CO*A CO*A Coa (CO:1) + 
Green Unknown6 
New Batch 
4_20140514_125813.csv   CO*B   Cob (CO:2) 0 
Green Unknown6 
New Batch 
4_20140514_125813.csv Cartwright YT*A YT*A Yta (YT:1) + 
Green Unknown6 
New Batch 
4_20140514_125813.csv   YT*B   Ytb (YT:2) 0 
Green Unknown6 
New Batch 
4_20140514_125813.csv Lutheran LU*A LU*B Lua (LU:1) 0 
Green Unknown6 
New Batch 
4_20140514_125813.csv   LU*B   Lub (LU:2) + 
Green Unknown7 
New Batch 
4_20140514_125813.csv Rh RHCE*ce RHCE*ce, RHCE*cE C (RH:2) 0 
Green Unknown7 
New Batch 
4_20140514_125813.csv   RHCE*Ce   E (RH:3) + 
Green Unknown7 
New Batch 
4_20140514_125813.csv   RHCE*cE   c (RH:4) + 
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green Unknown7 
New Batch 
4_20140514_125813.csv   RHCE*CE   e (RH:5) + 
Green Unknown7 
New Batch 
4_20140514_125813.csv   RHCE*CeCW   CW (RH:8) 0 
Green Unknown7 
New Batch 
4_20140514_125813.csv   RHCE*ceCW   V (RH:10) 0 
Green Unknown7 
New Batch 
4_20140514_125813.csv   RHCE*CECW   hrS (RH:19) + 
Green Unknown7 
New Batch 
4_20140514_125813.csv   RHCE*ceAR   VS (RH:20) 0 
Green Unknown7 
New Batch 
4_20140514_125813.csv   RHCE*CeFV   hrB (RH:31) + 
Green Unknown7 
New Batch 
4_20140514_125813.csv   RHCE*CeVG       
Green Unknown7 
New Batch 
4_20140514_125813.csv   RHCE*cEFM       
Green Unknown7 
New Batch 
4_20140514_125813.csv   RHCE*ce[712G]       
Green Unknown7 
New Batch 
4_20140514_125813.csv   RHCE*ce[733G]       
Green Unknown7 
New Batch 
4_20140514_125813.csv   RHCE*ce[733G,1006T]       
Green Unknown7 
New Batch 
4_20140514_125813.csv   RHCE*CE-D[2, 5, 7]-CE       
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green Unknown7 
New Batch 
4_20140514_125813.csv   RHCE*cE[697G,712G,733G]       
Green Unknown7 
New Batch 
4_20140514_125813.csv   
RHD*r’s-
RHCE*ce[733G,1006T]       
Green Unknown7 
New Batch 
4_20140514_125813.csv Kell KEL*K_KPB_JSB KEL*k_KPB_JSB K (KEL:1) 0 
Green Unknown7 
New Batch 
4_20140514_125813.csv   KEL*k_KPB_JSB   k (KEL:2) + 
Green Unknown7 
New Batch 
4_20140514_125813.csv   KEL*k_KPA_JSB   Kpa (KEL:3) 0 
Green Unknown7 
New Batch 
4_20140514_125813.csv   KEL*k_KPB_JSA   Kpb (KEL:4) + 
Green Unknown7 
New Batch 
4_20140514_125813.csv       Jsa (KEL:6) 0 
Green Unknown7 
New Batch 
4_20140514_125813.csv       Jsb (KEL:7) + 
Green Unknown7 
New Batch 
4_20140514_125813.csv Kidd JK*A JK*A, JK*B Jka (JK:1) + 
Green Unknown7 
New Batch 
4_20140514_125813.csv   JK*B   Jkb (JK:2) + 
Green Unknown7 
New Batch 
4_20140514_125813.csv   JK*B_null(IVS5-1a)       
Green Unknown7 
New Batch 
4_20140514_125813.csv   JK*B_null(871C)       
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green Unknown7 
New Batch 
4_20140514_125813.csv Duffy FY*A FY*A Fya (FY:1) + 
Green Unknown7 
New Batch 
4_20140514_125813.csv   FY*B   Fyb (FY:2) 0 
Green Unknown7 
New Batch 
4_20140514_125813.csv   FY*B_GATA       
Green Unknown7 
New Batch 
4_20140514_125813.csv   FY*B[265T]_FY*X       
Green Unknown7 
New Batch 
4_20140514_125813.csv MNS GYPA*M GYPA*M, GYPA*N M (MNS:1) + 
Green Unknown7 
New Batch 
4_20140514_125813.csv   GYPA*N   N (MNS:2) + 
Green Unknown7 
New Batch 
4_20140514_125813.csv   GYPB*S GYPB*S, GYPB*s S (MNS:3) + 
Green Unknown7 
New Batch 
4_20140514_125813.csv   GYPB*s   s (MNS:4) + 
Green Unknown7 
New Batch 
4_20140514_125813.csv   GYPB*S_null(IVS5+5t)   U (MNS:5) + 
Green Unknown7 
New Batch 
4_20140514_125813.csv   GYPB*S_null(230T)   Mia (MNS:7) 0 
Green Unknown7 
New Batch 
4_20140514_125813.csv   GYPB*deletion       
Green Unknown7 
New Batch 
4_20140514_125813.csv   GYPB*Mur       
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green Unknown7 
New Batch 
4_20140514_125813.csv Diego DI*A DI*B Dia (DI:1) 0 
Green Unknown7 
New Batch 
4_20140514_125813.csv   DI*B   Dib (DI:2) + 
Green Unknown7 
New Batch 
4_20140514_125813.csv Dombrock DO*A DO*A, DO*B Doa (DO:1) + 
Green Unknown7 
New Batch 
4_20140514_125813.csv   DO*B   Dob (DO:2) + 
Green Unknown7 
New Batch 
4_20140514_125813.csv   DO*B_HY-   Hy (DO:4) + 
Green Unknown7 
New Batch 
4_20140514_125813.csv   DO*A_JOA-   Joa (DO:5) + 
Green Unknown7 
New Batch 
4_20140514_125813.csv Colton CO*A CO*A Coa (CO:1) + 
Green Unknown7 
New Batch 
4_20140514_125813.csv   CO*B   Cob (CO:2) 0 
Green Unknown7 
New Batch 
4_20140514_125813.csv Cartwright YT*A YT*A Yta (YT:1) + 
Green Unknown7 
New Batch 
4_20140514_125813.csv   YT*B   Ytb (YT:2) 0 
Green Unknown7 
New Batch 
4_20140514_125813.csv Lutheran LU*A LU*B Lua (LU:1) 0 
Green Unknown7 
New Batch 
4_20140514_125813.csv   LU*B   Lub (LU:2) + 
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green Unknown8 
New Batch 
4_20140514_125813.csv Rh RHCE*ce RHCE*Ce C (RH:2) + 
Green Unknown8 
New Batch 
4_20140514_125813.csv   RHCE*Ce   E (RH:3) 0 
Green Unknown8 
New Batch 
4_20140514_125813.csv   RHCE*cE   c (RH:4) 0 
Green Unknown8 
New Batch 
4_20140514_125813.csv   RHCE*CE   e (RH:5) + 
Green Unknown8 
New Batch 
4_20140514_125813.csv   RHCE*CeCW   CW (RH:8) 0 
Green Unknown8 
New Batch 
4_20140514_125813.csv   RHCE*ceCW   V (RH:10) 0 
Green Unknown8 
New Batch 
4_20140514_125813.csv   RHCE*CECW   hrS (RH:19) + 
Green Unknown8 
New Batch 
4_20140514_125813.csv   RHCE*ceAR   VS (RH:20) 0 
Green Unknown8 
New Batch 
4_20140514_125813.csv   RHCE*CeFV   hrB (RH:31) + 
Green Unknown8 
New Batch 
4_20140514_125813.csv   RHCE*CeVG       
Green Unknown8 
New Batch 
4_20140514_125813.csv   RHCE*cEFM       
Green Unknown8 
New Batch 
4_20140514_125813.csv   RHCE*ce[712G]       
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green Unknown8 
New Batch 
4_20140514_125813.csv   RHCE*ce[733G]       
Green Unknown8 
New Batch 
4_20140514_125813.csv   RHCE*ce[733G,1006T]       
Green Unknown8 
New Batch 
4_20140514_125813.csv   RHCE*CE-D[2, 5, 7]-CE       
Green Unknown8 
New Batch 
4_20140514_125813.csv   RHCE*cE[697G,712G,733G]       
Green Unknown8 
New Batch 
4_20140514_125813.csv   
RHD*r’s-
RHCE*ce[733G,1006T]       
Green Unknown8 
New Batch 
4_20140514_125813.csv Kell KEL*K_KPB_JSB KEL*k_KPB_JSB K (KEL:1) 0 
Green Unknown8 
New Batch 
4_20140514_125813.csv   KEL*k_KPB_JSB   k (KEL:2) + 
Green Unknown8 
New Batch 
4_20140514_125813.csv   KEL*k_KPA_JSB   Kpa (KEL:3) 0 
Green Unknown8 
New Batch 
4_20140514_125813.csv   KEL*k_KPB_JSA   Kpb (KEL:4) + 
Green Unknown8 
New Batch 
4_20140514_125813.csv       Jsa (KEL:6) 0 
Green Unknown8 
New Batch 
4_20140514_125813.csv       Jsb (KEL:7) + 
Green Unknown8 
New Batch 
4_20140514_125813.csv Kidd JK*A JK*A, JK*B Jka (JK:1) + 
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green Unknown8 
New Batch 
4_20140514_125813.csv   JK*B   Jkb (JK:2) + 
Green Unknown8 
New Batch 
4_20140514_125813.csv   JK*B_null(IVS5-1a)       
Green Unknown8 
New Batch 
4_20140514_125813.csv   JK*B_null(871C)       
Green Unknown8 
New Batch 
4_20140514_125813.csv Duffy FY*A FY*A Fya (FY:1) + 
Green Unknown8 
New Batch 
4_20140514_125813.csv   FY*B   Fyb (FY:2) 0 
Green Unknown8 
New Batch 
4_20140514_125813.csv   FY*B_GATA       
Green Unknown8 
New Batch 
4_20140514_125813.csv   FY*B[265T]_FY*X       
Green Unknown8 
New Batch 
4_20140514_125813.csv MNS GYPA*M GYPA*M, GYPA*N M (MNS:1) + 
Green Unknown8 
New Batch 
4_20140514_125813.csv   GYPA*N   N (MNS:2) + 
Green Unknown8 
New Batch 
4_20140514_125813.csv   GYPB*S GYPB*S, GYPB*s S (MNS:3) + 
Green Unknown8 
New Batch 
4_20140514_125813.csv   GYPB*s   s (MNS:4) + 
Green Unknown8 
New Batch 
4_20140514_125813.csv   GYPB*S_null(IVS5+5t)   U (MNS:5) + 
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green Unknown8 
New Batch 
4_20140514_125813.csv   GYPB*S_null(230T)   Mia (MNS:7) 0 
Green Unknown8 
New Batch 
4_20140514_125813.csv   GYPB*deletion       
Green Unknown8 
New Batch 
4_20140514_125813.csv   GYPB*Mur       
Green Unknown8 
New Batch 
4_20140514_125813.csv Diego DI*A DI*B Dia (DI:1) 0 
Green Unknown8 
New Batch 
4_20140514_125813.csv   DI*B   Dib (DI:2) + 
Green Unknown8 
New Batch 
4_20140514_125813.csv Dombrock DO*A DO*B Doa (DO:1) 0 
Green Unknown8 
New Batch 
4_20140514_125813.csv   DO*B   Dob (DO:2) + 
Green Unknown8 
New Batch 
4_20140514_125813.csv   DO*B_HY-   Hy (DO:4) + 
Green Unknown8 
New Batch 
4_20140514_125813.csv   DO*A_JOA-   Joa (DO:5) + 
Green Unknown8 
New Batch 
4_20140514_125813.csv Colton CO*A CO*A Coa (CO:1) + 
Green Unknown8 
New Batch 
4_20140514_125813.csv   CO*B   Cob (CO:2) 0 
Green Unknown8 
New Batch 
4_20140514_125813.csv Cartwright YT*A YT*A Yta (YT:1) + 
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green Unknown8 
New Batch 
4_20140514_125813.csv   YT*B   Ytb (YT:2) 0 
Green Unknown8 
New Batch 
4_20140514_125813.csv Lutheran LU*A LU*B Lua (LU:1) 0 
Green Unknown8 
New Batch 
4_20140514_125813.csv   LU*B   Lub (LU:2) + 
Green EX1307335 
New Batch 
5_20140514_171740.csv Rh RHCE*ce RHCE*Ce C (RH:2) + 
Green EX1307335 
New Batch 
5_20140514_171740.csv   RHCE*Ce   E (RH:3) 0 
Green EX1307335 
New Batch 
5_20140514_171740.csv   RHCE*cE   c (RH:4) 0 
Green EX1307335 
New Batch 
5_20140514_171740.csv   RHCE*CE   e (RH:5) + 
Green EX1307335 
New Batch 
5_20140514_171740.csv   RHCE*CeCW   CW (RH:8) 0 
Green EX1307335 
New Batch 
5_20140514_171740.csv   RHCE*ceCW   V (RH:10) 0 
Green EX1307335 
New Batch 
5_20140514_171740.csv   RHCE*CECW   hrS (RH:19) + 
Green EX1307335 
New Batch 
5_20140514_171740.csv   RHCE*ceAR   VS (RH:20) 0 
Green EX1307335 
New Batch 
5_20140514_171740.csv   RHCE*CeFV   hrB (RH:31) + 
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1307335 
New Batch 
5_20140514_171740.csv   RHCE*CeVG       
Green EX1307335 
New Batch 
5_20140514_171740.csv   RHCE*cEFM       
Green EX1307335 
New Batch 
5_20140514_171740.csv   RHCE*ce[712G]       
Green EX1307335 
New Batch 
5_20140514_171740.csv   RHCE*ce[733G]       
Green EX1307335 
New Batch 
5_20140514_171740.csv   RHCE*ce[733G,1006T]       
Green EX1307335 
New Batch 
5_20140514_171740.csv   RHCE*CE-D[2, 5, 7]-CE       
Green EX1307335 
New Batch 
5_20140514_171740.csv   RHCE*cE[697G,712G,733G]       
Green EX1307335 
New Batch 
5_20140514_171740.csv   
RHD*r’s-
RHCE*ce[733G,1006T]       
Green EX1307335 
New Batch 
5_20140514_171740.csv Kell KEL*K_KPB_JSB KEL*k_KPB_JSB K (KEL:1) 0 
Green EX1307335 
New Batch 
5_20140514_171740.csv   KEL*k_KPB_JSB   k (KEL:2) + 
Green EX1307335 
New Batch 
5_20140514_171740.csv   KEL*k_KPA_JSB   Kpa (KEL:3) 0 
Green EX1307335 
New Batch 
5_20140514_171740.csv   KEL*k_KPB_JSA   Kpb (KEL:4) + 
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1307335 
New Batch 
5_20140514_171740.csv       Jsa (KEL:6) 0 
Green EX1307335 
New Batch 
5_20140514_171740.csv       Jsb (KEL:7) + 
Green EX1307335 
New Batch 
5_20140514_171740.csv Kidd JK*A JK*A, JK*B Jka (JK:1) + 
Green EX1307335 
New Batch 
5_20140514_171740.csv   JK*B   Jkb (JK:2) + 
Green EX1307335 
New Batch 
5_20140514_171740.csv   JK*B_null(IVS5-1a)       
Green EX1307335 
New Batch 
5_20140514_171740.csv   JK*B_null(871C)       
Green EX1307335 
New Batch 
5_20140514_171740.csv Duffy FY*A FY*B Fya (FY:1) 0 
Green EX1307335 
New Batch 
5_20140514_171740.csv   FY*B   Fyb (FY:2) + 
Green EX1307335 
New Batch 
5_20140514_171740.csv   FY*B_GATA       
Green EX1307335 
New Batch 
5_20140514_171740.csv   FY*B[265T]_FY*X       
Green EX1307335 
New Batch 
5_20140514_171740.csv MNS GYPA*M GYPA*M, GYPA*N M (MNS:1) + 
Green EX1307335 
New Batch 
5_20140514_171740.csv   GYPA*N   N (MNS:2) + 
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1307335 
New Batch 
5_20140514_171740.csv   GYPB*S GYPB*S, GYPB*s S (MNS:3) + 
Green EX1307335 
New Batch 
5_20140514_171740.csv   GYPB*s   s (MNS:4) + 
Green EX1307335 
New Batch 
5_20140514_171740.csv   GYPB*S_null(IVS5+5t)   U (MNS:5) + 
Green EX1307335 
New Batch 
5_20140514_171740.csv   GYPB*S_null(230T)   Mia (MNS:7) 0 
Green EX1307335 
New Batch 
5_20140514_171740.csv   GYPB*deletion       
Green EX1307335 
New Batch 
5_20140514_171740.csv   GYPB*Mur       
Green EX1307335 
New Batch 
5_20140514_171740.csv Diego DI*A DI*B Dia (DI:1) 0 
Green EX1307335 
New Batch 
5_20140514_171740.csv   DI*B   Dib (DI:2) + 
Green EX1307335 
New Batch 
5_20140514_171740.csv Dombrock DO*A DO*A, DO*B Doa (DO:1) + 
Green EX1307335 
New Batch 
5_20140514_171740.csv   DO*B   Dob (DO:2) + 
Green EX1307335 
New Batch 
5_20140514_171740.csv   DO*B_HY-   Hy (DO:4) + 
Green EX1307335 
New Batch 
5_20140514_171740.csv   DO*A_JOA-   Joa (DO:5) + 
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1307335 
New Batch 
5_20140514_171740.csv Colton CO*A CO*A Coa (CO:1) + 
Green EX1307335 
New Batch 
5_20140514_171740.csv   CO*B   Cob (CO:2) 0 
Green EX1307335 
New Batch 
5_20140514_171740.csv Cartwright YT*A YT*A Yta (YT:1) + 
Green EX1307335 
New Batch 
5_20140514_171740.csv   YT*B   Ytb (YT:2) 0 
Green EX1307335 
New Batch 
5_20140514_171740.csv Lutheran LU*A LU*B Lua (LU:1) 0 
Green EX1307335 
New Batch 
5_20140514_171740.csv   LU*B   Lub (LU:2) + 
Green EX1307336 
New Batch 
5_20140514_171740.csv Rh RHCE*ce RHCE*Ce, RHCE*cE(10) C (RH:2) + 
Green EX1307336 
New Batch 
5_20140514_171740.csv   RHCE*Ce   E (RH:3) + 
Green EX1307336 
New Batch 
5_20140514_171740.csv   RHCE*cE   c (RH:4) + 
Green EX1307336 
New Batch 
5_20140514_171740.csv   RHCE*CE   e (RH:5) + 
Green EX1307336 
New Batch 
5_20140514_171740.csv   RHCE*CeCW   CW (RH:8) 0 
Green EX1307336 
New Batch 
5_20140514_171740.csv   RHCE*ceCW   V (RH:10) 0 
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1307336 
New Batch 
5_20140514_171740.csv   RHCE*CECW   hrS (RH:19) + 
Green EX1307336 
New Batch 
5_20140514_171740.csv   RHCE*ceAR   VS (RH:20) 0 
Green EX1307336 
New Batch 
5_20140514_171740.csv   RHCE*CeFV   hrB (RH:31) + 
Green EX1307336 
New Batch 
5_20140514_171740.csv   RHCE*CeVG       
Green EX1307336 
New Batch 
5_20140514_171740.csv   RHCE*cEFM       
Green EX1307336 
New Batch 
5_20140514_171740.csv   RHCE*ce[712G]       
Green EX1307336 
New Batch 
5_20140514_171740.csv   RHCE*ce[733G]       
Green EX1307336 
New Batch 
5_20140514_171740.csv   RHCE*ce[733G,1006T]       
Green EX1307336 
New Batch 
5_20140514_171740.csv   RHCE*CE-D[2, 5, 7]-CE       
Green EX1307336 
New Batch 
5_20140514_171740.csv   RHCE*cE[697G,712G,733G]       
Green EX1307336 
New Batch 
5_20140514_171740.csv   
RHD*r’s-
RHCE*ce[733G,1006T]       
Green EX1307336 
New Batch 
5_20140514_171740.csv Kell KEL*K_KPB_JSB KEL*k_KPB_JSB K (KEL:1) 0 
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1307336 
New Batch 
5_20140514_171740.csv   KEL*k_KPB_JSB   k (KEL:2) + 
Green EX1307336 
New Batch 
5_20140514_171740.csv   KEL*k_KPA_JSB   Kpa (KEL:3) 0 
Green EX1307336 
New Batch 
5_20140514_171740.csv   KEL*k_KPB_JSA   Kpb (KEL:4) + 
Green EX1307336 
New Batch 
5_20140514_171740.csv       Jsa (KEL:6) 0 
Green EX1307336 
New Batch 
5_20140514_171740.csv       Jsb (KEL:7) + 
Green EX1307336 
New Batch 
5_20140514_171740.csv Kidd JK*A JK*A Jka (JK:1) + 
Green EX1307336 
New Batch 
5_20140514_171740.csv   JK*B   Jkb (JK:2) 0 
Green EX1307336 
New Batch 
5_20140514_171740.csv   JK*B_null(IVS5-1a)       
Green EX1307336 
New Batch 
5_20140514_171740.csv   JK*B_null(871C)       
Green EX1307336 
New Batch 
5_20140514_171740.csv Duffy FY*A FY*B, FY*B[265T]_FY*X Fya (FY:1) 0 
Green EX1307336 
New Batch 
5_20140514_171740.csv   FY*B   Fyb (FY:2) + 
Green EX1307336 
New Batch 
5_20140514_171740.csv   FY*B_GATA       
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1307336 
New Batch 
5_20140514_171740.csv   FY*B[265T]_FY*X       
Green EX1307336 
New Batch 
5_20140514_171740.csv MNS GYPA*M GYPA*M, GYPA*N M (MNS:1) + 
Green EX1307336 
New Batch 
5_20140514_171740.csv   GYPA*N   N (MNS:2) + 
Green EX1307336 
New Batch 
5_20140514_171740.csv   GYPB*S GYPB*S S (MNS:3) + 
Green EX1307336 
New Batch 
5_20140514_171740.csv   GYPB*s   s (MNS:4) 0 
Green EX1307336 
New Batch 
5_20140514_171740.csv   GYPB*S_null(IVS5+5t)   U (MNS:5) + 
Green EX1307336 
New Batch 
5_20140514_171740.csv   GYPB*S_null(230T)   Mia (MNS:7) 0 
Green EX1307336 
New Batch 
5_20140514_171740.csv   GYPB*deletion       
Green EX1307336 
New Batch 
5_20140514_171740.csv   GYPB*Mur       
Green EX1307336 
New Batch 
5_20140514_171740.csv Diego DI*A DI*B Dia (DI:1) 0 
Green EX1307336 
New Batch 
5_20140514_171740.csv   DI*B   Dib (DI:2) + 
Green EX1307336 
New Batch 
5_20140514_171740.csv Dombrock DO*A DO*B Doa (DO:1) 0 
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1307336 
New Batch 
5_20140514_171740.csv   DO*B   Dob (DO:2) + 
Green EX1307336 
New Batch 
5_20140514_171740.csv   DO*B_HY-   Hy (DO:4) + 
Green EX1307336 
New Batch 
5_20140514_171740.csv   DO*A_JOA-   Joa (DO:5) + 
Green EX1307336 
New Batch 
5_20140514_171740.csv Colton CO*A CO*A Coa (CO:1) + 
Green EX1307336 
New Batch 
5_20140514_171740.csv   CO*B   Cob (CO:2) 0 
Green EX1307336 
New Batch 
5_20140514_171740.csv Cartwright YT*A YT*A Yta (YT:1) + 
Green EX1307336 
New Batch 
5_20140514_171740.csv   YT*B   Ytb (YT:2) 0 
Green EX1307336 
New Batch 
5_20140514_171740.csv Lutheran LU*A LU*B Lua (LU:1) 0 
Green EX1307336 
New Batch 
5_20140514_171740.csv   LU*B   Lub (LU:2) + 
Green EX1307657 
New Batch 
5_20140514_171740.csv Rh RHCE*ce RHCE*Ce C (RH:2) + 
Green EX1307657 
New Batch 
5_20140514_171740.csv   RHCE*Ce   E (RH:3) 0 
Green EX1307657 
New Batch 
5_20140514_171740.csv   RHCE*cE   c (RH:4) 0 
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1307657 
New Batch 
5_20140514_171740.csv   RHCE*CE   e (RH:5) + 
Green EX1307657 
New Batch 
5_20140514_171740.csv   RHCE*CeCW   CW (RH:8) 0 
Green EX1307657 
New Batch 
5_20140514_171740.csv   RHCE*ceCW   V (RH:10) 0 
Green EX1307657 
New Batch 
5_20140514_171740.csv   RHCE*CECW   hrS (RH:19) + 
Green EX1307657 
New Batch 
5_20140514_171740.csv   RHCE*ceAR   VS (RH:20) 0 
Green EX1307657 
New Batch 
5_20140514_171740.csv   RHCE*CeFV   hrB (RH:31) + 
Green EX1307657 
New Batch 
5_20140514_171740.csv   RHCE*CeVG       
Green EX1307657 
New Batch 
5_20140514_171740.csv   RHCE*cEFM       
Green EX1307657 
New Batch 
5_20140514_171740.csv   RHCE*ce[712G]       
Green EX1307657 
New Batch 
5_20140514_171740.csv   RHCE*ce[733G]       
Green EX1307657 
New Batch 
5_20140514_171740.csv   RHCE*ce[733G,1006T]       
Green EX1307657 
New Batch 
5_20140514_171740.csv   RHCE*CE-D[2, 5, 7]-CE       
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1307657 
New Batch 
5_20140514_171740.csv   RHCE*cE[697G,712G,733G]       
Green EX1307657 
New Batch 
5_20140514_171740.csv   
RHD*r’s-
RHCE*ce[733G,1006T]       
Green EX1307657 
New Batch 
5_20140514_171740.csv Kell KEL*K_KPB_JSB KEL*k_KPB_JSB K (KEL:1) 0 
Green EX1307657 
New Batch 
5_20140514_171740.csv   KEL*k_KPB_JSB   k (KEL:2) + 
Green EX1307657 
New Batch 
5_20140514_171740.csv   KEL*k_KPA_JSB   Kpa (KEL:3) 0 
Green EX1307657 
New Batch 
5_20140514_171740.csv   KEL*k_KPB_JSA   Kpb (KEL:4) + 
Green EX1307657 
New Batch 
5_20140514_171740.csv       Jsa (KEL:6) 0 
Green EX1307657 
New Batch 
5_20140514_171740.csv       Jsb (KEL:7) + 
Green EX1307657 
New Batch 
5_20140514_171740.csv Kidd JK*A JK*A, JK*B Jka (JK:1) + 
Green EX1307657 
New Batch 
5_20140514_171740.csv   JK*B   Jkb (JK:2) + 
Green EX1307657 
New Batch 
5_20140514_171740.csv   JK*B_null(IVS5-1a)       
Green EX1307657 
New Batch 
5_20140514_171740.csv   JK*B_null(871C)       
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1307657 
New Batch 
5_20140514_171740.csv Duffy FY*A FY*A, FY*B Fya (FY:1) + 
Green EX1307657 
New Batch 
5_20140514_171740.csv   FY*B   Fyb (FY:2) + 
Green EX1307657 
New Batch 
5_20140514_171740.csv   FY*B_GATA       
Green EX1307657 
New Batch 
5_20140514_171740.csv   FY*B[265T]_FY*X       
Green EX1307657 
New Batch 
5_20140514_171740.csv MNS GYPA*M GYPA*M M (MNS:1) + 
Green EX1307657 
New Batch 
5_20140514_171740.csv   GYPA*N   N (MNS:2) 0 
Green EX1307657 
New Batch 
5_20140514_171740.csv   GYPB*S GYPB*s S (MNS:3) 0 
Green EX1307657 
New Batch 
5_20140514_171740.csv   GYPB*s   s (MNS:4) + 
Green EX1307657 
New Batch 
5_20140514_171740.csv   GYPB*S_null(IVS5+5t)   U (MNS:5) + 
Green EX1307657 
New Batch 
5_20140514_171740.csv   GYPB*S_null(230T)   Mia (MNS:7) 0 
Green EX1307657 
New Batch 
5_20140514_171740.csv   GYPB*deletion       
Green EX1307657 
New Batch 
5_20140514_171740.csv   GYPB*Mur       
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1307657 
New Batch 
5_20140514_171740.csv Diego DI*A DI*B Dia (DI:1) 0 
Green EX1307657 
New Batch 
5_20140514_171740.csv   DI*B   Dib (DI:2) + 
Green EX1307657 
New Batch 
5_20140514_171740.csv Dombrock DO*A DO*B Doa (DO:1) 0 
Green EX1307657 
New Batch 
5_20140514_171740.csv   DO*B   Dob (DO:2) + 
Green EX1307657 
New Batch 
5_20140514_171740.csv   DO*B_HY-   Hy (DO:4) + 
Green EX1307657 
New Batch 
5_20140514_171740.csv   DO*A_JOA-   Joa (DO:5) + 
Green EX1307657 
New Batch 
5_20140514_171740.csv Colton CO*A CO*A, CO*B Coa (CO:1) + 
Green EX1307657 
New Batch 
5_20140514_171740.csv   CO*B   Cob (CO:2) + 
Green EX1307657 
New Batch 
5_20140514_171740.csv Cartwright YT*A YT*A Yta (YT:1) + 
Green EX1307657 
New Batch 
5_20140514_171740.csv   YT*B   Ytb (YT:2) 0 
Green EX1307657 
New Batch 
5_20140514_171740.csv Lutheran LU*A LU*B Lua (LU:1) 0 
Green EX1307657 
New Batch 
5_20140514_171740.csv   LU*B   Lub (LU:2) + 
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1307898 
New Batch 
5_20140514_171740.csv Rh RHCE*ce RHCE*ce C (RH:2) 0 
Green EX1307898 
New Batch 
5_20140514_171740.csv   RHCE*Ce   E (RH:3) 0 
Green EX1307898 
New Batch 
5_20140514_171740.csv   RHCE*cE   c (RH:4) + 
Green EX1307898 
New Batch 
5_20140514_171740.csv   RHCE*CE   e (RH:5) + 
Green EX1307898 
New Batch 
5_20140514_171740.csv   RHCE*CeCW   CW (RH:8) 0 
Green EX1307898 
New Batch 
5_20140514_171740.csv   RHCE*ceCW   V (RH:10) 0 
Green EX1307898 
New Batch 
5_20140514_171740.csv   RHCE*CECW   hrS (RH:19) + 
Green EX1307898 
New Batch 
5_20140514_171740.csv   RHCE*ceAR   VS (RH:20) 0 
Green EX1307898 
New Batch 
5_20140514_171740.csv   RHCE*CeFV   hrB (RH:31) + 
Green EX1307898 
New Batch 
5_20140514_171740.csv   RHCE*CeVG       
Green EX1307898 
New Batch 
5_20140514_171740.csv   RHCE*cEFM       
Green EX1307898 
New Batch 
5_20140514_171740.csv   RHCE*ce[712G]       
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1307898 
New Batch 
5_20140514_171740.csv   RHCE*ce[733G]       
Green EX1307898 
New Batch 
5_20140514_171740.csv   RHCE*ce[733G,1006T]       
Green EX1307898 
New Batch 
5_20140514_171740.csv   RHCE*CE-D[2, 5, 7]-CE       
Green EX1307898 
New Batch 
5_20140514_171740.csv   RHCE*cE[697G,712G,733G]       
Green EX1307898 
New Batch 
5_20140514_171740.csv   
RHD*r’s-
RHCE*ce[733G,1006T]       
Green EX1307898 
New Batch 
5_20140514_171740.csv Kell KEL*K_KPB_JSB KEL*k_KPB_JSB K (KEL:1) 0 
Green EX1307898 
New Batch 
5_20140514_171740.csv   KEL*k_KPB_JSB   k (KEL:2) + 
Green EX1307898 
New Batch 
5_20140514_171740.csv   KEL*k_KPA_JSB   Kpa (KEL:3) 0 
Green EX1307898 
New Batch 
5_20140514_171740.csv   KEL*k_KPB_JSA   Kpb (KEL:4) + 
Green EX1307898 
New Batch 
5_20140514_171740.csv       Jsa (KEL:6) 0 
Green EX1307898 
New Batch 
5_20140514_171740.csv       Jsb (KEL:7) + 
Green EX1307898 
New Batch 
5_20140514_171740.csv Kidd JK*A JK*A Jka (JK:1) + 
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1307898 
New Batch 
5_20140514_171740.csv   JK*B   Jkb (JK:2) 0 
Green EX1307898 
New Batch 
5_20140514_171740.csv   JK*B_null(IVS5-1a)       
Green EX1307898 
New Batch 
5_20140514_171740.csv   JK*B_null(871C)       
Green EX1307898 
New Batch 
5_20140514_171740.csv Duffy FY*A FY*B Fya (FY:1) 0 
Green EX1307898 
New Batch 
5_20140514_171740.csv   FY*B   Fyb (FY:2) + 
Green EX1307898 
New Batch 
5_20140514_171740.csv   FY*B_GATA       
Green EX1307898 
New Batch 
5_20140514_171740.csv   FY*B[265T]_FY*X       
Green EX1307898 
New Batch 
5_20140514_171740.csv MNS GYPA*M GYPA*M, GYPA*N M (MNS:1) + 
Green EX1307898 
New Batch 
5_20140514_171740.csv   GYPA*N   N (MNS:2) + 
Green EX1307898 
New Batch 
5_20140514_171740.csv   GYPB*S GYPB*s S (MNS:3) 0 
Green EX1307898 
New Batch 
5_20140514_171740.csv   GYPB*s   s (MNS:4) + 
Green EX1307898 
New Batch 
5_20140514_171740.csv   GYPB*S_null(IVS5+5t)   U (MNS:5) + 
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1307898 
New Batch 
5_20140514_171740.csv   GYPB*S_null(230T)   Mia (MNS:7) 0 
Green EX1307898 
New Batch 
5_20140514_171740.csv   GYPB*deletion       
Green EX1307898 
New Batch 
5_20140514_171740.csv   GYPB*Mur       
Green EX1307898 
New Batch 
5_20140514_171740.csv Diego DI*A DI*B Dia (DI:1) 0 
Green EX1307898 
New Batch 
5_20140514_171740.csv   DI*B   Dib (DI:2) + 
Green EX1307898 
New Batch 
5_20140514_171740.csv Dombrock DO*A DO*A, DO*B Doa (DO:1) + 
Green EX1307898 
New Batch 
5_20140514_171740.csv   DO*B   Dob (DO:2) + 
Green EX1307898 
New Batch 
5_20140514_171740.csv   DO*B_HY-   Hy (DO:4) + 
Green EX1307898 
New Batch 
5_20140514_171740.csv   DO*A_JOA-   Joa (DO:5) + 
Green EX1307898 
New Batch 
5_20140514_171740.csv Colton CO*A CO*A Coa (CO:1) + 
Green EX1307898 
New Batch 
5_20140514_171740.csv   CO*B   Cob (CO:2) 0 
Green EX1307898 
New Batch 
5_20140514_171740.csv Cartwright YT*A YT*A Yta (YT:1) + 
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1307898 
New Batch 
5_20140514_171740.csv   YT*B   Ytb (YT:2) 0 
Green EX1307898 
New Batch 
5_20140514_171740.csv Lutheran LU*A LU*B Lua (LU:1) 0 
Green EX1307898 
New Batch 
5_20140514_171740.csv   LU*B   Lub (LU:2) + 
Green EX1307899 
New Batch 
5_20140514_171740.csv Rh RHCE*ce RHCE*ce, RHCE*cE C (RH:2) 0 
Green EX1307899 
New Batch 
5_20140514_171740.csv   RHCE*Ce   E (RH:3) + 
Green EX1307899 
New Batch 
5_20140514_171740.csv   RHCE*cE   c (RH:4) + 
Green EX1307899 
New Batch 
5_20140514_171740.csv   RHCE*CE   e (RH:5) + 
Green EX1307899 
New Batch 
5_20140514_171740.csv   RHCE*CeCW   CW (RH:8) 0 
Green EX1307899 
New Batch 
5_20140514_171740.csv   RHCE*ceCW   V (RH:10) 0 
Green EX1307899 
New Batch 
5_20140514_171740.csv   RHCE*CECW   hrS (RH:19) + 
Green EX1307899 
New Batch 
5_20140514_171740.csv   RHCE*ceAR   VS (RH:20) 0 
Green EX1307899 
New Batch 
5_20140514_171740.csv   RHCE*CeFV   hrB (RH:31) + 
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1307899 
New Batch 
5_20140514_171740.csv   RHCE*CeVG       
Green EX1307899 
New Batch 
5_20140514_171740.csv   RHCE*cEFM       
Green EX1307899 
New Batch 
5_20140514_171740.csv   RHCE*ce[712G]       
Green EX1307899 
New Batch 
5_20140514_171740.csv   RHCE*ce[733G]       
Green EX1307899 
New Batch 
5_20140514_171740.csv   RHCE*ce[733G,1006T]       
Green EX1307899 
New Batch 
5_20140514_171740.csv   RHCE*CE-D[2, 5, 7]-CE       
Green EX1307899 
New Batch 
5_20140514_171740.csv   RHCE*cE[697G,712G,733G]       
Green EX1307899 
New Batch 
5_20140514_171740.csv   
RHD*r’s-
RHCE*ce[733G,1006T]       
Green EX1307899 
New Batch 
5_20140514_171740.csv Kell KEL*K_KPB_JSB 
KEL*K_KPB_JSB, 
KEL*k_KPB_JSB K (KEL:1) + 
Green EX1307899 
New Batch 
5_20140514_171740.csv   KEL*k_KPB_JSB   k (KEL:2) + 
Green EX1307899 
New Batch 
5_20140514_171740.csv   KEL*k_KPA_JSB   Kpa (KEL:3) 0 
Green EX1307899 
New Batch 
5_20140514_171740.csv   KEL*k_KPB_JSA   Kpb (KEL:4) + 
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1307899 
New Batch 
5_20140514_171740.csv       Jsa (KEL:6) 0 
Green EX1307899 
New Batch 
5_20140514_171740.csv       Jsb (KEL:7) + 
Green EX1307899 
New Batch 
5_20140514_171740.csv Kidd JK*A JK*A, JK*B Jka (JK:1) + 
Green EX1307899 
New Batch 
5_20140514_171740.csv   JK*B   Jkb (JK:2) + 
Green EX1307899 
New Batch 
5_20140514_171740.csv   JK*B_null(IVS5-1a)       
Green EX1307899 
New Batch 
5_20140514_171740.csv   JK*B_null(871C)       
Green EX1307899 
New Batch 
5_20140514_171740.csv Duffy FY*A FY*A, FY*B Fya (FY:1) + 
Green EX1307899 
New Batch 
5_20140514_171740.csv   FY*B   Fyb (FY:2) + 
Green EX1307899 
New Batch 
5_20140514_171740.csv   FY*B_GATA       
Green EX1307899 
New Batch 
5_20140514_171740.csv   FY*B[265T]_FY*X       
Green EX1307899 
New Batch 
5_20140514_171740.csv MNS GYPA*M GYPA*M, GYPA*N M (MNS:1) + 
Green EX1307899 
New Batch 
5_20140514_171740.csv   GYPA*N   N (MNS:2) + 
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1307899 
New Batch 
5_20140514_171740.csv   GYPB*S GYPB*S, GYPB*s S (MNS:3) + 
Green EX1307899 
New Batch 
5_20140514_171740.csv   GYPB*s   s (MNS:4) + 
Green EX1307899 
New Batch 
5_20140514_171740.csv   GYPB*S_null(IVS5+5t)   U (MNS:5) + 
Green EX1307899 
New Batch 
5_20140514_171740.csv   GYPB*S_null(230T)   Mia (MNS:7) 0 
Green EX1307899 
New Batch 
5_20140514_171740.csv   GYPB*deletion       
Green EX1307899 
New Batch 
5_20140514_171740.csv   GYPB*Mur       
Green EX1307899 
New Batch 
5_20140514_171740.csv Diego DI*A DI*B Dia (DI:1) 0 
Green EX1307899 
New Batch 
5_20140514_171740.csv   DI*B   Dib (DI:2) + 
Green EX1307899 
New Batch 
5_20140514_171740.csv Dombrock DO*A DO*B Doa (DO:1) 0 
Green EX1307899 
New Batch 
5_20140514_171740.csv   DO*B   Dob (DO:2) + 
Green EX1307899 
New Batch 
5_20140514_171740.csv   DO*B_HY-   Hy (DO:4) + 
Green EX1307899 
New Batch 
5_20140514_171740.csv   DO*A_JOA-   Joa (DO:5) + 
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1307899 
New Batch 
5_20140514_171740.csv Colton CO*A CO*A Coa (CO:1) + 
Green EX1307899 
New Batch 
5_20140514_171740.csv   CO*B   Cob (CO:2) 0 
Green EX1307899 
New Batch 
5_20140514_171740.csv Cartwright YT*A YT*A Yta (YT:1) + 
Green EX1307899 
New Batch 
5_20140514_171740.csv   YT*B   Ytb (YT:2) 0 
Green EX1307899 
New Batch 
5_20140514_171740.csv Lutheran LU*A LU*B Lua (LU:1) 0 
Green EX1307899 
New Batch 
5_20140514_171740.csv   LU*B   Lub (LU:2) + 
Green EX1308240 
New Batch 
5_20140514_171740.csv Rh RHCE*ce RHCE*ce C (RH:2) 0 
Green EX1308240 
New Batch 
5_20140514_171740.csv   RHCE*Ce   E (RH:3) 0 
Green EX1308240 
New Batch 
5_20140514_171740.csv   RHCE*cE   c (RH:4) + 
Green EX1308240 
New Batch 
5_20140514_171740.csv   RHCE*CE   e (RH:5) + 
Green EX1308240 
New Batch 
5_20140514_171740.csv   RHCE*CeCW   CW (RH:8) 0 
Green EX1308240 
New Batch 
5_20140514_171740.csv   RHCE*ceCW   V (RH:10) 0 
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1308240 
New Batch 
5_20140514_171740.csv   RHCE*CECW   hrS (RH:19) + 
Green EX1308240 
New Batch 
5_20140514_171740.csv   RHCE*ceAR   VS (RH:20) 0 
Green EX1308240 
New Batch 
5_20140514_171740.csv   RHCE*CeFV   hrB (RH:31) + 
Green EX1308240 
New Batch 
5_20140514_171740.csv   RHCE*CeVG       
Green EX1308240 
New Batch 
5_20140514_171740.csv   RHCE*cEFM       
Green EX1308240 
New Batch 
5_20140514_171740.csv   RHCE*ce[712G]       
Green EX1308240 
New Batch 
5_20140514_171740.csv   RHCE*ce[733G]       
Green EX1308240 
New Batch 
5_20140514_171740.csv   RHCE*ce[733G,1006T]       
Green EX1308240 
New Batch 
5_20140514_171740.csv   RHCE*CE-D[2, 5, 7]-CE       
Green EX1308240 
New Batch 
5_20140514_171740.csv   RHCE*cE[697G,712G,733G]       
Green EX1308240 
New Batch 
5_20140514_171740.csv   
RHD*r’s-
RHCE*ce[733G,1006T]       
Green EX1308240 
New Batch 
5_20140514_171740.csv Kell KEL*K_KPB_JSB KEL*k_KPB_JSB K (KEL:1) 0 
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1308240 
New Batch 
5_20140514_171740.csv   KEL*k_KPB_JSB   k (KEL:2) + 
Green EX1308240 
New Batch 
5_20140514_171740.csv   KEL*k_KPA_JSB   Kpa (KEL:3) 0 
Green EX1308240 
New Batch 
5_20140514_171740.csv   KEL*k_KPB_JSA   Kpb (KEL:4) + 
Green EX1308240 
New Batch 
5_20140514_171740.csv       Jsa (KEL:6) 0 
Green EX1308240 
New Batch 
5_20140514_171740.csv       Jsb (KEL:7) + 
Green EX1308240 
New Batch 
5_20140514_171740.csv Kidd JK*A JK*A Jka (JK:1) + 
Green EX1308240 
New Batch 
5_20140514_171740.csv   JK*B   Jkb (JK:2) 0 
Green EX1308240 
New Batch 
5_20140514_171740.csv   JK*B_null(IVS5-1a)       
Green EX1308240 
New Batch 
5_20140514_171740.csv   JK*B_null(871C)       
Green EX1308240 
New Batch 
5_20140514_171740.csv Duffy FY*A FY*A, FY*B Fya (FY:1) + 
Green EX1308240 
New Batch 
5_20140514_171740.csv   FY*B   Fyb (FY:2) + 
Green EX1308240 
New Batch 
5_20140514_171740.csv   FY*B_GATA       
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1308240 
New Batch 
5_20140514_171740.csv   FY*B[265T]_FY*X       
Green EX1308240 
New Batch 
5_20140514_171740.csv MNS GYPA*M GYPA*N M (MNS:1) 0 
Green EX1308240 
New Batch 
5_20140514_171740.csv   GYPA*N   N (MNS:2) + 
Green EX1308240 
New Batch 
5_20140514_171740.csv   GYPB*S GYPB*s S (MNS:3) 0 
Green EX1308240 
New Batch 
5_20140514_171740.csv   GYPB*s   s (MNS:4) + 
Green EX1308240 
New Batch 
5_20140514_171740.csv   GYPB*S_null(IVS5+5t)   U (MNS:5) + 
Green EX1308240 
New Batch 
5_20140514_171740.csv   GYPB*S_null(230T)   Mia (MNS:7) 0 
Green EX1308240 
New Batch 
5_20140514_171740.csv   GYPB*deletion       
Green EX1308240 
New Batch 
5_20140514_171740.csv   GYPB*Mur       
Green EX1308240 
New Batch 
5_20140514_171740.csv Diego DI*A DI*B Dia (DI:1) 0 
Green EX1308240 
New Batch 
5_20140514_171740.csv   DI*B   Dib (DI:2) + 
Green EX1308240 
New Batch 
5_20140514_171740.csv Dombrock DO*A DO*B Doa (DO:1) 0 
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1308240 
New Batch 
5_20140514_171740.csv   DO*B   Dob (DO:2) + 
Green EX1308240 
New Batch 
5_20140514_171740.csv   DO*B_HY-   Hy (DO:4) + 
Green EX1308240 
New Batch 
5_20140514_171740.csv   DO*A_JOA-   Joa (DO:5) + 
Green EX1308240 
New Batch 
5_20140514_171740.csv Colton CO*A CO*A Coa (CO:1) + 
Green EX1308240 
New Batch 
5_20140514_171740.csv   CO*B   Cob (CO:2) 0 
Green EX1308240 
New Batch 
5_20140514_171740.csv Cartwright YT*A YT*A Yta (YT:1) + 
Green EX1308240 
New Batch 
5_20140514_171740.csv   YT*B   Ytb (YT:2) 0 
Green EX1308240 
New Batch 
5_20140514_171740.csv Lutheran LU*A LU*B Lua (LU:1) 0 
Green EX1308240 
New Batch 
5_20140514_171740.csv   LU*B   Lub (LU:2) + 
Green EX1308368 
New Batch 
5_20140514_171740.csv Rh RHCE*ce RHCE*ce, RHCE*Ce C (RH:2) + 
Green EX1308368 
New Batch 
5_20140514_171740.csv   RHCE*Ce   E (RH:3) 0 
Green EX1308368 
New Batch 
5_20140514_171740.csv   RHCE*cE   c (RH:4) + 
150 | A p p e n d i x  
 
Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1308368 
New Batch 
5_20140514_171740.csv   RHCE*CE   e (RH:5) + 
Green EX1308368 
New Batch 
5_20140514_171740.csv   RHCE*CeCW   CW (RH:8) 0 
Green EX1308368 
New Batch 
5_20140514_171740.csv   RHCE*ceCW   V (RH:10) 0 
Green EX1308368 
New Batch 
5_20140514_171740.csv   RHCE*CECW   hrS (RH:19) + 
Green EX1308368 
New Batch 
5_20140514_171740.csv   RHCE*ceAR   VS (RH:20) 0 
Green EX1308368 
New Batch 
5_20140514_171740.csv   RHCE*CeFV   hrB (RH:31) + 
Green EX1308368 
New Batch 
5_20140514_171740.csv   RHCE*CeVG       
Green EX1308368 
New Batch 
5_20140514_171740.csv   RHCE*cEFM       
Green EX1308368 
New Batch 
5_20140514_171740.csv   RHCE*ce[712G]       
Green EX1308368 
New Batch 
5_20140514_171740.csv   RHCE*ce[733G]       
Green EX1308368 
New Batch 
5_20140514_171740.csv   RHCE*ce[733G,1006T]       
Green EX1308368 
New Batch 
5_20140514_171740.csv   RHCE*CE-D[2, 5, 7]-CE       
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1308368 
New Batch 
5_20140514_171740.csv   RHCE*cE[697G,712G,733G]       
Green EX1308368 
New Batch 
5_20140514_171740.csv   
RHD*r’s-
RHCE*ce[733G,1006T]       
Green EX1308368 
New Batch 
5_20140514_171740.csv Kell KEL*K_KPB_JSB KEL*k_KPB_JSB K (KEL:1) 0 
Green EX1308368 
New Batch 
5_20140514_171740.csv   KEL*k_KPB_JSB   k (KEL:2) + 
Green EX1308368 
New Batch 
5_20140514_171740.csv   KEL*k_KPA_JSB   Kpa (KEL:3) 0 
Green EX1308368 
New Batch 
5_20140514_171740.csv   KEL*k_KPB_JSA   Kpb (KEL:4) + 
Green EX1308368 
New Batch 
5_20140514_171740.csv       Jsa (KEL:6) 0 
Green EX1308368 
New Batch 
5_20140514_171740.csv       Jsb (KEL:7) + 
Green EX1308368 
New Batch 
5_20140514_171740.csv Kidd JK*A JK*A, JK*B Jka (JK:1) + 
Green EX1308368 
New Batch 
5_20140514_171740.csv   JK*B   Jkb (JK:2) + 
Green EX1308368 
New Batch 
5_20140514_171740.csv   JK*B_null(IVS5-1a)       
Green EX1308368 
New Batch 
5_20140514_171740.csv   JK*B_null(871C)       
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1308368 
New Batch 
5_20140514_171740.csv Duffy FY*A FY*A Fya (FY:1) + 
Green EX1308368 
New Batch 
5_20140514_171740.csv   FY*B   Fyb (FY:2) 0 
Green EX1308368 
New Batch 
5_20140514_171740.csv   FY*B_GATA       
Green EX1308368 
New Batch 
5_20140514_171740.csv   FY*B[265T]_FY*X       
Green EX1308368 
New Batch 
5_20140514_171740.csv MNS GYPA*M GYPA*M M (MNS:1) + 
Green EX1308368 
New Batch 
5_20140514_171740.csv   GYPA*N   N (MNS:2) 0 
Green EX1308368 
New Batch 
5_20140514_171740.csv   GYPB*S GYPB*s S (MNS:3) 0 
Green EX1308368 
New Batch 
5_20140514_171740.csv   GYPB*s   s (MNS:4) + 
Green EX1308368 
New Batch 
5_20140514_171740.csv   GYPB*S_null(IVS5+5t)   U (MNS:5) + 
Green EX1308368 
New Batch 
5_20140514_171740.csv   GYPB*S_null(230T)   Mia (MNS:7) 0 
Green EX1308368 
New Batch 
5_20140514_171740.csv   GYPB*deletion       
Green EX1308368 
New Batch 
5_20140514_171740.csv   GYPB*Mur       
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1308368 
New Batch 
5_20140514_171740.csv Diego DI*A DI*B Dia (DI:1) 0 
Green EX1308368 
New Batch 
5_20140514_171740.csv   DI*B   Dib (DI:2) + 
Green EX1308368 
New Batch 
5_20140514_171740.csv Dombrock DO*A DO*A, DO*B Doa (DO:1) + 
Green EX1308368 
New Batch 
5_20140514_171740.csv   DO*B   Dob (DO:2) + 
Green EX1308368 
New Batch 
5_20140514_171740.csv   DO*B_HY-   Hy (DO:4) + 
Green EX1308368 
New Batch 
5_20140514_171740.csv   DO*A_JOA-   Joa (DO:5) + 
Green EX1308368 
New Batch 
5_20140514_171740.csv Colton CO*A CO*A Coa (CO:1) + 
Green EX1308368 
New Batch 
5_20140514_171740.csv   CO*B   Cob (CO:2) 0 
Green EX1308368 
New Batch 
5_20140514_171740.csv Cartwright YT*A YT*A Yta (YT:1) + 
Green EX1308368 
New Batch 
5_20140514_171740.csv   YT*B   Ytb (YT:2) 0 
Green EX1308368 
New Batch 
5_20140514_171740.csv Lutheran LU*A LU*B Lua (LU:1) 0 
Green EX1308368 
New Batch 
5_20140514_171740.csv   LU*B   Lub (LU:2) + 
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1308578 
New Batch 
5_20140514_171740.csv Rh RHCE*ce RHCE*ce, RHCE*cE C (RH:2) 
 
Green EX1308578 
New Batch 
5_20140514_171740.csv   RHCE*Ce   E (RH:3) + 
Green EX1308578 
New Batch 
5_20140514_171740.csv   RHCE*cE   c (RH:4) + 
Green EX1308578 
New Batch 
5_20140514_171740.csv   RHCE*CE   e (RH:5) + 
Green EX1308578 
New Batch 
5_20140514_171740.csv   RHCE*CeCW   CW (RH:8) 0 
Green EX1308578 
New Batch 
5_20140514_171740.csv   RHCE*ceCW   V (RH:10) 0 
Green EX1308578 
New Batch 
5_20140514_171740.csv   RHCE*CECW   hrS (RH:19) + 
Green EX1308578 
New Batch 
5_20140514_171740.csv   RHCE*ceAR   VS (RH:20) 0 
Green EX1308578 
New Batch 
5_20140514_171740.csv   RHCE*CeFV   hrB (RH:31) + 
Green EX1308578 
New Batch 
5_20140514_171740.csv   RHCE*CeVG       
Green EX1308578 
New Batch 
5_20140514_171740.csv   RHCE*cEFM       
Green EX1308578 
New Batch 
5_20140514_171740.csv   RHCE*ce[712G]       
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1308578 
New Batch 
5_20140514_171740.csv   RHCE*ce[733G]       
Green EX1308578 
New Batch 
5_20140514_171740.csv   RHCE*ce[733G,1006T]       
Green EX1308578 
New Batch 
5_20140514_171740.csv   RHCE*CE-D[2, 5, 7]-CE       
Green EX1308578 
New Batch 
5_20140514_171740.csv   RHCE*cE[697G,712G,733G]       
Green EX1308578 
New Batch 
5_20140514_171740.csv   
RHD*r’s-
RHCE*ce[733G,1006T]       
Green EX1308578 
New Batch 
5_20140514_171740.csv Kell KEL*K_KPB_JSB KEL*k_KPB_JSB K (KEL:1) 0 
Green EX1308578 
New Batch 
5_20140514_171740.csv   KEL*k_KPB_JSB   k (KEL:2) + 
Green EX1308578 
New Batch 
5_20140514_171740.csv   KEL*k_KPA_JSB   Kpa (KEL:3) 0 
Green EX1308578 
New Batch 
5_20140514_171740.csv   KEL*k_KPB_JSA   Kpb (KEL:4) + 
Green EX1308578 
New Batch 
5_20140514_171740.csv       Jsa (KEL:6) 0 
Green EX1308578 
New Batch 
5_20140514_171740.csv       Jsb (KEL:7) + 
Green EX1308578 
New Batch 
5_20140514_171740.csv Kidd JK*A JK*A, JK*B Jka (JK:1) + 
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1308578 
New Batch 
5_20140514_171740.csv   JK*B   Jkb (JK:2) + 
Green EX1308578 
New Batch 
5_20140514_171740.csv   JK*B_null(IVS5-1a)       
Green EX1308578 
New Batch 
5_20140514_171740.csv   JK*B_null(871C)       
Green EX1308578 
New Batch 
5_20140514_171740.csv Duffy FY*A FY*A, FY*B Fya (FY:1) + 
Green EX1308578 
New Batch 
5_20140514_171740.csv   FY*B   Fyb (FY:2) + 
Green EX1308578 
New Batch 
5_20140514_171740.csv   FY*B_GATA       
Green EX1308578 
New Batch 
5_20140514_171740.csv   FY*B[265T]_FY*X       
Green EX1308578 
New Batch 
5_20140514_171740.csv MNS GYPA*M GYPA*M, GYPA*N M (MNS:1) + 
Green EX1308578 
New Batch 
5_20140514_171740.csv   GYPA*N   N (MNS:2) + 
Green EX1308578 
New Batch 
5_20140514_171740.csv   GYPB*S GYPB*s S (MNS:3) 0 
Green EX1308578 
New Batch 
5_20140514_171740.csv   GYPB*s   s (MNS:4) + 
Green EX1308578 
New Batch 
5_20140514_171740.csv   GYPB*S_null(IVS5+5t)   U (MNS:5) + 
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1308578 
New Batch 
5_20140514_171740.csv   GYPB*S_null(230T)   Mia (MNS:7) 0 
Green EX1308578 
New Batch 
5_20140514_171740.csv   GYPB*deletion       
Green EX1308578 
New Batch 
5_20140514_171740.csv   GYPB*Mur       
Green EX1308578 
New Batch 
5_20140514_171740.csv Diego DI*A DI*B Dia (DI:1) 0 
Green EX1308578 
New Batch 
5_20140514_171740.csv   DI*B   Dib (DI:2) + 
Green EX1308578 
New Batch 
5_20140514_171740.csv Dombrock DO*A DO*A, DO*B Doa (DO:1) + 
Green EX1308578 
New Batch 
5_20140514_171740.csv   DO*B   Dob (DO:2) + 
Green EX1308578 
New Batch 
5_20140514_171740.csv   DO*B_HY-   Hy (DO:4) + 
Green EX1308578 
New Batch 
5_20140514_171740.csv   DO*A_JOA-   Joa (DO:5) + 
Green EX1308578 
New Batch 
5_20140514_171740.csv Colton CO*A CO*A Coa (CO:1) + 
Green EX1308578 
New Batch 
5_20140514_171740.csv   CO*B   Cob (CO:2) 0 
Green EX1308578 
New Batch 
5_20140514_171740.csv Cartwright YT*A YT*A, YT*B Yta (YT:1) + 
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1308578 
New Batch 
5_20140514_171740.csv   YT*B   Ytb (YT:2) + 
Green EX1308578 
New Batch 
5_20140514_171740.csv Lutheran LU*A LU*B Lua (LU:1) 0 
Green EX1308578 
New Batch 
5_20140514_171740.csv   LU*B   Lub (LU:2) + 
Green EX1308762 
New Batch 
5_20140514_171740.csv Rh RHCE*ce RHCE*Ce C (RH:2) + 
Green EX1308762 
New Batch 
5_20140514_171740.csv   RHCE*Ce   E (RH:3) 0 
Green EX1308762 
New Batch 
5_20140514_171740.csv   RHCE*cE   c (RH:4) 0 
Green EX1308762 
New Batch 
5_20140514_171740.csv   RHCE*CE   e (RH:5) + 
Green EX1308762 
New Batch 
5_20140514_171740.csv   RHCE*CeCW   CW (RH:8) 0 
Green EX1308762 
New Batch 
5_20140514_171740.csv   RHCE*ceCW   V (RH:10) 0 
Green EX1308762 
New Batch 
5_20140514_171740.csv   RHCE*CECW   hrS (RH:19) + 
Green EX1308762 
New Batch 
5_20140514_171740.csv   RHCE*ceAR   VS (RH:20) 0 
Green EX1308762 
New Batch 
5_20140514_171740.csv   RHCE*CeFV   hrB (RH:31) + 
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1308762 
New Batch 
5_20140514_171740.csv   RHCE*CeVG       
Green EX1308762 
New Batch 
5_20140514_171740.csv   RHCE*cEFM       
Green EX1308762 
New Batch 
5_20140514_171740.csv   RHCE*ce[712G]       
Green EX1308762 
New Batch 
5_20140514_171740.csv   RHCE*ce[733G]       
Green EX1308762 
New Batch 
5_20140514_171740.csv   RHCE*ce[733G,1006T]       
Green EX1308762 
New Batch 
5_20140514_171740.csv   RHCE*CE-D[2, 5, 7]-CE       
Green EX1308762 
New Batch 
5_20140514_171740.csv   RHCE*cE[697G,712G,733G]       
Green EX1308762 
New Batch 
5_20140514_171740.csv   
RHD*r’s-
RHCE*ce[733G,1006T]       
Green EX1308762 
New Batch 
5_20140514_171740.csv Kell KEL*K_KPB_JSB KEL*k_KPB_JSB K (KEL:1) 0 
Green EX1308762 
New Batch 
5_20140514_171740.csv   KEL*k_KPB_JSB   k (KEL:2) + 
Green EX1308762 
New Batch 
5_20140514_171740.csv   KEL*k_KPA_JSB   Kpa (KEL:3) 0 
Green EX1308762 
New Batch 
5_20140514_171740.csv   KEL*k_KPB_JSA   Kpb (KEL:4) + 
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1308762 
New Batch 
5_20140514_171740.csv       Jsa (KEL:6) 0 
Green EX1308762 
New Batch 
5_20140514_171740.csv       Jsb (KEL:7) + 
Green EX1308762 
New Batch 
5_20140514_171740.csv Kidd JK*A JK*A Jka (JK:1) + 
Green EX1308762 
New Batch 
5_20140514_171740.csv   JK*B   Jkb (JK:2) 0 
Green EX1308762 
New Batch 
5_20140514_171740.csv   JK*B_null(IVS5-1a)       
Green EX1308762 
New Batch 
5_20140514_171740.csv   JK*B_null(871C)       
Green EX1308762 
New Batch 
5_20140514_171740.csv Duffy FY*A FY*B Fya (FY:1) 0 
Green EX1308762 
New Batch 
5_20140514_171740.csv   FY*B   Fyb (FY:2) + 
Green EX1308762 
New Batch 
5_20140514_171740.csv   FY*B_GATA       
Green EX1308762 
New Batch 
5_20140514_171740.csv   FY*B[265T]_FY*X       
Green EX1308762 
New Batch 
5_20140514_171740.csv MNS GYPA*M GYPA*M M (MNS:1) + 
Green EX1308762 
New Batch 
5_20140514_171740.csv   GYPA*N   N (MNS:2) 0 
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1308762 
New Batch 
5_20140514_171740.csv   GYPB*S GYPB*S, GYPB*s S (MNS:3) + 
Green EX1308762 
New Batch 
5_20140514_171740.csv   GYPB*s   s (MNS:4) + 
Green EX1308762 
New Batch 
5_20140514_171740.csv   GYPB*S_null(IVS5+5t)   U (MNS:5) + 
Green EX1308762 
New Batch 
5_20140514_171740.csv   GYPB*S_null(230T)   Mia (MNS:7) 0 
Green EX1308762 
New Batch 
5_20140514_171740.csv   GYPB*deletion       
Green EX1308762 
New Batch 
5_20140514_171740.csv   GYPB*Mur       
Green EX1308762 
New Batch 
5_20140514_171740.csv Diego DI*A DI*B Dia (DI:1) 0 
Green EX1308762 
New Batch 
5_20140514_171740.csv   DI*B   Dib (DI:2) + 
Green EX1308762 
New Batch 
5_20140514_171740.csv Dombrock DO*A DO*A, DO*B Doa (DO:1) + 
Green EX1308762 
New Batch 
5_20140514_171740.csv   DO*B   Dob (DO:2) + 
Green EX1308762 
New Batch 
5_20140514_171740.csv   DO*B_HY-   Hy (DO:4) + 
Green EX1308762 
New Batch 
5_20140514_171740.csv   DO*A_JOA-   Joa (DO:5) + 
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1308762 
New Batch 
5_20140514_171740.csv Colton CO*A CO*A Coa (CO:1) + 
Green EX1308762 
New Batch 
5_20140514_171740.csv   CO*B   Cob (CO:2) 0 
Green EX1308762 
New Batch 
5_20140514_171740.csv Cartwright YT*A YT*A Yta (YT:1) + 
Green EX1308762 
New Batch 
5_20140514_171740.csv   YT*B   Ytb (YT:2) 0 
Green EX1308762 
New Batch 
5_20140514_171740.csv Lutheran LU*A LU*B Lua (LU:1) 0 
Green EX1308762 
New Batch 
5_20140514_171740.csv   LU*B   Lub (LU:2) + 
Green EX1308908 
New Batch 
5_20140514_171740.csv Rh RHCE*ce RHCE*ce C (RH:2) 0 
Green EX1308908 
New Batch 
5_20140514_171740.csv   RHCE*Ce   E (RH:3) 0 
Green EX1308908 
New Batch 
5_20140514_171740.csv   RHCE*cE   c (RH:4) + 
Green EX1308908 
New Batch 
5_20140514_171740.csv   RHCE*CE   e (RH:5) + 
Green EX1308908 
New Batch 
5_20140514_171740.csv   RHCE*CeCW   CW (RH:8) 0 
Green EX1308908 
New Batch 
5_20140514_171740.csv   RHCE*ceCW   V (RH:10) 0 
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1308908 
New Batch 
5_20140514_171740.csv   RHCE*CECW   hrS (RH:19) + 
Green EX1308908 
New Batch 
5_20140514_171740.csv   RHCE*ceAR   VS (RH:20) 0 
Green EX1308908 
New Batch 
5_20140514_171740.csv   RHCE*CeFV   hrB (RH:31) + 
Green EX1308908 
New Batch 
5_20140514_171740.csv   RHCE*CeVG       
Green EX1308908 
New Batch 
5_20140514_171740.csv   RHCE*cEFM       
Green EX1308908 
New Batch 
5_20140514_171740.csv   RHCE*ce[712G]       
Green EX1308908 
New Batch 
5_20140514_171740.csv   RHCE*ce[733G]       
Green EX1308908 
New Batch 
5_20140514_171740.csv   RHCE*ce[733G,1006T]       
Green EX1308908 
New Batch 
5_20140514_171740.csv   RHCE*CE-D[2, 5, 7]-CE       
Green EX1308908 
New Batch 
5_20140514_171740.csv   RHCE*cE[697G,712G,733G]       
Green EX1308908 
New Batch 
5_20140514_171740.csv   
RHD*r’s-
RHCE*ce[733G,1006T]       
Green EX1308908 
New Batch 
5_20140514_171740.csv Kell KEL*K_KPB_JSB KEL*k_KPB_JSB K (KEL:1) 0 
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1308908 
New Batch 
5_20140514_171740.csv   KEL*k_KPB_JSB   k (KEL:2) + 
Green EX1308908 
New Batch 
5_20140514_171740.csv   KEL*k_KPA_JSB   Kpa (KEL:3) 0 
Green EX1308908 
New Batch 
5_20140514_171740.csv   KEL*k_KPB_JSA   Kpb (KEL:4) + 
Green EX1308908 
New Batch 
5_20140514_171740.csv       Jsa (KEL:6) 0 
Green EX1308908 
New Batch 
5_20140514_171740.csv       Jsb (KEL:7) + 
Green EX1308908 
New Batch 
5_20140514_171740.csv Kidd JK*A JK*A Jka (JK:1) + 
Green EX1308908 
New Batch 
5_20140514_171740.csv   JK*B   Jkb (JK:2) 0 
Green EX1308908 
New Batch 
5_20140514_171740.csv   JK*B_null(IVS5-1a)       
Green EX1308908 
New Batch 
5_20140514_171740.csv   JK*B_null(871C)       
Green EX1308908 
New Batch 
5_20140514_171740.csv Duffy FY*A FY*A Fya (FY:1) + 
Green EX1308908 
New Batch 
5_20140514_171740.csv   FY*B   Fyb (FY:2) 0 
Green EX1308908 
New Batch 
5_20140514_171740.csv   FY*B_GATA       
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1308908 
New Batch 
5_20140514_171740.csv   FY*B[265T]_FY*X       
Green EX1308908 
New Batch 
5_20140514_171740.csv MNS GYPA*M GYPA*M, GYPA*N M (MNS:1) + 
Green EX1308908 
New Batch 
5_20140514_171740.csv   GYPA*N   N (MNS:2) + 
Green EX1308908 
New Batch 
5_20140514_171740.csv   GYPB*S GYPB*S, GYPB*s S (MNS:3) + 
Green EX1308908 
New Batch 
5_20140514_171740.csv   GYPB*s   s (MNS:4) + 
Green EX1308908 
New Batch 
5_20140514_171740.csv   GYPB*S_null(IVS5+5t)   U (MNS:5) + 
Green EX1308908 
New Batch 
5_20140514_171740.csv   GYPB*S_null(230T)   Mia (MNS:7) 0 
Green EX1308908 
New Batch 
5_20140514_171740.csv   GYPB*deletion       
Green EX1308908 
New Batch 
5_20140514_171740.csv   GYPB*Mur       
Green EX1308908 
New Batch 
5_20140514_171740.csv Diego DI*A DI*B Dia (DI:1) 0 
Green EX1308908 
New Batch 
5_20140514_171740.csv   DI*B   Dib (DI:2) + 
Green EX1308908 
New Batch 
5_20140514_171740.csv Dombrock DO*A DO*A, DO*B Doa (DO:1) + 
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1308908 
New Batch 
5_20140514_171740.csv   DO*B   Dob (DO:2) + 
Green EX1308908 
New Batch 
5_20140514_171740.csv   DO*B_HY-   Hy (DO:4) + 
Green EX1308908 
New Batch 
5_20140514_171740.csv   DO*A_JOA-   Joa (DO:5) + 
Green EX1308908 
New Batch 
5_20140514_171740.csv Colton CO*A CO*A Coa (CO:1) + 
Green EX1308908 
New Batch 
5_20140514_171740.csv   CO*B   Cob (CO:2) 0 
Green EX1308908 
New Batch 
5_20140514_171740.csv Cartwright YT*A YT*A Yta (YT:1) + 
Green EX1308908 
New Batch 
5_20140514_171740.csv   YT*B   Ytb (YT:2) 0 
Green EX1308908 
New Batch 
5_20140514_171740.csv Lutheran LU*A LU*B Lua (LU:1) 0 
Green EX1308908 
New Batch 
5_20140514_171740.csv   LU*B   Lub (LU:2) + 
Green EX1308909 
New Batch 
5_20140514_171740.csv Rh RHCE*ce RHCE*Ce, RHCE*cE(10) C (RH:2) + 
Green EX1308909 
New Batch 
5_20140514_171740.csv   RHCE*Ce   E (RH:3) + 
Green EX1308909 
New Batch 
5_20140514_171740.csv   RHCE*cE   c (RH:4) + 
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1308909 
New Batch 
5_20140514_171740.csv   RHCE*CE   e (RH:5) + 
Green EX1308909 
New Batch 
5_20140514_171740.csv   RHCE*CeCW   CW (RH:8) 0 
Green EX1308909 
New Batch 
5_20140514_171740.csv   RHCE*ceCW   V (RH:10) 0 
Green EX1308909 
New Batch 
5_20140514_171740.csv   RHCE*CECW   hrS (RH:19) + 
Green EX1308909 
New Batch 
5_20140514_171740.csv   RHCE*ceAR   VS (RH:20) 0 
Green EX1308909 
New Batch 
5_20140514_171740.csv   RHCE*CeFV   hrB (RH:31) + 
Green EX1308909 
New Batch 
5_20140514_171740.csv   RHCE*CeVG       
Green EX1308909 
New Batch 
5_20140514_171740.csv   RHCE*cEFM       
Green EX1308909 
New Batch 
5_20140514_171740.csv   RHCE*ce[712G]       
Green EX1308909 
New Batch 
5_20140514_171740.csv   RHCE*ce[733G]       
Green EX1308909 
New Batch 
5_20140514_171740.csv   RHCE*ce[733G,1006T]       
Green EX1308909 
New Batch 
5_20140514_171740.csv   RHCE*CE-D[2, 5, 7]-CE       
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1308909 
New Batch 
5_20140514_171740.csv   RHCE*cE[697G,712G,733G]       
Green EX1308909 
New Batch 
5_20140514_171740.csv   
RHD*r’s-
RHCE*ce[733G,1006T]       
Green EX1308909 
New Batch 
5_20140514_171740.csv Kell KEL*K_KPB_JSB KEL*k_KPB_JSB K (KEL:1) 0 
Green EX1308909 
New Batch 
5_20140514_171740.csv   KEL*k_KPB_JSB   k (KEL:2) + 
Green EX1308909 
New Batch 
5_20140514_171740.csv   KEL*k_KPA_JSB   Kpa (KEL:3) 0 
Green EX1308909 
New Batch 
5_20140514_171740.csv   KEL*k_KPB_JSA   Kpb (KEL:4) + 
Green EX1308909 
New Batch 
5_20140514_171740.csv       Jsa (KEL:6) 0 
Green EX1308909 
New Batch 
5_20140514_171740.csv       Jsb (KEL:7) + 
Green EX1308909 
New Batch 
5_20140514_171740.csv Kidd JK*A JK*A Jka (JK:1) + 
Green EX1308909 
New Batch 
5_20140514_171740.csv   JK*B   Jkb (JK:2) 0 
Green EX1308909 
New Batch 
5_20140514_171740.csv   JK*B_null(IVS5-1a)       
Green EX1308909 
New Batch 
5_20140514_171740.csv   JK*B_null(871C)       
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1308909 
New Batch 
5_20140514_171740.csv Duffy FY*A FY*A, FY*B Fya (FY:1) + 
Green EX1308909 
New Batch 
5_20140514_171740.csv   FY*B   Fyb (FY:2) + 
Green EX1308909 
New Batch 
5_20140514_171740.csv   FY*B_GATA       
Green EX1308909 
New Batch 
5_20140514_171740.csv   FY*B[265T]_FY*X       
Green EX1308909 
New Batch 
5_20140514_171740.csv MNS GYPA*M GYPA*M, GYPA*N M (MNS:1) + 
Green EX1308909 
New Batch 
5_20140514_171740.csv   GYPA*N   N (MNS:2) + 
Green EX1308909 
New Batch 
5_20140514_171740.csv   GYPB*S GYPB*s S (MNS:3) 0 
Green EX1308909 
New Batch 
5_20140514_171740.csv   GYPB*s   s (MNS:4) + 
Green EX1308909 
New Batch 
5_20140514_171740.csv   GYPB*S_null(IVS5+5t)   U (MNS:5) + 
Green EX1308909 
New Batch 
5_20140514_171740.csv   GYPB*S_null(230T)   Mia (MNS:7) 0 
Green EX1308909 
New Batch 
5_20140514_171740.csv   GYPB*deletion       
Green EX1308909 
New Batch 
5_20140514_171740.csv   GYPB*Mur       
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1308909 
New Batch 
5_20140514_171740.csv Diego DI*A DI*B Dia (DI:1) 0 
Green EX1308909 
New Batch 
5_20140514_171740.csv   DI*B   Dib (DI:2) + 
Green EX1308909 
New Batch 
5_20140514_171740.csv Dombrock DO*A DO*A, DO*B Doa (DO:1) + 
Green EX1308909 
New Batch 
5_20140514_171740.csv   DO*B   Dob (DO:2) + 
Green EX1308909 
New Batch 
5_20140514_171740.csv   DO*B_HY-   Hy (DO:4) + 
Green EX1308909 
New Batch 
5_20140514_171740.csv   DO*A_JOA-   Joa (DO:5) + 
Green EX1308909 
New Batch 
5_20140514_171740.csv Colton CO*A CO*A Coa (CO:1) + 
Green EX1308909 
New Batch 
5_20140514_171740.csv   CO*B   Cob (CO:2) 0 
Green EX1308909 
New Batch 
5_20140514_171740.csv Cartwright YT*A YT*A Yta (YT:1) + 
Green EX1308909 
New Batch 
5_20140514_171740.csv   YT*B   Ytb (YT:2) 0 
Green EX1308909 
New Batch 
5_20140514_171740.csv Lutheran LU*A LU*B Lua (LU:1) 0 
Green EX1308909 
New Batch 
5_20140514_171740.csv   LU*B   Lub (LU:2) + 
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1308959 
New Batch 
5_20140514_171740.csv Rh RHCE*ce RHCE*ce, RHCE*Ce C (RH:2) + 
Green EX1308959 
New Batch 
5_20140514_171740.csv   RHCE*Ce   E (RH:3) 0 
Green EX1308959 
New Batch 
5_20140514_171740.csv   RHCE*cE   c (RH:4) + 
Green EX1308959 
New Batch 
5_20140514_171740.csv   RHCE*CE   e (RH:5) + 
Green EX1308959 
New Batch 
5_20140514_171740.csv   RHCE*CeCW   CW (RH:8) 0 
Green EX1308959 
New Batch 
5_20140514_171740.csv   RHCE*ceCW   V (RH:10) 0 
Green EX1308959 
New Batch 
5_20140514_171740.csv   RHCE*CECW   hrS (RH:19) + 
Green EX1308959 
New Batch 
5_20140514_171740.csv   RHCE*ceAR   VS (RH:20) 0 
Green EX1308959 
New Batch 
5_20140514_171740.csv   RHCE*CeFV   hrB (RH:31) + 
Green EX1308959 
New Batch 
5_20140514_171740.csv   RHCE*CeVG       
Green EX1308959 
New Batch 
5_20140514_171740.csv   RHCE*cEFM       
Green EX1308959 
New Batch 
5_20140514_171740.csv   RHCE*ce[712G]       
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1308959 
New Batch 
5_20140514_171740.csv   RHCE*ce[733G]       
Green EX1308959 
New Batch 
5_20140514_171740.csv   RHCE*ce[733G,1006T]       
Green EX1308959 
New Batch 
5_20140514_171740.csv   RHCE*CE-D[2, 5, 7]-CE       
Green EX1308959 
New Batch 
5_20140514_171740.csv   RHCE*cE[697G,712G,733G]       
Green EX1308959 
New Batch 
5_20140514_171740.csv   
RHD*r’s-
RHCE*ce[733G,1006T]       
Green EX1308959 
New Batch 
5_20140514_171740.csv Kell KEL*K_KPB_JSB KEL*k_KPB_JSB K (KEL:1) 0 
Green EX1308959 
New Batch 
5_20140514_171740.csv   KEL*k_KPB_JSB   k (KEL:2) + 
Green EX1308959 
New Batch 
5_20140514_171740.csv   KEL*k_KPA_JSB   Kpa (KEL:3) 0 
Green EX1308959 
New Batch 
5_20140514_171740.csv   KEL*k_KPB_JSA   Kpb (KEL:4) + 
Green EX1308959 
New Batch 
5_20140514_171740.csv       Jsa (KEL:6) 0 
Green EX1308959 
New Batch 
5_20140514_171740.csv       Jsb (KEL:7) + 
Green EX1308959 
New Batch 
5_20140514_171740.csv Kidd JK*A JK*B Jka (JK:1) 0 
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1308959 
New Batch 
5_20140514_171740.csv   JK*B   Jkb (JK:2) + 
Green EX1308959 
New Batch 
5_20140514_171740.csv   JK*B_null(IVS5-1a)       
Green EX1308959 
New Batch 
5_20140514_171740.csv   JK*B_null(871C)       
Green EX1308959 
New Batch 
5_20140514_171740.csv Duffy FY*A FY*B Fya (FY:1) 0 
Green EX1308959 
New Batch 
5_20140514_171740.csv   FY*B   Fyb (FY:2) + 
Green EX1308959 
New Batch 
5_20140514_171740.csv   FY*B_GATA       
Green EX1308959 
New Batch 
5_20140514_171740.csv   FY*B[265T]_FY*X       
Green EX1308959 
New Batch 
5_20140514_171740.csv MNS GYPA*M GYPA*M, GYPA*N M (MNS:1) + 
Green EX1308959 
New Batch 
5_20140514_171740.csv   GYPA*N   N (MNS:2) + 
Green EX1308959 
New Batch 
5_20140514_171740.csv   GYPB*S GYPB*s S (MNS:3) 0 
Green EX1308959 
New Batch 
5_20140514_171740.csv   GYPB*s   s (MNS:4) + 
Green EX1308959 
New Batch 
5_20140514_171740.csv   GYPB*S_null(IVS5+5t)   U (MNS:5) + 
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1308959 
New Batch 
5_20140514_171740.csv   GYPB*S_null(230T)   Mia (MNS:7) 0 
Green EX1308959 
New Batch 
5_20140514_171740.csv   GYPB*deletion       
Green EX1308959 
New Batch 
5_20140514_171740.csv   GYPB*Mur       
Green EX1308959 
New Batch 
5_20140514_171740.csv Diego DI*A DI*B Dia (DI:1) 0 
Green EX1308959 
New Batch 
5_20140514_171740.csv   DI*B   Dib (DI:2) + 
Green EX1308959 
New Batch 
5_20140514_171740.csv Dombrock DO*A DO*B Doa (DO:1) 0 
Green EX1308959 
New Batch 
5_20140514_171740.csv   DO*B   Dob (DO:2) + 
Green EX1308959 
New Batch 
5_20140514_171740.csv   DO*B_HY-   Hy (DO:4) + 
Green EX1308959 
New Batch 
5_20140514_171740.csv   DO*A_JOA-   Joa (DO:5) + 
Green EX1308959 
New Batch 
5_20140514_171740.csv Colton CO*A CO*A, CO*B Coa (CO:1) + 
Green EX1308959 
New Batch 
5_20140514_171740.csv   CO*B   Cob (CO:2) + 
Green EX1308959 
New Batch 
5_20140514_171740.csv Cartwright YT*A YT*A Yta (YT:1) + 
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1308959 
New Batch 
5_20140514_171740.csv   YT*B   Ytb (YT:2) 0 
Green EX1308959 
New Batch 
5_20140514_171740.csv Lutheran LU*A LU*B Lua (LU:1) 0 
Green EX1308959 
New Batch 
5_20140514_171740.csv   LU*B   Lub (LU:2) + 
Green EX1311437 
New Batch 
5_20140514_171740.csv Rh RHCE*ce RHCE*Ce, RHCE*CeCW C (RH:2) + 
Green EX1311437 
New Batch 
5_20140514_171740.csv   RHCE*Ce   E (RH:3) 0 
Green EX1311437 
New Batch 
5_20140514_171740.csv   RHCE*cE   c (RH:4) 0 
Green EX1311437 
New Batch 
5_20140514_171740.csv   RHCE*CE   e (RH:5) + 
Green EX1311437 
New Batch 
5_20140514_171740.csv   RHCE*CeCW   CW (RH:8) + 
Green EX1311437 
New Batch 
5_20140514_171740.csv   RHCE*ceCW   V (RH:10) 0 
Green EX1311437 
New Batch 
5_20140514_171740.csv   RHCE*CECW   hrS (RH:19) + 
Green EX1311437 
New Batch 
5_20140514_171740.csv   RHCE*ceAR   VS (RH:20) 0 
Green EX1311437 
New Batch 
5_20140514_171740.csv   RHCE*CeFV   hrB (RH:31) + 
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1311437 
New Batch 
5_20140514_171740.csv   RHCE*CeVG       
Green EX1311437 
New Batch 
5_20140514_171740.csv   RHCE*cEFM       
Green EX1311437 
New Batch 
5_20140514_171740.csv   RHCE*ce[712G]       
Green EX1311437 
New Batch 
5_20140514_171740.csv   RHCE*ce[733G]       
Green EX1311437 
New Batch 
5_20140514_171740.csv   RHCE*ce[733G,1006T]       
Green EX1311437 
New Batch 
5_20140514_171740.csv   RHCE*CE-D[2, 5, 7]-CE       
Green EX1311437 
New Batch 
5_20140514_171740.csv   RHCE*cE[697G,712G,733G]       
Green EX1311437 
New Batch 
5_20140514_171740.csv   
RHD*r’s-
RHCE*ce[733G,1006T]       
Green EX1311437 
New Batch 
5_20140514_171740.csv Kell KEL*K_KPB_JSB KEL*k_KPB_JSB K (KEL:1) 0 
Green EX1311437 
New Batch 
5_20140514_171740.csv   KEL*k_KPB_JSB   k (KEL:2) + 
Green EX1311437 
New Batch 
5_20140514_171740.csv   KEL*k_KPA_JSB   Kpa (KEL:3) 0 
Green EX1311437 
New Batch 
5_20140514_171740.csv   KEL*k_KPB_JSA   Kpb (KEL:4) + 
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1311437 
New Batch 
5_20140514_171740.csv       Jsa (KEL:6) 0 
Green EX1311437 
New Batch 
5_20140514_171740.csv       Jsb (KEL:7) + 
Green EX1311437 
New Batch 
5_20140514_171740.csv Kidd JK*A JK*B Jka (JK:1) 0 
Green EX1311437 
New Batch 
5_20140514_171740.csv   JK*B   Jkb (JK:2) + 
Green EX1311437 
New Batch 
5_20140514_171740.csv   JK*B_null(IVS5-1a)       
Green EX1311437 
New Batch 
5_20140514_171740.csv   JK*B_null(871C)       
Green EX1311437 
New Batch 
5_20140514_171740.csv Duffy FY*A FY*B Fya (FY:1) 0 
Green EX1311437 
New Batch 
5_20140514_171740.csv   FY*B   Fyb (FY:2) + 
Green EX1311437 
New Batch 
5_20140514_171740.csv   FY*B_GATA       
Green EX1311437 
New Batch 
5_20140514_171740.csv   FY*B[265T]_FY*X       
Green EX1311437 
New Batch 
5_20140514_171740.csv MNS GYPA*M GYPA*M M (MNS:1) + 
Green EX1311437 
New Batch 
5_20140514_171740.csv   GYPA*N   N (MNS:2) 0 
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1311437 
New Batch 
5_20140514_171740.csv   GYPB*S GYPB*s S (MNS:3) 0 
Green EX1311437 
New Batch 
5_20140514_171740.csv   GYPB*s   s (MNS:4) + 
Green EX1311437 
New Batch 
5_20140514_171740.csv   GYPB*S_null(IVS5+5t)   U (MNS:5) + 
Green EX1311437 
New Batch 
5_20140514_171740.csv   GYPB*S_null(230T)   Mia (MNS:7) 0 
Green EX1311437 
New Batch 
5_20140514_171740.csv   GYPB*deletion       
Green EX1311437 
New Batch 
5_20140514_171740.csv   GYPB*Mur       
Green EX1311437 
New Batch 
5_20140514_171740.csv Diego DI*A DI*B Dia (DI:1) 0 
Green EX1311437 
New Batch 
5_20140514_171740.csv   DI*B   Dib (DI:2) + 
Green EX1311437 
New Batch 
5_20140514_171740.csv Dombrock DO*A DO*B Doa (DO:1) 0 
Green EX1311437 
New Batch 
5_20140514_171740.csv   DO*B   Dob (DO:2) + 
Green EX1311437 
New Batch 
5_20140514_171740.csv   DO*B_HY-   Hy (DO:4) + 
Green EX1311437 
New Batch 
5_20140514_171740.csv   DO*A_JOA-   Joa (DO:5) + 
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1311437 
New Batch 
5_20140514_171740.csv Colton CO*A CO*A Coa (CO:1) + 
Green EX1311437 
New Batch 
5_20140514_171740.csv   CO*B   Cob (CO:2) 0 
Green EX1311437 
New Batch 
5_20140514_171740.csv Cartwright YT*A YT*A Yta (YT:1) + 
Green EX1311437 
New Batch 
5_20140514_171740.csv   YT*B   Ytb (YT:2) 0 
Green EX1311437 
New Batch 
5_20140514_171740.csv Lutheran LU*A LU*B Lua (LU:1) 0 
Green EX1311437 
New Batch 
5_20140514_171740.csv   LU*B   Lub (LU:2) + 
Green EX1311438 
New Batch 
5_20140514_171740.csv Rh RHCE*ce RHCE*ce, RHCE*cE C (RH:2) 0 
Green EX1311438 
New Batch 
5_20140514_171740.csv   RHCE*Ce   E (RH:3) + 
Green EX1311438 
New Batch 
5_20140514_171740.csv   RHCE*cE   c (RH:4) + 
Green EX1311438 
New Batch 
5_20140514_171740.csv   RHCE*CE   e (RH:5) + 
Green EX1311438 
New Batch 
5_20140514_171740.csv   RHCE*CeCW   CW (RH:8) 0 
Green EX1311438 
New Batch 
5_20140514_171740.csv   RHCE*ceCW   V (RH:10) 0 
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1311438 
New Batch 
5_20140514_171740.csv   RHCE*CECW   hrS (RH:19) + 
Green EX1311438 
New Batch 
5_20140514_171740.csv   RHCE*ceAR   VS (RH:20) 0 
Green EX1311438 
New Batch 
5_20140514_171740.csv   RHCE*CeFV   hrB (RH:31) + 
Green EX1311438 
New Batch 
5_20140514_171740.csv   RHCE*CeVG       
Green EX1311438 
New Batch 
5_20140514_171740.csv   RHCE*cEFM       
Green EX1311438 
New Batch 
5_20140514_171740.csv   RHCE*ce[712G]       
Green EX1311438 
New Batch 
5_20140514_171740.csv   RHCE*ce[733G]       
Green EX1311438 
New Batch 
5_20140514_171740.csv   RHCE*ce[733G,1006T]       
Green EX1311438 
New Batch 
5_20140514_171740.csv   RHCE*CE-D[2, 5, 7]-CE       
Green EX1311438 
New Batch 
5_20140514_171740.csv   RHCE*cE[697G,712G,733G]       
Green EX1311438 
New Batch 
5_20140514_171740.csv   
RHD*r’s-
RHCE*ce[733G,1006T]       
Green EX1311438 
New Batch 
5_20140514_171740.csv Kell KEL*K_KPB_JSB KEL*k_KPB_JSB K (KEL:1) 0 
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1311438 
New Batch 
5_20140514_171740.csv   KEL*k_KPB_JSB   k (KEL:2) + 
Green EX1311438 
New Batch 
5_20140514_171740.csv   KEL*k_KPA_JSB   Kpa (KEL:3) 0 
Green EX1311438 
New Batch 
5_20140514_171740.csv   KEL*k_KPB_JSA   Kpb (KEL:4) + 
Green EX1311438 
New Batch 
5_20140514_171740.csv       Jsa (KEL:6) 0 
Green EX1311438 
New Batch 
5_20140514_171740.csv       Jsb (KEL:7) + 
Green EX1311438 
New Batch 
5_20140514_171740.csv Kidd JK*A JK*A, JK*B Jka (JK:1) + 
Green EX1311438 
New Batch 
5_20140514_171740.csv   JK*B   Jkb (JK:2) + 
Green EX1311438 
New Batch 
5_20140514_171740.csv   JK*B_null(IVS5-1a)       
Green EX1311438 
New Batch 
5_20140514_171740.csv   JK*B_null(871C)       
Green EX1311438 
New Batch 
5_20140514_171740.csv Duffy FY*A FY*A, FY*B Fya (FY:1) + 
Green EX1311438 
New Batch 
5_20140514_171740.csv   FY*B   Fyb (FY:2) + 
Green EX1311438 
New Batch 
5_20140514_171740.csv   FY*B_GATA       
182 | A p p e n d i x  
 
Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1311438 
New Batch 
5_20140514_171740.csv   FY*B[265T]_FY*X       
Green EX1311438 
New Batch 
5_20140514_171740.csv MNS GYPA*M GYPA*M M (MNS:1) + 
Green EX1311438 
New Batch 
5_20140514_171740.csv   GYPA*N   N (MNS:2) 0 
Green EX1311438 
New Batch 
5_20140514_171740.csv   GYPB*S GYPB*S S (MNS:3) + 
Green EX1311438 
New Batch 
5_20140514_171740.csv   GYPB*s   s (MNS:4) 0 
Green EX1311438 
New Batch 
5_20140514_171740.csv   GYPB*S_null(IVS5+5t)   U (MNS:5) + 
Green EX1311438 
New Batch 
5_20140514_171740.csv   GYPB*S_null(230T)   Mia (MNS:7) 0 
Green EX1311438 
New Batch 
5_20140514_171740.csv   GYPB*deletion       
Green EX1311438 
New Batch 
5_20140514_171740.csv   GYPB*Mur       
Green EX1311438 
New Batch 
5_20140514_171740.csv Diego DI*A DI*B Dia (DI:1) 0 
Green EX1311438 
New Batch 
5_20140514_171740.csv   DI*B   Dib (DI:2) + 
Green EX1311438 
New Batch 
5_20140514_171740.csv Dombrock DO*A DO*B Doa (DO:1) 0 
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1311438 
New Batch 
5_20140514_171740.csv   DO*B   Dob (DO:2) + 
Green EX1311438 
New Batch 
5_20140514_171740.csv   DO*B_HY-   Hy (DO:4) + 
Green EX1311438 
New Batch 
5_20140514_171740.csv   DO*A_JOA-   Joa (DO:5) + 
Green EX1311438 
New Batch 
5_20140514_171740.csv Colton CO*A CO*A Coa (CO:1) + 
Green EX1311438 
New Batch 
5_20140514_171740.csv   CO*B   Cob (CO:2) 0 
Green EX1311438 
New Batch 
5_20140514_171740.csv Cartwright YT*A YT*A Yta (YT:1) + 
Green EX1311438 
New Batch 
5_20140514_171740.csv   YT*B   Ytb (YT:2) 0 
Green EX1311438 
New Batch 
5_20140514_171740.csv Lutheran LU*A LU*B Lua (LU:1) 0 
Green EX1311438 
New Batch 
5_20140514_171740.csv   LU*B   Lub (LU:2) + 
Green EX1311986 
New Batch 
5_20140514_171740.csv Rh RHCE*ce RHCE*Ce, RHCE*cE(10) C (RH:2) + 
Green EX1311986 
New Batch 
5_20140514_171740.csv   RHCE*Ce   E (RH:3) + 
Green EX1311986 
New Batch 
5_20140514_171740.csv   RHCE*cE   c (RH:4) + 
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1311986 
New Batch 
5_20140514_171740.csv   RHCE*CE   e (RH:5) + 
Green EX1311986 
New Batch 
5_20140514_171740.csv   RHCE*CeCW   CW (RH:8) 0 
Green EX1311986 
New Batch 
5_20140514_171740.csv   RHCE*ceCW   V (RH:10) 0 
Green EX1311986 
New Batch 
5_20140514_171740.csv   RHCE*CECW   hrS (RH:19) + 
Green EX1311986 
New Batch 
5_20140514_171740.csv   RHCE*ceAR   VS (RH:20) 0 
Green EX1311986 
New Batch 
5_20140514_171740.csv   RHCE*CeFV   hrB (RH:31) + 
Green EX1311986 
New Batch 
5_20140514_171740.csv   RHCE*CeVG       
Green EX1311986 
New Batch 
5_20140514_171740.csv   RHCE*cEFM       
Green EX1311986 
New Batch 
5_20140514_171740.csv   RHCE*ce[712G]       
Green EX1311986 
New Batch 
5_20140514_171740.csv   RHCE*ce[733G]       
Green EX1311986 
New Batch 
5_20140514_171740.csv   RHCE*ce[733G,1006T]       
Green EX1311986 
New Batch 
5_20140514_171740.csv   RHCE*CE-D[2, 5, 7]-CE       
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1311986 
New Batch 
5_20140514_171740.csv   RHCE*cE[697G,712G,733G]       
Green EX1311986 
New Batch 
5_20140514_171740.csv   
RHD*r’s-
RHCE*ce[733G,1006T]       
Green EX1311986 
New Batch 
5_20140514_171740.csv Kell KEL*K_KPB_JSB KEL*k_KPB_JSB K (KEL:1) 0 
Green EX1311986 
New Batch 
5_20140514_171740.csv   KEL*k_KPB_JSB   k (KEL:2) + 
Green EX1311986 
New Batch 
5_20140514_171740.csv   KEL*k_KPA_JSB   Kpa (KEL:3) 0 
Green EX1311986 
New Batch 
5_20140514_171740.csv   KEL*k_KPB_JSA   Kpb (KEL:4) + 
Green EX1311986 
New Batch 
5_20140514_171740.csv       Jsa (KEL:6) 0 
Green EX1311986 
New Batch 
5_20140514_171740.csv       Jsb (KEL:7) + 
Green EX1311986 
New Batch 
5_20140514_171740.csv Kidd JK*A JK*A Jka (JK:1) + 
Green EX1311986 
New Batch 
5_20140514_171740.csv   JK*B   Jkb (JK:2) 0 
Green EX1311986 
New Batch 
5_20140514_171740.csv   JK*B_null(IVS5-1a)       
Green EX1311986 
New Batch 
5_20140514_171740.csv   JK*B_null(871C)       
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1311986 
New Batch 
5_20140514_171740.csv Duffy FY*A FY*A, FY*B Fya (FY:1) + 
Green EX1311986 
New Batch 
5_20140514_171740.csv   FY*B   Fyb (FY:2) + 
Green EX1311986 
New Batch 
5_20140514_171740.csv   FY*B_GATA       
Green EX1311986 
New Batch 
5_20140514_171740.csv   FY*B[265T]_FY*X       
Green EX1311986 
New Batch 
5_20140514_171740.csv MNS GYPA*M GYPA*M, GYPA*N M (MNS:1) + 
Green EX1311986 
New Batch 
5_20140514_171740.csv   GYPA*N   N (MNS:2) + 
Green EX1311986 
New Batch 
5_20140514_171740.csv   GYPB*S GYPB*S, GYPB*s S (MNS:3) + 
Green EX1311986 
New Batch 
5_20140514_171740.csv   GYPB*s   s (MNS:4) + 
Green EX1311986 
New Batch 
5_20140514_171740.csv   GYPB*S_null(IVS5+5t)   U (MNS:5) + 
Green EX1311986 
New Batch 
5_20140514_171740.csv   GYPB*S_null(230T)   Mia (MNS:7) 0 
Green EX1311986 
New Batch 
5_20140514_171740.csv   GYPB*deletion       
Green EX1311986 
New Batch 
5_20140514_171740.csv   GYPB*Mur       
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1311986 
New Batch 
5_20140514_171740.csv Diego DI*A DI*B Dia (DI:1) 0 
Green EX1311986 
New Batch 
5_20140514_171740.csv   DI*B   Dib (DI:2) + 
Green EX1311986 
New Batch 
5_20140514_171740.csv Dombrock DO*A DO*B Doa (DO:1) 0 
Green EX1311986 
New Batch 
5_20140514_171740.csv   DO*B   Dob (DO:2) + 
Green EX1311986 
New Batch 
5_20140514_171740.csv   DO*B_HY-   Hy (DO:4) + 
Green EX1311986 
New Batch 
5_20140514_171740.csv   DO*A_JOA-   Joa (DO:5) + 
Green EX1311986 
New Batch 
5_20140514_171740.csv Colton CO*A CO*A Coa (CO:1) + 
Green EX1311986 
New Batch 
5_20140514_171740.csv   CO*B   Cob (CO:2) 0 
Green EX1311986 
New Batch 
5_20140514_171740.csv Cartwright YT*A YT*A Yta (YT:1) + 
Green EX1311986 
New Batch 
5_20140514_171740.csv   YT*B   Ytb (YT:2) 0 
Green EX1311986 
New Batch 
5_20140514_171740.csv Lutheran LU*A LU*B Lua (LU:1) 0 
Green EX1311986 
New Batch 
5_20140514_171740.csv   LU*B   Lub (LU:2) + 
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1311987 
New Batch 
5_20140514_171740.csv Rh RHCE*ce RHCE*Ce, RHCE*cE(10) C (RH:2) + 
Green EX1311987 
New Batch 
5_20140514_171740.csv   RHCE*Ce   E (RH:3) + 
Green EX1311987 
New Batch 
5_20140514_171740.csv   RHCE*cE   c (RH:4) + 
Green EX1311987 
New Batch 
5_20140514_171740.csv   RHCE*CE   e (RH:5) + 
Green EX1311987 
New Batch 
5_20140514_171740.csv   RHCE*CeCW   CW (RH:8) 0 
Green EX1311987 
New Batch 
5_20140514_171740.csv   RHCE*ceCW   V (RH:10) 0 
Green EX1311987 
New Batch 
5_20140514_171740.csv   RHCE*CECW   hrS (RH:19) + 
Green EX1311987 
New Batch 
5_20140514_171740.csv   RHCE*ceAR   VS (RH:20) 0 
Green EX1311987 
New Batch 
5_20140514_171740.csv   RHCE*CeFV   hrB (RH:31) + 
Green EX1311987 
New Batch 
5_20140514_171740.csv   RHCE*CeVG       
Green EX1311987 
New Batch 
5_20140514_171740.csv   RHCE*cEFM       
Green EX1311987 
New Batch 
5_20140514_171740.csv   RHCE*ce[712G]       
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1311987 
New Batch 
5_20140514_171740.csv   RHCE*ce[733G]       
Green EX1311987 
New Batch 
5_20140514_171740.csv   RHCE*ce[733G,1006T]       
Green EX1311987 
New Batch 
5_20140514_171740.csv   RHCE*CE-D[2, 5, 7]-CE       
Green EX1311987 
New Batch 
5_20140514_171740.csv   RHCE*cE[697G,712G,733G]       
Green EX1311987 
New Batch 
5_20140514_171740.csv   
RHD*r’s-
RHCE*ce[733G,1006T]       
Green EX1311987 
New Batch 
5_20140514_171740.csv Kell KEL*K_KPB_JSB KEL*k_KPB_JSB K (KEL:1) 0 
Green EX1311987 
New Batch 
5_20140514_171740.csv   KEL*k_KPB_JSB   k (KEL:2) + 
Green EX1311987 
New Batch 
5_20140514_171740.csv   KEL*k_KPA_JSB   Kpa (KEL:3) 0 
Green EX1311987 
New Batch 
5_20140514_171740.csv   KEL*k_KPB_JSA   Kpb (KEL:4) + 
Green EX1311987 
New Batch 
5_20140514_171740.csv       Jsa (KEL:6) 0 
Green EX1311987 
New Batch 
5_20140514_171740.csv       Jsb (KEL:7) + 
Green EX1311987 
New Batch 
5_20140514_171740.csv Kidd JK*A JK*A, JK*B Jka (JK:1) + 
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1311987 
New Batch 
5_20140514_171740.csv   JK*B   Jkb (JK:2) + 
Green EX1311987 
New Batch 
5_20140514_171740.csv   JK*B_null(IVS5-1a)       
Green EX1311987 
New Batch 
5_20140514_171740.csv   JK*B_null(871C)       
Green EX1311987 
New Batch 
5_20140514_171740.csv Duffy FY*A FY*B Fya (FY:1) 0 
Green EX1311987 
New Batch 
5_20140514_171740.csv   FY*B   Fyb (FY:2) + 
Green EX1311987 
New Batch 
5_20140514_171740.csv   FY*B_GATA       
Green EX1311987 
New Batch 
5_20140514_171740.csv   FY*B[265T]_FY*X       
Green EX1311987 
New Batch 
5_20140514_171740.csv MNS GYPA*M GYPA*M, GYPA*N M (MNS:1) + 
Green EX1311987 
New Batch 
5_20140514_171740.csv   GYPA*N   N (MNS:2) + 
Green EX1311987 
New Batch 
5_20140514_171740.csv   GYPB*S GYPB*S, GYPB*s S (MNS:3) + 
Green EX1311987 
New Batch 
5_20140514_171740.csv   GYPB*s   s (MNS:4) + 
Green EX1311987 
New Batch 
5_20140514_171740.csv   GYPB*S_null(IVS5+5t)   U (MNS:5) + 
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1311987 
New Batch 
5_20140514_171740.csv   GYPB*S_null(230T)   Mia (MNS:7) 0 
Green EX1311987 
New Batch 
5_20140514_171740.csv   GYPB*deletion       
Green EX1311987 
New Batch 
5_20140514_171740.csv   GYPB*Mur       
Green EX1311987 
New Batch 
5_20140514_171740.csv Diego DI*A DI*B Dia (DI:1) 0 
Green EX1311987 
New Batch 
5_20140514_171740.csv   DI*B   Dib (DI:2) + 
Green EX1311987 
New Batch 
5_20140514_171740.csv Dombrock DO*A DO*B Doa (DO:1) 0 
Green EX1311987 
New Batch 
5_20140514_171740.csv   DO*B   Dob (DO:2) + 
Green EX1311987 
New Batch 
5_20140514_171740.csv   DO*B_HY-   Hy (DO:4) + 
Green EX1311987 
New Batch 
5_20140514_171740.csv   DO*A_JOA-   Joa (DO:5) + 
Green EX1311987 
New Batch 
5_20140514_171740.csv Colton CO*A CO*A Coa (CO:1) + 
Green EX1311987 
New Batch 
5_20140514_171740.csv   CO*B   Cob (CO:2) 0 
Green EX1311987 
New Batch 
5_20140514_171740.csv Cartwright YT*A YT*A Yta (YT:1) + 
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1311987 
New Batch 
5_20140514_171740.csv   YT*B   Ytb (YT:2) 0 
Green EX1311987 
New Batch 
5_20140514_171740.csv Lutheran LU*A LU*B Lua (LU:1) 0 
Green EX1311987 
New Batch 
5_20140514_171740.csv   LU*B   Lub (LU:2) + 
Green EX1311988 
New Batch 
6_20140515_111617.csv Rh RHCE*ce RHCE*ce, RHCE*Ce C (RH:2) + 
Green EX1311988 
New Batch 
6_20140515_111617.csv   RHCE*Ce   E (RH:3) 0 
Green EX1311988 
New Batch 
6_20140515_111617.csv   RHCE*cE   c (RH:4) + 
Green EX1311988 
New Batch 
6_20140515_111617.csv   RHCE*CE   e (RH:5) + 
Green EX1311988 
New Batch 
6_20140515_111617.csv   RHCE*CeCW   CW (RH:8) 0 
Green EX1311988 
New Batch 
6_20140515_111617.csv   RHCE*ceCW   V (RH:10) 0 
Green EX1311988 
New Batch 
6_20140515_111617.csv   RHCE*CECW   hrS (RH:19) + 
Green EX1311988 
New Batch 
6_20140515_111617.csv   RHCE*ceAR   VS (RH:20) 0 
Green EX1311988 
New Batch 
6_20140515_111617.csv   RHCE*CeFV   hrB (RH:31) + 
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1311988 
New Batch 
6_20140515_111617.csv   RHCE*CeVG       
Green EX1311988 
New Batch 
6_20140515_111617.csv   RHCE*cEFM       
Green EX1311988 
New Batch 
6_20140515_111617.csv   RHCE*ce[712G]       
Green EX1311988 
New Batch 
6_20140515_111617.csv   RHCE*ce[733G]       
Green EX1311988 
New Batch 
6_20140515_111617.csv   RHCE*ce[733G,1006T]       
Green EX1311988 
New Batch 
6_20140515_111617.csv   RHCE*CE-D[2, 5, 7]-CE       
Green EX1311988 
New Batch 
6_20140515_111617.csv   RHCE*cE[697G,712G,733G]       
Green EX1311988 
New Batch 
6_20140515_111617.csv   
RHD*r’s-
RHCE*ce[733G,1006T]       
Green EX1311988 
New Batch 
6_20140515_111617.csv Kell KEL*K_KPB_JSB 
KEL*K_KPB_JSB, 
KEL*k_KPB_JSB K (KEL:1) + 
Green EX1311988 
New Batch 
6_20140515_111617.csv   KEL*k_KPB_JSB   k (KEL:2) + 
Green EX1311988 
New Batch 
6_20140515_111617.csv   KEL*k_KPA_JSB   Kpa (KEL:3) 0 
Green EX1311988 
New Batch 
6_20140515_111617.csv   KEL*k_KPB_JSA   Kpb (KEL:4) + 
194 | A p p e n d i x  
 
Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1311988 
New Batch 
6_20140515_111617.csv       Jsa (KEL:6) 0 
Green EX1311988 
New Batch 
6_20140515_111617.csv       Jsb (KEL:7) + 
Green EX1311988 
New Batch 
6_20140515_111617.csv Kidd JK*A JK*A, JK*B Jka (JK:1) + 
Green EX1311988 
New Batch 
6_20140515_111617.csv   JK*B   Jkb (JK:2) + 
Green EX1311988 
New Batch 
6_20140515_111617.csv   JK*B_null(IVS5-1a)       
Green EX1311988 
New Batch 
6_20140515_111617.csv   JK*B_null(871C)       
Green EX1311988 
New Batch 
6_20140515_111617.csv Duffy FY*A FY*B Fya (FY:1) 0 
Green EX1311988 
New Batch 
6_20140515_111617.csv   FY*B   Fyb (FY:2) + 
Green EX1311988 
New Batch 
6_20140515_111617.csv   FY*B_GATA       
Green EX1311988 
New Batch 
6_20140515_111617.csv   FY*B[265T]_FY*X       
Green EX1311988 
New Batch 
6_20140515_111617.csv MNS GYPA*M GYPA*M, GYPA*N M (MNS:1) + 
Green EX1311988 
New Batch 
6_20140515_111617.csv   GYPA*N   N (MNS:2) + 
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1311988 
New Batch 
6_20140515_111617.csv   GYPB*S GYPB*S, GYPB*s S (MNS:3) + 
Green EX1311988 
New Batch 
6_20140515_111617.csv   GYPB*s   s (MNS:4) + 
Green EX1311988 
New Batch 
6_20140515_111617.csv   GYPB*S_null(IVS5+5t)   U (MNS:5) + 
Green EX1311988 
New Batch 
6_20140515_111617.csv   GYPB*S_null(230T)   Mia (MNS:7) 0 
Green EX1311988 
New Batch 
6_20140515_111617.csv   GYPB*deletion       
Green EX1311988 
New Batch 
6_20140515_111617.csv   GYPB*Mur       
Green EX1311988 
New Batch 
6_20140515_111617.csv Diego DI*A DI*B Dia (DI:1) 0 
Green EX1311988 
New Batch 
6_20140515_111617.csv   DI*B   Dib (DI:2) + 
Green EX1311988 
New Batch 
6_20140515_111617.csv Dombrock DO*A DO*B Doa (DO:1) 0 
Green EX1311988 
New Batch 
6_20140515_111617.csv   DO*B   Dob (DO:2) + 
Green EX1311988 
New Batch 
6_20140515_111617.csv   DO*B_HY-   Hy (DO:4) + 
Green EX1311988 
New Batch 
6_20140515_111617.csv   DO*A_JOA-   Joa (DO:5) + 
196 | A p p e n d i x  
 
Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1311988 
New Batch 
6_20140515_111617.csv Colton CO*A CO*A Coa (CO:1) + 
Green EX1311988 
New Batch 
6_20140515_111617.csv   CO*B   Cob (CO:2) 0 
Green EX1311988 
New Batch 
6_20140515_111617.csv Cartwright YT*A YT*A Yta (YT:1) + 
Green EX1311988 
New Batch 
6_20140515_111617.csv   YT*B   Ytb (YT:2) 0 
Green EX1311988 
New Batch 
6_20140515_111617.csv Lutheran LU*A LU*B Lua (LU:1) 0 
Green EX1311988 
New Batch 
6_20140515_111617.csv   LU*B   Lub (LU:2) + 
Green EX1311989 
New Batch 
6_20140515_111617.csv Rh RHCE*ce RHCE*ce, RHCE*Ce C (RH:2) + 
Green EX1311989 
New Batch 
6_20140515_111617.csv   RHCE*Ce   E (RH:3) 0 
Green EX1311989 
New Batch 
6_20140515_111617.csv   RHCE*cE   c (RH:4) + 
Green EX1311989 
New Batch 
6_20140515_111617.csv   RHCE*CE   e (RH:5) + 
Green EX1311989 
New Batch 
6_20140515_111617.csv   RHCE*CeCW   CW (RH:8) 0 
Green EX1311989 
New Batch 
6_20140515_111617.csv   RHCE*ceCW   V (RH:10) 0 
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1311989 
New Batch 
6_20140515_111617.csv   RHCE*CECW   hrS (RH:19) + 
Green EX1311989 
New Batch 
6_20140515_111617.csv   RHCE*ceAR   VS (RH:20) 0 
Green EX1311989 
New Batch 
6_20140515_111617.csv   RHCE*CeFV   hrB (RH:31) + 
Green EX1311989 
New Batch 
6_20140515_111617.csv   RHCE*CeVG       
Green EX1311989 
New Batch 
6_20140515_111617.csv   RHCE*cEFM       
Green EX1311989 
New Batch 
6_20140515_111617.csv   RHCE*ce[712G]       
Green EX1311989 
New Batch 
6_20140515_111617.csv   RHCE*ce[733G]       
Green EX1311989 
New Batch 
6_20140515_111617.csv   RHCE*ce[733G,1006T]       
Green EX1311989 
New Batch 
6_20140515_111617.csv   RHCE*CE-D[2, 5, 7]-CE       
Green EX1311989 
New Batch 
6_20140515_111617.csv   RHCE*cE[697G,712G,733G]       
Green EX1311989 
New Batch 
6_20140515_111617.csv   
RHD*r’s-
RHCE*ce[733G,1006T]       
Green EX1311989 
New Batch 
6_20140515_111617.csv Kell KEL*K_KPB_JSB KEL*k_KPB_JSB K (KEL:1) 0 
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1311989 
New Batch 
6_20140515_111617.csv   KEL*k_KPB_JSB   k (KEL:2) + 
Green EX1311989 
New Batch 
6_20140515_111617.csv   KEL*k_KPA_JSB   Kpa (KEL:3) 0 
Green EX1311989 
New Batch 
6_20140515_111617.csv   KEL*k_KPB_JSA   Kpb (KEL:4) + 
Green EX1311989 
New Batch 
6_20140515_111617.csv       Jsa (KEL:6) 0 
Green EX1311989 
New Batch 
6_20140515_111617.csv       Jsb (KEL:7) + 
Green EX1311989 
New Batch 
6_20140515_111617.csv Kidd JK*A JK*A, JK*B Jka (JK:1) + 
Green EX1311989 
New Batch 
6_20140515_111617.csv   JK*B   Jkb (JK:2) + 
Green EX1311989 
New Batch 
6_20140515_111617.csv   JK*B_null(IVS5-1a)       
Green EX1311989 
New Batch 
6_20140515_111617.csv   JK*B_null(871C)       
Green EX1311989 
New Batch 
6_20140515_111617.csv Duffy FY*A FY*A, FY*B Fya (FY:1) + 
Green EX1311989 
New Batch 
6_20140515_111617.csv   FY*B   Fyb (FY:2) + 
Green EX1311989 
New Batch 
6_20140515_111617.csv   FY*B_GATA       
199 | A p p e n d i x  
 
Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1311989 
New Batch 
6_20140515_111617.csv   FY*B[265T]_FY*X       
Green EX1311989 
New Batch 
6_20140515_111617.csv MNS GYPA*M GYPA*M M (MNS:1) + 
Green EX1311989 
New Batch 
6_20140515_111617.csv   GYPA*N   N (MNS:2) 0 
Green EX1311989 
New Batch 
6_20140515_111617.csv   GYPB*S GYPB*S, GYPB*s S (MNS:3) + 
Green EX1311989 
New Batch 
6_20140515_111617.csv   GYPB*s   s (MNS:4) + 
Green EX1311989 
New Batch 
6_20140515_111617.csv   GYPB*S_null(IVS5+5t)   U (MNS:5) + 
Green EX1311989 
New Batch 
6_20140515_111617.csv   GYPB*S_null(230T)   Mia (MNS:7) 0 
Green EX1311989 
New Batch 
6_20140515_111617.csv   GYPB*deletion       
Green EX1311989 
New Batch 
6_20140515_111617.csv   GYPB*Mur       
Green EX1311989 
New Batch 
6_20140515_111617.csv Diego DI*A DI*B Dia (DI:1) 0 
Green EX1311989 
New Batch 
6_20140515_111617.csv   DI*B   Dib (DI:2) + 
Green EX1311989 
New Batch 
6_20140515_111617.csv Dombrock DO*A DO*A Doa (DO:1) + 
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1311989 
New Batch 
6_20140515_111617.csv   DO*B   Dob (DO:2) 0 
Green EX1311989 
New Batch 
6_20140515_111617.csv   DO*B_HY-   Hy (DO:4) + 
Green EX1311989 
New Batch 
6_20140515_111617.csv   DO*A_JOA-   Joa (DO:5) + 
Green EX1311989 
New Batch 
6_20140515_111617.csv Colton CO*A CO*A Coa (CO:1) + 
Green EX1311989 
New Batch 
6_20140515_111617.csv   CO*B   Cob (CO:2) 0 
Green EX1311989 
New Batch 
6_20140515_111617.csv Cartwright YT*A YT*A Yta (YT:1) + 
Green EX1311989 
New Batch 
6_20140515_111617.csv   YT*B   Ytb (YT:2) 0 
Green EX1311989 
New Batch 
6_20140515_111617.csv Lutheran LU*A LU*A, LU*B Lua (LU:1) + 
Green EX1311989 
New Batch 
6_20140515_111617.csv   LU*B   Lub (LU:2) + 
Green EX1312294 
New Batch 
6_20140515_111617.csv Rh RHCE*ce RHCE*ce C (RH:2) 0 
Green EX1312294 
New Batch 
6_20140515_111617.csv   RHCE*Ce   E (RH:3) 0 
Green EX1312294 
New Batch 
6_20140515_111617.csv   RHCE*cE   c (RH:4) + 
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1312294 
New Batch 
6_20140515_111617.csv   RHCE*CE   e (RH:5) + 
Green EX1312294 
New Batch 
6_20140515_111617.csv   RHCE*CeCW   CW (RH:8) 0 
Green EX1312294 
New Batch 
6_20140515_111617.csv   RHCE*ceCW   V (RH:10) 0 
Green EX1312294 
New Batch 
6_20140515_111617.csv   RHCE*CECW   hrS (RH:19) + 
Green EX1312294 
New Batch 
6_20140515_111617.csv   RHCE*ceAR   VS (RH:20) 0 
Green EX1312294 
New Batch 
6_20140515_111617.csv   RHCE*CeFV   hrB (RH:31) + 
Green EX1312294 
New Batch 
6_20140515_111617.csv   RHCE*CeVG       
Green EX1312294 
New Batch 
6_20140515_111617.csv   RHCE*cEFM       
Green EX1312294 
New Batch 
6_20140515_111617.csv   RHCE*ce[712G]       
Green EX1312294 
New Batch 
6_20140515_111617.csv   RHCE*ce[733G]       
Green EX1312294 
New Batch 
6_20140515_111617.csv   RHCE*ce[733G,1006T]       
Green EX1312294 
New Batch 
6_20140515_111617.csv   RHCE*CE-D[2, 5, 7]-CE       
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1312294 
New Batch 
6_20140515_111617.csv   RHCE*cE[697G,712G,733G]       
Green EX1312294 
New Batch 
6_20140515_111617.csv   
RHD*r’s-
RHCE*ce[733G,1006T]       
Green EX1312294 
New Batch 
6_20140515_111617.csv Kell KEL*K_KPB_JSB KEL*k_KPB_JSB K (KEL:1) 0 
Green EX1312294 
New Batch 
6_20140515_111617.csv   KEL*k_KPB_JSB   k (KEL:2) + 
Green EX1312294 
New Batch 
6_20140515_111617.csv   KEL*k_KPA_JSB   Kpa (KEL:3) 0 
Green EX1312294 
New Batch 
6_20140515_111617.csv   KEL*k_KPB_JSA   Kpb (KEL:4) + 
Green EX1312294 
New Batch 
6_20140515_111617.csv       Jsa (KEL:6) 0 
Green EX1312294 
New Batch 
6_20140515_111617.csv       Jsb (KEL:7) + 
Green EX1312294 
New Batch 
6_20140515_111617.csv Kidd JK*A JK*A, JK*B Jka (JK:1) + 
Green EX1312294 
New Batch 
6_20140515_111617.csv   JK*B   Jkb (JK:2) + 
Green EX1312294 
New Batch 
6_20140515_111617.csv   JK*B_null(IVS5-1a)       
Green EX1312294 
New Batch 
6_20140515_111617.csv   JK*B_null(871C)       
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1312294 
New Batch 
6_20140515_111617.csv Duffy FY*A FY*A, FY*B Fya (FY:1) + 
Green EX1312294 
New Batch 
6_20140515_111617.csv   FY*B   Fyb (FY:2) + 
Green EX1312294 
New Batch 
6_20140515_111617.csv   FY*B_GATA       
Green EX1312294 
New Batch 
6_20140515_111617.csv   FY*B[265T]_FY*X       
Green EX1312294 
New Batch 
6_20140515_111617.csv MNS GYPA*M GYPA*M M (MNS:1) + 
Green EX1312294 
New Batch 
6_20140515_111617.csv   GYPA*N   N (MNS:2) 0 
Green EX1312294 
New Batch 
6_20140515_111617.csv   GYPB*S GYPB*s S (MNS:3) 0 
Green EX1312294 
New Batch 
6_20140515_111617.csv   GYPB*s   s (MNS:4) + 
Green EX1312294 
New Batch 
6_20140515_111617.csv   GYPB*S_null(IVS5+5t)   U (MNS:5) + 
Green EX1312294 
New Batch 
6_20140515_111617.csv   GYPB*S_null(230T)   Mia (MNS:7) 0 
Green EX1312294 
New Batch 
6_20140515_111617.csv   GYPB*deletion       
Green EX1312294 
New Batch 
6_20140515_111617.csv   GYPB*Mur       
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1312294 
New Batch 
6_20140515_111617.csv Diego DI*A DI*B Dia (DI:1) 0 
Green EX1312294 
New Batch 
6_20140515_111617.csv   DI*B   Dib (DI:2) + 
Green EX1312294 
New Batch 
6_20140515_111617.csv Dombrock DO*A DO*A Doa (DO:1) + 
Green EX1312294 
New Batch 
6_20140515_111617.csv   DO*B   Dob (DO:2) 0 
Green EX1312294 
New Batch 
6_20140515_111617.csv   DO*B_HY-   Hy (DO:4) + 
Green EX1312294 
New Batch 
6_20140515_111617.csv   DO*A_JOA-   Joa (DO:5) + 
Green EX1312294 
New Batch 
6_20140515_111617.csv Colton CO*A CO*A Coa (CO:1) + 
Green EX1312294 
New Batch 
6_20140515_111617.csv   CO*B   Cob (CO:2) 0 
Green EX1312294 
New Batch 
6_20140515_111617.csv Cartwright YT*A YT*A Yta (YT:1) + 
Green EX1312294 
New Batch 
6_20140515_111617.csv   YT*B   Ytb (YT:2) 0 
Green EX1312294 
New Batch 
6_20140515_111617.csv Lutheran LU*A LU*A, LU*B Lua (LU:1) + 
Green EX1312294 
New Batch 
6_20140515_111617.csv   LU*B   Lub (LU:2) + 
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1312295 
New Batch 
6_20140515_111617.csv Rh RHCE*ce RHCE*ce, RHCE*Ce C (RH:2) + 
Green EX1312295 
New Batch 
6_20140515_111617.csv   RHCE*Ce   E (RH:3) 0 
Green EX1312295 
New Batch 
6_20140515_111617.csv   RHCE*cE   c (RH:4) + 
Green EX1312295 
New Batch 
6_20140515_111617.csv   RHCE*CE   e (RH:5) + 
Green EX1312295 
New Batch 
6_20140515_111617.csv   RHCE*CeCW   CW (RH:8) 0 
Green EX1312295 
New Batch 
6_20140515_111617.csv   RHCE*ceCW   V (RH:10) 0 
Green EX1312295 
New Batch 
6_20140515_111617.csv   RHCE*CECW   hrS (RH:19) + 
Green EX1312295 
New Batch 
6_20140515_111617.csv   RHCE*ceAR   VS (RH:20) 0 
Green EX1312295 
New Batch 
6_20140515_111617.csv   RHCE*CeFV   hrB (RH:31) + 
Green EX1312295 
New Batch 
6_20140515_111617.csv   RHCE*CeVG       
Green EX1312295 
New Batch 
6_20140515_111617.csv   RHCE*cEFM       
Green EX1312295 
New Batch 
6_20140515_111617.csv   RHCE*ce[712G]       
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1312295 
New Batch 
6_20140515_111617.csv   RHCE*ce[733G]       
Green EX1312295 
New Batch 
6_20140515_111617.csv   RHCE*ce[733G,1006T]       
Green EX1312295 
New Batch 
6_20140515_111617.csv   RHCE*CE-D[2, 5, 7]-CE       
Green EX1312295 
New Batch 
6_20140515_111617.csv   RHCE*cE[697G,712G,733G]       
Green EX1312295 
New Batch 
6_20140515_111617.csv   
RHD*r’s-
RHCE*ce[733G,1006T]       
Green EX1312295 
New Batch 
6_20140515_111617.csv Kell KEL*K_KPB_JSB KEL*k_KPB_JSB K (KEL:1) 0 
Green EX1312295 
New Batch 
6_20140515_111617.csv   KEL*k_KPB_JSB   k (KEL:2) + 
Green EX1312295 
New Batch 
6_20140515_111617.csv   KEL*k_KPA_JSB   Kpa (KEL:3) 0 
Green EX1312295 
New Batch 
6_20140515_111617.csv   KEL*k_KPB_JSA   Kpb (KEL:4) + 
Green EX1312295 
New Batch 
6_20140515_111617.csv       Jsa (KEL:6) 0 
Green EX1312295 
New Batch 
6_20140515_111617.csv       Jsb (KEL:7) + 
Green EX1312295 
New Batch 
6_20140515_111617.csv Kidd JK*A JK*B Jka (JK:1) 0 
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1312295 
New Batch 
6_20140515_111617.csv   JK*B   Jkb (JK:2) + 
Green EX1312295 
New Batch 
6_20140515_111617.csv   JK*B_null(IVS5-1a)       
Green EX1312295 
New Batch 
6_20140515_111617.csv   JK*B_null(871C)       
Green EX1312295 
New Batch 
6_20140515_111617.csv Duffy FY*A FY*B Fya (FY:1) 0 
Green EX1312295 
New Batch 
6_20140515_111617.csv   FY*B   Fyb (FY:2) + 
Green EX1312295 
New Batch 
6_20140515_111617.csv   FY*B_GATA       
Green EX1312295 
New Batch 
6_20140515_111617.csv   FY*B[265T]_FY*X       
Green EX1312295 
New Batch 
6_20140515_111617.csv MNS GYPA*M GYPA*M M (MNS:1) + 
Green EX1312295 
New Batch 
6_20140515_111617.csv   GYPA*N   N (MNS:2) 0 
Green EX1312295 
New Batch 
6_20140515_111617.csv   GYPB*S GYPB*S, GYPB*s S (MNS:3) + 
Green EX1312295 
New Batch 
6_20140515_111617.csv   GYPB*s   s (MNS:4) + 
Green EX1312295 
New Batch 
6_20140515_111617.csv   GYPB*S_null(IVS5+5t)   U (MNS:5) + 
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1312295 
New Batch 
6_20140515_111617.csv   GYPB*S_null(230T)   Mia (MNS:7) 0 
Green EX1312295 
New Batch 
6_20140515_111617.csv   GYPB*deletion       
Green EX1312295 
New Batch 
6_20140515_111617.csv   GYPB*Mur       
Green EX1312295 
New Batch 
6_20140515_111617.csv Diego DI*A DI*B Dia (DI:1) 0 
Green EX1312295 
New Batch 
6_20140515_111617.csv   DI*B   Dib (DI:2) + 
Green EX1312295 
New Batch 
6_20140515_111617.csv Dombrock DO*A DO*B Doa (DO:1) 0 
Green EX1312295 
New Batch 
6_20140515_111617.csv   DO*B   Dob (DO:2) + 
Green EX1312295 
New Batch 
6_20140515_111617.csv   DO*B_HY-   Hy (DO:4) + 
Green EX1312295 
New Batch 
6_20140515_111617.csv   DO*A_JOA-   Joa (DO:5) + 
Green EX1312295 
New Batch 
6_20140515_111617.csv Colton CO*A CO*A Coa (CO:1) + 
Green EX1312295 
New Batch 
6_20140515_111617.csv   CO*B   Cob (CO:2) 0 
Green EX1312295 
New Batch 
6_20140515_111617.csv Cartwright YT*A YT*A Yta (YT:1) + 
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1312295 
New Batch 
6_20140515_111617.csv   YT*B   Ytb (YT:2) 0 
Green EX1312295 
New Batch 
6_20140515_111617.csv Lutheran LU*A LU*B Lua (LU:1) 0 
Green EX1312295 
New Batch 
6_20140515_111617.csv   LU*B   Lub (LU:2) + 
Green EX1312296 
New Batch 
6_20140515_111617.csv Rh RHCE*ce RHCE*ce, RHCE*Ce C (RH:2) + 
Green EX1312296 
New Batch 
6_20140515_111617.csv   RHCE*Ce   E (RH:3) 0 
Green EX1312296 
New Batch 
6_20140515_111617.csv   RHCE*cE   c (RH:4) + 
Green EX1312296 
New Batch 
6_20140515_111617.csv   RHCE*CE   e (RH:5) + 
Green EX1312296 
New Batch 
6_20140515_111617.csv   RHCE*CeCW   CW (RH:8) 0 
Green EX1312296 
New Batch 
6_20140515_111617.csv   RHCE*ceCW   V (RH:10) 0 
Green EX1312296 
New Batch 
6_20140515_111617.csv   RHCE*CECW   hrS (RH:19) + 
Green EX1312296 
New Batch 
6_20140515_111617.csv   RHCE*ceAR   VS (RH:20) 0 
Green EX1312296 
New Batch 
6_20140515_111617.csv   RHCE*CeFV   hrB (RH:31) + 
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1312296 
New Batch 
6_20140515_111617.csv   RHCE*CeVG       
Green EX1312296 
New Batch 
6_20140515_111617.csv   RHCE*cEFM       
Green EX1312296 
New Batch 
6_20140515_111617.csv   RHCE*ce[712G]       
Green EX1312296 
New Batch 
6_20140515_111617.csv   RHCE*ce[733G]       
Green EX1312296 
New Batch 
6_20140515_111617.csv   RHCE*ce[733G,1006T]       
Green EX1312296 
New Batch 
6_20140515_111617.csv   RHCE*CE-D[2, 5, 7]-CE       
Green EX1312296 
New Batch 
6_20140515_111617.csv   RHCE*cE[697G,712G,733G]       
Green EX1312296 
New Batch 
6_20140515_111617.csv   
RHD*r’s-
RHCE*ce[733G,1006T]       
Green EX1312296 
New Batch 
6_20140515_111617.csv Kell KEL*K_KPB_JSB KEL*k_KPB_JSB K (KEL:1) 0 
Green EX1312296 
New Batch 
6_20140515_111617.csv   KEL*k_KPB_JSB   k (KEL:2) + 
Green EX1312296 
New Batch 
6_20140515_111617.csv   KEL*k_KPA_JSB   Kpa (KEL:3) 0 
Green EX1312296 
New Batch 
6_20140515_111617.csv   KEL*k_KPB_JSA   Kpb (KEL:4) + 
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1312296 
New Batch 
6_20140515_111617.csv       Jsa (KEL:6) 0 
Green EX1312296 
New Batch 
6_20140515_111617.csv       Jsb (KEL:7) + 
Green EX1312296 
New Batch 
6_20140515_111617.csv Kidd JK*A JK*A Jka (JK:1) + 
Green EX1312296 
New Batch 
6_20140515_111617.csv   JK*B   Jkb (JK:2) 0 
Green EX1312296 
New Batch 
6_20140515_111617.csv   JK*B_null(IVS5-1a)       
Green EX1312296 
New Batch 
6_20140515_111617.csv   JK*B_null(871C)       
Green EX1312296 
New Batch 
6_20140515_111617.csv Duffy FY*A FY*A Fya (FY:1) + 
Green EX1312296 
New Batch 
6_20140515_111617.csv   FY*B   Fyb (FY:2) 0 
Green EX1312296 
New Batch 
6_20140515_111617.csv   FY*B_GATA       
Green EX1312296 
New Batch 
6_20140515_111617.csv   FY*B[265T]_FY*X       
Green EX1312296 
New Batch 
6_20140515_111617.csv MNS GYPA*M GYPA*M M (MNS:1) + 
Green EX1312296 
New Batch 
6_20140515_111617.csv   GYPA*N   N (MNS:2) 0 
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1312296 
New Batch 
6_20140515_111617.csv   GYPB*S GYPB*s S (MNS:3) 0 
Green EX1312296 
New Batch 
6_20140515_111617.csv   GYPB*s   s (MNS:4) + 
Green EX1312296 
New Batch 
6_20140515_111617.csv   GYPB*S_null(IVS5+5t)   U (MNS:5) + 
Green EX1312296 
New Batch 
6_20140515_111617.csv   GYPB*S_null(230T)   Mia (MNS:7) 0 
Green EX1312296 
New Batch 
6_20140515_111617.csv   GYPB*deletion       
Green EX1312296 
New Batch 
6_20140515_111617.csv   GYPB*Mur       
Green EX1312296 
New Batch 
6_20140515_111617.csv Diego DI*A DI*B Dia (DI:1) 0 
Green EX1312296 
New Batch 
6_20140515_111617.csv   DI*B   Dib (DI:2) + 
Green EX1312296 
New Batch 
6_20140515_111617.csv Dombrock DO*A DO*A, DO*B Doa (DO:1) + 
Green EX1312296 
New Batch 
6_20140515_111617.csv   DO*B   Dob (DO:2) + 
Green EX1312296 
New Batch 
6_20140515_111617.csv   DO*B_HY-   Hy (DO:4) + 
Green EX1312296 
New Batch 
6_20140515_111617.csv   DO*A_JOA-   Joa (DO:5) + 
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1312296 
New Batch 
6_20140515_111617.csv Colton CO*A CO*A Coa (CO:1) + 
Green EX1312296 
New Batch 
6_20140515_111617.csv   CO*B   Cob (CO:2) 0 
Green EX1312296 
New Batch 
6_20140515_111617.csv Cartwright YT*A YT*A Yta (YT:1) + 
Green EX1312296 
New Batch 
6_20140515_111617.csv   YT*B   Ytb (YT:2) 0 
Green EX1312296 
New Batch 
6_20140515_111617.csv Lutheran LU*A LU*B Lua (LU:1) 0 
Green EX1312296 
New Batch 
6_20140515_111617.csv   LU*B   Lub (LU:2) + 
Green EX1312297 
New Batch 
6_20140515_111617.csv Rh RHCE*ce RHCE*ce, RHCE*Ce C (RH:2) + 
Green EX1312297 
New Batch 
6_20140515_111617.csv   RHCE*Ce   E (RH:3) 0 
Green EX1312297 
New Batch 
6_20140515_111617.csv   RHCE*cE   c (RH:4) + 
Green EX1312297 
New Batch 
6_20140515_111617.csv   RHCE*CE   e (RH:5) + 
Green EX1312297 
New Batch 
6_20140515_111617.csv   RHCE*CeCW   CW (RH:8) 0 
Green EX1312297 
New Batch 
6_20140515_111617.csv   RHCE*ceCW   V (RH:10) 0 
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1312297 
New Batch 
6_20140515_111617.csv   RHCE*CECW   hrS (RH:19) + 
Green EX1312297 
New Batch 
6_20140515_111617.csv   RHCE*ceAR   VS (RH:20) 0 
Green EX1312297 
New Batch 
6_20140515_111617.csv   RHCE*CeFV   hrB (RH:31) + 
Green EX1312297 
New Batch 
6_20140515_111617.csv   RHCE*CeVG       
Green EX1312297 
New Batch 
6_20140515_111617.csv   RHCE*cEFM       
Green EX1312297 
New Batch 
6_20140515_111617.csv   RHCE*ce[712G]       
Green EX1312297 
New Batch 
6_20140515_111617.csv   RHCE*ce[733G]       
Green EX1312297 
New Batch 
6_20140515_111617.csv   RHCE*ce[733G,1006T]       
Green EX1312297 
New Batch 
6_20140515_111617.csv   RHCE*CE-D[2, 5, 7]-CE       
Green EX1312297 
New Batch 
6_20140515_111617.csv   RHCE*cE[697G,712G,733G]       
Green EX1312297 
New Batch 
6_20140515_111617.csv   
RHD*r’s-
RHCE*ce[733G,1006T]       
Green EX1312297 
New Batch 
6_20140515_111617.csv Kell KEL*K_KPB_JSB 
KEL*K_KPB_JSB, 
KEL*k_KPB_JSB K (KEL:1) + 
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1312297 
New Batch 
6_20140515_111617.csv   KEL*k_KPB_JSB   k (KEL:2) + 
Green EX1312297 
New Batch 
6_20140515_111617.csv   KEL*k_KPA_JSB   Kpa (KEL:3) 0 
Green EX1312297 
New Batch 
6_20140515_111617.csv   KEL*k_KPB_JSA   Kpb (KEL:4) + 
Green EX1312297 
New Batch 
6_20140515_111617.csv       Jsa (KEL:6) 0 
Green EX1312297 
New Batch 
6_20140515_111617.csv       Jsb (KEL:7) + 
Green EX1312297 
New Batch 
6_20140515_111617.csv Kidd JK*A JK*A Jka (JK:1) + 
Green EX1312297 
New Batch 
6_20140515_111617.csv   JK*B   Jkb (JK:2) 0 
Green EX1312297 
New Batch 
6_20140515_111617.csv   JK*B_null(IVS5-1a)       
Green EX1312297 
New Batch 
6_20140515_111617.csv   JK*B_null(871C)       
Green EX1312297 
New Batch 
6_20140515_111617.csv Duffy FY*A FY*B Fya (FY:1) 0 
Green EX1312297 
New Batch 
6_20140515_111617.csv   FY*B   Fyb (FY:2) + 
Green EX1312297 
New Batch 
6_20140515_111617.csv   FY*B_GATA       
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1312297 
New Batch 
6_20140515_111617.csv   FY*B[265T]_FY*X       
Green EX1312297 
New Batch 
6_20140515_111617.csv MNS GYPA*M GYPA*M, GYPA*N M (MNS:1) + 
Green EX1312297 
New Batch 
6_20140515_111617.csv   GYPA*N   N (MNS:2) + 
Green EX1312297 
New Batch 
6_20140515_111617.csv   GYPB*S GYPB*s S (MNS:3) 0 
Green EX1312297 
New Batch 
6_20140515_111617.csv   GYPB*s   s (MNS:4) + 
Green EX1312297 
New Batch 
6_20140515_111617.csv   GYPB*S_null(IVS5+5t)   U (MNS:5) + 
Green EX1312297 
New Batch 
6_20140515_111617.csv   GYPB*S_null(230T)   Mia (MNS:7) 0 
Green EX1312297 
New Batch 
6_20140515_111617.csv   GYPB*deletion       
Green EX1312297 
New Batch 
6_20140515_111617.csv   GYPB*Mur       
Green EX1312297 
New Batch 
6_20140515_111617.csv Diego DI*A DI*B Dia (DI:1) 0 
Green EX1312297 
New Batch 
6_20140515_111617.csv   DI*B   Dib (DI:2) + 
Green EX1312297 
New Batch 
6_20140515_111617.csv Dombrock DO*A DO*A Doa (DO:1) + 
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1312297 
New Batch 
6_20140515_111617.csv   DO*B   Dob (DO:2) 0 
Green EX1312297 
New Batch 
6_20140515_111617.csv   DO*B_HY-   Hy (DO:4) + 
Green EX1312297 
New Batch 
6_20140515_111617.csv   DO*A_JOA-   Joa (DO:5) + 
Green EX1312297 
New Batch 
6_20140515_111617.csv Colton CO*A CO*A Coa (CO:1) + 
Green EX1312297 
New Batch 
6_20140515_111617.csv   CO*B   Cob (CO:2) 0 
Green EX1312297 
New Batch 
6_20140515_111617.csv Cartwright YT*A YT*A Yta (YT:1) + 
Green EX1312297 
New Batch 
6_20140515_111617.csv   YT*B   Ytb (YT:2) 0 
Green EX1312297 
New Batch 
6_20140515_111617.csv Lutheran LU*A LU*B Lua (LU:1) 0 
Green EX1312297 
New Batch 
6_20140515_111617.csv   LU*B   Lub (LU:2) + 
Green EX1312311 
New Batch 
6_20140515_111617.csv Rh RHCE*ce RHCE*ce, RHCE*Ce C (RH:2) + 
Green EX1312311 
New Batch 
6_20140515_111617.csv   RHCE*Ce   E (RH:3) 0 
Green EX1312311 
New Batch 
6_20140515_111617.csv   RHCE*cE   c (RH:4) + 
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1312311 
New Batch 
6_20140515_111617.csv   RHCE*CE   e (RH:5) + 
Green EX1312311 
New Batch 
6_20140515_111617.csv   RHCE*CeCW   CW (RH:8) 0 
Green EX1312311 
New Batch 
6_20140515_111617.csv   RHCE*ceCW   V (RH:10) 0 
Green EX1312311 
New Batch 
6_20140515_111617.csv   RHCE*CECW   hrS (RH:19) + 
Green EX1312311 
New Batch 
6_20140515_111617.csv   RHCE*ceAR   VS (RH:20) 0 
Green EX1312311 
New Batch 
6_20140515_111617.csv   RHCE*CeFV   hrB (RH:31) + 
Green EX1312311 
New Batch 
6_20140515_111617.csv   RHCE*CeVG       
Green EX1312311 
New Batch 
6_20140515_111617.csv   RHCE*cEFM       
Green EX1312311 
New Batch 
6_20140515_111617.csv   RHCE*ce[712G]       
Green EX1312311 
New Batch 
6_20140515_111617.csv   RHCE*ce[733G]       
Green EX1312311 
New Batch 
6_20140515_111617.csv   RHCE*ce[733G,1006T]       
Green EX1312311 
New Batch 
6_20140515_111617.csv   RHCE*CE-D[2, 5, 7]-CE       
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1312311 
New Batch 
6_20140515_111617.csv   RHCE*cE[697G,712G,733G]       
Green EX1312311 
New Batch 
6_20140515_111617.csv   
RHD*r’s-
RHCE*ce[733G,1006T]       
Green EX1312311 
New Batch 
6_20140515_111617.csv Kell KEL*K_KPB_JSB KEL*k_KPB_JSB K (KEL:1) 0 
Green EX1312311 
New Batch 
6_20140515_111617.csv   KEL*k_KPB_JSB   k (KEL:2) + 
Green EX1312311 
New Batch 
6_20140515_111617.csv   KEL*k_KPA_JSB   Kpa (KEL:3) 0 
Green EX1312311 
New Batch 
6_20140515_111617.csv   KEL*k_KPB_JSA   Kpb (KEL:4) + 
Green EX1312311 
New Batch 
6_20140515_111617.csv       Jsa (KEL:6) 0 
Green EX1312311 
New Batch 
6_20140515_111617.csv       Jsb (KEL:7) + 
Green EX1312311 
New Batch 
6_20140515_111617.csv Kidd JK*A JK*B Jka (JK:1) 0 
Green EX1312311 
New Batch 
6_20140515_111617.csv   JK*B   Jkb (JK:2) + 
Green EX1312311 
New Batch 
6_20140515_111617.csv   JK*B_null(IVS5-1a)       
Green EX1312311 
New Batch 
6_20140515_111617.csv   JK*B_null(871C)       
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1312311 
New Batch 
6_20140515_111617.csv Duffy FY*A FY*B Fya (FY:1) 0 
Green EX1312311 
New Batch 
6_20140515_111617.csv   FY*B   Fyb (FY:2) + 
Green EX1312311 
New Batch 
6_20140515_111617.csv   FY*B_GATA       
Green EX1312311 
New Batch 
6_20140515_111617.csv   FY*B[265T]_FY*X       
Green EX1312311 
New Batch 
6_20140515_111617.csv MNS GYPA*M GYPA*N M (MNS:1) 0 
Green EX1312311 
New Batch 
6_20140515_111617.csv   GYPA*N   N (MNS:2) + 
Green EX1312311 
New Batch 
6_20140515_111617.csv   GYPB*S GYPB*s S (MNS:3) 0 
Green EX1312311 
New Batch 
6_20140515_111617.csv   GYPB*s   s (MNS:4) + 
Green EX1312311 
New Batch 
6_20140515_111617.csv   GYPB*S_null(IVS5+5t)   U (MNS:5) + 
Green EX1312311 
New Batch 
6_20140515_111617.csv   GYPB*S_null(230T)   Mia (MNS:7) 0 
Green EX1312311 
New Batch 
6_20140515_111617.csv   GYPB*deletion       
Green EX1312311 
New Batch 
6_20140515_111617.csv   GYPB*Mur       
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1312311 
New Batch 
6_20140515_111617.csv Diego DI*A DI*B Dia (DI:1) 0 
Green EX1312311 
New Batch 
6_20140515_111617.csv   DI*B   Dib (DI:2) + 
Green EX1312311 
New Batch 
6_20140515_111617.csv Dombrock DO*A DO*B Doa (DO:1) 0 
Green EX1312311 
New Batch 
6_20140515_111617.csv   DO*B   Dob (DO:2) + 
Green EX1312311 
New Batch 
6_20140515_111617.csv   DO*B_HY-   Hy (DO:4) + 
Green EX1312311 
New Batch 
6_20140515_111617.csv   DO*A_JOA-   Joa (DO:5) + 
Green EX1312311 
New Batch 
6_20140515_111617.csv Colton CO*A CO*A Coa (CO:1) + 
Green EX1312311 
New Batch 
6_20140515_111617.csv   CO*B   Cob (CO:2) 0 
Green EX1312311 
New Batch 
6_20140515_111617.csv Cartwright YT*A YT*A Yta (YT:1) + 
Green EX1312311 
New Batch 
6_20140515_111617.csv   YT*B   Ytb (YT:2) 0 
Green EX1312311 
New Batch 
6_20140515_111617.csv Lutheran LU*A LU*B Lua (LU:1) 0 
Green EX1312311 
New Batch 
6_20140515_111617.csv   LU*B   Lub (LU:2) + 
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1322312 
New Batch 
6_20140515_111617.csv Rh RHCE*ce RHCE*Ce C (RH:2) + 
Green EX1322312 
New Batch 
6_20140515_111617.csv   RHCE*Ce   E (RH:3) 0 
Green EX1322312 
New Batch 
6_20140515_111617.csv   RHCE*cE   c (RH:4) 0 
Green EX1322312 
New Batch 
6_20140515_111617.csv   RHCE*CE   e (RH:5) + 
Green EX1322312 
New Batch 
6_20140515_111617.csv   RHCE*CeCW   CW (RH:8) 0 
Green EX1322312 
New Batch 
6_20140515_111617.csv   RHCE*ceCW   V (RH:10) 0 
Green EX1322312 
New Batch 
6_20140515_111617.csv   RHCE*CECW   hrS (RH:19) + 
Green EX1322312 
New Batch 
6_20140515_111617.csv   RHCE*ceAR   VS (RH:20) 0 
Green EX1322312 
New Batch 
6_20140515_111617.csv   RHCE*CeFV   hrB (RH:31) + 
Green EX1322312 
New Batch 
6_20140515_111617.csv   RHCE*CeVG       
Green EX1322312 
New Batch 
6_20140515_111617.csv   RHCE*cEFM       
Green EX1322312 
New Batch 
6_20140515_111617.csv   RHCE*ce[712G]       
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1322312 
New Batch 
6_20140515_111617.csv   RHCE*ce[733G]       
Green EX1322312 
New Batch 
6_20140515_111617.csv   RHCE*ce[733G,1006T]       
Green EX1322312 
New Batch 
6_20140515_111617.csv   RHCE*CE-D[2, 5, 7]-CE       
Green EX1322312 
New Batch 
6_20140515_111617.csv   RHCE*cE[697G,712G,733G]       
Green EX1322312 
New Batch 
6_20140515_111617.csv   
RHD*r’s-
RHCE*ce[733G,1006T]       
Green EX1322312 
New Batch 
6_20140515_111617.csv Kell KEL*K_KPB_JSB KEL*k_KPB_JSB K (KEL:1) 0 
Green EX1322312 
New Batch 
6_20140515_111617.csv   KEL*k_KPB_JSB   k (KEL:2) + 
Green EX1322312 
New Batch 
6_20140515_111617.csv   KEL*k_KPA_JSB   Kpa (KEL:3) 0 
Green EX1322312 
New Batch 
6_20140515_111617.csv   KEL*k_KPB_JSA   Kpb (KEL:4) + 
Green EX1322312 
New Batch 
6_20140515_111617.csv       Jsa (KEL:6) 0 
Green EX1322312 
New Batch 
6_20140515_111617.csv       Jsb (KEL:7) + 
Green EX1322312 
New Batch 
6_20140515_111617.csv Kidd JK*A JK*A, JK*B Jka (JK:1) + 
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1322312 
New Batch 
6_20140515_111617.csv   JK*B   Jkb (JK:2) + 
Green EX1322312 
New Batch 
6_20140515_111617.csv   JK*B_null(IVS5-1a)       
Green EX1322312 
New Batch 
6_20140515_111617.csv   JK*B_null(871C)       
Green EX1322312 
New Batch 
6_20140515_111617.csv Duffy FY*A FY*B Fya (FY:1) 0 
Green EX1322312 
New Batch 
6_20140515_111617.csv   FY*B   Fyb (FY:2) + 
Green EX1322312 
New Batch 
6_20140515_111617.csv   FY*B_GATA       
Green EX1322312 
New Batch 
6_20140515_111617.csv   FY*B[265T]_FY*X       
Green EX1322312 
New Batch 
6_20140515_111617.csv MNS GYPA*M GYPA*M, GYPA*N M (MNS:1) + 
Green EX1322312 
New Batch 
6_20140515_111617.csv   GYPA*N   N (MNS:2) + 
Green EX1322312 
New Batch 
6_20140515_111617.csv   GYPB*S GYPB*s S (MNS:3) 0 
Green EX1322312 
New Batch 
6_20140515_111617.csv   GYPB*s   s (MNS:4) + 
Green EX1322312 
New Batch 
6_20140515_111617.csv   GYPB*S_null(IVS5+5t)   U (MNS:5) + 
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1322312 
New Batch 
6_20140515_111617.csv   GYPB*S_null(230T)   Mia (MNS:7) 0 
Green EX1322312 
New Batch 
6_20140515_111617.csv   GYPB*deletion       
Green EX1322312 
New Batch 
6_20140515_111617.csv   GYPB*Mur       
Green EX1322312 
New Batch 
6_20140515_111617.csv Diego DI*A DI*B Dia (DI:1) 0 
Green EX1322312 
New Batch 
6_20140515_111617.csv   DI*B   Dib (DI:2) + 
Green EX1322312 
New Batch 
6_20140515_111617.csv Dombrock DO*A DO*B Doa (DO:1) 0 
Green EX1322312 
New Batch 
6_20140515_111617.csv   DO*B   Dob (DO:2) + 
Green EX1322312 
New Batch 
6_20140515_111617.csv   DO*B_HY-   Hy (DO:4) + 
Green EX1322312 
New Batch 
6_20140515_111617.csv   DO*A_JOA-   Joa (DO:5) + 
Green EX1322312 
New Batch 
6_20140515_111617.csv Colton CO*A CO*A Coa (CO:1) + 
Green EX1322312 
New Batch 
6_20140515_111617.csv   CO*B   Cob (CO:2) 0 
Green EX1322312 
New Batch 
6_20140515_111617.csv Cartwright YT*A YT*A Yta (YT:1) + 
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1322312 
New Batch 
6_20140515_111617.csv   YT*B   Ytb (YT:2) 0 
Green EX1322312 
New Batch 
6_20140515_111617.csv Lutheran LU*A LU*B Lua (LU:1) 0 
Green EX1322312 
New Batch 
6_20140515_111617.csv   LU*B   Lub (LU:2) + 
Green EX1312453 
New Batch 
6_20140515_111617.csv Rh RHCE*ce RHCE*ce, RHCE*cE C (RH:2) 0 
Green EX1312453 
New Batch 
6_20140515_111617.csv   RHCE*Ce   E (RH:3) + 
Green EX1312453 
New Batch 
6_20140515_111617.csv   RHCE*cE   c (RH:4) + 
Green EX1312453 
New Batch 
6_20140515_111617.csv   RHCE*CE   e (RH:5) + 
Green EX1312453 
New Batch 
6_20140515_111617.csv   RHCE*CeCW   CW (RH:8) 0 
Green EX1312453 
New Batch 
6_20140515_111617.csv   RHCE*ceCW   V (RH:10) 0 
Green EX1312453 
New Batch 
6_20140515_111617.csv   RHCE*CECW   hrS (RH:19) + 
Green EX1312453 
New Batch 
6_20140515_111617.csv   RHCE*ceAR   VS (RH:20) 0 
Green EX1312453 
New Batch 
6_20140515_111617.csv   RHCE*CeFV   hrB (RH:31) + 
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1312453 
New Batch 
6_20140515_111617.csv   RHCE*CeVG       
Green EX1312453 
New Batch 
6_20140515_111617.csv   RHCE*cEFM       
Green EX1312453 
New Batch 
6_20140515_111617.csv   RHCE*ce[712G]       
Green EX1312453 
New Batch 
6_20140515_111617.csv   RHCE*ce[733G]       
Green EX1312453 
New Batch 
6_20140515_111617.csv   RHCE*ce[733G,1006T]       
Green EX1312453 
New Batch 
6_20140515_111617.csv   RHCE*CE-D[2, 5, 7]-CE       
Green EX1312453 
New Batch 
6_20140515_111617.csv   RHCE*cE[697G,712G,733G]       
Green EX1312453 
New Batch 
6_20140515_111617.csv   
RHD*r’s-
RHCE*ce[733G,1006T]       
Green EX1312453 
New Batch 
6_20140515_111617.csv Kell KEL*K_KPB_JSB KEL*k_KPB_JSB K (KEL:1) 0 
Green EX1312453 
New Batch 
6_20140515_111617.csv   KEL*k_KPB_JSB   k (KEL:2) + 
Green EX1312453 
New Batch 
6_20140515_111617.csv   KEL*k_KPA_JSB   Kpa (KEL:3) 0 
Green EX1312453 
New Batch 
6_20140515_111617.csv   KEL*k_KPB_JSA   Kpb (KEL:4) + 
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1312453 
New Batch 
6_20140515_111617.csv       Jsa (KEL:6) 0 
Green EX1312453 
New Batch 
6_20140515_111617.csv       Jsb (KEL:7) + 
Green EX1312453 
New Batch 
6_20140515_111617.csv Kidd JK*A JK*A, JK*B Jka (JK:1) + 
Green EX1312453 
New Batch 
6_20140515_111617.csv   JK*B   Jkb (JK:2) + 
Green EX1312453 
New Batch 
6_20140515_111617.csv   JK*B_null(IVS5-1a)       
Green EX1312453 
New Batch 
6_20140515_111617.csv   JK*B_null(871C)       
Green EX1312453 
New Batch 
6_20140515_111617.csv Duffy FY*A FY*B Fya (FY:1) 0 
Green EX1312453 
New Batch 
6_20140515_111617.csv   FY*B   Fyb (FY:2) + 
Green EX1312453 
New Batch 
6_20140515_111617.csv   FY*B_GATA       
Green EX1312453 
New Batch 
6_20140515_111617.csv   FY*B[265T]_FY*X       
Green EX1312453 
New Batch 
6_20140515_111617.csv MNS GYPA*M GYPA*M M (MNS:1) + 
Green EX1312453 
New Batch 
6_20140515_111617.csv   GYPA*N   N (MNS:2) 0 
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1312453 
New Batch 
6_20140515_111617.csv   GYPB*S GYPB*S S (MNS:3) + 
Green EX1312453 
New Batch 
6_20140515_111617.csv   GYPB*s   s (MNS:4) 0 
Green EX1312453 
New Batch 
6_20140515_111617.csv   GYPB*S_null(IVS5+5t)   U (MNS:5) + 
Green EX1312453 
New Batch 
6_20140515_111617.csv   GYPB*S_null(230T)   Mia (MNS:7) 0 
Green EX1312453 
New Batch 
6_20140515_111617.csv   GYPB*deletion       
Green EX1312453 
New Batch 
6_20140515_111617.csv   GYPB*Mur       
Green EX1312453 
New Batch 
6_20140515_111617.csv Diego DI*A DI*B Dia (DI:1) 0 
Green EX1312453 
New Batch 
6_20140515_111617.csv   DI*B   Dib (DI:2) + 
Green EX1312453 
New Batch 
6_20140515_111617.csv Dombrock DO*A DO*B Doa (DO:1) 0 
Green EX1312453 
New Batch 
6_20140515_111617.csv   DO*B   Dob (DO:2) + 
Green EX1312453 
New Batch 
6_20140515_111617.csv   DO*B_HY-   Hy (DO:4) + 
Green EX1312453 
New Batch 
6_20140515_111617.csv   DO*A_JOA-   Joa (DO:5) + 
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1312453 
New Batch 
6_20140515_111617.csv Colton CO*A CO*A Coa (CO:1) + 
Green EX1312453 
New Batch 
6_20140515_111617.csv   CO*B   Cob (CO:2) 0 
Green EX1312453 
New Batch 
6_20140515_111617.csv Cartwright YT*A YT*A Yta (YT:1) + 
Green EX1312453 
New Batch 
6_20140515_111617.csv   YT*B   Ytb (YT:2) 0 
Green EX1312453 
New Batch 
6_20140515_111617.csv Lutheran LU*A LU*B Lua (LU:1) 0 
Green EX1312453 
New Batch 
6_20140515_111617.csv   LU*B   Lub (LU:2) + 
Green EX1312673 
New Batch 
6_20140515_111617.csv Rh RHCE*ce RHCE*ce, RHCE*Ce C (RH:2) + 
Green EX1312673 
New Batch 
6_20140515_111617.csv   RHCE*Ce   E (RH:3) 0 
Green EX1312673 
New Batch 
6_20140515_111617.csv   RHCE*cE   c (RH:4) + 
Green EX1312673 
New Batch 
6_20140515_111617.csv   RHCE*CE   e (RH:5) + 
Green EX1312673 
New Batch 
6_20140515_111617.csv   RHCE*CeCW   CW (RH:8) 0 
Green EX1312673 
New Batch 
6_20140515_111617.csv   RHCE*ceCW   V (RH:10) 0 
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1312673 
New Batch 
6_20140515_111617.csv   RHCE*CECW   hrS (RH:19) + 
Green EX1312673 
New Batch 
6_20140515_111617.csv   RHCE*ceAR   VS (RH:20) 0 
Green EX1312673 
New Batch 
6_20140515_111617.csv   RHCE*CeFV   hrB (RH:31) + 
Green EX1312673 
New Batch 
6_20140515_111617.csv   RHCE*CeVG       
Green EX1312673 
New Batch 
6_20140515_111617.csv   RHCE*cEFM       
Green EX1312673 
New Batch 
6_20140515_111617.csv   RHCE*ce[712G]       
Green EX1312673 
New Batch 
6_20140515_111617.csv   RHCE*ce[733G]       
Green EX1312673 
New Batch 
6_20140515_111617.csv   RHCE*ce[733G,1006T]       
Green EX1312673 
New Batch 
6_20140515_111617.csv   RHCE*CE-D[2, 5, 7]-CE       
Green EX1312673 
New Batch 
6_20140515_111617.csv   RHCE*cE[697G,712G,733G]       
Green EX1312673 
New Batch 
6_20140515_111617.csv   
RHD*r’s-
RHCE*ce[733G,1006T]       
Green EX1312673 
New Batch 
6_20140515_111617.csv Kell KEL*K_KPB_JSB KEL*k_KPB_JSB K (KEL:1) 0 
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1312673 
New Batch 
6_20140515_111617.csv   KEL*k_KPB_JSB   k (KEL:2) + 
Green EX1312673 
New Batch 
6_20140515_111617.csv   KEL*k_KPA_JSB   Kpa (KEL:3) 0 
Green EX1312673 
New Batch 
6_20140515_111617.csv   KEL*k_KPB_JSA   Kpb (KEL:4) + 
Green EX1312673 
New Batch 
6_20140515_111617.csv       Jsa (KEL:6) 0 
Green EX1312673 
New Batch 
6_20140515_111617.csv       Jsb (KEL:7) + 
Green EX1312673 
New Batch 
6_20140515_111617.csv Kidd JK*A JK*A, JK*B Jka (JK:1) + 
Green EX1312673 
New Batch 
6_20140515_111617.csv   JK*B   Jkb (JK:2) + 
Green EX1312673 
New Batch 
6_20140515_111617.csv   JK*B_null(IVS5-1a)       
Green EX1312673 
New Batch 
6_20140515_111617.csv   JK*B_null(871C)       
Green EX1312673 
New Batch 
6_20140515_111617.csv Duffy FY*A FY*B Fya (FY:1) 0 
Green EX1312673 
New Batch 
6_20140515_111617.csv   FY*B   Fyb (FY:2) + 
Green EX1312673 
New Batch 
6_20140515_111617.csv   FY*B_GATA       
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1312673 
New Batch 
6_20140515_111617.csv   FY*B[265T]_FY*X       
Green EX1312673 
New Batch 
6_20140515_111617.csv MNS GYPA*M GYPA*M, GYPA*N M (MNS:1) + 
Green EX1312673 
New Batch 
6_20140515_111617.csv   GYPA*N   N (MNS:2) + 
Green EX1312673 
New Batch 
6_20140515_111617.csv   GYPB*S GYPB*s S (MNS:3) 0 
Green EX1312673 
New Batch 
6_20140515_111617.csv   GYPB*s   s (MNS:4) + 
Green EX1312673 
New Batch 
6_20140515_111617.csv   GYPB*S_null(IVS5+5t)   U (MNS:5) + 
Green EX1312673 
New Batch 
6_20140515_111617.csv   GYPB*S_null(230T)   Mia (MNS:7) 0 
Green EX1312673 
New Batch 
6_20140515_111617.csv   GYPB*deletion       
Green EX1312673 
New Batch 
6_20140515_111617.csv   GYPB*Mur       
Green EX1312673 
New Batch 
6_20140515_111617.csv Diego DI*A DI*B Dia (DI:1) 0 
Green EX1312673 
New Batch 
6_20140515_111617.csv   DI*B   Dib (DI:2) + 
Green EX1312673 
New Batch 
6_20140515_111617.csv Dombrock DO*A DO*A, DO*B Doa (DO:1) + 
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1312673 
New Batch 
6_20140515_111617.csv   DO*B   Dob (DO:2) + 
Green EX1312673 
New Batch 
6_20140515_111617.csv   DO*B_HY-   Hy (DO:4) + 
Green EX1312673 
New Batch 
6_20140515_111617.csv   DO*A_JOA-   Joa (DO:5) + 
Green EX1312673 
New Batch 
6_20140515_111617.csv Colton CO*A CO*A Coa (CO:1) + 
Green EX1312673 
New Batch 
6_20140515_111617.csv   CO*B   Cob (CO:2) 0 
Green EX1312673 
New Batch 
6_20140515_111617.csv Cartwright YT*A YT*A Yta (YT:1) + 
Green EX1312673 
New Batch 
6_20140515_111617.csv   YT*B   Ytb (YT:2) 0 
Green EX1312673 
New Batch 
6_20140515_111617.csv Lutheran LU*A LU*B Lua (LU:1) 0 
Green EX1312673 
New Batch 
6_20140515_111617.csv   LU*B   Lub (LU:2) + 
Green EX1312674 
New Batch 
6_20140515_111617.csv Rh RHCE*ce RHCE*Ce C (RH:2) + 
Green EX1312674 
New Batch 
6_20140515_111617.csv   RHCE*Ce   E (RH:3) 0 
Green EX1312674 
New Batch 
6_20140515_111617.csv   RHCE*cE   c (RH:4) 0 
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1312674 
New Batch 
6_20140515_111617.csv   RHCE*CE   e (RH:5) + 
Green EX1312674 
New Batch 
6_20140515_111617.csv   RHCE*CeCW   CW (RH:8) 0 
Green EX1312674 
New Batch 
6_20140515_111617.csv   RHCE*ceCW   V (RH:10) 0 
Green EX1312674 
New Batch 
6_20140515_111617.csv   RHCE*CECW   hrS (RH:19) + 
Green EX1312674 
New Batch 
6_20140515_111617.csv   RHCE*ceAR   VS (RH:20) 0 
Green EX1312674 
New Batch 
6_20140515_111617.csv   RHCE*CeFV   hrB (RH:31) + 
Green EX1312674 
New Batch 
6_20140515_111617.csv   RHCE*CeVG       
Green EX1312674 
New Batch 
6_20140515_111617.csv   RHCE*cEFM       
Green EX1312674 
New Batch 
6_20140515_111617.csv   RHCE*ce[712G]       
Green EX1312674 
New Batch 
6_20140515_111617.csv   RHCE*ce[733G]       
Green EX1312674 
New Batch 
6_20140515_111617.csv   RHCE*ce[733G,1006T]       
Green EX1312674 
New Batch 
6_20140515_111617.csv   RHCE*CE-D[2, 5, 7]-CE       
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1312674 
New Batch 
6_20140515_111617.csv   RHCE*cE[697G,712G,733G]       
Green EX1312674 
New Batch 
6_20140515_111617.csv   
RHD*r’s-
RHCE*ce[733G,1006T]       
Green EX1312674 
New Batch 
6_20140515_111617.csv Kell KEL*K_KPB_JSB KEL*k_KPB_JSB K (KEL:1) 0 
Green EX1312674 
New Batch 
6_20140515_111617.csv   KEL*k_KPB_JSB   k (KEL:2) + 
Green EX1312674 
New Batch 
6_20140515_111617.csv   KEL*k_KPA_JSB   Kpa (KEL:3) 0 
Green EX1312674 
New Batch 
6_20140515_111617.csv   KEL*k_KPB_JSA   Kpb (KEL:4) + 
Green EX1312674 
New Batch 
6_20140515_111617.csv       Jsa (KEL:6) 0 
Green EX1312674 
New Batch 
6_20140515_111617.csv       Jsb (KEL:7) + 
Green EX1312674 
New Batch 
6_20140515_111617.csv Kidd JK*A JK*A, JK*B Jka (JK:1) + 
Green EX1312674 
New Batch 
6_20140515_111617.csv   JK*B   Jkb (JK:2) + 
Green EX1312674 
New Batch 
6_20140515_111617.csv   JK*B_null(IVS5-1a)       
Green EX1312674 
New Batch 
6_20140515_111617.csv   JK*B_null(871C)       
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1312674 
New Batch 
6_20140515_111617.csv Duffy FY*A FY*A Fya (FY:1) + 
Green EX1312674 
New Batch 
6_20140515_111617.csv   FY*B   Fyb (FY:2) 0 
Green EX1312674 
New Batch 
6_20140515_111617.csv   FY*B_GATA       
Green EX1312674 
New Batch 
6_20140515_111617.csv   FY*B[265T]_FY*X       
Green EX1312674 
New Batch 
6_20140515_111617.csv MNS GYPA*M GYPA*M, GYPA*N M (MNS:1) + 
Green EX1312674 
New Batch 
6_20140515_111617.csv   GYPA*N   N (MNS:2) + 
Green EX1312674 
New Batch 
6_20140515_111617.csv   GYPB*S GYPB*s S (MNS:3) 0 
Green EX1312674 
New Batch 
6_20140515_111617.csv   GYPB*s   s (MNS:4) + 
Green EX1312674 
New Batch 
6_20140515_111617.csv   GYPB*S_null(IVS5+5t)   U (MNS:5) + 
Green EX1312674 
New Batch 
6_20140515_111617.csv   GYPB*S_null(230T)   Mia (MNS:7) 0 
Green EX1312674 
New Batch 
6_20140515_111617.csv   GYPB*deletion       
Green EX1312674 
New Batch 
6_20140515_111617.csv   GYPB*Mur       
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1312674 
New Batch 
6_20140515_111617.csv Diego DI*A DI*B Dia (DI:1) 0 
Green EX1312674 
New Batch 
6_20140515_111617.csv   DI*B   Dib (DI:2) + 
Green EX1312674 
New Batch 
6_20140515_111617.csv Dombrock DO*A DO*B Doa (DO:1) 0 
Green EX1312674 
New Batch 
6_20140515_111617.csv   DO*B   Dob (DO:2) + 
Green EX1312674 
New Batch 
6_20140515_111617.csv   DO*B_HY-   Hy (DO:4) + 
Green EX1312674 
New Batch 
6_20140515_111617.csv   DO*A_JOA-   Joa (DO:5) + 
Green EX1312674 
New Batch 
6_20140515_111617.csv Colton CO*A CO*A Coa (CO:1) + 
Green EX1312674 
New Batch 
6_20140515_111617.csv   CO*B   Cob (CO:2) 0 
Green EX1312674 
New Batch 
6_20140515_111617.csv Cartwright YT*A YT*A Yta (YT:1) + 
Green EX1312674 
New Batch 
6_20140515_111617.csv   YT*B   Ytb (YT:2) 0 
Green EX1312674 
New Batch 
6_20140515_111617.csv Lutheran LU*A LU*B Lua (LU:1) 0 
Green EX1312674 
New Batch 
6_20140515_111617.csv   LU*B   Lub (LU:2) + 
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1312675 
New Batch 
6_20140515_111617.csv Rh RHCE*ce RHCE*Ce, RHCE*CeCW C (RH:2) + 
Green EX1312675 
New Batch 
6_20140515_111617.csv   RHCE*Ce   E (RH:3) 0 
Green EX1312675 
New Batch 
6_20140515_111617.csv   RHCE*cE   c (RH:4) 0 
Green EX1312675 
New Batch 
6_20140515_111617.csv   RHCE*CE   e (RH:5) + 
Green EX1312675 
New Batch 
6_20140515_111617.csv   RHCE*CeCW   CW (RH:8) + 
Green EX1312675 
New Batch 
6_20140515_111617.csv   RHCE*ceCW   V (RH:10) 0 
Green EX1312675 
New Batch 
6_20140515_111617.csv   RHCE*CECW   hrS (RH:19) + 
Green EX1312675 
New Batch 
6_20140515_111617.csv   RHCE*ceAR   VS (RH:20) 0 
Green EX1312675 
New Batch 
6_20140515_111617.csv   RHCE*CeFV   hrB (RH:31) + 
Green EX1312675 
New Batch 
6_20140515_111617.csv   RHCE*CeVG       
Green EX1312675 
New Batch 
6_20140515_111617.csv   RHCE*cEFM       
Green EX1312675 
New Batch 
6_20140515_111617.csv   RHCE*ce[712G]       
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1312675 
New Batch 
6_20140515_111617.csv   RHCE*ce[733G]       
Green EX1312675 
New Batch 
6_20140515_111617.csv   RHCE*ce[733G,1006T]       
Green EX1312675 
New Batch 
6_20140515_111617.csv   RHCE*CE-D[2, 5, 7]-CE       
Green EX1312675 
New Batch 
6_20140515_111617.csv   RHCE*cE[697G,712G,733G]       
Green EX1312675 
New Batch 
6_20140515_111617.csv   
RHD*r’s-
RHCE*ce[733G,1006T]       
Green EX1312675 
New Batch 
6_20140515_111617.csv Kell KEL*K_KPB_JSB KEL*k_KPB_JSB K (KEL:1) 0 
Green EX1312675 
New Batch 
6_20140515_111617.csv   KEL*k_KPB_JSB   k (KEL:2) + 
Green EX1312675 
New Batch 
6_20140515_111617.csv   KEL*k_KPA_JSB   Kpa (KEL:3) 0 
Green EX1312675 
New Batch 
6_20140515_111617.csv   KEL*k_KPB_JSA   Kpb (KEL:4) + 
Green EX1312675 
New Batch 
6_20140515_111617.csv       Jsa (KEL:6) 0 
Green EX1312675 
New Batch 
6_20140515_111617.csv       Jsb (KEL:7) + 
Green EX1312675 
New Batch 
6_20140515_111617.csv Kidd JK*A JK*B Jka (JK:1) 0 
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1312675 
New Batch 
6_20140515_111617.csv   JK*B   Jkb (JK:2) + 
Green EX1312675 
New Batch 
6_20140515_111617.csv   JK*B_null(IVS5-1a)       
Green EX1312675 
New Batch 
6_20140515_111617.csv   JK*B_null(871C)       
Green EX1312675 
New Batch 
6_20140515_111617.csv Duffy FY*A FY*B Fya (FY:1) 0 
Green EX1312675 
New Batch 
6_20140515_111617.csv   FY*B   Fyb (FY:2) + 
Green EX1312675 
New Batch 
6_20140515_111617.csv   FY*B_GATA       
Green EX1312675 
New Batch 
6_20140515_111617.csv   FY*B[265T]_FY*X       
Green EX1312675 
New Batch 
6_20140515_111617.csv MNS GYPA*M GYPA*N M (MNS:1) 0 
Green EX1312675 
New Batch 
6_20140515_111617.csv   GYPA*N   N (MNS:2) + 
Green EX1312675 
New Batch 
6_20140515_111617.csv   GYPB*S GYPB*s S (MNS:3) 0 
Green EX1312675 
New Batch 
6_20140515_111617.csv   GYPB*s   s (MNS:4) + 
Green EX1312675 
New Batch 
6_20140515_111617.csv   GYPB*S_null(IVS5+5t)   U (MNS:5) + 
242 | A p p e n d i x  
 
Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1312675 
New Batch 
6_20140515_111617.csv   GYPB*S_null(230T)   Mia (MNS:7) 0 
Green EX1312675 
New Batch 
6_20140515_111617.csv   GYPB*deletion       
Green EX1312675 
New Batch 
6_20140515_111617.csv   GYPB*Mur       
Green EX1312675 
New Batch 
6_20140515_111617.csv Diego DI*A DI*B Dia (DI:1) 0 
Green EX1312675 
New Batch 
6_20140515_111617.csv   DI*B   Dib (DI:2) + 
Green EX1312675 
New Batch 
6_20140515_111617.csv Dombrock DO*A DO*A, DO*B Doa (DO:1) + 
Green EX1312675 
New Batch 
6_20140515_111617.csv   DO*B   Dob (DO:2) + 
Green EX1312675 
New Batch 
6_20140515_111617.csv   DO*B_HY-   Hy (DO:4) + 
Green EX1312675 
New Batch 
6_20140515_111617.csv   DO*A_JOA-   Joa (DO:5) + 
Green EX1312675 
New Batch 
6_20140515_111617.csv Colton CO*A CO*A Coa (CO:1) + 
Green EX1312675 
New Batch 
6_20140515_111617.csv   CO*B   Cob (CO:2) 0 
Green EX1312675 
New Batch 
6_20140515_111617.csv Cartwright YT*A YT*A Yta (YT:1) + 
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1312675 
New Batch 
6_20140515_111617.csv   YT*B   Ytb (YT:2) 0 
Green EX1312675 
New Batch 
6_20140515_111617.csv Lutheran LU*A LU*B Lua (LU:1) 0 
Green EX1312675 
New Batch 
6_20140515_111617.csv   LU*B   Lub (LU:2) + 
Green EX1312967 
New Batch 
6_20140515_111617.csv Rh RHCE*ce RHCE*ce, RHCE*cE C (RH:2) 0 
Green EX1312967 
New Batch 
6_20140515_111617.csv   RHCE*Ce   E (RH:3) + 
Green EX1312967 
New Batch 
6_20140515_111617.csv   RHCE*cE   c (RH:4) + 
Green EX1312967 
New Batch 
6_20140515_111617.csv   RHCE*CE   e (RH:5) + 
Green EX1312967 
New Batch 
6_20140515_111617.csv   RHCE*CeCW   CW (RH:8) 0 
Green EX1312967 
New Batch 
6_20140515_111617.csv   RHCE*ceCW   V (RH:10) 0 
Green EX1312967 
New Batch 
6_20140515_111617.csv   RHCE*CECW   hrS (RH:19) + 
Green EX1312967 
New Batch 
6_20140515_111617.csv   RHCE*ceAR   VS (RH:20) 0 
Green EX1312967 
New Batch 
6_20140515_111617.csv   RHCE*CeFV   hrB (RH:31) + 
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1312967 
New Batch 
6_20140515_111617.csv   RHCE*CeVG       
Green EX1312967 
New Batch 
6_20140515_111617.csv   RHCE*cEFM       
Green EX1312967 
New Batch 
6_20140515_111617.csv   RHCE*ce[712G]       
Green EX1312967 
New Batch 
6_20140515_111617.csv   RHCE*ce[733G]       
Green EX1312967 
New Batch 
6_20140515_111617.csv   RHCE*ce[733G,1006T]       
Green EX1312967 
New Batch 
6_20140515_111617.csv   RHCE*CE-D[2, 5, 7]-CE       
Green EX1312967 
New Batch 
6_20140515_111617.csv   RHCE*cE[697G,712G,733G]       
Green EX1312967 
New Batch 
6_20140515_111617.csv   
RHD*r’s-
RHCE*ce[733G,1006T]       
Green EX1312967 
New Batch 
6_20140515_111617.csv Kell KEL*K_KPB_JSB KEL*k_KPB_JSB K (KEL:1) 0 
Green EX1312967 
New Batch 
6_20140515_111617.csv   KEL*k_KPB_JSB   k (KEL:2) + 
Green EX1312967 
New Batch 
6_20140515_111617.csv   KEL*k_KPA_JSB   Kpa (KEL:3) 0 
Green EX1312967 
New Batch 
6_20140515_111617.csv   KEL*k_KPB_JSA   Kpb (KEL:4) + 
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1312967 
New Batch 
6_20140515_111617.csv       Jsa (KEL:6) 0 
Green EX1312967 
New Batch 
6_20140515_111617.csv       Jsb (KEL:7) + 
Green EX1312967 
New Batch 
6_20140515_111617.csv Kidd JK*A JK*B Jka (JK:1) 0 
Green EX1312967 
New Batch 
6_20140515_111617.csv   JK*B   Jkb (JK:2) + 
Green EX1312967 
New Batch 
6_20140515_111617.csv   JK*B_null(IVS5-1a)       
Green EX1312967 
New Batch 
6_20140515_111617.csv   JK*B_null(871C)       
Green EX1312967 
New Batch 
6_20140515_111617.csv Duffy FY*A FY*B Fya (FY:1) 0 
Green EX1312967 
New Batch 
6_20140515_111617.csv   FY*B   Fyb (FY:2) + 
Green EX1312967 
New Batch 
6_20140515_111617.csv   FY*B_GATA       
Green EX1312967 
New Batch 
6_20140515_111617.csv   FY*B[265T]_FY*X       
Green EX1312967 
New Batch 
6_20140515_111617.csv MNS GYPA*M GYPA*M, GYPA*N M (MNS:1) + 
Green EX1312967 
New Batch 
6_20140515_111617.csv   GYPA*N   N (MNS:2) + 
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1312967 
New Batch 
6_20140515_111617.csv   GYPB*S GYPB*S, GYPB*s S (MNS:3) + 
Green EX1312967 
New Batch 
6_20140515_111617.csv   GYPB*s   s (MNS:4) + 
Green EX1312967 
New Batch 
6_20140515_111617.csv   GYPB*S_null(IVS5+5t)   U (MNS:5) + 
Green EX1312967 
New Batch 
6_20140515_111617.csv   GYPB*S_null(230T)   Mia (MNS:7) 0 
Green EX1312967 
New Batch 
6_20140515_111617.csv   GYPB*deletion       
Green EX1312967 
New Batch 
6_20140515_111617.csv   GYPB*Mur       
Green EX1312967 
New Batch 
6_20140515_111617.csv Diego DI*A DI*B Dia (DI:1) 0 
Green EX1312967 
New Batch 
6_20140515_111617.csv   DI*B   Dib (DI:2) + 
Green EX1312967 
New Batch 
6_20140515_111617.csv Dombrock DO*A DO*B Doa (DO:1) 0 
Green EX1312967 
New Batch 
6_20140515_111617.csv   DO*B   Dob (DO:2) + 
Green EX1312967 
New Batch 
6_20140515_111617.csv   DO*B_HY-   Hy (DO:4) + 
Green EX1312967 
New Batch 
6_20140515_111617.csv   DO*A_JOA-   Joa (DO:5) + 
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1312967 
New Batch 
6_20140515_111617.csv Colton CO*A CO*A Coa (CO:1) + 
Green EX1312967 
New Batch 
6_20140515_111617.csv   CO*B   Cob (CO:2) 0 
Green EX1312967 
New Batch 
6_20140515_111617.csv Cartwright YT*A YT*A Yta (YT:1) + 
Green EX1312967 
New Batch 
6_20140515_111617.csv   YT*B   Ytb (YT:2) 0 
Green EX1312967 
New Batch 
6_20140515_111617.csv Lutheran LU*A LU*B Lua (LU:1) 0 
Green EX1312967 
New Batch 
6_20140515_111617.csv   LU*B   Lub (LU:2) + 
Green EX1313154 
New Batch 
6_20140515_111617.csv Rh RHCE*ce RHCE*ce, RHCE*Ce C (RH:2) + 
Green EX1313154 
New Batch 
6_20140515_111617.csv   RHCE*Ce   E (RH:3) 0 
Green EX1313154 
New Batch 
6_20140515_111617.csv   RHCE*cE   c (RH:4) + 
Green EX1313154 
New Batch 
6_20140515_111617.csv   RHCE*CE   e (RH:5) + 
Green EX1313154 
New Batch 
6_20140515_111617.csv   RHCE*CeCW   CW (RH:8) 0 
Green EX1313154 
New Batch 
6_20140515_111617.csv   RHCE*ceCW   V (RH:10) 0 
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1313154 
New Batch 
6_20140515_111617.csv   RHCE*CECW   hrS (RH:19) + 
Green EX1313154 
New Batch 
6_20140515_111617.csv   RHCE*ceAR   VS (RH:20) 0 
Green EX1313154 
New Batch 
6_20140515_111617.csv   RHCE*CeFV   hrB (RH:31) + 
Green EX1313154 
New Batch 
6_20140515_111617.csv   RHCE*CeVG       
Green EX1313154 
New Batch 
6_20140515_111617.csv   RHCE*cEFM       
Green EX1313154 
New Batch 
6_20140515_111617.csv   RHCE*ce[712G]       
Green EX1313154 
New Batch 
6_20140515_111617.csv   RHCE*ce[733G]       
Green EX1313154 
New Batch 
6_20140515_111617.csv   RHCE*ce[733G,1006T]       
Green EX1313154 
New Batch 
6_20140515_111617.csv   RHCE*CE-D[2, 5, 7]-CE       
Green EX1313154 
New Batch 
6_20140515_111617.csv   RHCE*cE[697G,712G,733G]       
Green EX1313154 
New Batch 
6_20140515_111617.csv   
RHD*r’s-
RHCE*ce[733G,1006T]       
Green EX1313154 
New Batch 
6_20140515_111617.csv Kell KEL*K_KPB_JSB KEL*k_KPB_JSB K (KEL:1) 0 
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1313154 
New Batch 
6_20140515_111617.csv   KEL*k_KPB_JSB   k (KEL:2) + 
Green EX1313154 
New Batch 
6_20140515_111617.csv   KEL*k_KPA_JSB   Kpa (KEL:3) 0 
Green EX1313154 
New Batch 
6_20140515_111617.csv   KEL*k_KPB_JSA   Kpb (KEL:4) + 
Green EX1313154 
New Batch 
6_20140515_111617.csv       Jsa (KEL:6) 0 
Green EX1313154 
New Batch 
6_20140515_111617.csv       Jsb (KEL:7) + 
Green EX1313154 
New Batch 
6_20140515_111617.csv Kidd JK*A JK*B Jka (JK:1) 0 
Green EX1313154 
New Batch 
6_20140515_111617.csv   JK*B   Jkb (JK:2) + 
Green EX1313154 
New Batch 
6_20140515_111617.csv   JK*B_null(IVS5-1a)       
Green EX1313154 
New Batch 
6_20140515_111617.csv   JK*B_null(871C)       
Green EX1313154 
New Batch 
6_20140515_111617.csv Duffy FY*A FY*A, FY*B Fya (FY:1) + 
Green EX1313154 
New Batch 
6_20140515_111617.csv   FY*B   Fyb (FY:2) + 
Green EX1313154 
New Batch 
6_20140515_111617.csv   FY*B_GATA       
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1313154 
New Batch 
6_20140515_111617.csv   FY*B[265T]_FY*X       
Green EX1313154 
New Batch 
6_20140515_111617.csv MNS GYPA*M GYPA*M M (MNS:1) + 
Green EX1313154 
New Batch 
6_20140515_111617.csv   GYPA*N   N (MNS:2) 0 
Green EX1313154 
New Batch 
6_20140515_111617.csv   GYPB*S GYPB*S S (MNS:3) + 
Green EX1313154 
New Batch 
6_20140515_111617.csv   GYPB*s   s (MNS:4) 0 
Green EX1313154 
New Batch 
6_20140515_111617.csv   GYPB*S_null(IVS5+5t)   U (MNS:5) + 
Green EX1313154 
New Batch 
6_20140515_111617.csv   GYPB*S_null(230T)   Mia (MNS:7) 0 
Green EX1313154 
New Batch 
6_20140515_111617.csv   GYPB*deletion       
Green EX1313154 
New Batch 
6_20140515_111617.csv   GYPB*Mur       
Green EX1313154 
New Batch 
6_20140515_111617.csv Diego DI*A DI*B Dia (DI:1) 0 
Green EX1313154 
New Batch 
6_20140515_111617.csv   DI*B   Dib (DI:2) + 
Green EX1313154 
New Batch 
6_20140515_111617.csv Dombrock DO*A DO*A Doa (DO:1) + 
251 | A p p e n d i x  
 
Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1313154 
New Batch 
6_20140515_111617.csv   DO*B   Dob (DO:2) 0 
Green EX1313154 
New Batch 
6_20140515_111617.csv   DO*B_HY-   Hy (DO:4) + 
Green EX1313154 
New Batch 
6_20140515_111617.csv   DO*A_JOA-   Joa (DO:5) + 
Green EX1313154 
New Batch 
6_20140515_111617.csv Colton CO*A CO*A Coa (CO:1) + 
Green EX1313154 
New Batch 
6_20140515_111617.csv   CO*B   Cob (CO:2) 0 
Green EX1313154 
New Batch 
6_20140515_111617.csv Cartwright YT*A YT*A, YT*B Yta (YT:1) + 
Green EX1313154 
New Batch 
6_20140515_111617.csv   YT*B   Ytb (YT:2) + 
Green EX1313154 
New Batch 
6_20140515_111617.csv Lutheran LU*A LU*B Lua (LU:1) 0 
Green EX1313154 
New Batch 
6_20140515_111617.csv   LU*B   Lub (LU:2) + 
Green EX1313155 
New Batch 
6_20140515_111617.csv Rh RHCE*ce RHCE*ce, RHCE*cE C (RH:2) 0 
Green EX1313155 
New Batch 
6_20140515_111617.csv   RHCE*Ce   E (RH:3) + 
Green EX1313155 
New Batch 
6_20140515_111617.csv   RHCE*cE   c (RH:4) + 
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1313155 
New Batch 
6_20140515_111617.csv   RHCE*CE   e (RH:5) + 
Green EX1313155 
New Batch 
6_20140515_111617.csv   RHCE*CeCW   CW (RH:8) 0 
Green EX1313155 
New Batch 
6_20140515_111617.csv   RHCE*ceCW   V (RH:10) 0 
Green EX1313155 
New Batch 
6_20140515_111617.csv   RHCE*CECW   hrS (RH:19) + 
Green EX1313155 
New Batch 
6_20140515_111617.csv   RHCE*ceAR   VS (RH:20) 0 
Green EX1313155 
New Batch 
6_20140515_111617.csv   RHCE*CeFV   hrB (RH:31) + 
Green EX1313155 
New Batch 
6_20140515_111617.csv   RHCE*CeVG       
Green EX1313155 
New Batch 
6_20140515_111617.csv   RHCE*cEFM       
Green EX1313155 
New Batch 
6_20140515_111617.csv   RHCE*ce[712G]       
Green EX1313155 
New Batch 
6_20140515_111617.csv   RHCE*ce[733G]       
Green EX1313155 
New Batch 
6_20140515_111617.csv   RHCE*ce[733G,1006T]       
Green EX1313155 
New Batch 
6_20140515_111617.csv   RHCE*CE-D[2, 5, 7]-CE       
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1313155 
New Batch 
6_20140515_111617.csv   RHCE*cE[697G,712G,733G]       
Green EX1313155 
New Batch 
6_20140515_111617.csv   
RHD*r’s-
RHCE*ce[733G,1006T]       
Green EX1313155 
New Batch 
6_20140515_111617.csv Kell KEL*K_KPB_JSB KEL*k_KPB_JSB K (KEL:1) 0 
Green EX1313155 
New Batch 
6_20140515_111617.csv   KEL*k_KPB_JSB   k (KEL:2) + 
Green EX1313155 
New Batch 
6_20140515_111617.csv   KEL*k_KPA_JSB   Kpa (KEL:3) 0 
Green EX1313155 
New Batch 
6_20140515_111617.csv   KEL*k_KPB_JSA   Kpb (KEL:4) + 
Green EX1313155 
New Batch 
6_20140515_111617.csv       Jsa (KEL:6) 0 
Green EX1313155 
New Batch 
6_20140515_111617.csv       Jsb (KEL:7) + 
Green EX1313155 
New Batch 
6_20140515_111617.csv Kidd JK*A JK*B Jka (JK:1) 0 
Green EX1313155 
New Batch 
6_20140515_111617.csv   JK*B   Jkb (JK:2) + 
Green EX1313155 
New Batch 
6_20140515_111617.csv   JK*B_null(IVS5-1a)       
Green EX1313155 
New Batch 
6_20140515_111617.csv   JK*B_null(871C)       
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1313155 
New Batch 
6_20140515_111617.csv Duffy FY*A FY*A Fya (FY:1) + 
Green EX1313155 
New Batch 
6_20140515_111617.csv   FY*B   Fyb (FY:2) 0 
Green EX1313155 
New Batch 
6_20140515_111617.csv   FY*B_GATA       
Green EX1313155 
New Batch 
6_20140515_111617.csv   FY*B[265T]_FY*X       
Green EX1313155 
New Batch 
6_20140515_111617.csv MNS GYPA*M GYPA*N M (MNS:1) 0 
Green EX1313155 
New Batch 
6_20140515_111617.csv   GYPA*N   N (MNS:2) + 
Green EX1313155 
New Batch 
6_20140515_111617.csv   GYPB*S GYPB*s S (MNS:3) 0 
Green EX1313155 
New Batch 
6_20140515_111617.csv   GYPB*s   s (MNS:4) + 
Green EX1313155 
New Batch 
6_20140515_111617.csv   GYPB*S_null(IVS5+5t)   U (MNS:5) + 
Green EX1313155 
New Batch 
6_20140515_111617.csv   GYPB*S_null(230T)   Mia (MNS:7) 0 
Green EX1313155 
New Batch 
6_20140515_111617.csv   GYPB*deletion       
Green EX1313155 
New Batch 
6_20140515_111617.csv   GYPB*Mur       
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1313155 
New Batch 
6_20140515_111617.csv Diego DI*A DI*B Dia (DI:1) 0 
Green EX1313155 
New Batch 
6_20140515_111617.csv   DI*B   Dib (DI:2) + 
Green EX1313155 
New Batch 
6_20140515_111617.csv Dombrock DO*A DO*A, DO*B Doa (DO:1) + 
Green EX1313155 
New Batch 
6_20140515_111617.csv   DO*B   Dob (DO:2) + 
Green EX1313155 
New Batch 
6_20140515_111617.csv   DO*B_HY-   Hy (DO:4) + 
Green EX1313155 
New Batch 
6_20140515_111617.csv   DO*A_JOA-   Joa (DO:5) + 
Green EX1313155 
New Batch 
6_20140515_111617.csv Colton CO*A CO*A Coa (CO:1) + 
Green EX1313155 
New Batch 
6_20140515_111617.csv   CO*B   Cob (CO:2) 0 
Green EX1313155 
New Batch 
6_20140515_111617.csv Cartwright YT*A YT*A Yta (YT:1) + 
Green EX1313155 
New Batch 
6_20140515_111617.csv   YT*B   Ytb (YT:2) 0 
Green EX1313155 
New Batch 
6_20140515_111617.csv Lutheran LU*A LU*B Lua (LU:1) 0 
Green EX1313155 
New Batch 
6_20140515_111617.csv   LU*B   Lub (LU:2) + 
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1313515 
New Batch 
6_20140515_111617.csv Rh RHCE*ce RHCE*cE C (RH:2) 0 
Green EX1313515 
New Batch 
6_20140515_111617.csv   RHCE*Ce   E (RH:3) + 
Green EX1313515 
New Batch 
6_20140515_111617.csv   RHCE*cE   c (RH:4) + 
Green EX1313515 
New Batch 
6_20140515_111617.csv   RHCE*CE   e (RH:5) 0 
Green EX1313515 
New Batch 
6_20140515_111617.csv   RHCE*CeCW   CW (RH:8) 0 
Green EX1313515 
New Batch 
6_20140515_111617.csv   RHCE*ceCW   V (RH:10) 0 
Green EX1313515 
New Batch 
6_20140515_111617.csv   RHCE*CECW   hrS (RH:19) + 
Green EX1313515 
New Batch 
6_20140515_111617.csv   RHCE*ceAR   VS (RH:20) 0 
Green EX1313515 
New Batch 
6_20140515_111617.csv   RHCE*CeFV   hrB (RH:31) 0 
Green EX1313515 
New Batch 
6_20140515_111617.csv   RHCE*CeVG       
Green EX1313515 
New Batch 
6_20140515_111617.csv   RHCE*cEFM       
Green EX1313515 
New Batch 
6_20140515_111617.csv   RHCE*ce[712G]       
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1313515 
New Batch 
6_20140515_111617.csv   RHCE*ce[733G]       
Green EX1313515 
New Batch 
6_20140515_111617.csv   RHCE*ce[733G,1006T]       
Green EX1313515 
New Batch 
6_20140515_111617.csv   RHCE*CE-D[2, 5, 7]-CE       
Green EX1313515 
New Batch 
6_20140515_111617.csv   RHCE*cE[697G,712G,733G]       
Green EX1313515 
New Batch 
6_20140515_111617.csv   
RHD*r’s-
RHCE*ce[733G,1006T]       
Green EX1313515 
New Batch 
6_20140515_111617.csv Kell KEL*K_KPB_JSB KEL*k_KPB_JSB K (KEL:1) 0 
Green EX1313515 
New Batch 
6_20140515_111617.csv   KEL*k_KPB_JSB   k (KEL:2) + 
Green EX1313515 
New Batch 
6_20140515_111617.csv   KEL*k_KPA_JSB   Kpa (KEL:3) 0 
Green EX1313515 
New Batch 
6_20140515_111617.csv   KEL*k_KPB_JSA   Kpb (KEL:4) + 
Green EX1313515 
New Batch 
6_20140515_111617.csv       Jsa (KEL:6) 0 
Green EX1313515 
New Batch 
6_20140515_111617.csv       Jsb (KEL:7) + 
Green EX1313515 
New Batch 
6_20140515_111617.csv Kidd JK*A JK*A Jka (JK:1) + 
258 | A p p e n d i x  
 
Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1313515 
New Batch 
6_20140515_111617.csv   JK*B   Jkb (JK:2) 0 
Green EX1313515 
New Batch 
6_20140515_111617.csv   JK*B_null(IVS5-1a)       
Green EX1313515 
New Batch 
6_20140515_111617.csv   JK*B_null(871C)       
Green EX1313515 
New Batch 
6_20140515_111617.csv Duffy FY*A FY*B Fya (FY:1) 0 
Green EX1313515 
New Batch 
6_20140515_111617.csv   FY*B   Fyb (FY:2) + 
Green EX1313515 
New Batch 
6_20140515_111617.csv   FY*B_GATA       
Green EX1313515 
New Batch 
6_20140515_111617.csv   FY*B[265T]_FY*X       
Green EX1313515 
New Batch 
6_20140515_111617.csv MNS GYPA*M GYPA*N M (MNS:1) 0 
Green EX1313515 
New Batch 
6_20140515_111617.csv   GYPA*N   N (MNS:2) + 
Green EX1313515 
New Batch 
6_20140515_111617.csv   GYPB*S GYPB*S, GYPB*s S (MNS:3) + 
Green EX1313515 
New Batch 
6_20140515_111617.csv   GYPB*s   s (MNS:4) + 
Green EX1313515 
New Batch 
6_20140515_111617.csv   GYPB*S_null(IVS5+5t)   U (MNS:5) + 
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1313515 
New Batch 
6_20140515_111617.csv   GYPB*S_null(230T)   Mia (MNS:7) 0 
Green EX1313515 
New Batch 
6_20140515_111617.csv   GYPB*deletion       
Green EX1313515 
New Batch 
6_20140515_111617.csv   GYPB*Mur       
Green EX1313515 
New Batch 
6_20140515_111617.csv Diego DI*A DI*B Dia (DI:1) 0 
Green EX1313515 
New Batch 
6_20140515_111617.csv   DI*B   Dib (DI:2) + 
Green EX1313515 
New Batch 
6_20140515_111617.csv Dombrock DO*A DO*A, DO*B Doa (DO:1) + 
Green EX1313515 
New Batch 
6_20140515_111617.csv   DO*B   Dob (DO:2) + 
Green EX1313515 
New Batch 
6_20140515_111617.csv   DO*B_HY-   Hy (DO:4) + 
Green EX1313515 
New Batch 
6_20140515_111617.csv   DO*A_JOA-   Joa (DO:5) + 
Green EX1313515 
New Batch 
6_20140515_111617.csv Colton CO*A CO*A Coa (CO:1) + 
Green EX1313515 
New Batch 
6_20140515_111617.csv   CO*B   Cob (CO:2) 0 
Green EX1313515 
New Batch 
6_20140515_111617.csv Cartwright YT*A YT*A Yta (YT:1) + 
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1313515 
New Batch 
6_20140515_111617.csv   YT*B   Ytb (YT:2) 0 
Green EX1313515 
New Batch 
6_20140515_111617.csv Lutheran LU*A LU*B Lua (LU:1) 0 
Green EX1313515 
New Batch 
6_20140515_111617.csv   LU*B   Lub (LU:2) + 
Green EX1313516 
New Batch 
6_20140515_111617.csv Rh RHCE*ce RHCE*ce, RHCE*CeCW(12) C (RH:2) + 
Green EX1313516 
New Batch 
6_20140515_111617.csv   RHCE*Ce   E (RH:3) 0 
Green EX1313516 
New Batch 
6_20140515_111617.csv   RHCE*cE   c (RH:4) + 
Green EX1313516 
New Batch 
6_20140515_111617.csv   RHCE*CE   e (RH:5) + 
Green EX1313516 
New Batch 
6_20140515_111617.csv   RHCE*CeCW   CW (RH:8) + 
Green EX1313516 
New Batch 
6_20140515_111617.csv   RHCE*ceCW   V (RH:10) 0 
Green EX1313516 
New Batch 
6_20140515_111617.csv   RHCE*CECW   hrS (RH:19) + 
Green EX1313516 
New Batch 
6_20140515_111617.csv   RHCE*ceAR   VS (RH:20) 0 
Green EX1313516 
New Batch 
6_20140515_111617.csv   RHCE*CeFV   hrB (RH:31) + 
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1313516 
New Batch 
6_20140515_111617.csv   RHCE*CeVG       
Green EX1313516 
New Batch 
6_20140515_111617.csv   RHCE*cEFM       
Green EX1313516 
New Batch 
6_20140515_111617.csv   RHCE*ce[712G]       
Green EX1313516 
New Batch 
6_20140515_111617.csv   RHCE*ce[733G]       
Green EX1313516 
New Batch 
6_20140515_111617.csv   RHCE*ce[733G,1006T]       
Green EX1313516 
New Batch 
6_20140515_111617.csv   RHCE*CE-D[2, 5, 7]-CE       
Green EX1313516 
New Batch 
6_20140515_111617.csv   RHCE*cE[697G,712G,733G]       
Green EX1313516 
New Batch 
6_20140515_111617.csv   
RHD*r’s-
RHCE*ce[733G,1006T]       
Green EX1313516 
New Batch 
6_20140515_111617.csv Kell KEL*K_KPB_JSB KEL*k_KPB_JSB K (KEL:1) 0 
Green EX1313516 
New Batch 
6_20140515_111617.csv   KEL*k_KPB_JSB   k (KEL:2) + 
Green EX1313516 
New Batch 
6_20140515_111617.csv   KEL*k_KPA_JSB   Kpa (KEL:3) 0 
Green EX1313516 
New Batch 
6_20140515_111617.csv   KEL*k_KPB_JSA   Kpb (KEL:4) + 
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1313516 
New Batch 
6_20140515_111617.csv       Jsa (KEL:6) 0 
Green EX1313516 
New Batch 
6_20140515_111617.csv       Jsb (KEL:7) + 
Green EX1313516 
New Batch 
6_20140515_111617.csv Kidd JK*A JK*A Jka (JK:1) + 
Green EX1313516 
New Batch 
6_20140515_111617.csv   JK*B   Jkb (JK:2) 0 
Green EX1313516 
New Batch 
6_20140515_111617.csv   JK*B_null(IVS5-1a)       
Green EX1313516 
New Batch 
6_20140515_111617.csv   JK*B_null(871C)       
Green EX1313516 
New Batch 
6_20140515_111617.csv Duffy FY*A FY*A, FY*B Fya (FY:1) + 
Green EX1313516 
New Batch 
6_20140515_111617.csv   FY*B   Fyb (FY:2) + 
Green EX1313516 
New Batch 
6_20140515_111617.csv   FY*B_GATA       
Green EX1313516 
New Batch 
6_20140515_111617.csv   FY*B[265T]_FY*X       
Green EX1313516 
New Batch 
6_20140515_111617.csv MNS GYPA*M GYPA*M M (MNS:1) + 
Green EX1313516 
New Batch 
6_20140515_111617.csv   GYPA*N   N (MNS:2) 0 
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1313516 
New Batch 
6_20140515_111617.csv   GYPB*S GYPB*s S (MNS:3) 0 
Green EX1313516 
New Batch 
6_20140515_111617.csv   GYPB*s   s (MNS:4) + 
Green EX1313516 
New Batch 
6_20140515_111617.csv   GYPB*S_null(IVS5+5t)   U (MNS:5) + 
Green EX1313516 
New Batch 
6_20140515_111617.csv   GYPB*S_null(230T)   Mia (MNS:7) 0 
Green EX1313516 
New Batch 
6_20140515_111617.csv   GYPB*deletion       
Green EX1313516 
New Batch 
6_20140515_111617.csv   GYPB*Mur       
Green EX1313516 
New Batch 
6_20140515_111617.csv Diego DI*A DI*B Dia (DI:1) 0 
Green EX1313516 
New Batch 
6_20140515_111617.csv   DI*B   Dib (DI:2) + 
Green EX1313516 
New Batch 
6_20140515_111617.csv Dombrock DO*A DO*A, DO*B Doa (DO:1) + 
Green EX1313516 
New Batch 
6_20140515_111617.csv   DO*B   Dob (DO:2) + 
Green EX1313516 
New Batch 
6_20140515_111617.csv   DO*B_HY-   Hy (DO:4) + 
Green EX1313516 
New Batch 
6_20140515_111617.csv   DO*A_JOA-   Joa (DO:5) + 
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1313516 
New Batch 
6_20140515_111617.csv Colton CO*A CO*A Coa (CO:1) + 
Green EX1313516 
New Batch 
6_20140515_111617.csv   CO*B   Cob (CO:2) 0 
Green EX1313516 
New Batch 
6_20140515_111617.csv Cartwright YT*A YT*A Yta (YT:1) + 
Green EX1313516 
New Batch 
6_20140515_111617.csv   YT*B   Ytb (YT:2) 0 
Green EX1313516 
New Batch 
6_20140515_111617.csv Lutheran LU*A LU*B Lua (LU:1) 0 
Green EX1313516 
New Batch 
6_20140515_111617.csv   LU*B   Lub (LU:2) + 
Green EX1313820 
New Batch 
6_20140515_111617.csv Rh RHCE*ce RHCE*ce, RHCE*Ce C (RH:2) + 
Green EX1313820 
New Batch 
6_20140515_111617.csv   RHCE*Ce   E (RH:3) 0 
Green EX1313820 
New Batch 
6_20140515_111617.csv   RHCE*cE   c (RH:4) + 
Green EX1313820 
New Batch 
6_20140515_111617.csv   RHCE*CE   e (RH:5) + 
Green EX1313820 
New Batch 
6_20140515_111617.csv   RHCE*CeCW   CW (RH:8) 0 
Green EX1313820 
New Batch 
6_20140515_111617.csv   RHCE*ceCW   V (RH:10) 0 
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1313820 
New Batch 
6_20140515_111617.csv   RHCE*CECW   hrS (RH:19) + 
Green EX1313820 
New Batch 
6_20140515_111617.csv   RHCE*ceAR   VS (RH:20) 0 
Green EX1313820 
New Batch 
6_20140515_111617.csv   RHCE*CeFV   hrB (RH:31) + 
Green EX1313820 
New Batch 
6_20140515_111617.csv   RHCE*CeVG       
Green EX1313820 
New Batch 
6_20140515_111617.csv   RHCE*cEFM       
Green EX1313820 
New Batch 
6_20140515_111617.csv   RHCE*ce[712G]       
Green EX1313820 
New Batch 
6_20140515_111617.csv   RHCE*ce[733G]       
Green EX1313820 
New Batch 
6_20140515_111617.csv   RHCE*ce[733G,1006T]       
Green EX1313820 
New Batch 
6_20140515_111617.csv   RHCE*CE-D[2, 5, 7]-CE       
Green EX1313820 
New Batch 
6_20140515_111617.csv   RHCE*cE[697G,712G,733G]       
Green EX1313820 
New Batch 
6_20140515_111617.csv   
RHD*r’s-
RHCE*ce[733G,1006T]       
Green EX1313820 
New Batch 
6_20140515_111617.csv Kell KEL*K_KPB_JSB KEL*k_KPB_JSB K (KEL:1) 0 
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1313820 
New Batch 
6_20140515_111617.csv   KEL*k_KPB_JSB   k (KEL:2) + 
Green EX1313820 
New Batch 
6_20140515_111617.csv   KEL*k_KPA_JSB   Kpa (KEL:3) 0 
Green EX1313820 
New Batch 
6_20140515_111617.csv   KEL*k_KPB_JSA   Kpb (KEL:4) + 
Green EX1313820 
New Batch 
6_20140515_111617.csv       Jsa (KEL:6) 0 
Green EX1313820 
New Batch 
6_20140515_111617.csv       Jsb (KEL:7) + 
Green EX1313820 
New Batch 
6_20140515_111617.csv Kidd JK*A JK*B Jka (JK:1) 0 
Green EX1313820 
New Batch 
6_20140515_111617.csv   JK*B   Jkb (JK:2) + 
Green EX1313820 
New Batch 
6_20140515_111617.csv   JK*B_null(IVS5-1a)       
Green EX1313820 
New Batch 
6_20140515_111617.csv   JK*B_null(871C)       
Green EX1313820 
New Batch 
6_20140515_111617.csv Duffy FY*A FY*B Fya (FY:1) 0 
Green EX1313820 
New Batch 
6_20140515_111617.csv   FY*B   Fyb (FY:2) + 
Green EX1313820 
New Batch 
6_20140515_111617.csv   FY*B_GATA       
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1313820 
New Batch 
6_20140515_111617.csv   FY*B[265T]_FY*X       
Green EX1313820 
New Batch 
6_20140515_111617.csv MNS GYPA*M GYPA*M, GYPA*N M (MNS:1) + 
Green EX1313820 
New Batch 
6_20140515_111617.csv   GYPA*N   N (MNS:2) + 
Green EX1313820 
New Batch 
6_20140515_111617.csv   GYPB*S GYPB*s S (MNS:3) 0 
Green EX1313820 
New Batch 
6_20140515_111617.csv   GYPB*s   s (MNS:4) + 
Green EX1313820 
New Batch 
6_20140515_111617.csv   GYPB*S_null(IVS5+5t)   U (MNS:5) + 
Green EX1313820 
New Batch 
6_20140515_111617.csv   GYPB*S_null(230T)   Mia (MNS:7) 0 
Green EX1313820 
New Batch 
6_20140515_111617.csv   GYPB*deletion       
Green EX1313820 
New Batch 
6_20140515_111617.csv   GYPB*Mur       
Green EX1313820 
New Batch 
6_20140515_111617.csv Diego DI*A DI*B Dia (DI:1) 0 
Green EX1313820 
New Batch 
6_20140515_111617.csv   DI*B   Dib (DI:2) + 
Green EX1313820 
New Batch 
6_20140515_111617.csv Dombrock DO*A DO*B Doa (DO:1) 0 
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1313820 
New Batch 
6_20140515_111617.csv   DO*B   Dob (DO:2) + 
Green EX1313820 
New Batch 
6_20140515_111617.csv   DO*B_HY-   Hy (DO:4) + 
Green EX1313820 
New Batch 
6_20140515_111617.csv   DO*A_JOA-   Joa (DO:5) + 
Green EX1313820 
New Batch 
6_20140515_111617.csv Colton CO*A CO*A, CO*B Coa (CO:1) + 
Green EX1313820 
New Batch 
6_20140515_111617.csv   CO*B   Cob (CO:2) + 
Green EX1313820 
New Batch 
6_20140515_111617.csv Cartwright YT*A YT*A Yta (YT:1) + 
Green EX1313820 
New Batch 
6_20140515_111617.csv   YT*B   Ytb (YT:2) 0 
Green EX1313820 
New Batch 
6_20140515_111617.csv Lutheran LU*A LU*B Lua (LU:1) 0 
Green EX1313820 
New Batch 
6_20140515_111617.csv   LU*B   Lub (LU:2) + 
Green EX1400171 
New Batch 
6_20140515_111617.csv Rh RHCE*ce RHCE*ce, RHCE*Ce C (RH:2) + 
Green EX1400171 
New Batch 
6_20140515_111617.csv   RHCE*Ce   E (RH:3) 0 
Green EX1400171 
New Batch 
6_20140515_111617.csv   RHCE*cE   c (RH:4) + 
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1400171 
New Batch 
6_20140515_111617.csv   RHCE*CE   e (RH:5) + 
Green EX1400171 
New Batch 
6_20140515_111617.csv   RHCE*CeCW   CW (RH:8) 0 
Green EX1400171 
New Batch 
6_20140515_111617.csv   RHCE*ceCW   V (RH:10) 0 
Green EX1400171 
New Batch 
6_20140515_111617.csv   RHCE*CECW   hrS (RH:19) + 
Green EX1400171 
New Batch 
6_20140515_111617.csv   RHCE*ceAR   VS (RH:20) 0 
Green EX1400171 
New Batch 
6_20140515_111617.csv   RHCE*CeFV   hrB (RH:31) + 
Green EX1400171 
New Batch 
6_20140515_111617.csv   RHCE*CeVG       
Green EX1400171 
New Batch 
6_20140515_111617.csv   RHCE*cEFM       
Green EX1400171 
New Batch 
6_20140515_111617.csv   RHCE*ce[712G]       
Green EX1400171 
New Batch 
6_20140515_111617.csv   RHCE*ce[733G]       
Green EX1400171 
New Batch 
6_20140515_111617.csv   RHCE*ce[733G,1006T]       
Green EX1400171 
New Batch 
6_20140515_111617.csv   RHCE*CE-D[2, 5, 7]-CE       
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1400171 
New Batch 
6_20140515_111617.csv   RHCE*cE[697G,712G,733G]       
Green EX1400171 
New Batch 
6_20140515_111617.csv   
RHD*r’s-
RHCE*ce[733G,1006T]       
Green EX1400171 
New Batch 
6_20140515_111617.csv Kell KEL*K_KPB_JSB KEL*k_KPB_JSB K (KEL:1) 0 
Green EX1400171 
New Batch 
6_20140515_111617.csv   KEL*k_KPB_JSB   k (KEL:2) + 
Green EX1400171 
New Batch 
6_20140515_111617.csv   KEL*k_KPA_JSB   Kpa (KEL:3) 0 
Green EX1400171 
New Batch 
6_20140515_111617.csv   KEL*k_KPB_JSA   Kpb (KEL:4) + 
Green EX1400171 
New Batch 
6_20140515_111617.csv       Jsa (KEL:6) 0 
Green EX1400171 
New Batch 
6_20140515_111617.csv       Jsb (KEL:7) + 
Green EX1400171 
New Batch 
6_20140515_111617.csv Kidd JK*A JK*A, JK*B Jka (JK:1) + 
Green EX1400171 
New Batch 
6_20140515_111617.csv   JK*B   Jkb (JK:2) + 
Green EX1400171 
New Batch 
6_20140515_111617.csv   JK*B_null(IVS5-1a)       
Green EX1400171 
New Batch 
6_20140515_111617.csv   JK*B_null(871C)       
271 | A p p e n d i x  
 
Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1400171 
New Batch 
6_20140515_111617.csv Duffy FY*A FY*B Fya (FY:1) 0 
Green EX1400171 
New Batch 
6_20140515_111617.csv   FY*B   Fyb (FY:2) + 
Green EX1400171 
New Batch 
6_20140515_111617.csv   FY*B_GATA       
Green EX1400171 
New Batch 
6_20140515_111617.csv   FY*B[265T]_FY*X       
Green EX1400171 
New Batch 
6_20140515_111617.csv MNS GYPA*M GYPA*M, GYPA*N M (MNS:1) + 
Green EX1400171 
New Batch 
6_20140515_111617.csv   GYPA*N   N (MNS:2) + 
Green EX1400171 
New Batch 
6_20140515_111617.csv   GYPB*S GYPB*s S (MNS:3) 0 
Green EX1400171 
New Batch 
6_20140515_111617.csv   GYPB*s   s (MNS:4) + 
Green EX1400171 
New Batch 
6_20140515_111617.csv   GYPB*S_null(IVS5+5t)   U (MNS:5) + 
Green EX1400171 
New Batch 
6_20140515_111617.csv   GYPB*S_null(230T)   Mia (MNS:7) 0 
Green EX1400171 
New Batch 
6_20140515_111617.csv   GYPB*deletion       
Green EX1400171 
New Batch 
6_20140515_111617.csv   GYPB*Mur       
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1400171 
New Batch 
6_20140515_111617.csv Diego DI*A DI*B Dia (DI:1) 0 
Green EX1400171 
New Batch 
6_20140515_111617.csv   DI*B   Dib (DI:2) + 
Green EX1400171 
New Batch 
6_20140515_111617.csv Dombrock DO*A DO*B Doa (DO:1) 0 
Green EX1400171 
New Batch 
6_20140515_111617.csv   DO*B   Dob (DO:2) + 
Green EX1400171 
New Batch 
6_20140515_111617.csv   DO*B_HY-   Hy (DO:4) + 
Green EX1400171 
New Batch 
6_20140515_111617.csv   DO*A_JOA-   Joa (DO:5) + 
Green EX1400171 
New Batch 
6_20140515_111617.csv Colton CO*A CO*A Coa (CO:1) + 
Green EX1400171 
New Batch 
6_20140515_111617.csv   CO*B   Cob (CO:2) 0 
Green EX1400171 
New Batch 
6_20140515_111617.csv Cartwright YT*A YT*A Yta (YT:1) + 
Green EX1400171 
New Batch 
6_20140515_111617.csv   YT*B   Ytb (YT:2) 0 
Green EX1400171 
New Batch 
6_20140515_111617.csv Lutheran LU*A LU*B Lua (LU:1) 0 
Green EX1400171 
New Batch 
6_20140515_111617.csv   LU*B   Lub (LU:2) + 
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1400887 
New Batch 
6_20140515_111617.csv Rh RHCE*ce RHCE*ce, RHCE*Ce C (RH:2) + 
Green EX1400887 
New Batch 
6_20140515_111617.csv   RHCE*Ce   E (RH:3) 0 
Green EX1400887 
New Batch 
6_20140515_111617.csv   RHCE*cE   c (RH:4) + 
Green EX1400887 
New Batch 
6_20140515_111617.csv   RHCE*CE   e (RH:5) + 
Green EX1400887 
New Batch 
6_20140515_111617.csv   RHCE*CeCW   CW (RH:8) 0 
Green EX1400887 
New Batch 
6_20140515_111617.csv   RHCE*ceCW   V (RH:10) 0 
Green EX1400887 
New Batch 
6_20140515_111617.csv   RHCE*CECW   hrS (RH:19) + 
Green EX1400887 
New Batch 
6_20140515_111617.csv   RHCE*ceAR   VS (RH:20) 0 
Green EX1400887 
New Batch 
6_20140515_111617.csv   RHCE*CeFV   hrB (RH:31) + 
Green EX1400887 
New Batch 
6_20140515_111617.csv   RHCE*CeVG       
Green EX1400887 
New Batch 
6_20140515_111617.csv   RHCE*cEFM       
Green EX1400887 
New Batch 
6_20140515_111617.csv   RHCE*ce[712G]       
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1400887 
New Batch 
6_20140515_111617.csv   RHCE*ce[733G]       
Green EX1400887 
New Batch 
6_20140515_111617.csv   RHCE*ce[733G,1006T]       
Green EX1400887 
New Batch 
6_20140515_111617.csv   RHCE*CE-D[2, 5, 7]-CE       
Green EX1400887 
New Batch 
6_20140515_111617.csv   RHCE*cE[697G,712G,733G]       
Green EX1400887 
New Batch 
6_20140515_111617.csv   
RHD*r’s-
RHCE*ce[733G,1006T]       
Green EX1400887 
New Batch 
6_20140515_111617.csv Kell KEL*K_KPB_JSB KEL*k_KPB_JSB K (KEL:1) 0 
Green EX1400887 
New Batch 
6_20140515_111617.csv   KEL*k_KPB_JSB   k (KEL:2) + 
Green EX1400887 
New Batch 
6_20140515_111617.csv   KEL*k_KPA_JSB   Kpa (KEL:3) 0 
Green EX1400887 
New Batch 
6_20140515_111617.csv   KEL*k_KPB_JSA   Kpb (KEL:4) + 
Green EX1400887 
New Batch 
6_20140515_111617.csv       Jsa (KEL:6) 0 
Green EX1400887 
New Batch 
6_20140515_111617.csv       Jsb (KEL:7) + 
Green EX1400887 
New Batch 
6_20140515_111617.csv Kidd JK*A JK*B Jka (JK:1) 0 
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1400887 
New Batch 
6_20140515_111617.csv   JK*B   Jkb (JK:2) + 
Green EX1400887 
New Batch 
6_20140515_111617.csv   JK*B_null(IVS5-1a)       
Green EX1400887 
New Batch 
6_20140515_111617.csv   JK*B_null(871C)       
Green EX1400887 
New Batch 
6_20140515_111617.csv Duffy FY*A FY*B Fya (FY:1) 0 
Green EX1400887 
New Batch 
6_20140515_111617.csv   FY*B   Fyb (FY:2) + 
Green EX1400887 
New Batch 
6_20140515_111617.csv   FY*B_GATA       
Green EX1400887 
New Batch 
6_20140515_111617.csv   FY*B[265T]_FY*X       
Green EX1400887 
New Batch 
6_20140515_111617.csv MNS GYPA*M GYPA*N M (MNS:1) 0 
Green EX1400887 
New Batch 
6_20140515_111617.csv   GYPA*N   N (MNS:2) + 
Green EX1400887 
New Batch 
6_20140515_111617.csv   GYPB*S GYPB*s S (MNS:3) 0 
Green EX1400887 
New Batch 
6_20140515_111617.csv   GYPB*s   s (MNS:4) + 
Green EX1400887 
New Batch 
6_20140515_111617.csv   GYPB*S_null(IVS5+5t)   U (MNS:5) + 
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1400887 
New Batch 
6_20140515_111617.csv   GYPB*S_null(230T)   Mia (MNS:7) 0 
Green EX1400887 
New Batch 
6_20140515_111617.csv   GYPB*deletion       
Green EX1400887 
New Batch 
6_20140515_111617.csv   GYPB*Mur       
Green EX1400887 
New Batch 
6_20140515_111617.csv Diego DI*A DI*B Dia (DI:1) 0 
Green EX1400887 
New Batch 
6_20140515_111617.csv   DI*B   Dib (DI:2) + 
Green EX1400887 
New Batch 
6_20140515_111617.csv Dombrock DO*A DO*B Doa (DO:1) 0 
Green EX1400887 
New Batch 
6_20140515_111617.csv   DO*B   Dob (DO:2) + 
Green EX1400887 
New Batch 
6_20140515_111617.csv   DO*B_HY-   Hy (DO:4) + 
Green EX1400887 
New Batch 
6_20140515_111617.csv   DO*A_JOA-   Joa (DO:5) + 
Green EX1400887 
New Batch 
6_20140515_111617.csv Colton CO*A CO*A Coa (CO:1) + 
Green EX1400887 
New Batch 
6_20140515_111617.csv   CO*B   Cob (CO:2) 0 
Green EX1400887 
New Batch 
6_20140515_111617.csv Cartwright YT*A YT*A Yta (YT:1) + 
277 | A p p e n d i x  
 
Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1400887 
New Batch 
6_20140515_111617.csv   YT*B   Ytb (YT:2) 0 
Green EX1400887 
New Batch 
6_20140515_111617.csv Lutheran LU*A LU*B Lua (LU:1) 0 
Green EX1400887 
New Batch 
6_20140515_111617.csv   LU*B   Lub (LU:2) + 
Green EX1401612 
New Batch 
6_20140515_111617.csv Rh RHCE*ce RHCE*Ce, RHCE*cE(10) C (RH:2) + 
Green EX1401612 
New Batch 
6_20140515_111617.csv   RHCE*Ce   E (RH:3) + 
Green EX1401612 
New Batch 
6_20140515_111617.csv   RHCE*cE   c (RH:4) + 
Green EX1401612 
New Batch 
6_20140515_111617.csv   RHCE*CE   e (RH:5) + 
Green EX1401612 
New Batch 
6_20140515_111617.csv   RHCE*CeCW   CW (RH:8) 0 
Green EX1401612 
New Batch 
6_20140515_111617.csv   RHCE*ceCW   V (RH:10) 0 
Green EX1401612 
New Batch 
6_20140515_111617.csv   RHCE*CECW   hrS (RH:19) + 
Green EX1401612 
New Batch 
6_20140515_111617.csv   RHCE*ceAR   VS (RH:20) 0 
Green EX1401612 
New Batch 
6_20140515_111617.csv   RHCE*CeFV   hrB (RH:31) + 
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1401612 
New Batch 
6_20140515_111617.csv   RHCE*CeVG       
Green EX1401612 
New Batch 
6_20140515_111617.csv   RHCE*cEFM       
Green EX1401612 
New Batch 
6_20140515_111617.csv   RHCE*ce[712G]       
Green EX1401612 
New Batch 
6_20140515_111617.csv   RHCE*ce[733G]       
Green EX1401612 
New Batch 
6_20140515_111617.csv   RHCE*ce[733G,1006T]       
Green EX1401612 
New Batch 
6_20140515_111617.csv   RHCE*CE-D[2, 5, 7]-CE       
Green EX1401612 
New Batch 
6_20140515_111617.csv   RHCE*cE[697G,712G,733G]       
Green EX1401612 
New Batch 
6_20140515_111617.csv   
RHD*r’s-
RHCE*ce[733G,1006T]       
Green EX1401612 
New Batch 
6_20140515_111617.csv Kell KEL*K_KPB_JSB KEL*k_KPB_JSB K (KEL:1) 0 
Green EX1401612 
New Batch 
6_20140515_111617.csv   KEL*k_KPB_JSB   k (KEL:2) + 
Green EX1401612 
New Batch 
6_20140515_111617.csv   KEL*k_KPA_JSB   Kpa (KEL:3) 0 
Green EX1401612 
New Batch 
6_20140515_111617.csv   KEL*k_KPB_JSA   Kpb (KEL:4) + 
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1401612 
New Batch 
6_20140515_111617.csv       Jsa (KEL:6) 0 
Green EX1401612 
New Batch 
6_20140515_111617.csv       Jsb (KEL:7) + 
Green EX1401612 
New Batch 
6_20140515_111617.csv Kidd JK*A JK*A, JK*B Jka (JK:1) + 
Green EX1401612 
New Batch 
6_20140515_111617.csv   JK*B   Jkb (JK:2) + 
Green EX1401612 
New Batch 
6_20140515_111617.csv   JK*B_null(IVS5-1a)       
Green EX1401612 
New Batch 
6_20140515_111617.csv   JK*B_null(871C)       
Green EX1401612 
New Batch 
6_20140515_111617.csv Duffy FY*A FY*B Fya (FY:1) 0 
Green EX1401612 
New Batch 
6_20140515_111617.csv   FY*B   Fyb (FY:2) + 
Green EX1401612 
New Batch 
6_20140515_111617.csv   FY*B_GATA       
Green EX1401612 
New Batch 
6_20140515_111617.csv   FY*B[265T]_FY*X       
Green EX1401612 
New Batch 
6_20140515_111617.csv MNS GYPA*M GYPA*M M (MNS:1) + 
Green EX1401612 
New Batch 
6_20140515_111617.csv   GYPA*N   N (MNS:2) 0 
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1401612 
New Batch 
6_20140515_111617.csv   GYPB*S GYPB*S S (MNS:3) + 
Green EX1401612 
New Batch 
6_20140515_111617.csv   GYPB*s   s (MNS:4) 0 
Green EX1401612 
New Batch 
6_20140515_111617.csv   GYPB*S_null(IVS5+5t)   U (MNS:5) + 
Green EX1401612 
New Batch 
6_20140515_111617.csv   GYPB*S_null(230T)   Mia (MNS:7) 0 
Green EX1401612 
New Batch 
6_20140515_111617.csv   GYPB*deletion       
Green EX1401612 
New Batch 
6_20140515_111617.csv   GYPB*Mur       
Green EX1401612 
New Batch 
6_20140515_111617.csv Diego DI*A DI*B Dia (DI:1) 0 
Green EX1401612 
New Batch 
6_20140515_111617.csv   DI*B   Dib (DI:2) + 
Green EX1401612 
New Batch 
6_20140515_111617.csv Dombrock DO*A DO*A, DO*B Doa (DO:1) + 
Green EX1401612 
New Batch 
6_20140515_111617.csv   DO*B   Dob (DO:2) + 
Green EX1401612 
New Batch 
6_20140515_111617.csv   DO*B_HY-   Hy (DO:4) + 
Green EX1401612 
New Batch 
6_20140515_111617.csv   DO*A_JOA-   Joa (DO:5) + 
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1401612 
New Batch 
6_20140515_111617.csv Colton CO*A CO*A Coa (CO:1) + 
Green EX1401612 
New Batch 
6_20140515_111617.csv   CO*B   Cob (CO:2) 0 
Green EX1401612 
New Batch 
6_20140515_111617.csv Cartwright YT*A YT*A Yta (YT:1) + 
Green EX1401612 
New Batch 
6_20140515_111617.csv   YT*B   Ytb (YT:2) 0 
Green EX1401612 
New Batch 
6_20140515_111617.csv Lutheran LU*A LU*B Lua (LU:1) 0 
Green EX1401612 
New Batch 
6_20140515_111617.csv   LU*B   Lub (LU:2) + 
Green EX1401613 
New Batch 
6_20140515_111617.csv Rh RHCE*ce RHCE*ce, RHCE*Ce C (RH:2) + 
Green EX1401613 
New Batch 
6_20140515_111617.csv   RHCE*Ce   E (RH:3) 0 
Green EX1401613 
New Batch 
6_20140515_111617.csv   RHCE*cE   c (RH:4) + 
Green EX1401613 
New Batch 
6_20140515_111617.csv   RHCE*CE   e (RH:5) + 
Green EX1401613 
New Batch 
6_20140515_111617.csv   RHCE*CeCW   CW (RH:8) 0 
Green EX1401613 
New Batch 
6_20140515_111617.csv   RHCE*ceCW   V (RH:10) 0 
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1401613 
New Batch 
6_20140515_111617.csv   RHCE*CECW   hrS (RH:19) + 
Green EX1401613 
New Batch 
6_20140515_111617.csv   RHCE*ceAR   VS (RH:20) 0 
Green EX1401613 
New Batch 
6_20140515_111617.csv   RHCE*CeFV   hrB (RH:31) + 
Green EX1401613 
New Batch 
6_20140515_111617.csv   RHCE*CeVG       
Green EX1401613 
New Batch 
6_20140515_111617.csv   RHCE*cEFM       
Green EX1401613 
New Batch 
6_20140515_111617.csv   RHCE*ce[712G]       
Green EX1401613 
New Batch 
6_20140515_111617.csv   RHCE*ce[733G]       
Green EX1401613 
New Batch 
6_20140515_111617.csv   RHCE*ce[733G,1006T]       
Green EX1401613 
New Batch 
6_20140515_111617.csv   RHCE*CE-D[2, 5, 7]-CE       
Green EX1401613 
New Batch 
6_20140515_111617.csv   RHCE*cE[697G,712G,733G]       
Green EX1401613 
New Batch 
6_20140515_111617.csv   
RHD*r’s-
RHCE*ce[733G,1006T]       
Green EX1401613 
New Batch 
6_20140515_111617.csv Kell KEL*K_KPB_JSB KEL*k_KPB_JSB K (KEL:1) 0 
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1401613 
New Batch 
6_20140515_111617.csv   KEL*k_KPB_JSB   k (KEL:2) + 
Green EX1401613 
New Batch 
6_20140515_111617.csv   KEL*k_KPA_JSB   Kpa (KEL:3) 0 
Green EX1401613 
New Batch 
6_20140515_111617.csv   KEL*k_KPB_JSA   Kpb (KEL:4) + 
Green EX1401613 
New Batch 
6_20140515_111617.csv       Jsa (KEL:6) 0 
Green EX1401613 
New Batch 
6_20140515_111617.csv       Jsb (KEL:7) + 
Green EX1401613 
New Batch 
6_20140515_111617.csv Kidd JK*A JK*A Jka (JK:1) + 
Green EX1401613 
New Batch 
6_20140515_111617.csv   JK*B   Jkb (JK:2) 0 
Green EX1401613 
New Batch 
6_20140515_111617.csv   JK*B_null(IVS5-1a)       
Green EX1401613 
New Batch 
6_20140515_111617.csv   JK*B_null(871C)       
Green EX1401613 
New Batch 
6_20140515_111617.csv Duffy FY*A FY*A, FY*B Fya (FY:1) + 
Green EX1401613 
New Batch 
6_20140515_111617.csv   FY*B   Fyb (FY:2) + 
Green EX1401613 
New Batch 
6_20140515_111617.csv   FY*B_GATA       
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1401613 
New Batch 
6_20140515_111617.csv   FY*B[265T]_FY*X       
Green EX1401613 
New Batch 
6_20140515_111617.csv MNS GYPA*M GYPA*M M (MNS:1) + 
Green EX1401613 
New Batch 
6_20140515_111617.csv   GYPA*N   N (MNS:2) 0 
Green EX1401613 
New Batch 
6_20140515_111617.csv   GYPB*S GYPB*S, GYPB*s S (MNS:3) + 
Green EX1401613 
New Batch 
6_20140515_111617.csv   GYPB*s   s (MNS:4) + 
Green EX1401613 
New Batch 
6_20140515_111617.csv   GYPB*S_null(IVS5+5t)   U (MNS:5) + 
Green EX1401613 
New Batch 
6_20140515_111617.csv   GYPB*S_null(230T)   Mia (MNS:7) 0 
Green EX1401613 
New Batch 
6_20140515_111617.csv   GYPB*deletion       
Green EX1401613 
New Batch 
6_20140515_111617.csv   GYPB*Mur       
Green EX1401613 
New Batch 
6_20140515_111617.csv Diego DI*A DI*B Dia (DI:1) 0 
Green EX1401613 
New Batch 
6_20140515_111617.csv   DI*B   Dib (DI:2) + 
Green EX1401613 
New Batch 
6_20140515_111617.csv Dombrock DO*A DO*A, DO*B Doa (DO:1) + 
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1401613 
New Batch 
6_20140515_111617.csv   DO*B   Dob (DO:2) + 
Green EX1401613 
New Batch 
6_20140515_111617.csv   DO*B_HY-   Hy (DO:4) + 
Green EX1401613 
New Batch 
6_20140515_111617.csv   DO*A_JOA-   Joa (DO:5) + 
Green EX1401613 
New Batch 
6_20140515_111617.csv Colton CO*A CO*A Coa (CO:1) + 
Green EX1401613 
New Batch 
6_20140515_111617.csv   CO*B   Cob (CO:2) 0 
Green EX1401613 
New Batch 
6_20140515_111617.csv Cartwright YT*A YT*A Yta (YT:1) + 
Green EX1401613 
New Batch 
6_20140515_111617.csv   YT*B   Ytb (YT:2) 0 
Green EX1401613 
New Batch 
6_20140515_111617.csv Lutheran LU*A LU*B Lua (LU:1) 0 
Green EX1401613 
New Batch 
6_20140515_111617.csv   LU*B   Lub (LU:2) + 
Green EX1401737 
New Batch 
6_20140515_111617.csv Rh RHCE*ce RHCE*Ce, RHCE*cE(10) C (RH:2) + 
Green EX1401737 
New Batch 
6_20140515_111617.csv   RHCE*Ce   E (RH:3) + 
Green EX1401737 
New Batch 
6_20140515_111617.csv   RHCE*cE   c (RH:4) + 
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1401737 
New Batch 
6_20140515_111617.csv   RHCE*CE   e (RH:5) + 
Green EX1401737 
New Batch 
6_20140515_111617.csv   RHCE*CeCW   CW (RH:8) 0 
Green EX1401737 
New Batch 
6_20140515_111617.csv   RHCE*ceCW   V (RH:10) 0 
Green EX1401737 
New Batch 
6_20140515_111617.csv   RHCE*CECW   hrS (RH:19) + 
Green EX1401737 
New Batch 
6_20140515_111617.csv   RHCE*ceAR   VS (RH:20) 0 
Green EX1401737 
New Batch 
6_20140515_111617.csv   RHCE*CeFV   hrB (RH:31) + 
Green EX1401737 
New Batch 
6_20140515_111617.csv   RHCE*CeVG       
Green EX1401737 
New Batch 
6_20140515_111617.csv   RHCE*cEFM       
Green EX1401737 
New Batch 
6_20140515_111617.csv   RHCE*ce[712G]       
Green EX1401737 
New Batch 
6_20140515_111617.csv   RHCE*ce[733G]       
Green EX1401737 
New Batch 
6_20140515_111617.csv   RHCE*ce[733G,1006T]       
Green EX1401737 
New Batch 
6_20140515_111617.csv   RHCE*CE-D[2, 5, 7]-CE       
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1401737 
New Batch 
6_20140515_111617.csv   RHCE*cE[697G,712G,733G]       
Green EX1401737 
New Batch 
6_20140515_111617.csv   
RHD*r’s-
RHCE*ce[733G,1006T]       
Green EX1401737 
New Batch 
6_20140515_111617.csv Kell KEL*K_KPB_JSB KEL*k_KPB_JSB K (KEL:1) 0 
Green EX1401737 
New Batch 
6_20140515_111617.csv   KEL*k_KPB_JSB   k (KEL:2) + 
Green EX1401737 
New Batch 
6_20140515_111617.csv   KEL*k_KPA_JSB   Kpa (KEL:3) 0 
Green EX1401737 
New Batch 
6_20140515_111617.csv   KEL*k_KPB_JSA   Kpb (KEL:4) + 
Green EX1401737 
New Batch 
6_20140515_111617.csv       Jsa (KEL:6) 0 
Green EX1401737 
New Batch 
6_20140515_111617.csv       Jsb (KEL:7) + 
Green EX1401737 
New Batch 
6_20140515_111617.csv Kidd JK*A JK*B Jka (JK:1) 0 
Green EX1401737 
New Batch 
6_20140515_111617.csv   JK*B   Jkb (JK:2) + 
Green EX1401737 
New Batch 
6_20140515_111617.csv   JK*B_null(IVS5-1a)       
Green EX1401737 
New Batch 
6_20140515_111617.csv   JK*B_null(871C)       
288 | A p p e n d i x  
 
Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1401737 
New Batch 
6_20140515_111617.csv Duffy FY*A FY*A, FY*B Fya (FY:1) + 
Green EX1401737 
New Batch 
6_20140515_111617.csv   FY*B   Fyb (FY:2) + 
Green EX1401737 
New Batch 
6_20140515_111617.csv   FY*B_GATA       
Green EX1401737 
New Batch 
6_20140515_111617.csv   FY*B[265T]_FY*X       
Green EX1401737 
New Batch 
6_20140515_111617.csv MNS GYPA*M GYPA*M, GYPA*N M (MNS:1) + 
Green EX1401737 
New Batch 
6_20140515_111617.csv   GYPA*N   N (MNS:2) + 
Green EX1401737 
New Batch 
6_20140515_111617.csv   GYPB*S GYPB*S, GYPB*s S (MNS:3) + 
Green EX1401737 
New Batch 
6_20140515_111617.csv   GYPB*s   s (MNS:4) + 
Green EX1401737 
New Batch 
6_20140515_111617.csv   GYPB*S_null(IVS5+5t)   U (MNS:5) + 
Green EX1401737 
New Batch 
6_20140515_111617.csv   GYPB*S_null(230T)   Mia (MNS:7) 0 
Green EX1401737 
New Batch 
6_20140515_111617.csv   GYPB*deletion       
Green EX1401737 
New Batch 
6_20140515_111617.csv   GYPB*Mur       
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Symbol Sample CSV Blood 
Group 
System 
Alleles Assayed Genotype Result Interrogated 
Antigens 
(ISBT 
Phenotype) 
Predicted 
Phenotype 
Result 
Green EX1401737 
New Batch 
6_20140515_111617.csv Diego DI*A DI*B Dia (DI:1) 0 
Green EX1401737 
New Batch 
6_20140515_111617.csv   DI*B   Dib (DI:2) + 
Green EX1401737 
New Batch 
6_20140515_111617.csv Dombrock DO*A DO*B Doa (DO:1) 0 
Green EX1401737 
New Batch 
6_20140515_111617.csv   DO*B   Dob (DO:2) + 
Green EX1401737 
New Batch 
6_20140515_111617.csv   DO*B_HY-   Hy (DO:4) + 
Green EX1401737 
New Batch 
6_20140515_111617.csv   DO*A_JOA-   Joa (DO:5) + 
Green EX1401737 
New Batch 
6_20140515_111617.csv Colton CO*A CO*A, CO*B Coa (CO:1) + 
Green EX1401737 
New Batch 
6_20140515_111617.csv   CO*B   Cob (CO:2) + 
Green EX1401737 
New Batch 
6_20140515_111617.csv Cartwright YT*A YT*A Yta (YT:1) + 
Green EX1401737 
New Batch 
6_20140515_111617.csv   YT*B   Ytb (YT:2) 0 
Green EX1401737 
New Batch 
6_20140515_111617.csv Lutheran LU*A LU*B Lua (LU:1) 0 
Green EX1401737 
New Batch 
6_20140515_111617.csv   LU*B   Lub (LU:2) + 
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10.5 Appendix 5: Patient information leaflet given to the 
participants in the pilot study 
 
 
 
 
 
PATIENT INFORMATION SHEET 
 
BLOOD GROUP TYPING AND MATCHING OF BLOOD FOR 
TRANSFUSION IN CHRONICALLY TRANSFUSED PATIENTS  
Part 1 of the Information Sheet 
 
1. Invitation 
You are being invited to take part in a research study.    Before you 
decide whether or not to take part, it is important for you to understand 
why the research is being done and what it will involve. Please take time 
to read the following information carefully, and discuss it with others if you 
wish. One of our team will go through the information with you and 
answer any questions you have. 
 
Ask us if there is anything that is not clear, or if you would like more 
information. Take time to decide whether or not you wish to take part. 
 
Normally blood for transfusion is matched for major blood groups only. 
The purpose of this study is to see if it is feasible to provide blood that is 
more fully matched with your blood type.  
 
2. What is the purpose of the study? 
The study will give us information on whether it is possible to provide 
blood that is more fully matched with your blood type. This information 
can then be used for a larger study that will look at whether giving blood 
that is a closer match to your own can reduce the amount of transfusions 
needed for your disease type. 
 
3. Why have I been invited?  
You have been chosen because your condition means that you will need 
regular blood transfusions. 
 
4. Do I have to take part? 
No. It is up to you to decide whether or not to take part.   If you decide to 
take part you will be given this information sheet to keep and be asked to 
sign a consent form to confirm that you understand what is involved when 
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taking part in this study. If you decide to take part you are free to leave 
the study at any time and without giving a reason. If you withdraw, unless 
you object, we will still keep records relating to the treatment given to you, 
as this is valuable to the study. A decision to withdraw at any time, or a 
decision not to take part, will not affect the quality of care you receive 
 
 
5.  What will happen to me if I take part? 
 You will have the normal blood samples taken as part of the pre-
transfusion testing protocol.  
 You will only need to attend as usual for your normal blood tests 
and blood transfusions as required by your doctor. 
 Your blood will be tested for blood type using your blood cells and 
your DNA.  
 This study will last for up to 3 years.  
 This study is a Randomised Trial. Sometimes we don‘t know which 
way of treating patients is best. To find out, we need to compare 
different treatments. We put people into groups and give each 
group a different treatment. The results are compared to see if one 
is better. To try to make sure the groups are the same to start with, 
each patient is put into a group by chance (randomly). This study 
involves two groups; one group will be given blood matched to 
current level and the other group will be given the blood that is a 
closer match. You have a 50% chance of being in the group being 
given blood of a closer match to your own type. 
 
6. Expenses and Payment 
There are no expenses or payments associated with this trial. 
 
7.  What will I need to do? 
You will only need to attend as usual for your normal blood tests and 
blood transfusions as required by your doctor. 
 
8. What are the alternatives for diagnosis or treatment? 
The alternative is the current practice, providing blood that is matched 
only for the major blood types. 
 
 
9. What are the possible disadvantages and risks when taking 
part? 
No side effects are expected as a result of participation in this trial. 
However, if you do decide to take part in the study, you must report any 
problems you have to your study nurse or doctor. There is also a contact 
number given at the end of this information sheet for you to phone if you 
become worried at any time. In the unlikely event of an emergency 
occurring during the conduct of the study, we may contact your 
nominated next of kin. 
 
10. What are the possible benefits of taking part?  
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We cannot promise the study will help you but the information we get 
might help improve the future treatment of people with chronic transfusion 
requirements. 
 
11. What happens when the research study stops? 
You will continue to receive your blood transfusion as required and 
discussed with your doctor. 
 
12. What if there is a problem? 
If you have a concern about any aspect of this study, you should ask to 
speak with the researchers who will do their best to answer your 
question. The researchers contact details can be found at the end of this 
information sheet. If you remain unhappy and wish to complain formally, 
you can do this through the NHS Complaints Procedure.  Details can be 
obtained from the hospital. 
 
In the event that something does go wrong and you are harmed during 
the research study there are no special compensation arrangements.  If 
you are harmed and this is due to someone’s negligence then you may 
have grounds for a legal action for compensation but you may have to 
pay your legal costs.  The normal National Health Service complaints 
mechanisms will still be available to you. 
 
13. Will my part in this study be kept confidential? 
 Yes. We will follow ethical and legal practice and all information 
about you will be handled in confidence. Any information about you which 
leaves the hospital will have your name and address removed so that you 
cannot be recognised. 
 
This completes part 1 of the information sheet. 
 
If the information in part 1 has interested you and you are considering 
participation, please read the information in part 2 before making any 
decisions. 
 
 
 
Part 2 of the information sheet 
 
14.  What if new information becomes available? 
 
Sometimes during the course of a clinical trial, new information becomes 
available on the procedures that are being studied. If this happens, we 
will tell you about it and discuss with you whether you want to or should 
continue in the study. If you decide to withdraw, we will make 
arrangements for your care to continue. If you decide to continue in the 
study you will be asked to sign an updated consent form. 
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On receiving new information, we might consider it to be in your best 
interests to withdraw you from the study. If so, we will explain the reasons 
and arrange for your care to continue. 
 
If the study is stopped for any other reason, you will be told why and your 
continuing care will be arranged. 
 
15. What will happen if I don’t want to carry on with the study? 
You can withdraw from the study at any time, this will not affect your care. 
 
16.  Informing your General Practitioner (GP) 
Your GP will be made aware that you are involved in this trial. 
 
17.  What will happen to any samples I give? 
Your samples will be tested as described in this information sheet. They 
will not be used for any other research purposes and they will be 
disposed of in accordance with Trust guidelines. 
 
18. Will any Genetic testing be done? 
Your DNA will be used to do blood group typing but no other genetic 
analysis will be performed on your DNA and your DNA will not be used 
for any other research. 
 
19. What will happen to the results of this clinical trial? 
 
The results of the study will be available after it finishes and will usually 
be published in a medical journal or be presented at a scientific 
conference. The data will be anonymous and none of the patients 
involved in the trial will be identified in any report or publication.  
 
Should you wish to see the results, or the publication, please ask your 
study doctor.  
 
20. Who is organising and funding this clinical trial? 
  This study is being organised by a member of staff in the Haematology 
Department at the RD&E who is undertaking a Professional Doctorate at 
the University of the West of England. It is being funded by the RD&E. 
 
21. Who has reviewed the study? 
All research in the NHS is looked at by independent group of people, 
called a Research Ethics Committee, to protect your interests. This study 
has been reviewed and given favourable opinion by 
______________Research Ethics Committee. 
 
22. Contact for further information 
 
You are encouraged to ask any questions you wish, before, during or 
after your treatment.  
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General information on research can be found on the Health Research 
Authority website the web address is given below: 
http://www.hra.nhs.uk/hra/patients-and-the-public/ 
 
If you have any questions about this study, please speak to your research 
specialist/coordinator or your haematology doctor, who will be able to 
provide you with up to date information about the treatment involved. If 
you wish to read the research on which this study is based, please ask 
your research specialist/coordinator.  
 
If you would like advice as to whether you should participate please 
contact your research specialist/coordinator or your haematology doctor. 
 
If you have any concerns during the study then you can contact the 
research specialist/coordinator on the details given in this leaflet, or you 
can contact the Haematology ward on 01392 402882. 
 
If you decide you would like to take part then please read and sign the 
consent form. You will be given a copy of this information sheet and the 
consent form to keep. A copy of the consent form will be filed in your 
patient notes, one will be filed with the study records and one may be 
sent to the Research Sponsor. 
 
You can have more time to think this over if you are at all unsure. 
 
Thank you for taking the time to read this information sheet and to 
consider this study. 
 
Contact Details 
 
Your Research/Specialist Coordinator 
 
Name  Jennifer Davies  Tel. Number: 01392 402959 
 
If you have any further questions or require clarification please feel 
free to contact: 
Jennifer Davies 
Haematology Department 
Royal Devon and Exeter NHS Foundation Trust 
Barrack Road 
Exeter 
EX2 5DW 
01392 402959 
Jeni.davies@rdeft.nhs.uk 
 
 Chairman:  James Brent    Chief Executive: Angela Pedder 
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10.2 Appendix 6: Consent form signed by participants in the pilot 
study 
 
 
 
